

AW: Governor Ricketts - invitation to speak at the 2020 Horasis Extraordinary Meeting, 1 October

Frank-Jurgen Richter <richter@horasis.org>

Sun 8/16/2020 3:28 PM

To: Miltenberger, Matt <matt.miltenberger@nebraska.gov>

Cc: Salisbury, Jean A <Jean.A.Salisbury@nebraska.gov>

📎 2 attachments (1 MB)

Horasis Extraordinary Meeting-2020 - programme.pdf; High-level delegates - Horasis Extraordinary Meeting 2020.pdf;

Dear Matt, I hope this message finds you well. Do you already know if Governor Ricketts is going to speak at the Horasis Extraordinary Meeting on Oct 1st?

Attached the updated agenda. His session would be at 10.00-10.45 Nebraska time (there is no need to join other sessions, just these 45min)

Best regards

Frank

Dr Frank-Jürgen Richter

Founder and Chairman

Horasis: The Global Visions Community

<http://www.horasis.org>

Maurerstrasse 2, CH-8500 Frauenfeld, Switzerland

richter@horasis.org, phone [REDACTED]

[Twitter](#) | [LinkedIn](#) | [Facebook](#) | [Youtube](#)

Please consider the impact on the environment before printing this e-mail.

Von: Frank-Jurgen Richter

Gesendet: Montag, 13. Juli 2020 21:17

An: Miltenberger, Matt <matt.miltenberger@nebraska.gov>

Cc: Salisbury, Jean A <Jean.A.Salisbury@nebraska.gov>

Betreff: AW: Governor Ricketts - invitation to speak at the 2020 Horasis Extraordinary Meeting, 1 October

Many thanks, Matt! We would be glad to welcome Governor Ricketts.

Best

Frank

Dr Frank-Jürgen Richter

Founder and Chairman

Horasis: The Global Visions Community

<http://www.horasis.org>

Maurerstrasse 2, CH-8500 Frauenfeld, Switzerland

richter@hosis.org, phone [REDACTED]
[Twitter](#) | [LinkedIn](#) | [Facebook](#) | [Youtube](#)

Please consider the impact on the environment before printing this e-mail.

Von: Miltenberger, Matt [<mailto:matt.miltenberger@nebraska.gov>]
Gesendet: Montag, 13. Juli 2020 20:17
An: Frank-Jurgen Richter <richter@hosis.org>
Cc: Salisbury, Jean A <Jean.A.Salisbury@nebraska.gov>
Betreff: RE: Governor Ricketts - invitation to speak at the 2020 Hosis Extraordinary Meeting, 1 October

Frank-

Thank you for reaching out and inviting Governor Ricketts to speak at the 2020 Hosis Extraordinary Meeting. The Governor's scheduler and I will speak with the Governor and follow back up with you shortly.

Thank you again

Matt

From: Frank-Jurgen Richter <richter@hosis.org>
Sent: Saturday, July 11, 2020 4:29 AM
To: Miltenberger, Matt <matt.miltenberger@nebraska.gov>
Subject: Governor Ricketts - invitation to speak at the 2020 Hosis Extraordinary Meeting, 1 October

Hosis Extraordinary Meeting, 1 October 2020
Unite. Inspire. Create.

Cc Matt Miltenberger

Pete Ricketts
Governor
Nebraska

Dear Governor Ricketts,

Many thanks again for speaking at the Hosis China Meeting in Las Vegas last October!

I take great pleasure to invite you to **speak** at the (virtual) **Hosis Extraordinary Meeting** on 1 October, held on the side-lines of the **UN General Assembly** on Hosis' new ground-breaking digital conferencing platform. Under the theme *Unite. Inspire. Create*, 500 of the most senior members of the Hosis Visions Community (including several heads of governments and key ministers) will gather virtually to overcome the profound economic, political and social disruptions caused by Covid-19. Please find attached **draft programme** and abridged list of **high-level participants** which include:

António Costa, Prime Minister of Portugal, Portugal
Hage G. Geingob, President of Namibia, Namibia
Iliana Iotova, Vice President of Bulgaria, Bulgaria
Armen Sarkissian, President of Armenia, Armenia
Paul Quist Kelley, Minister of Presidency and National Policies, Nicaragua
Shamma Al Mazrui, Minister of State for Youth Affairs, UAE
Péter Szijjártó, Minister of Foreign Affairs, Hungary
Fabrizio Hochschild, Under-Secretary General, United Nations, USA
HH Princess Märtha Louise of Norway
Hank McKinnell, Chairman, Moody's, USA

Would you be interested to speak on the following plenary panel?

1 Oct 11.00-11.45 (US Eastern Time) Plenary: The US – On the Brink of Change

The US elections, the most followed across the world, are going to be challenging. How is the COVID-pandemic impacting the elections and who will win? What is going to change? What might the future hold – for the US and for the rest of the world?

We are convinced that the world will not go back to a New Normal using a simplistic resetting of legacy systems – extraordinary times demand an extraordinary transformation. With the Horasis Extraordinary Meeting we offer the conceptual backbone and action platform to advance the recovery - envisioning and implementing novel business models, new political cooperation and deep social cohesion.

Horasis is a global visions community committed to inspiring our future. In addition to the Horasis Extraordinary Meeting, Horasis hosts the annual Horasis Global Meeting as well as regional meetings focusing on India, China and Southeast Asia. I am glad to share the meeting reports of the 2019, 2018, 2017 and 2016 Horasis Global Meetings to give you an idea on scope and content of our meetings. Here our institutional video, introducing the Horasis history and mission.

I would feel very privileged to have you with us. Please let me know if your schedule will allow you to take part in the meeting.

Best regards,
Frank-Jürgen Richter

Dr Frank-Jürgen Richter
Founder and Chairman
Horasis: The Global Visions Community
<http://www.horasis.org>

Burgstrasse 8, CH-8280 Kreuzlingen, Switzerland,

richter@horasis.org, phone: [REDACTED]

[Twitter](#) | [LinkedIn](#) | [Facebook](#) | [Youtube](#)

Horasis Extraordinary Meeting

Virtual Event, 1 October 2020

06.30-23.00 Central European Summer Time

Unite. Inspire. Create.

Co-chairs:

- Ibukun Awosika, Chairman, First Bank of Nigeria, Nigeria
- J. Erik Fyrwald, Chief Executive Officer, Syngenta, Switzerland
- Roshni Nadar Malhotra, Chairperson, HCL Corporation Ltd., India
- Hank McKinnell, Chairman, Moody's, USA
- Martin Richenhagen, Chairman, President and CEO, AGCO, USA

Partner Organizations:

- Confederation of British Industry (CBI)
- Confederation of Indian Industry (CII)
- U.S. Chamber of Commerce

Supporting Partners:

- ADAM Global
- Allianz
- All India Management Association (AIMA)
- Caspian Week
- CEO Clubs Network Worldwide
- Dream Tank
- Global Steering Group for Impact Investment (GSG)
- IE University
- Oxford Analytica
- Publicize
- QI Group
- Run The World
- The Digital Economist
- Thinking the Unthinkable
- Thunderbird School of Global Management
- Wingsure

Horasis

The Global Visions Community

Schedule October 1 (Central European Summer Time)

Unite.	Inspire.	Create.
06.30-07.15 Uniting in the morning Horasis Community Building	11.00-11.45 Plenary: Developing leadership and inspiration South Asia	17.00-17.45 Plenary USA Europe
07.15-08.00 Digital Breakfast Sessions Are we at an evolutionary moment? Revitalizing economic growth COVID vaccination availability Technology for social impact Future-proof business Changing world of e-commerce Mental health crisis Celebrating diversity Power of media Regeneration of world trade Sustainable brands Pivoting your businesses China	11.45-12.30 Plenary: Sustainable Development Goals Why we Must Think as Citizens	17.45-18.30 Plenary UN Global Compact post-COVID Repositioning Capitalism
08.00-08.45 Parallel Sessions Competing in leaderless world Corporate strategy through pandemic Balancing long & short term Progress on global UN commitments Water: The Innovation Imperative Owning your own data Fair Taxation for All Developing entrepreneurial spirit Developing NewTech despite COVID New Cold War Developing Digital Prowess Family Business Future Role of the Digital Leader South East Asia	12.30-13.15 Parallel Sessions The elephants in the room Inspirational leadership Economic recovery by digitization Unlikely collaborators Rekindling education post-COVID Regeneration or evolution of cities Building peace We are living longer Deriving ideas for start-ups Global Coordination Competitive Green Economies African Peace Engineering Corps Foreign Direct Investment (FDI) Armenia United Kingdom	18.30-19.15 Parallel Sessions Stock market volatility FinTech Post-COVID Responsibility for blockchain usage Black lives matter New Deal for Globalization Innovation in a pandemic world Making more from less Digital utopia Implanting Industry 4.0 Fighting Poverty Solutions for an impact-led recovery Latin America
08.45-08.50 Plenary Extraordinary times and transformations	13.15-14.00 Virtual Lunch Plenary Climate change commitments Horasis community building	19.15-20.00 Plenary Governing a world out of balance Africa
08.50-09.30 Plenary Unite. Inspire. Create	14.00-14.45 Plenary The global economic outlook	20.00-20.45 Closing Plenary Unity, inspiration and creativity
09.30-10.15 Plenary Nurturing inclusive leadership Worldwide update on COVID-19	14.45-15.30 Plenary Celebrating UN 75 in times of COVID	20.45-20.50 Closing Remarks Unpalatables in times of COVID-19
10.15-11.00 Parallel Sessions Where are we at? Where are we Going? Impact investing Stronger together Millennials & Gen-Z Competition for economic leadership AI as force for good Art supporting leadership transformations Reconstructing supply chains New Unicorn ventures Managed philanthropy Business Toughness Austerity or Plenty Global Solidarity Greater Caspian Region	15.30-16.15 Parallel Sessions United Nations: The Next 75 years Public-private partnerships Redefining HRM as human relations Strategic infrastructure investment Developing emotional intelligence Entrepreneurial gale Developing deep learning Changing future of work Overcoming gender inequality South-South cooperation Future of finance Future of money Middle East	20.50-21.30 Virtual Closing Dinners Our world in 2030 Equitable growth post-COVID Leading change The CEO in age of disruption Ensuring inclusive prosperity Navigating business on the edge Building Trust Technology is Running Amok Political revolutions The Conservation Continent The Future is bright Global Climate Transformation
	16.15-17.00 Parallel Sessions SDG goal #3 – its deeper meaning Technology harnessing Partnering for food security Harnessing migration Inspiring social innovation Our need of fulfillment Ethics in a troubled world Managing funds post-COVID Blended finance for future benefits Start-up Nations Bridging the Digital Divide Fostering Purpose through Movies Africa	21.30-22.15 Closing Parallel Sessions Corporate leadership Behavioral changes Populism vs. multilateralism Venture capital Awakening to a digital world Clusters Advancing the 5 th industrial revolution The zing of cryptocurrency Coaching through COVID Mutuality amid COVID-19 Globally Green Policies Reaching for the Future with Technology Un-led global crisis
		22.15-23.00 Virtual Receptions Horasis community building Young Horasis Visionaries The 2021 Horasis Global Meeting

October 1, 2020

Central European Summer Time

06.30-07.15 Uniting in the Morning: Horasis Community Building

Horasis is providing a matchmaking tool to connect with other delegates - each participant will be randomly matched with another to speak for 5 minutes by video, then become paired with another, and so on. It is hoped that these brainstorming links will unite delegates and initiate creativity to inspire the rest of the meeting time.

07.15-08.00 Digital Breakfast Sessions

Futurist Panel: Are we at an Evolutionary Moment?

Intuitively we all know that the future is accelerating at us, and we live in the midst of historical times. Our imaginative panel will tackle the big questions. How will revolutionary technology - from AI to Web 3.0 - impact our world? How will our economies, geopolitics and organizations change? Will we shift to a Post Industrial Civilization? Will we witness the evolution of the human species?

- **Kishore Mahbubani**, Distinguished Fellow, Asia Research Institute, National University of Singapore, Singapore
- **Shashi Tharoor**, Chairman, Parliamentary Standing Committee on Information Technology, India
- **Benjamin J. Butler**, Co-Founder, Quantum Futures, Hong Kong

Revitalizing Economic Growth

With the current COVID-related economic and political uncertainties, budgets of both advanced and emerging economies are going to be under stress in years to come, creating a difficult environment for global economic growth. What are the key challenges that we are going to face? And what are the policy options to inspire economic recovery?

- **Erik Berglof**, Professor, London School of Economics and Political Science, United Kingdom
 - **Francisco G. Dakila**, Deputy Governor, Central Bank of the Philippines, The Philippines
 - **Fawzia Koofi**, Vice President, National Assembly, Afghanistan
 - **Sujata Koirala**, Former Deputy Prime Minister, Nepal
 - **Oki Matsumoto**, Chairman, Monex Group, Japan
- Chaired by*
- **Martina Fuchs**, Anchor, China Global Television Network (CGTN), United Kingdom

Vaccination Availability post-COVID

COVID-19 vaccines will take a long time to pass regulatory hurdles, even with agile parallel development: some people may risk lightly regulated early release COVID vaccines. Is global co-operation going to take place? When will a COVID vaccine finally be ready?

- **José Ramón Calvo**, President, Institute of Multidisciplinary Research, Spain
 - **Luba Greenwood**, Lecturer, Harvard University, USA
 - **Ken Hu**, President and Chief Executive Officer, HKF Technology, USA
 - **Yang Min**, Co-founder, ONE Health, China
 - **Faheem Younus**, Professor, University of Maryland Upper Chesapeake Hospital, USA
- Chaired by*
- **tbc**

Horasis

The Global Visions Community

Leveraging Technology for Social Impact

Technology is a driver of change but it requires a purpose to serve the greater public good. Sometimes new types of technologies do not achieve lasting meaning for a wide audience, and with COVID-isolation many innovators are stifled and their creativity is unfulfilled. How to embrace technology to achieve real social impact? How to judge what may be best for our future?

- **Mustafa Ergen**, Founder, Ambeent, Turkey
- **Gail Christine Gannon**, Managing Director, WaveEdge Capital, USA
- **Joan O'Donnell**, Co-founder, FreedomTech, Ireland
- **Vineet Rai**, Founder, Aavishkaar Intellectap Group, USA
- **Bo Stjerne Thomsen**, Chair of Learning through Play, LEGO Foundation, Denmark

Chaired by

- **Rohit Pujari**, Dy Chief Whip of Legislative Assembly, Odisha, India

Future-proofing the Business

In chaotic times rapid strategy re-formulation is often needed. How to find the time for this? Where to do it – a distant retreat is not possible with COVID lockdown, or the Board room? How was this managed in the first wave of COVID? Is home-working here to stay? Does work from home reduce innovation and entrepreneurship overall?

- **Khalid Taimur Akram**, Executive Director, Center for Global & Strategic Studies, Pakistan
- **Annalise Jennings**, Director, Dynamic Exchange, Australia
- **Meriem Kebiri**, Chief Executive Officer, L'Atelierlital, Tunisia
- **Adham Nadim**, Chairman and Managing Director, Nadim Industries, Egypt
- **Katsuyuki Tochimoto**, Founder, M-Theory Inc., Japan

Chaired by

- **Henry Shterenberg**, Founder & Chief Executive Officer, Global Transformation Platform, Ukraine

The Changing World of E-commerce

The lockdown due to COVID-19 has boosted remote shopping and strongly personalized digital trade shows have united consumers. How to decide between the personal touch or the digital persuasion? Are the returns of digital goods significantly higher than for traditional purchases thus increase pollution?

- **Brendon Dennewill**, Chief Executive Officer, Denamico Inc, USA
- **Sandi Češko**, Co-founder, Studio Moderna, Slovenia
- **Tina Mani**, Chief Executive Officer, Yfret, USA
- **Fahim Naim**, Founder, eShoppportunity, USA
- **Rolf Schrömgens**, Co-Founder and Chief Executive Officer, Trivago, Germany

Chaired by

- **George I. Fomitchev**, Founder and Chief Executive Officer, Endurance, USA

A Deepening of the Mental Health Crisis

Mental health is a necessity for human well-being, with mental illness affecting 1 in 5 adults occasionally in their lives. The COVID lockdown increases personal stress and low contact work modes have massively increased stress levels. How to combat the crisis of mental illness? How can organizations lead in its resolution?

- **Liz Brandt**, Chief Executive Officer, Ctrl-Shift, United Kingdom
- **Anton Grech**, Chairman, Mental Health Services, Malta
- **Lene Søvold**, Clinical Psychologist, Norway
- **Marteka Swaby**, Founder, Benevolent Health, United Kingdom
- **Anil Thapliyal**, Chief Executive Officer, HealthTRx, New Zealand

Chaired by

- **Gregor Henderson**, Director of Mental Health, Public Health England, United Kingdom

Horasis

The Global Visions Community

Celebrating Diversity, Spurring Innovation

As we emerge from the COVID-19 crisis, we have a unique opportunity to ensure that gender, age, sexual orientation, different abilities, racial, religious and political identity all other forms of human diversity are accepted in business and society. How to implement diversity and inclusion at leadership level? How can diversity inspire innovation?

- **Cynthia Castro**, Co-founder, Efecto Boomerang, Costa Rica
 - **Geesje van Haren**, Chief Editor, Small Stream Media, The Netherlands
 - **Michel Deleuran**, Partner, Better Organisations, Denmark
 - **Nimnual Piewthongngam**, Founder, Gumpun Muaythai LTD, Thailand
 - **Vered Pnueli**, Co-founder, Shenkar Game Design Program, Shenkar College, Israel
- Chaired by*
- **Vanessa Arelle**, Founder and Chief Executive Officer, Evolaity, Portugal

The Power of the Media and Influencers

During the stress of COVID-19 isolation it is tempting to follow the media and influencers. But how do we assure ourselves they purvey facts and truthful product information? They have the power to unite, inspire and change people's perceptions – but how to verify their words? Should we be draconian or libertarian?

- **Andrew Chow**, Founder, Asia Future TV, Singapore
 - **Hassan Dawood**, Vice Chairman, AISayegh Media, UAE
 - **Maxim Jago**, Independent Filmmaker, Futurist, and Author, United Kingdom
 - **Peta Milan**, Co-Founder, Transcendent Media Capital, Hong Kong SAR
 - **Rogério Simoes**, Chief Executive Officer, Unnon, United Kingdom
- Chaired by*
- **Jim Glade**, Director, Publicize, Colombia

Collapse or Regeneration of World Trade

Post-COVID some governments will support populism yet others will create wide-reaching accords to develop trade and more freely exchange resources. Does free-trade unite, inspire and lift creativity? What do business leaders want? Importantly, what do the people want?

- **Yonov Fred Agah**, Deputy Director-General, World Trade Organization (WTO), Switzerland
 - **Diane Edwards**, President, Trade & Invest Jamaica, Jamaica
 - **Robert Hermann**, Chief Executive Officer, Germany Trade & Invest, Germany
 - **Lisa McAuley**, Chief Executive Officer, Global Trade Professionals Alliance (GTPA), Australia
 - **Sidharth Nath Singh**, Minister for Export and Investment Promotion, Uttar Pradesh, India
- Chaired by*
- **Pranjal Sharma**, Contributing Editor, Business Standard, India

Sustainable Brands in the Wake of COVID-19

The pressure of COVID management has created a new subtlety about sustainability - there is support for brands that support policies that incline to environment, sustainability and governance from end-to-end of the supply chain. Will the brands, both new and traditional, be sustainable into the fully recovered future? What more is needed to encourage deep sustainability?

- **Hiroshi Komiyama**, President, Kitakyushu Asian Center for Low Carbon Society, Japan
 - **Dilip Piramal**, Chairman, VIP Industries, India
 - **Rosauro Angelo Rodriguez**, Founder, PAD1925, Inc., The Philippines
 - **Sonu Shivdasani**, Founder and Chief Executive Officer, Soneva, Thailand
 - **Sinartus Sosrodjojo**, Co-founders, Alami Ventures, Indonesia
- Chaired by*
- **Thomas Eymond-Laritz**, Chief Executive Officer, Highgate, United Kingdom

Horasis

The Global Visions Community

Pivoting your Businesses

Business leaders have to come up with creative ideas to cope with a world in its lock-down crisis. To pivot, they need to think outside the box, take risks and experiment with new business models. What are the opportunities and challenges of pivoting your business when the future is uncertain? How to plan your company's future post-COVID?

- **Hassan Daud Butt**, Chief Executive Officer, Khyber Pakhtunkhwa Board of Investment & Trade, Pakistan
- **Dmitri Gromov**, Chairman, RTS Telecom, Russia
- **Torsten Oltmanns**, Managing Partner, Gaulty Advisors, Germany
- **Sumant Sinha**, Founder and Chairman, ReNew Power Ventures, India
- **Zhou Yi**, Co-founder, MarvelTec, Hong Kong SAR

Chaired by

- **Michael Stopford**, Founder and Managing Partner, ACORED, Italy

China and its New Economy

Following the outbreak of COVID-19, allegedly in Wuhan, its economy is rising once more. Its rapid response to the novelty of COVID with no immediate treatment mode was exemplary, and it formed a model for other nations. How will its global power grow over the next year? Or next decade as logistics chains are reborn?

- **Anthony Chan**, Chairman, Gretchen, Hong Kong
- **Chen Tianmei**, Founder, Cosmic Citizens, China
- **Michael Cheng**, Managing Director, Drum Tower Ventures, China
- **Ikram Sehgal**, Chairman, Pathfinder Group, Pakistan
- **Li Xu**, Founder, Li Xu International, USA

Chaired by

- **Uwe Michel**, Executive Vice President, Allianz, Germany

08.00-08.45 Parallel Sessions

Competing in a Leaderless World

Modern textbook theory on strategy and corporate planning is based on a world which is flat, highly globalized and defined by multipolar leadership. How shall firms adjust to the new reality of leaderlessness, heightening uncertainty and creeping de-globalization? And, when the COVID pandemic causes outbreaks of unmanageable behavior?

- **Rogério Alexandre**, President, Barclays Portugal, Portugal
- **Bo Inge Andersson**, President, Yazaki North and Central America, Europe and Africa, USA
- **Nicholas Johnson**, Chief Executive Officer, Economists Without Borders, Australia
- **Mariana Todorova**, Founder and Chief Executive Officer, DG-Agora 2.0, Bulgaria
- **Luc Wei**, Co-Founder, Madmonkey, China

Chaired by

- **Vivek Atray**, Founder, Vibrant Advisory Services, India

Horasis

The Global Visions Community

Corporate Strategies in the Digital Pandemized Age

Goods are created, offered and delivered via a digital mesh of lean, fast associations of producers, logistics and FinTech firms across the globe connected in real time each gaining Value Added income. How will firms change their structures and strategies to compete for virtual personnel, services, and goods in a world shattered into local cells by COVID-19 lockdowns?

- **Serge Dumont**, Chairman, Boston Management Ltd., Hong Kong
- **Yoshito Hori**, Founder and President, GLOBIS University, Japan
- **Jaana Nykänen**, Chief Executive Officer, Divine Robot, Sweden
- **Wiktor Schmidt**, Chief Executive Officer, Netguru, Poland
- **Mikhail Tretyakov**, President, OmniGrade Universal Crowdsourcing Agency, Russia

Chaired by

- **Saskia Eversloh**, Columnist, WirtschaftsWoche; Author of "New Work-Knigge", Germany

Balancing Long- and Short-termism

Leaders complain that quarterly financial reporting has enforced short-termism but new long-term pressures are the ESGs (environmental, sustainable, governance measures). And outbreaks of COVID-19 can crash active investor's plans. How are CEOs to grasp good governance if advice is itself risky?

- **Peter Armand**, Founder and Chief Financial Officer, RuGeeks, Russia
- **John Cook**, Chairman, Rock Lake Partners, Switzerland
- **Pamela Mar**, Executive Vice President, Fung Academy, Hong Kong SAR
- **Felix von Schubert**, Executive Chairman, Infrontier, United Kingdom
- **Sudhir Sharma**, Chairman, Mitkat Advisory Services, India

Chaired by

- **Angela Beardsley**, Founder, Resonate Together, United Kingdom

The Progress on Global UN Commitments

World leaders agreed on UN key targets to be met by 2030, especially on sustainability. Why are so many leaders still lagging targets, especially on the climate emergency? Now there is the complex issue of COVID management. Are the complexities too large? Why are governments slow to present their commitment plans? Is there will to meet targets beyond the rhetoric of governments and corporates?

- **Abdulwahab Al-Sadoun**, B20 SHERPA, B20 Saudi Arabia, Saudi Arabia
- **Jun Arima**, Senior Policy Fellow, ERIA, Japan
- **Yilmaz Argüden**, Chairman, ARGE Consulting, Turkey
- **Christopher Boyejo**, Executive Presidential Special Adviser, International Organization for Economic Development (IOED), Nigeria
- **Konstantin Dobrynin**, former Senator of the Russian Parliament; State Secretary, Federal Chamber of Lawyers of Russia, Russia

Chaired by

- **Miki Ebara**, Chief International Correspondent, NHK World, Japan

Horasis

The Global Visions Community

Water: The Innovation Imperative

With fresh water resources depleting at a fast pace, in the face of growing population, economies and urbanization, 40% of the world's population may not have access to water by 2050. How can businesses respond to this challenge with new technologies, new governance tools, innovative models of public-private partnership, and new avenues of cross-boundary cooperation?

- **Vedika Bhandarkar**, Chief Global Impact Officer, water.org, USA
- **Nicholas Parker**, Chairman, Parker Management Venture Inc., Canada
- **Maxim Pasik**, Executive Chairman, Watergen, Israel
- **Ravi Sewak**, Director, Safe Water Network, India
- **Jean-Pierre Sweerts**, Managing Director, Water Finance Facility, The Netherlands

Chaired by

- **Sundeep Waslekar**, President, Strategic Foresight Group, India

Owning Your Data Is Owning Your Future

The potential of massive and cheap computer power permits Big Data analyses. Who really owns the data, who is able to use it, and where will it be stored? With devices permanently monitoring users and digital services demanding personal data; for instance, for large-scale collection for COVID tracking, is privacy still possible, or even desirable?

- **Kouhei Kurihara**, Co-Founder, CollaboGate, Japan
- **Patrick Lynch**, Clinical Assistant Professor of Analytics and Leadership, Thunderbird School of Global Management, USA
- **Jerry Power**, Founder, I3 Systems, USA
- **Mykolas Rambus**, Entrepreneur in Residence, Detroit Venture Partners., USA
- **Robert Zhang**, Co-founder, CloudMinds Technology, USA

Chaired by

- **Stan Stalaker**, Founding Director, Hub Culture, United Kingdom

Fair Taxation for All

Few like being taxed, many think the rich (individuals and firms) escape fair taxation, and some firms are expert at multi-location tax-dodging: some manage to obtain COVID-19 financial aid meant for small firms.

How to address pan-continental taxation when many nations, even towns, hope to attract big business with tax breaks: who is fooling who?

Who are the ultimate decision takers?

- **Jasper Cao**, President, Wisetrade Inc, USA
- **Gustavo L Ghory**, Chairman, Smarterchains, Switzerland
- **Paul Tang**, Member, European Parliament, European Union
- **Toshihiro Toyoshima**, Chief Executive Officer, Mercuria Investment Co., Japan
- **Anthony Travers**, Senior Partner, Travers Thorp Alberga, Cayman Islands

Chaired by

- **Francis Wong**, Managing Director, Encounter Australia, Australia

Horasis

The Global Visions Community

Developing the Entrepreneurial Spirit

Individuals everywhere have through necessity to be innovative to live, though not all wish to be – however, personal COVID protection demands new lifestyles. How do we develop an entrepreneurial spirit? What aid will nurture entrepreneurs in a confusing, rapidly developing world? How should we protect the people of undeveloped regions so they may become entrepreneurs unfearful of massive losses?

- **Yolian Ivanov**, Executive Director - Southern Europe, The Collins Group, Bulgaria
- **Chai Manalo**, President and Chief Executive Officer, MASPAN Holdings Inc., The Philippines
- **Srikar Reddy**, Chief Executive Officer, Sonata Software, India
- **Jitesh Shetty**, Founder, Qwiklabs (Subsidiary of Google), USA
- **Ronald Yu**, Chairman, Autopass, Taiwan

Chaired by

- **Ji Bo**, Assistant Dean, Cheung Kong Graduate School of Business, China

The Development of New Tech in a COVID World

Tech has always been developed by firms geographically dispersed, perhaps globally. But in each firm staff were in close contact so could be instant problem solvers. How will this take place in a personally distanced COVID management mode? Can we be entrepreneurs at a distance, or innovators when not in a crowd of like-minded colleagues? What will the future be?

- **Andrew Bate**, Chief Executive Office, Safely, USA
- **Harry Hui**, Founder and Managing Partner, ClearVue Partners, China
- **Shin Ito**, Chief Executive Officer, iKoyoo Inc., Japan
- **Clas Neumann**, Senior Vice President, Fast Growth Market Strategy, SAP, China
- **Xiaoyin Qu**, Founder, Run The World, USA

Chaired by

- **Mark Esposito**, Clinical Professor at Thunderbird School of Global Management, USA

On Being Vigilant Against a New Cold War

The US and China seem intent on mutually escalating their trade friction by widening their restrictive scope: but so far, irrevocable actions have not been taken. This is a geopolitical gamble – how can global governments press for greater stability between the superpowers? How to prevent a new cold war? What means of dialogue and engagement are feasible?

- **Anson Chan**, Chairman, Bonds Group of Companies, Hong Kong SAR
- **Hans-Peter Friedrich**, Vice-President, German Bundestag, Germany
- **Victor Gao**, Vice President, Center for China & Globalization, China
- **Orville Schell**, Director Center on US-China Relations, Asia Society, USA
- **Shirley Yu**, Asia Fellow, Ash Center, Harvard Kennedy School, USA

Chaired by

- **Jay Cao**, Bureau Chief London, Phoenix TV, United Kingdom

Horasis

The Global Visions Community

Developing Digital Prowess

We must ensure all understand STEM (Science, Technology, Engineering and Math) skills as the world is moving to an interlocked digital delivery of political, social and commercial knowledge which will encompass anti-Covid social distancing. How can businesses partner with counterparts in the developing work to raise their abilities? What is needed to accomplish this to open opportunities?

- **Joel Bomisso**, Chief Executive Officer and Founder, Shaivi-Tech, Cote D'Ivoire
- **Silvano Coletti**, Managing Director, Chelonia SA, Switzerland
- **Bernard Moon**, Co-founder and Partner, SparkLabs Group, USA
- **Keshav R. Murugesh**, Group Chief Executive Officer, WNS Global Services, India
- **Viraj Phanse**, Fellow, Berkeley Angel Network, USA

Chaired by

- **Bruce Muirhead**, Founder and Chief Executive Officer, MindHive, Australia

Family Business: How to Shape the next Chapter post-COVID?

By the 3rd generation, the majority of a family's wealth is lost as younger generations' values disintegrate, lack the all-important work ethic or seek to implement new non-traditional investment strategies more aligned with millennials mindsets. Can this change happen in harmony with a constantly changing environment? What best practices and tools are available to embrace technology, innovation and entrepreneurial thinking in this critical area, especially post-COVID?

Chaired by

- **Rebeca Hwang**, Professor, Thunderbird School of Global Management, USA

The Future Role of the Digital Leader

Business leaders need to think digital in the age of COVID-19 – they must be agile and build organizations that embraces change and manage them effectively. How can companies use digitalization to stay afloat and stay relevant? Are social media and other always-on connections as good as face-to-face meetings as ideas and negotiations are thrashed out? What is the future role of digitized business leaders?

- **Aniel Autar**, Managing Partner, Kooijman Autar, The Netherlands
- **Prinn Panitchpakdi**, Deputy Leader, Democrat Party, Thailand

Chaired by

- tbc

Equitable Development of South-East Asia

The region comprises many big contrasts – small states and large countries, very rich to the poorest, some with traditionally open economies others just emerging from years of isolation: there is no unique mode of development. What inequality, where, ought to be addressed first? Will the receiving nation affected by COVID accept aid without feeling humbled?

- **Ira Kiener**, Co-Founder, Chairman & Chief Executive Officer, Dealogikal, The Philippines
- **Nuttakorn Rattanachaisit**, Founder & Managing Director, Predictive, Thailand
- **Eri Reksoprodjo**, Managing Partner, Kejora Ventures, Indonesia
- **Eddie Thai**, Partner, 500 Startups, Vietnam
- **Kanesan Veluppillai**, Partner, INSYNQ Partners Group, Malaysia

Chaired by

- **Vikram Khanna**, Associate Editor, The Straits Times, Singapore

Horasis

The Global Visions Community

08.45-08.50 Introduction: Extraordinary Times demand Extraordinary Transformation
Horasis welcomes participants to the inaugural Horasis Extraordinary Meeting. The world will not go back to a New Normal by simplistically resetting legacy systems – extraordinary times demand an extraordinary transformation. How to advance this post-COVID transformation - envisioning and implementing novel business models new political cooperation and deep social cohesion?

Chaired by

• **Frank-Jürgen Richter**, Chairman, Horasis, Switzerland

08.50-09.30 Opening Plenary: Unite. Inspire. Create.

Global accords have been broken by edict at a time when nations need to unite and fight common battles – and to ultimately combat COVID-19 for equable growth and security. Action plans emerge that inspire sections of communities, but we need to be united and creative – and on a new base, reach for the future. Who can do this, which nation will lead? What are the fundamentals we need to address?

• **Hage G. Geingob**, President of Namibia, Namibia

• **Iliana Iotova**, Vice President of Bulgaria, Bulgaria

Chaired by

• **Axel Threlfall**, Editor-at-Large, Reuters, United Kingdom

09.30-10.15 Plenary Sessions

Nurturing Inclusive Leadership

Many of the world's leaders continue to support inward-looking goals even in the face of the COVID pandemic. How to develop and deploy international leadership within quarantine chaos given the geopolitical fault lines? Can accords be found in the face of anti-globalization – substituting united policies to lift inspiration and creativity?

• **Rania A. Al-Mashat**, Minister of International Cooperation, Egypt

• **Vera Daves de Sousa**, Minister of Finance, Angola

• **HH Princess Märtha Louise of Norway**, Norway

• **António Vitorino**, Director General, International Organization for Migration (IOM), Switzerland

Chaired by

• **Nik Gowing**, Founder and Director, Thinking the Unthinkable, United Kingdom

Worldwide Update on COVID-19

The COVID-19 pandemic has proved difficult for epidemiologists to quantify; it is highly contagious and often passed by asymptomatic persons. How should we combat any second wave? Without any treatments or vaccines at present how to protect vulnerable communities?

• **Julie Anne Genter**, Minister for Women, Associate Minister for Health, New Zealand

• **Adam Vojtěch**, Minister of Health, Czech Republic

Chaired by

• **tbc**

10.15-11.00 Parallel Sessions

Where are we at? Where are we Going?

The world's economic and geo-political framework has been increasingly characterized by uncertainties. The current COVID-19 pandemic has heightened those uncertainties in a big way. How and to where ought we to navigate? What are the choke-points and how might we redefine them as opportunities to establish confidence?

- **Shaukat Aziz**, Former Prime Minister of Pakistan, Pakistan
- **Nikhil Seth**, Executive Director, United Nations Institute for Training and Research, Switzerland
- **Supachai Panitchpakdi**, Former Secretary-General, UN Conference on Trade and Development (UNCTAD), Thailand
- **Jacob Sotiriadis**, Chief Strategic Foresight, United States Air Force, USA
- **Ranil Wickremesinghe**, Former Prime Minister, Sri Lanka

Chaired by

- **Richard Lister**, Writer and Broadcaster, United Kingdom

Covid Pandemic and the Force of Impact Investing

Pre-Covid impact Investors were beginning to favor sustainability and diversity. The lockdown chaos has altered the investment landscape but impact investment continues. What effect is it having regarding climate change and the SDGs goals? And how to inspire investors to transit from theory to practice fostering opportunities for action?

- **Ben Banerjee**, President, Swiss Impact Investment Association, Switzerland
- **David Carlisle**, Chairman, Holoscribe, United Kingdom
- **Rodria Laline**, Chairwoman, Intrabond Capital, Hong Kong SAR
- **Scott Mackin**, Managing Partner, Denham Capital Management, United Kingdom
- **Leon Toh**, Executive Director, Damson Capital, Singapore

Chaired by

- **Hannah Wise**, Anchor, CNN Money, Switzerland

Stronger Together as Us not Them

Too often we have a divisive us/them pitted against each other, but we are stronger when we unite and are inspired to creatively work together. How best to achieve this in a post-COVID world that is inward looking? How do we refashion our attitudes?

- **Harald Einsmann**, Member of the Supervisory Board, Tesco, United Kingdom
- **Evin Incir**, Member of the European Parliament, European Union
- **Venkat Matoory**, Institutional Advisor, India
- **Irvandias Sanjaya**, Chief Executive Officer, Designfordream.id, Indonesia
- **Ricardo Viana Vargas**, Executive Director, Brightline Initiative, USA

Chaired by

- **Shivaji Bagchi**, Managing Editor, Unravel, India

Horasis

The Global Visions Community

Millennials and Generation-Z: Shaping the Far Future

The Millennials and Gen-Z will soon comprise two thirds of the global workforce, but their COVID-caused loss of education and employment has reduced their potential across the world. How can we engage their creativity to inspire a better global compact? What are the best ways for our current leadership to support and inspire the young?

- **Vijay Eswaran**, Chairman, QI Group, Hong Kong SAR
- **Jacob Larsson**, Future Thinker and Advisor, Global Utmaning, Sweden
- **Kevin Lee**, Chief Operating Officer, China Youthology, China
- **Amandeep Midha**, Founder, Nerd9, Denmark
- **Aleksandr Stommels**, President, Circle of Sustainable Europe, Belgium

Chaired by

- **Marcelo Garcia**, Founder, WisdomAccelerator.org, Switzerland

Being Competitive breeds Economic Leadership

Being a leader comes from a sense of competitiveness and following through new ideas offering better economic values. How can they unite and transform economies for the better? What new post-COVID economic models are on offer? And how to make our societies and economies more sustainable, inclusive and long-term orientated?

- **Jaloul Ayed**, Chairman, MED Confederation; Former Minister of Finance, Tunisia
- **Luca Jahier**, President, European Economic and Social Committee, European Union
- **Enzo Quattrocio**, Secretary General, EBRD, United Kingdom
- **Diana Sabrain**, Co-founder, OneAgrix, Singapore
- **Marguerite Soeteman-Reijnen**, Chairman Executive Board, Aon Holding, The Netherlands

Chaired by

- **Courtney Fingar**, Editor-in-chief FDI, NS Media Group, United Kingdom

Artificial Intelligence as a Force for Good

For all its hype in post-COVID digital mania, Artificial Intelligence (AI) alone cannot complete diverse tasks: it has to be trained in a specific action domain and its training is subject to human bias. AI can be a very powerful amplifier of human endeavor, and can inspire our future creativity. How can we ensure it is always working for us? How can we ensure it acts ethically?

- **Ayla Annac**, Chief Executive Officer, InvivoSciences, USA
- **Rana Gujral**, Chief Executive Officer, Behavioral Signals, USA
- **Jean Lehmann**, Chief Executive Officer, Cyber Capital HQ, United Kingdom
- **Sami Mahroum**, Affiliate Professor, Solvay Business School, Belgium
- **Julien Weissenberg**, Founder, VisualSense AI, Switzerland

Chaired by

- **Gurvinder Ahluwalia**, Founder and Chief Executive Officer, Digital Twin Labs, USA

Horasis

The Global Visions Community

The Arts Supporting Leadership Transformations

Patrons of the Arts were sometimes shocked to observe an artist's portrayal of their patron's alter-ego: today Arts can transcend difficulties. How can patrons support great works through the Great Isolation of COVID? What roles do artists play in the processes of leadership transformations? And how can artists offer hope during the COVID crisis?

- **Petra Becker**, Founder & Chief Executive Officer, International Art Bridge, Germany
 - **Metin Guvener**, Founding Chairman, The Salon, United Kingdom
 - **Abdul Aziz Rajab**, Chairman, Rajab Group, UAE
 - **Carla Riggi**, Founder and Chief Executive Officer, BandDjinni, USA
 - **Neil Lawson-May**, Joint Chief Executive, Palatium Investment Management, United Kingdom
- Chaired by*
- **Alistair Hicks**, Writer and Art Curator, United Kingdom

Reconstructing our Supply Chains

Our supply chains have been broken by the COVID pandemic, by the de-globalization efforts of populist actions and by conflicted global leadership - we must again rebuild. Obtaining materials from the best sources is the goal of good management – how best to do this? What are the impediments? What leadership skills are needed to overcome the constraints of COVID?

- **Kareem Alkaseer**, Chief Executive Officer, MentorLycon, Russia
 - **Jean-François Geneste**, Chief Executive Officer, Warpa, France
 - **Alexander R. Malaket**, President, OPUS Advisory Services International Inc, Canada
 - **Hugo Roppel**, Chairman, GLG Logistics Systems, Switzerland
 - **David K. Young**, Chief Executive Officer, Oxford Analytica, USA
- Chaired by*
- **Wolfgang Lehmacher**, Associate Director, Corporate Value Associates, Hong Kong SAR

The New Unicorn Ventures

The Unicorn concept – the 1\$b private company – is young, yet many such firms have matured into the public market. Who will replace them, or are they a dying breed? In post-COVID times, in an isolationist culture, is there less scope for a Unicorn? What is the next Phoenix firm? How should they be mentored to develop their creative progress?

- **Parag Amin**, Chief Mentor and Founding Director, iCreate, USA
 - **Mario Aquino**, Chief Executive Officer, FutureLabs, Singapore
 - **Terry von Bibra**, Director, Numenos, Germany
 - **Katherine Kan**, Co-founder, Rovilus, Taiwan
 - **Yossi Vardi**, Chairman, International Technologies, Israel
- Chaired by*
- **Annette Nijs**, Former Cabinet Minister for Education, Science and Culture, The Netherlands

Horasis

The Global Visions Community

The Benefits of Managed Philanthropy

Philanthropy is like any other business, its application and results must be measured and judged. This need is greater than ever post-COVID. Why do some oppose measurement that ensures the inspirational application of needed funds? Who will offer insights to exemplary donor-fund management? Is there a most-favored investment sector?

- **Ebenezer Kwame Addo**, President, Travel Center Enterprise, Ghana
- **Sami Agli**, President, Forum des chefs d'entreprise, Algeria
- **Michael Carlos**, Member of the Supervisory Board, Givaudan, Switzerland
- **Pierre E. Cohade**, Member of the Supervisory Board, Johnson Controls, USA
- **Grace Sabandar**, Chief Executive Officer, Global Business Services, Indonesia

Chaired by

- **Jane Dudman**, Public Leadership Editor, The Guardian, United Kingdom

Business Toughness During COVID-19

Strategic management is being tested during the unique COVID pandemic, and many firms demand more cash be available to make their regular activities more resilient. What more can be done to support firms? Will leaders be strong enough to take far-reaching decisions while facing potential bankruptcy? What is the best role for governments?

- **Ed Bullecer**, Chief Executive Officer, Paglas Group, Philippines
- **Ananda Setiyo Ivannanto**, Chief Executive Officer, A-Wing Group, Indonesia
- **Tadahiro Kawada**, President, Kawada Technologies, Japan
- **Shashi Kiran Shetty**, Chairman, Allcargo Logistics Limited, India
- **Hayley Warren**, Chief Executive Officer, HALO Medical Devices, USA

Chaired by

- **Tariq Ahmed Nizami**, Founder & Chief Executive Officer, CEO Clubs Network Worldwide, UAE

Austerity or Plenty– Weathering the Economic Crisis

Across the globe Central Banks are pressing cash into their economies to support the rapid economic downturn caused by COVID-19 halting production and consumption, though to be fair, that trend was beginning pre-COVID. How should governments avoid the trap of austerity as they recuperate these massive fiscal stimuli? How can the service and productive sectors contribute to an upturn in the economy?

- **Alain Godard**, Chief Executive, European Investment Fund, Luxembourg
- **Winston Mok**, Private Investor and Columnist, South China Morning Post, China
- **Lilyana Pavlova**, Vice President, European Investment Bank, Luxembourg
- **Russell Saunders**, Member of the Supervisory Board, SWIFT, United Kingdom
- **Bart Turtelboom**, Chief Executive Officer, AFQ Global, Guernsey

Chaired by

- **Saruhan Hatipoglu**, Chief Executive Officer, BERI, USA

Global Solidarity: Impact of Sports and Movies

While individuals steer uprisings, it is the Sports and Movie industry who emphasise it by their immediacy worldwide. How can this Industry play that balancing, responsible role globally to inspire today's Youth for an inclusive, aspirational, yet sustainable life? What challenges exist and how do we work together to make this happen?

- **Jeev Milkha Singh**, Professional Golfer, India

Chaired by

- **Niraj Sharan**, Chairman and Chief Executive Officer, Aura, India

Horasis

The Global Visions Community

The Greater Caspian Region: Spearheading Shared Leadership

The Greater Caspian Region has always been at the crossroads of geopolitical and economic interests of a number of major powers. With the signing of the Convention on the Legal Status of the Caspian Sea creating greater certainty around waterways and oil and gas reserves: what is next, particularly now in times of the pandemics? What are the Region's most pressing needs?

• **Daniel Zaretsky**, Co-Founder, World Influencers Network, Uzbekistan

Chaired by

• **Murat Seitnepesov**, Chairman, Caspian Week, Switzerland

11.00-11.45 Plenary Sessions

Developing New Leadership and Inspiration

Global leaders are reluctant to inspire others to join in mutually beneficial ventures: nationalism and protectionism have come to the fore. How to break this cycle? What are the steps we need to take to structure new progress? How are global leaders going to unite and inspire their people?

• **Nina Angelovska**, Minister of Finance, North Macedonia

• **Dalibor Jevtic**, Minister for Communities and Return, Kosovo

Chaired by

• **Spriha Srivastava**, Executive Editor for Europe, Business Insider, United Kingdom

The Potentials for South Asia

All nations across South Asia have been battered by the COVID-19 pandemic as well as occasionally by geo-political tension: but they offer hope for the world if they succeed in mutually beneficial growth. How should they begin, what are their most difficult tasks? What is SAARC's (South Asian Association for Regional Cooperation) role in boosting regional integration?

• **V.K. Singh**, Minister of State for Road Transport and Highways, India

Chaired by

• **Binod K. Chaudhary**, President, Chaudhary Group, Nepal

11.45-12.30 Plenary: The Global Imperative - How to Achieve the SDGs?

The UN Sustainable Development Goals (SDGs) were adopted to devise ways to protect the planet and human mankind. Many nations have struggled to meet their intermediate goals and the work is suffering in the COVID-19 pandemic. How to get back on track? How do we instigate more unity and creative solutions?

• **Carmelo Abela**, Minister Within the Office of the Prime Minister, Malta

• **Ibrahima Guimba-Saidou**, Minister and Special Advisor to the President of Niger, Niger

• **Tatiana Valovaya**, Director-General, United Nations Office at Geneva, Switzerland

• **Lindiwe Zulu**, Minister of Social Development, South Africa

Chaired by

• **Rosalind Mathieson**, Executive Editor, International Government, Bloomberg News, United Kingdom

Horasis

The Global Visions Community

11.45-12.00 Why we Must Think as Citizens

Adverse economic change is undermining the foundations of liberal democracy. The response must be to cease thinking of ourselves predominantly as self-seeking individuals or our companies as solely focused on pursuit of profit. We must think of ourselves as democratic citizens, responsible for the fate of both our own societies and the world.

- **Martin Wolf**, Chief Economics Commentator, Financial Times, United Kingdom

12.30-13.15 Parallel Sessions

COVID-19: The Elephants in the Room

New strategic analyses are needed to cope with unknown unknowns, or events with Elephants in the Room having consequences that are imagined but suppressed. What will it take to develop the new decisive manager? Are we too subject to government whims and suppressed by regulators that nullify our inspiration and creativity?

- **Tarun Anand**, Chairman and Founder, Universal Business School, India
- **Shailendra Goswami**, Chairman and Managing Director, Pushkaraj Group, India
- **Adam A. Jacoby**, Founder and Chief Steward, MiVote, Australia
- **John Studzinski**, Vice Chairman, PIMCO, USA
- **Edsel Tupaz**, Partner, Gorriceta Africa Cauton & Saavedra, The Philippines

Chaired by

- **Patricia Falco Beccalli**, Chief Executive Officer, Principle AG, Switzerland

Inspirational Leadership through and beyond COVID-19

An inspirational leader serves the needs of his/her employees, listens, and develops trust. Are there international differences that make leadership comparisons difficult, or are there discernable absolute traits? Can exceptional leadership be taught? How long does it take to develop globalized management skills dedicated to inspire the future?

- **Emma Arakelyan**, Co-founder and Chief Executive Officer, Orion Worldwide Innovations, USA
- **Igor Izraylevych**, Co-Founder and Chief Executive Officer, S-PRO, Ukraine
- **Anna McCoy**, Chief Executive Officer, Anna McCoy Global Ventures, USA
- **Alf Rehn**, Professor of Innovation and Design, University of Southern Denmark, Denmark
- **Aditya Singh**, Director, Athena School of Management, India

Chaired by

- **Margarita Mayo**, Professor of Leadership, IE Business School, Spain

Digitalization for the Economic Recovery

The rapid migration to digital technologies driven by COVID-19 will continue into the economic recovery. How can new technologies be deployed faster as COVID has demonstrated the needs? And how can digitalization remain the new engine of growth post-COVID?

- **Stefano Bianchi**, Founder and Chief Executive Officer, It Is The End, United Kingdom
- **Usama Fayyad**, Chairman and Chief Executive Officer, Open Insights, USA
- **Lorenz Granrath**, Coordinator, National Institute of Advanced Industrial Science and Technology (AIST), Japan
- **Mohit Joshi**, President, Infosys, United Kingdom
- **Rob Leslie**, Founder, Sedicii, Ireland

Chaired by

- **Ganesh Natrajan**, Chairman, 5F World, India

Horasis

The Global Visions Community

Sustainable Development: Unlikely Collaborators and Innovators

To realize Sustainable Development, it will take not just a whole of government approach, but a whole of society approach: to collaborate, to inspire, and create change. How do we engage unorthodox actors and empower their work together - and how can completely different industries and sectors find unlikely collaborators who will revolutionize the changes that we require post-COVID?

- **Matthias Bosch**, Founder, Bosch Jehle, Germany
 - **Payal Dalal**, Senior Vice President, Social Impact, International Markets, Mastercard Center for Inclusive Growth., United Kingdom
 - **Florian Kemmerich**, Managing Partner, Bamboo Capital Partners, Switzerland
 - **Mirjana D. Perko**, Chairperson, inCon, Slovenia
 - **Christoph von Toggenburg**, Chief Executive Officer, World Vision Switzerland, Switzerland
- Chaired by*
- **Lou Marinoff**, Professor of Philosophy, City College of New York, USA

Rekindling Education Post-COVID

The global pressure to self-isolate as the only protection against COVID transmission pushed children into household education: they have lost vital days and months of formal learning. How can this be recovered? What minimum skills must be taught for our future survival?

- **Ahoud Alshaikh**, School Governor, London Borough of Hounslow, United Kingdom
 - **Marklen Konurbaev**, Professor, Moscow State University, Russia
 - **Michele Notari**, Professor, Bern University of Teacher Education, Switzerland
 - **Sandeep Pachpande**, Chairman, ASM Group of Institutes, India
 - **Jim Yuan**, Co-founder and Partner, Joyview Education, China
- Chaired by*
- **Andrei Sharonov**, President, The Moscow School of Management SKOLKOVO, Russia

Regeneration or Evolution of Cities

Cities grew to serve many - attracting innovators, merchants and tourists. How might our over-grown cities evolve? Post-COVID, we are fearful of over-crowding, so should we completely rebuild nearby according to some grand open plan? Is any plan suitable for global imitation?

- **John Batten**, Executive Vice President, Arcadis, USA
 - **Catherine Carlton**, Council Member and Former Mayor, Menlo Park, USA
 - **Marianela Mirpuri**, Founder, Hera, Portugal
 - **Magnus Qvant**, Secretary General, Resilient Regions Association, Sweden
 - **Bernd Vöhringer**, Mayor, City of Sindelfingen, Germany
- Chaired by*
- **Sergio A. Fernández de Córdova**, Chairman, P3SmartCity & PVBLIC Foundation, USA

Horasis

The Global Visions Community

Building Peace

Mankind wants peace – but it has been hardly achieved, neither today nor in ancient times. Despite our sophisticated global governance systems there is still much violence expressed by countries, regimes and individuals on others. How does the pandemic affect the risk of violent conflict and prospects for peace around the world? How to resolve violent conflicts by peaceful means?

- **Arslan Chikhaoui**, Executive Chairman, NSV Consultancy & Studies Centre, Algeria
 - **Ahmad Wali Masoud**, Chairman, Massoud Foundation, Afghanistan
 - **Faisal Bin Muaammar**, Secretary General, KAICIID Dialogue Centre, Austria
 - **Sekai Holland**, Chairperson of Board of Trustees, Zimbabwe Peacebuilding Initiative, Zimbabwe
 - **Canon Sarah Snyder**, Archbishop of Canterbury's Adviser for Reconciliation, United Kingdom
- Chaired by*
- **Yasmin Ahmed**, Legal and Sanctions Adviser, Office of the President of Somalia, Somalia

We are Living Longer

In the 1900s global life-expectancy was only 31 years, now it exceeds 72 years: governments' pension provisions and social care costs (especially now in times of COVID-19) are under pressure. How can science and business collaborate with governments to tackle the many issues concerning their aging societies? And what are the secrets of longevity, and how can everybody live a long live?

- **Ciara Clancy**, Chief Executive Officer, Beats Medical, Ireland
 - **Greg Crichton**, Managing Director, Greater Asian Advisors Limited, Hong Kong SAR
 - **Peje Emilsson**, Founder and Chairman Silver Life, Sweden
 - **Gary Phillips**, Chief Executive Officer, OrphoMed Inc, USA
 - **Tina Woods**, Director General, All Party Parliamentary Group for Longevity, United Kingdom
- Chaired by*
- **Kenji Yokoyama**, President, Association of Asia Pacific Business Schools, Japan

Deriving Ideas for Start-ups

Often start-up ideas arise round a table, in a meeting, in a congress or hi-tech exhibition: all have been banned due to anti-COVID-19 policy. Have start-ups reduced during home-work modes? All support modes continue, but in lock-down and so not functioning well – how to find an entry point to this aid? How have start-ups managed to secure mentoring, financial assistance and venture capital?

- **Ben Costantini**, Chief Executive Officer, Startup Sesame, France
 - **Osakuade Ifeoluwa**, Chief Executive Officer, NEO360 Africa, Nigeria
 - **Liesbet Peeters**, Managing Partner, Volta Capital, United Kingdom
 - **Yoshiki Sasaki**, Chief Executive Officer, Japan Strategic Capital, Japan
 - **Ragnar Sigurdsson**, Chief Executive Officer, AwareGO.com, Iceland
- Chaired by*
- **Pieter Perrett**, Professor, University of Applied Sciences Northwestern Switzerland, Switzerland

Horasis

The Global Visions Community

Global Coordination to Conquer the Effects of COVID

The COVID Pandemic has shocked governments and enterprises alike and has created a unique need to create counter-measures across many fronts: fiscal, social and humanitarian. What has to be done to recover our former stability? Will global institutions be effective against COVID and all its many ravages? How to develop cooperation across nations to inspire mutual support?

- **Vicente Abad**, Chief Executive Officer, Romantic Capital, Spain
 - **Hedwige Nuyens**, Managing Director, International Banking Federation, United Kingdom
 - **Jayesh Ranjan**, Principal Secretary, Government of Telangana, India
 - **Ismail Serageldin**, Founding Director, Library of Alexandria, Egypt
 - **Christoph Stueckelberger**, Founder and President, Globethics.net Foundation, Switzerland
- Chaired by*
- **Suhasini Haidar**, Diplomatic Editor, The Hindu, India

Social Investment for Competitive Green Economies

The global COVID pandemic is causing vast changes to work modes in the developed world and a noticeable reduction in atmospheric pollution as economic activity reduces. How ought we to invest to increase the social involvement of everyone in developed and developing economies? How will green economies present competitiveness, and would these have global potential?

- **Michael Johnston**, Member of the Board, The Capital Group Companies, USA
 - **Senida Mesi**, Member of Parliament; Former Deputy Prime Minister, Albania
 - **Mridula Ramesh**, Founder, Sundaram Climate Institute, India
 - **Ingrid Rodriguez**, Founder and Managing Director, Eikonic, Australia
 - **Sein-Way Tan**, Chairman, Green World City, Australia
- Chaired by*
- **Sean Cleary**, Chairman, Strategic Concepts, South Africa

An Avenue for Peace, Security and Sustainable Development: The African Peace Engineering Corps

Over the past decade, Africa has seen an encouraging shift in global narrative. However, and in spite of the overall progress, there are still significant challenges related to peace and security. How can Africa leverage multilateralism to promote dialogue and understanding in enhancing sustainable peace and security? What is the potential of an African Peace Engineering Corps?

- **Ernest Bai Koroma**, Former President of Sierra Leone, Sierra Leone
- Chaired by*
- **tbc**

Horasis

The Global Visions Community

Strengthening Foreign Direct Investment

Even before the COVID pandemic global GDP was falling and thus the appetite for Foreign Direct Investment (FDI). Which countries will be most affected and what will the effect be of lower FDI? How can FDI be boosted to spur their economic and social development?

- **Clare Akamanzi**, Chief Executive Officer, Rwanda Development Board, Rwanda
- **Teka Gebreyesus**, State Minister of Trade and Industry, Ethiopia
- **Richard Isava**, Chief Executive Officer, GBTI Bank, Guyana
- **Dinesh Joshi**, Chairman and Managing Director, SatyaGiri Ventures, India
- **Stephen Phillips**, Director General, Invest Hong Kong, Hong Kong SAR

Chaired by

- **Bindu Dalmia**, National Chairperson, Committee for Financial Inclusion, Niti Aayog, India

Advancing Armenia's Knowledge-based Economy

Despite the global COVID-induced economic uncertainties, the Armenian economy is expected to grow in the years to come. Armenia's strategic planning for growth across its knowledge-based economy is of paramount importance. How can the country nurture benevolent disruption and innovation? And what does Armenia's investment landscape look like?

- **Armen Sarkissian**, President of Armenia, Armenia

Chaired by

- tbc

United Kingdom: Brainstorming on the Future, post-Brexit

Following many setbacks, the Brexit process beginning with the UK referendum in 2016 will be completed by December 2020. What will this mean for the UK, for Europe and the world? How will it affect ex-patriots, our global warriors? How will economies change, particularly now with COVID? With whom will major trade agreements be developed?

- **Lord Karan Bilimoria**, President, Confederation of British Industry, United Kingdom
- **Lord John Bird**, Member of the House of Lords; Fonder, The Big Issue, United Kingdom
- **Jeffries Briginshaw**, Chief Executive Officer, Transatlantic Business Britain, United Kingdom
- **Baroness Susan Kramer**, Member of the House of Lords, United Kingdom
- **David Lidington**, Former Minister for the Cabinet Office, United Kingdom

Chaired by

- **Chris Morris**, Senior, Correspondent, BBC News, United Kingdom

13.15-14.00 Digital Lunch Sessions

Lunch Plenary: Climate Change Commitments have not Receded

The COVID pandemic and lock downs have automatically reduced pollution making cities appear clean. But what will occur on the resumption of commerce – are businesses actively evolving de-carbonizing policies? How can businesses adapt to international environmental concerns? What changes are being considered by governments to mitigate climate change?

- **Jean Claude Gakosso**, Minister of Foreign Affairs, Congo
- **Petteri Taalas**, Secretary-General, World Meteorological Organization, Switzerland

Chaired by

- tbc

Horasis

The Global Visions Community

Working Lunch: Horasis Community Building and Networking

Please prepare your own food and enjoy it whilst sitting in front of your screen and continue to engage with participants. Horasis is providing a matchmaking tool to connect with other delegates - each participant will be randomly matched with another to speak for 5 minutes by video, then become paired with another, and so on.

14.00-14.45 Plenary: The Global Economic Outlook

The co-evolution of global pressures – trade disputes, the joint failure of supply and demand, the oil price dispute, plus the effect of the COVID-pandemic leads to speculation of recovery. Can we expect a V-shape, U-shape, L-shape recovery? How to avoid a global depression similar to the one of 1929? And how to re-ignite innovation and creativity through a vision of unity?

- **Nitin Gadkari**, Minister for Road Transport & Highways, India
 - **Mothanna Gharaibeh**, Minister of Digital Economy and Entrepreneurship, Jordan
- Chaired by*
- **Gerard Baker**, Editor at Large, Wall Street Journal, USA

14.45-15.30 Plenary: Celebrating UN 75 - Multilateralism in Times of COVID

To mark its 75th anniversary the United Nations is conducting a global conversation – across borders, sectors and with all generations. The onset of COVID has brought a new urgency to this conversation, highlighting even more the benefits of multilateralism. What needs to be done to make the world a better place? And how to aid the UN's quest?

- **Nana Akufo-Addo**, President of Ghana, Ghana
 - **Shamma Al Mazrui**, Minister of State for Youth Affairs, UAE
 - **Armen Sarkissian**, President of Armenia, Armenia
 - **Kassym-Jomart Tokayev**, President of Kazakhstan, Kazakhstan
- Chaired by*
- **Fabrizio Hochschild**, Under-Secretary General, Special Adviser on Preparations for 75th United Nations Anniversary, United Nations, USA

15.30-16.15 Parallel Sessions

United Nations: The Next 75 years... for our Children and Grandchildren

Though the present stresses on our planet are considerable, the future is likely to be even more challenging. What will the UN mean to our children and grandchildren, and how will it help them address nuclear proliferation, rising sea levels, hunger, war, inequality, pestilence and tribalism... survival and their very future? How best can the UN keep them safe and empower their hopes and dreams?

- **Stuart E. Eizenstat**, Former US Deputy Secretary of the Treasury, USA
 - **Fabrizio Hochschild**, Under-Secretary General, Special Adviser on Preparations for 75th United Nations Anniversary, United Nations, USA
 - **Simón Levy**, Chairman, The Ideas Fund, Mexico
 - **Jane Wurwand**, Founder, Dermalogica, USA
- Chaired by*
- **Peter Samuelson**, Chief Executive Officer, PhilmCo Media LLC, USA

Horasis

The Global Visions Community

Catalyzing Capitalism through Public-Private Partnerships

Post-COVID Capitalism is in crisis - excessive short-term focus is hurting companies' ability to create value and purpose in the long run. Can Public-Private Partnerships create a social dimension to capitalism? How can the public and the private sector cooperate post-COVID to create a better, more inclusive world?

- **Nico Anten**, Executive Chairman, Connekt, The Netherlands
- **Alan Lau**, President, Anglo Euro Energi Indonesia, Indonesia
- **Peter Lazou**, Founding Member, Otherdots Foundation, United Kingdom
- **Viljar Lubi**, Vice Minister of Economic Affairs and Communications, Estonia
- **Teresa Ribeiro**, Secretary of State of Foreign Affairs and Cooperation, Portugal

Chaired by

- **Peter McGill**, Contributing Editor, The Banker, United Kingdom

Redefining Human Resources Management as Human Relations

Human Resources Management has gained a business foothold, but it ought to return to its roots, especially now post-COVID – focusing on human welfare: to inspire the wide variety of human relations. How will better understanding of human relations unite all businesses? There is no 'one size fits all', so how long will it take for this new management to evolve?

- **Shoummo K Acharya**, Chief Executive Officer, eTrans Solutions, India
- **Türker Bas**, Professor, Galatasaray University, Turkey
- **Christine Pearson**, Professor, Thunderbird School of Global Management, USA
- **Marina Schmatova**, Member of the Scientific Council, Financial University under the Government of the Russian Federation, Russia

Chaired by

- **Timothy J. Nichol**, Dean, Liverpool Business School, United Kingdom

Strategic Infrastructure Investment

History notes how economies are boosted after new infrastructures enable better interactions, but many governments have let slip these investments. Now, with their massive fiscal intervention concerning COVID, how will they get the cash for needed infrastructure building? Have businesses the capacity to react and drive the rebuilding? Are new models of Public/Private investment needed?

- **Cedric Brusselmans**, Founder, Euroasia, France
- **Jürgen Reinert**, Chief Executive Officer, SMA Solar Technology, Germany
- **Paul Clark**, Former Parliamentary Under Secretary of State, United Kingdom
- **Vitaly Vanshelboim**, Assistant Secretary-General, United Nations Office for Project Services, (UNOPS), Denmark
- **Michael Wilson**, Managing Partner, The Migson Group, Ghana

Chaired by

- **Andrew Cave**, Business Columnist, Daily Telegraph, United Kingdom

Horasis

The Global Visions Community

Developing Emotional and Cultural Intelligence during the Pandemic

Emotional Intelligence (EI) is one of the most heavily tested skills throughout the pandemic. With EI comes a greater personal insight about how we unite and inspire others. How can we ensure this is taught to children and developed through college level in all subjects? Will EI help overcome gender and cultural differences?

- **Donny Huang**, Founder and Managing Director, 4stones, China
- **Carolyn Buck Luce**, Co-Founder, Imaginal Labs, USA
- **Elizabeth Markle**, Executive Director and Founder, Open Source Wellness, USA
- **Scott Mordell**, Chief Executive Officer, YPO, USA
- **Long Viet Nguyen**, Deputy Chief Executive Officer, Becamex IDC, Vietnam

Chaired by

- **Maxim Kiselev**, Professor, Skolkovo Institute of Science and Technology, Russia

Preparing for an Entrepreneurial Gale Post-COVID

The incessant creative destruction of the old was called a gale by economist Joseph Schumpeter. The isolation caused by COVID-19 has thwarted innovators, but they are indestructible: they are creators. How can we ride this gale and innovate for a common good? What are the strategies of entrepreneurs for inspiring in this new age?

- **Tris Dyson**, Founder and Managing Director, Nesta Challenges, United Kingdom
- **Francisco Estevan**, Chief Executive Officer, Innsomnia, Spain
- **Dariusz Gibasiewicz**, Chief Executive Officer, SATIS, Poland
- **Hans Hosenfeld**, Founder, Archisave, Germany
- **Adriaan Ligtenberg**, Founder and Chairman, SparkHealth, The Netherlands

Chaired by

- **Tim Hinchliffe**, Editor-in-Chief, The Sociable, Colombia

Developing Deep Learning while in Isolation

The need for Deep Learning (the combination of AI and machine learning) spans industrial, commercial, scientific and service sectors but most developers have been in lockdown. How can we ensure the access to data to develop deep learning? How can we judge the results of these systems if we remain isolated? Are we educated well enough to judge?

- **Andrew McGregor**, Director and Founder, Oomvelt Research, USA
- **Michelle N. Moore**, Founder, MindEquity, Canada
- **Toufi Saliba**, Chief Executive Officer, Toda.Network, USA
- **Lila Tretikov**, Corporate Vice President, Microsoft, USA

Chaired by

- **Mark Mueller-Eberstein**, Chief Executive Officer and Founder, Adgetec Corporation, USA

The Changing Future of Work

Robots are taking over our jobs leading to massive unemployment. The COVID pandemic showed our versatility in moving to home-work where possible but we enjoy gathering for work and play – what will the future of work really be like? How to absorb redundant staff through greater investment in as yet unknown industries? How to create these opportunities?

- **Ruben Atekpe**, Executive Chairman, Merchant Company of West Africa, Ghana
- **Andreas Irmen**, Professor of Economics, University of Luxembourg, Luxembourg
- **Jed Rakoff**, Senior Judge, United States District Court for the Southern District of New York, USA
- **Luca Visentini**, General Secretary, European Trade Union Confederation (ETUC), Belgium
- **Naeem Zafar**, Co-founder and Chief Executive Officer, TeleSense, USA

Chaired by

- **Riva Gold**, Editor, Daily News, LinkedIn News, United Kingdom

Horasis

The Global Visions Community

Overcoming Gender Inequality

Women and girls are still constrained by inequalities and by differences in power, privilege and opportunity. And the lock-down triggered by COVID-19 is taking a disproportionate toll on women in the labor market. How can their economic, social and mental well-being be protected? Post-COVID how will women's rights to gender equality be guaranteed?

- **Janine de Nysschen**, General Manager, Sweden Ghana Medical Centre, Ghana
- **Bukky Shonibare**, Executive Director, Invictus Africa, Nigeria
- **Ray Walshe**, Chair of Gender Responsive Standards Initiative - Network Development Group, United Nations Economic Commission for Europe, Ireland

Chaired by

- **Meryem Ilayda Atlas**, Editorial Coordinator, Daily Sabah, Turkey

Spearheading South-South Cooperation to overcome the COVID Crisis

Developing economies are particularly being hit by the pandemic. Even more than developed nations, they need faster economic growth to recover from the pandemic. How might nations of the global South spearhead South-South cooperation? What are the primary aims of these programs and in what timescales?

- **José da Silva Goncalves**, Former Minister of Economy and Employment, Cape Verde
- **Bogolo Kenewendo**, Former Minister of Investment, Trade and Industry, Botswana
- **Sérgio Sá Leitão**, State Secretary of Culture, State of Sao Paulo, Brazil
- **Ajmal Shams**, President, Afghan Social Democratic Party, Afghanistan
- **Rana Gurmit Singh Sodhi**, Minister of Sports & Youth Affairs, Government of Punjab, India

Chaired by

- **Borzou Daragahi**, Correspondent, The Independent, United Kingdom

Leading the Future of Finance Post-COVID

The COVID-triggered economic crisis is exposing and worsening financial vulnerabilities and disruptions that have built up during a decade of extremely low rates and volatility. What developments during the pandemic were the most impactful across asset classes, and how should investors further position themselves to guard against a 2nd wave of COVID? What are the implications for resilience and financial stability?

- **Ajmal Ahmady**, Governor of the Central Bank, Afghanistan
- **Robert H. Kahn**, Managing Director, Automated Financial Systems, USA
- **Robert Scharfe**, Chief Executive Officer, Luxembourg Stock Exchange, Luxembourg
- **Alejandro Valenzuela**, Chief Executive Officer, Banco Azteca, Mexico

Chaired by

- **Nandini Sukumar**, Chief Executive Officer, The World Federation of Exchanges, United Kingdom

The Future of Money: Youth-Centered Innovation to Change the World

We've seen great strides in the area of impact or purpose based investing, but before COVID, much of the investment growth in this area was still being done by sector, in silos of impact. How can young people leverage their 'digital native' skillsets to leap forward to innovate new ways of impact investing? How can they enable global abundance on a massive scale?

Chaired by

- **Heidi Cuppari**, Chief Executive Officer and Co-founder, Dream Tank, USA

Horasis

The Global Visions Community

The Middle East – a Quest for Re-development

The Middle East is a transcontinental region presenting several different economies; many of which depend on the energy sector: its oil producing dominance is challenged by a COVID-caused loss of global demand and the continued quest for reduced global pollution. What does the future hold for this region? Will it achieve a financial equilibrium through its own strategic reorientation? How can it unite across its region to inspire creativity?

- **Ahmad Al Sari**, Chairman, Malaz Capital, Saudi Arabia
- **Ahmed Emara**, Founder and Group Chief Executive Officer, ReAya Holding, Saudi Arabia
- **Imad Ghandour**, President, Cedarbridge, UAE
- **Majid Rafizadeh**, President, International American Council, USA
- **Shireen Shelleh**, Managing Director, Center for Engineering and Planning, Palestine

Chaired by

- **Hugh Miles**, Founder, Arab Digest, United Kingdom

16.15-17.00 Parallel Sessions

Sustainable Development Goal Number Three

Good health is goal three of the UN's SDG list, and is central to achieving all of the global goals. It's key that we work with creative partners – to tackle COVID-19 and create a healthy world where all the global goals remain the guiding plan to be achieved by 2030. How to do this in a world driven by strife? Who will lead to unite the globe?

- **William Haseltine**, Founder and Chairman, ACCESS Health International, USA
- **Anh Hoang**, Co-Founder, Sofregen Medical, USA
- **Mary Lou Jepsen**, Founder and Chief Executive Officer, Openwater, USA
- **Jussi Määttä**, Founder and Chief Executive Officer, Buddy Healthcare, Finland
- **Pam Randhawa**, Chief Executive Officer and Founder, Empiriko Corporation, USA

Chaired by

- **Scott Rosenstein**, Professor, Bard College Globalization and International Affairs Program, USA

Technology: Harnessing the Potential to Disrupt

Disruptive technologies change the way in which markets operate. What are the most important emerging technologies with the potential to transform post-COVID society, economy and industries? Which sectors, products and related investments may yield the best results for commerce and humankind?

- **Faisal Ahmad**, Chief Executive Officer, BIS Research, USA
- **Mark Gazit**, Chief Executive Officer, ThetaRay, USA
- **Stacy Kenworthy**, Chief Executive Officer, HellaStorm, USA
- **Haoyuan Li**, Founder and Chairman, Alluxio, USA
- **Melanie Mohr**, Chief Executive Officer, womprotocol.io, Singapore

Chaired by

- **Soumitra Dutta**, Professor of Management, Cornell University, USA

Horasis

The Global Visions Community

Building Partnerships for Food Security

As global population increases and COVID-related supply chain disruptions escalate there is a need to develop enhanced food security. How to end global hunger? How can the private sector develop meatless food sources, rainfall harvesting as well as new storage and packaging to minimize energy use so reduce global pollution? How can governments cooperate to boost food security?

- **Stiphan Behér**, Former Adviser to President of Kyrgyzstan, Kyrgyzstan
- **Luigi Cavallito**, Chief Operating Officer, Seeds&Chips Africa, Lebanon
- **Mark Hollingsworth**, Chief Executive Officer, The Nutrition Society, United Kingdom
- **Constantin Marakhov**, Founder and Chief Executive Officer, Hempfy, Switzerland
- **Igor Saveliev**, Director, Adam Global, Russia

Chaired by

- **Steven V. Melnik**, Founder, PoliticalAndBusinessDiplomacy.org, USA

Harnessing Migration for Business and Employment

Migrant flows continue at about 3% of the global population despite COVID ravages. Given the low birth-rates across the globe how ought government representatives discuss migration – as a humanitarian issue, or as an urgent need to re-balance their own nation's human stock? How to unite hosts and migrants? What role do business leaders hold in this process?

- **Royston Flude**, President, CSPOC, Switzerland
- **Bibi Sattar Marques**, Partner, BlueCrow Capital, Portugal
- **Mohana Prabhakar**, Chief Executive Officer, Meissa Creative Services, Oman
- **Michael Spindelegger**, Director General, International Centre for Migration Policy Development, Austria

Chaired by

- **Cristi Hegraneş**, Founder and Chief Executive Officer, Global Press Institute, USA

Driving Social Innovation through Inspiration

Some innovators and entrepreneurs see glory as a goal, partly by making a profit. But profit alone is not enough – social betterment and ethical application with positive impacts are better goals. How can entrepreneurs ride high on social innovation, particularly to soften the economic impact of COVID-19?

- **Abdulaziz Albakr**, Chairman, BMT, Saudi Arabia
- **Nathalie Goethals**, Founder, iDROPS, Belgium
- **Jeanette Fangel Løgstrup**, Non-executive Director, JP Politikens Hus, Denmark
- **Jordi Ràfols**, Chief Executive Officer, Innoget.com, Spain
- **Riccarda Zezza**, Chief Executive Officer, Life Based Value, Italy

Chaired by

- **tbc**

Horasis

The Global Visions Community

Our Changing Needs for Fulfilment

Individuals have differing abilities and needs; many of the latter are under fulfilled: and presently, COVID-19 isolation removes interpersonal contacts. How can we boost contentment while not making a life-style trivial? How to achieve inner peace, spiritual health and overall balance? What means do our leaders have to offer satisfaction to their citizens, now and in the future?

- **Patricia Bonaert**, Enlightener, MixR.net, Italy
- **Satya Brahma**, Chairman & Editor-In-Chief, Network 7 Media Group, India
- **Simone Cipriani**, Founder, ITC Ethical Fashion Initiative, Switzerland
- **Vandana Harris**, Managing Director, The Unreasonable Group, USA

Chaired by

- tbc

Ethics in a Troubled Depersonalized World

Ethical values have been the foundation for states and religions for eons, providing the bedrock for modern laws. The globe is troubled by a pandemic and increased perceptions of racial suppression - ethical values are being stretched. Can a generalized ethics solve the problems of the world? What are the philosophical, political, legal and religious perspectives that must be addressed?

- **Mohammed Abdel Mohammad**, Chief Executive Officer, CannDollar Silver Blockchain, Canada
- **Klaus Moosmayer**, Member of the Executive Committee and Chief Ethics, Risk and Compliance Officer, Novartis, Switzerland
- **David Reiling**, Chairman and Chief Executive Officer, Sunrise Banks, USA
- **Brahmeshanandacharya Swamiji**, Spiritual Leader, India
- **Verica Trstenjak**, Former Judge and Advocate General at Court of Justice of the EU, Slovenia

Chaired by

- **Brian J. Grim**, President, Religious Freedom & Business Foundation, USA

Managing Funds in the Post-COVID Era

Governments and their central banks have striven to boost their economies as their work forces have moved into self-isolation. This has increased global debt issuance by trillions of dollars. How will private-equity, venture capital, hedge funds, asset management, angel investments and family offices manage in post-COVID times? What concerns will they have to address initially?

- **Angelica Anton**, Founding Partner, Silk Ventures, United Kingdom
- **Barbara Ann Bernard**, Chief Executive Officer, Wincrest Capital, Bahamas
- **Tomasz Czechowicz**, Founder and Managing Director, MCI Capital, Poland
- **Marie Dzanis**, Chief Executive Officer, Northern Trust Global Investments, United Kingdom
- **James McCaughan**, Asset Management Executive, USA

Chaired by

- **Matthias Kamp**, Journalist, Neue Zürcher Zeitung (NZZ), Switzerland

Horasis

The Global Visions Community

Blended Financing for our Future Benefit

Globally there is nearly \$ 900 trillion of unused capital: perhaps the COVID-19 pandemic and its lockdowns have hampered cash deployment. In parallel central banks have deployed trillions to support COVID-related causes vastly increasing national debts - how to reconcile these two effects? Will blended investing in Sustainable Development Goals offering traditional profits overcome resistance?

- **Bernhard Bauhofer**, Founder and Managing Partner, Sparring Partners, Switzerland
- **Michael Drexler**, Senior Strategic Advisor, Brightstar Capital Partners, USA
- **Peter Lorenz Nest**, Chief Executive Officer, AAVI Advanced Added Value International, Germany
- **Rodrigo Tavares**, Founder and President, Granito Group, United Kingdom
- **John J. Ying**, Managing Director, Peak Capital, Hong Kong SAR

Chaired by

- **Piers Cumberlege**, Chair, Straightview International, United Kingdom

Maintaining a Start-up Nation's Impetus Post-Covid

Some nations pre-Covid seemed adept at constant reinvention, but the global lockdown has hampered innovation and creativity. What can be done to open nations to the rejuvenation process given the pain and anguish suffered by all? What are the critical actions to be taken by people, firms and governments? Are there process commonalities internationally?

- **Suman Bose**, Co-founder, GoFar Advisory and Investments, Singapore
- **Svana Gunnarsdóttir**, Founding Partner, Frumtak Ventures, Iceland
- **Yuan Mingli**, Co-Founder, ColorfulClouds Tech Co., China
- **Lin Yang**, Founder and President, Innovation Ideas Institute, USA

Chaired by

- **Martin Giles**, Senior Editor CIO Network, Forbes, USA

Bridging the Digital Divide

Everyone should have safe and affordable Internet access by 2030. Born global in 2020, the UN High-level Panel on Digital Cooperation has high ideals to create a more equitable knowledge-sharing world. This will directly help the goals of sustainable development. What is needed to get the UN goals enacted? Is it an aspiration too far?

- **Isabel Guerrero**, Co-founder, IMAGO Global Grassroots, USA
- **Manish Kothari**, President, SRI International, USA
- **Jovan Kurbalija**, Executive Director, Secretariat of the United Nations High-level Panel on Digital Cooperation, Switzerland
- **Adrian Lovett**, President and Chief Executive Officer, World Wide Web Foundation, USA
- **Frank G. Wisner**, Former US Under Secretary of Defense, USA

Chaired by

- **Avi Basu**, Chief Executive Officer and Founder, Wingsure, USA

Horasis

The Global Visions Community

Fostering Purpose through Movies

The movie industry is arguably one of the most impactful sectors in modern society as movies create awareness on multiple aspects of life. How can movies inspire the viewer? And how can the movie industry foster purpose and embrace social impact?

- **Majid Majidi**, Film Director, Producer, and Screenwriter, Iran

Chaired by

- **Priya Samant**, Impact Advisor and Director, Sequoia Applied Technologies, USA

The Revitalization of Africa

Debates by African leaders have proposed solutions to combat desertification, food and water shortage, and poverty across Africa. What solutions will unite and create local wealth to combat migration and inspire a new vibrant economy? And, importantly, how will the region recover from the ravages of COVID-19? What are the most important opportunities for this ethnically diverse continent?

- **Blessing Ayemhere**, Chief Executive Officer, Umugini Pipeline Infrastructure., Nigeria

- **Nkem Khumbah**, Chairman, Africa Development Futures Group, USA

- **Cynthia Munwangari**, Co-Founder, Ukosokoni, Uganda

- **Jean Paul Nanfack**, Managing Director, Prime Invest Co, Cameroon

Chaired by

- **Anushka Bogdanov**, Managing Director, Risk Insights, South Africa

17.00-17.45 Plenary Sessions

The US – On the Brink of Change

The US elections, the most followed across the world, are going to be challenging. How is the COVID-pandemic impacting the elections and who will win? What is going to change? What might the future hold – for the US and for the rest of the world?

- **Kate Brown**, Governor of Oregon, USA

Chaired by

- **John Harris**, Co-founder, Politico, USA

Europe - New Unity Post-COVID

Europe, has to rearrange its priorities in these complex times with global financial pressures upon it and the continuing issue of COVID-19 pandemic. Its Central Bank must stimulate a faltering economy and fund worker support as demands and supplies of most goods are blocked and workers furloughed. How to redevelop the EU? How to unite and inspire its people to become creative again?

- **Jenny Gilruth**, Minister for Europe and International Development Government of Scotland, United Kingdom

- **Mariyana Nikolova**, Deputy Prime Minister for Economic and Demographic Policies, Bulgaria

Chaired by

- **Karen Tso**, Anchor, CNBC Europe, United Kingdom

17.45-18.30 Plenary Sessions

UN Global Compact for the Post-COVID Decade

Founded in July 2000, the Global Compact has created a non-binding pact to encourage all businesses to act in socially responsible ways. The initiative is now calling on business leaders to unite to support communities affected by the COVID pandemic. How can each of us contribute and take action?

- **Ibukun Awosika**, Chairman, First Bank of Nigeria, Nigeria
- **J. Erik Fyrwald**, Chief Executive Officer, Syngenta, Switzerland
- **Hank McKinnell**, Chairman, Moody's, USA

Chaired by

- **Clifton Leaf**, Editor in Chief, Fortune Magazine, USA

Post-COVID – Repositioning Capitalism

Visionaries have clamored to make our society and economies more sustainable, inclusive and long-term orientated: now, after the shock of the COVID pandemic there is a chance to undertake this massive reorientation. How to proceed with this task? How can business and governments cooperate to create a better, more inclusive world?

- **Roshni Nadar Malhotra**, Chairperson, HCL Corporation Ltd., India
- **Martin Riehenhagen**, Chairman, President and CEO, AGCO, USA

Chaired by

- **Myron Brilliant**, Executive Vice President, U.S. Chamber of Commerce, USA

18.30-19.15 Parallel Sessions

Stock Market Volatility during and post-COVID

Letting COVID-19 run rampant or instituting heavy lockdowns were two policy decisions taken round the world: both provoked market losses and raised volatility. Markets have responded variably according to national financial policies that introduced huge uncertainties. How to reduce volatility for investors? What are the long-term issues with helicopter money, negative rates and unconstrained QE?

- **Yves Bonzon**, Chief Investment Officer & Member of the Executive Board, Julius Baer, Switzerland
- **David Drake**, Founder and Chairman, LDJ Capital, USA
- **William Hobbs**, Chief Investment Officer, Barclays Investment Solutions, United Kingdom
- **Colin Hunt**, Chief Executive Officer, Allied Irish Banks, Ireland
- **Daniel S. Kern**, Chief Investment Officer, TFC Financial Management, USA

Chaired by

- tbc

Horasis

The Global Visions Community

FinTech post-COVID

New FinTech products used to be invented often prior to COVID lockdown. During COVID many people were confined to self-isolation yet still needed finance – some for ordinary activity, others to fund new ventures: the digital nature of FinTech ensured its continuance. How will FinTech develop post-COVID? What new products have been suggested to cope with greater home working?

- **Susanne Hannestad**, Chief Executive Officer, Fintech Mundi, Norway
- **Chitro Majumdar**, Co-Founder, AI Ethics Validation, Luxembourg
- **Colin Walsh**, Chief Executive Officer and Co-Founder, Varo, USA
- **Cherie Wang**, Founder, Plannerbee, Singapore
- **Marcel Ziaga**, Founder and Chief Executive Officer, Ed.Finances, Cote D'Ivoire

Chaired by

- **Martha Mghendi-Fisher**, Founder, European Women Payments Network (EWPAN), The Netherlands

Being Responsible for Blockchain Events

COVID-19 has highlighted weaknesses in global supply chains. Blockchains may offer solutions to increase greater transparency and end-to-end control along complex systems, thus fostering resiliency. How to use blockchain technologies to build transparent and connective supply chains? And how should governments legislate this new frontier?

- **Abiodun Ayorinde**, Founder and Chief Executive Officer, LIFTIX Technologies Limited, Nigeria
- **Agnes Budzyn**, Co-founder, Strategic Focus Investments, USA
- **Carlos Moreira**, Founder and Chief Executive Officer, WISEKey International Holding, Switzerland
- **Parth Patil**, Co-Founder and Chief Executive Officer, InfiniChains, USA
- **Hrvoje Stancic**, Professor of Archival Science, University of Zagreb, Croatia

Chaired by

- **Paolo Tasca**, Executive Director, UCL Centre for Blockchain Technologies (CBT), United Kingdom

Black Lives Matter

The Black Lives Matter Movement have brought a new wave of attention to the issues of inequality which might have been aggravated by COVID-19. How can we stop discrimination and create a fair future for all? And how to shape societies so that growth benefits the many and not just the few?

- **Noel Akpata**, Chief Executive Officer, Stratex Pro, Nigeria
- **Alfa Demmellash**, Chief Executive Officer, Rising Tide Capital, USA
- **Steven Greer**, Professor of Human Rights, University of Bristol, United Kingdom
- **James Kong**, Secretary General, The World Federation of Confucius Descendants, Hong Kong
- **Alec Wang**, Founder and President, Tana Investment Group, USA

Chaired by

- tbc

Horasis

The Global Visions Community

Inspiring a New Deal on Globalization

Globalization has shaped the modern world of economic exchange, but COVID-19 has left it weakened – some observers argue that pandemics could unravel globalization altogether. Others hold that globalization may have an even bigger role to play in healing the economic malaise. How can we inspire a new deal on globalization to overcome the fragmentation and isolation of our economies?

- **Michael Hacking**, Chief Executive Officer and Founder, MocoH SA, Switzerland
- **Mats Hellström**, Former Minister for Foreign Trade, Sweden
- **Alexander Kulitz**, Member of the German Parliament, Germany
- **Jonathan T. M. Reckford**, Chief Executive Officer, Habitat for Humanity International, USA
- **Steve Waugh**, Chief Scientist, Johns Hopkins University - Applied Physics Lab, USA

Chaired by

- **Beth Mendelson**, Senior Executive Producer, Voice of America, USA

The Future of Innovation in a Pandemized World

The complexity and scale of transformation taking place as a result of the pandemics require novel strategies for unlocking innovation. What are the major drivers transforming innovation globally and how should policy makers and entrepreneurs prepare for this new context?

- **Jakob Edler**, Executive Director, Fraunhofer Institute for Systems and Innovation Research, Germany
- **Soulaymane Kachani**, Vice Provost for Teaching, Learning, & Innovation, Columbia University, USA
- **Sam Stathis**, Founder and Chairman, Stathis Enterprises, USA
- **Nguyen Anh Tuan**, Chief Executive Officer, Boston Global Forum, USA

Chaired by

- **Martin Reeves**, Managing Director, BCG Henderson Institute, USA

Making More from Less

COVID-19 has given the earth some breathing space but the pandemics does not offer effective conservation solutions - we live in a finite world with decreasing natural resources. How do we learn to make more for all our well-being while consuming less? Can we do this while becoming more equal?

- **Lord Barker of Battle PC**, Executive Chairman, En+ Group, United Kingdom
- **Stephen Brenninkmeijer**, Chairman, European Climate Foundation, United Kingdom
- **Pia Henrietta Kekäläinen**, Co-Founder and Chief Executive Officer, Carbo Culture, USA
- **Gunjan Sinha**, Chairman, MetricStream, USA
- **Deborah Wince-Smith**, President, United States Council on Competitiveness, USA

Chaired by

- **Gary V. Litman**, Vice President, U.S. Chamber of Commerce, USA

Digital Utopia

The COVID crisis is giving digitalization a major boost potentially leading to a New Renaissance – as the way we work and live is fundamentally changing. Digitalization allows mankind to make social, economic, political, and cultural quantum leaps. What might the new digital utopia bring?

- **Kirk Bresnaker**, Chief Architect, Hewlett Packard Labs, USA
- **Constanze Buchheim**, Managing Director, i-potentials, Germany
- **Edwin Chan**, Founder and Creative Director, EC3, USA
- **Astrid Haug**, Digital Advisor and Author, Astrid Haug Bureau, Denmark
- **Andrew Nachison**, Founder, We Media, USA

Chaired by

- **Mihaela Ulieru**, President, IMPACT Institute for the Digital Economy, USA

Horasis

The Global Visions Community

Implanting Industry 4.0 into The Future

Industrial development segues naturally into level 4.0 wherein computers, automation and autonomy work coherently, and the Internet of Things (IoT) with its massive interconnect ability is the new revolution. Is this future, post-COVID, lost? How will business evolve as we grapple with greater home-working? How will processes and management styles cope with upheaval?

- **Stan Fung**, Managing Director, FarSight Ventures, China
- **Viren Joshi**, Chief Executive Officer, Sigma Electric Manufacturing Corporation, USA
- **Kira Radinsky**, Founder and Chairwomen, Diagnostic Robotics, Israel
- **Rufus Lidman**, Founder, AIAR EdTech, Singapore
- **Victor Martin**, Chief Executive Officer, Macco Robotics, Spain

Chaired by

- **Ed Adams**, Chief Executive Officer, Security Innovation, USA

Fighting Poverty Through and Beyond COVID

The gap between rich and poor has been emphasised by the COVID pandemic with the rich being able to command greater health protection. Many initiatives to aid the poor have begun but seem not to deliver their promise. Why not? Where should we begin to really overcome this scourge? Who could create a global management caucus?

- **Kim Samuel**, Founder, Samuel Centre for Social Connectedness, Canada
- **Shweta Shallni**, Executive Director, Maharashtra Village Social Transformation Foundation, India
- **Danny Sriskandarajah**, Chief Executive, Oxfam GB, United Kingdom
- **Linda Villarreal-Paierl**, Chief Executive Officer, Paierl Consulting, Austria
- **Tanya Woods**, Chief Impact Officer, The Kind Village, Canada

Chaired by

- **Brian A. Gallagher**, President and Chief Executive Officer, United Way Worldwide, USA

Solutions for an Impact-led Recovery

The global impact of COVID-19 has already been enormous; however, in adversity there is opportunity. Although firms and institutions globally are furloughed, some are seizing the moment to realign profit with social and environmental impact. Who will lead a global regeneration based on ESG and impact investing principles? What are the best ideas to begin with? How can they be globally integrated?

Chaired by

- **tbc**

The New Reality: Governance after COVID-19

The responsibilities of corporate boards and senior executives have shifted radically in the post-COVID world, reflecting the changing nature of risks and the transition to virtual governance. Are corporate governance regulatory frameworks sufficiently adapted for the changes we are seeing in the corporate sector? What skills will boards in different sectors need to address emerging economic, social and environmental risks and challenges?

- **Abdulaziz Al-Sulaiti**, Co-Chairman, Al-Sulaiti, Tin & Co., Qatar
- **Marcia Dyson**, Chief Executive Officer and Founder, Women's Global Initiative, USA
- **Steven Klemencic**, Managing Director, Ankura, USA

Chaired by

- **Alissa Kole Amico**, Managing Director, GOVERN, France

Horasis

The Global Visions Community

Latin America: Promoting Inter-nation Cooperation

The 20 nations of Latin America are resource rich but economically fragile, especially now during the pandemic. How might they develop to become more politically stable? What tipping points will define the future of Latin America? To what do their business leaders aspire?

- **Ronaldo Lemos**, Partner, PNM Advogados, Brazil
- **Daniel Melhem**, Managing Partner, Knightsbridge Partners, Argentina
- **Rodrick Miller**, Chief Executive Officer, Invest Puerto Rico, USA
- **Victor Sabbia**, Chief Executive Officer, Brokerware, Uruguay

Chaired by

- **Roy Nelson**, Associate Professor at Thunderbird School of Global Management, USA

19.15-20.00 Plenary Sessions

Governing a World Out of Balance

The COVID-19 pandemic has set the world out of balance. As technology and globalization transform the post-COVID world, what models of governance and collaboration are needed to support an equitable future? How to develop a global order that will ensure peace and allow countries to play by the rules? And how to stay true to our core values as we work to build a more focused life for ourselves and our societies?

- **Jonathan Malagón**, Minister of Housing, Cities and Territories, Colombia
- **Audley Shaw**, Minister of Industry, Commerce, Agriculture and Fisheries, Jamaica

Chaired by

- **Swaha Pattanaik**, Global Economics Editor, Reuters Breakingviews, United Kingdom

Africa is Opening for Business

Business on many fronts in Africa is booming – its pan-Africa Passport can aid business interactions once the COVID-19 pandemic eases; banks are helping ride COVID issues and manage debt relief, as well as strengthen regional integration; and it is boosting renewables power delivering energy for growth across the continent. What are the opportunities? How can multinationalism help growth?

- **Aurélien Agbénonci**, Minister of Foreign Affairs, Benin
- **Yemane Ghebremeskel**, Minister of Information, Eritrea
- **Robert Dussey**, Minister of Foreign Affairs & Cooperation, Togo
- **Soraya M. Hakuziyaremye**, Minister for Trade and Industry, Rwanda

Chaired by

- **Sanjeev Khagram**, Dean, Thunderbird School of Global Management, USA

20.00-20.45 Closing Plenary: Developing Unity, Inspiration and Creativity

The way in which we work together needs to change to overcome the profound economic, political and social disruptions caused by COVID-19. The discussions during this meeting have shown how we may overcome those disruptions through unity, inspiration and creativity. What solutions have been noted through this meeting? How may they be carried forward?

- **Paul Oquist Kelley**, Minister of Presidency and National Policies, Nicaragua
- **Diego Mesa**, Minister of Mines and Energy, Colombia
- **Sadiq Hirsi Warfa**, Minister for Labor and Social Affairs, Somalia

Chaired by

- **Norman Pearlstine**, Executive Editor, Los Angeles Times, USA

Horasis

The Global Visions Community

20.45-20.50 Closing Remarks: Unpalatables in Times of COVID-19

What have we learned? What Big Ideas have emerged from the Horasis Extraordinary Meeting to inspire leaders and leadership faced with the new unpalatables in times of COVID-19? What are the radical points you wish to make?

Chaired by

- **Frank-Jürgen Richter**, Chairman, Horasis, Switzerland

20.50-21.30 Virtual Dinner Sessions

Our World in 2030

As politics and epidemics around the world show, predicting even the immediate future is no easy feat. When it comes to what our world will look like in the medium-term – how we will organize our cities, from where we will get our power, what we will eat, will there be pandemics, what it will mean to be a refugee – it gets even trickier. But imagining the societies of tomorrow can give us a fresh perspective on the challenges and opportunities of today.

- **Mohamed ElBaradei**, Former Vice-President of Egypt, Nobel Peace Prize 2005, Egypt
- **Helen Clark**, Former UNDP Administrator, Former Prime Minister, New Zealand
- **Arthur Mutambara**, Former Deputy Prime Minister, Zimbabwe
- **Ehud Olmert**, Former Prime Minister, Israel
- **Danilo Türk**, Former President of Slovenia, Slovenia

Chaired by

- **Simone Filippini**, President, Leadership4SDGs Foundation, Netherlands

Re-designing for post-COVID Equitable Growth

Post-COVID global economic growth is highly uncertain and will be uneven across the world. How can governments and businesses raise their social commitments both at home and in their overseas operations? How can we change the perception of overseas aid to one of support rather than economic colonialism? What are the opportunities for entrepreneurs?

- **Rosalía Arteaga Serrano**, Former President of Ecuador, Ecuador
- **Mohamed Ahmed Awad**, Minister of Investment, Somaliland
- **Michael D. Brown**, United States Shadow Senator, District of Columbia, USA
- **Yves Leterme**, Former Prime Minister of Belgium, Belgium
- **Eduard Shalsi**, Minister of State for the Protection of Entrepreneurship, Albania

Chaired by

- **Paul Sheard**, Research Fellow, Harvard Kennedy School, USA

Leading Change, Thriving on Risk

The world economy changes at an unprecedented pace as a result of hyper-connectivity and external shocks. What are the risks at the top of the global agenda in 2021 aside from COVID-19 that has no cure at present? And how can leaders best guide their institutions and nations as the social, political and economic landscapes continually shift?

- **Esko Aho**, Former Prime Minister of Finland, Finland
- **J.D. Gordon**, Former Pentagon Spokesperson, USA
- **Dylan Jones**, Deputy Minister for Western Economic Diversification, Canada
- **Fatmir Mediu**, Chairman, Albanian Republican Party, Albania
- **Vladimir Radulovic**, State Secretary, Ministry of Foreign Affairs, Montenegro

Chaired by

- **Wendy Dent**, Journalist, Guardian US, USA

Horasis

The Global Visions Community

The CEO in an Age of Disruption

The disrupted post-COVID economy demands new skills for its provision and innovative approaches by CEOs as they are no longer measured on results alone – their success depends on their ability to show visionary leadership, motivate employees, serve customers, please shareholders and contribute to society. What skill set do today's CEOs need to master?

- **Olusola Adenuga**, Chief Executive Officer, Olla Systems, Nigeria
- **Joe Hyrkin**, Chief Executive Officer, Issuu, USA
- **Joanna Riley**, Chief Executive Officer and Co-founder, Censia, USA
- **Eva-Lotta Sjöstedt**, Member of the Supervisory Board, Metro, Germany
- **Ann Winblad**, Managing Partner, Hummer Winblad Venture Partners, USA

Chaired by

- **Allen Morrison**, Professor, Thunderbird School of Global Management, USA

Ensuring Inclusive Prosperity

COVID-19 exacerbates poverty risks in the poorest countries and lower income groups in developed nations seem worse off facing an uncertain future, beset often by high personal debt. How can capitalism and globalization be reshaped to give equal benefits to all? How long might this take?

- **Wade Channell**, Senior Economic Growth Advisor for Gender, USAID, USA
- **Vít Jedlicka**, President, Liberland
- **John Montgomery**, Founder, Lex Ultima, USA
- **André Navarro**, Chief Executive Officer, Millennium Investment Bank, Portugal

Chaired by

- tbc

Navigating Business in a World on the Edge

The pandemic has the potential to influence the balance of global power. How will COVID-19 affect geopolitical risks around the world? What steps can business leaders take to address these concerns? And how can they create positive change circumventing geopolitical tensions?

- **Calvin D'souza**, Associate Managing Director, Kroll, Canada
- **Joel Rubin**, Former Deputy Assistant Secretary of State, USA
- **Vikas Shah**, Chief Executive Officer, Swiscot Group, United Kingdom
- **Pascale Siegel**, Managing Director, Ankura Consulting, USA
- **Vasco Da Cruz Amador**, Chief Executive Officer, Global Intelligence Insight, United Kingdom

Chaired by

- **Richard Hames**, Founder and Chairman, Centre for the Future, Australia

Building Trust post-Covid

Leaders often promise much yet fail to deliver, sometimes because of global events beyond their control: then the people become disillusioned, without hope. Will Covid-19 management destroy or build trust? How may we develop a trust to enable progress that can absorb economic, political and spiritual surprises originating locally or globally?

- **Linda Klein**, Senior Managing Shareholder, Baker Donelson, USA
- **Eti Livni**, Member of the Steering Committee, Women Wage Peace, Israel
- **Valmiki Mukherjee**, Chairman and Founder, Cyber Future Foundation, USA
- **Farah Pandith**, Senior Fellow, Kennedy School of Government, Harvard University's, USA
- **Alexsis Wintour**, Founder, Lapin Limited, United Kingdom

Chaired by

- **Monica Marshall**, Managing Partner, Ruder Finn, USA

Horasis

The Global Visions Community

Technology is Running Amok

Technology development is managed lightly but its ultimate use might not – the spread of intrusive technologies and surveillance during the COVID-19 outbreak are a reality. How can we assure ourselves that unintended uses are all benevolent? In parallel, how can we educate leaders to take more care, and not release doomsday devices?

- **David Bruemmer**, Chief Executive Officer and Founder, Adaptive Motion Group, USA
- **Vivian Guo**, President, Jacksonville Artificial Intelligence Group, USA
- **Dan Mapes**, Founder, Verses.io, USA
- **Edson Prestes**, Head, Robotics Research Group, Federal University of Rio Grande do Sul, Brazil
- **David E. Smith**, President, ZanstraSat, USA

Chaired by

- **Navroop Sahdev**, Founder and Chief Executive Officer, The Digital Economist, USA

Quietly a Revolution may be Fomenting

Pre-COVID people were beginning to resist their government's rules, and creating action groups: because of COVID millions within the middle classes are losing their jobs. Is there a revolution in the making? How will grievances be acted upon to create a more wholesome life for all? What new attitudes need to be developed for our future benefit?

- **Elaine Dezenski**, Founder and Managing Partner, LumiRisk LLC, USA
- **David Fergusson**, Executive Managing Director, Generational Equity, USA
- **Alan G. Hassenfeld**, Honorary Chairman, Hasbro, USA
- **Marietta Robinson**, Former Commissioner, Consumer Product Safety Commission, USA
- **Matt Spence**, Former US Deputy Assistant Secretary of Defense, USA

Chaired by

- **Anna Tunkel**, Head of Global Strategic Initiatives & Partnerships, APCO Worldwide, USA

The Conservation Continent: Africa's New Opportunity for Development

The outbreak of COVID-19 has dramatically impacted Africa's economy, but in every crisis, there is an opportunity. For Africa, this is an opportunity to invest in nature, carving a path to prosperity. How can Africa protect biodiversity and its economic future and why is it so vital? Can Africa be the poster child for nature and humans living side by side in a sustainable way?

- **Russ Feingold**, Former US Envoy to the Great Lakes Region, USA

The Future is Bright

In every crisis there is opportunity: and with a bright future we can look forward to growth after COVID. What special care is needed internationally to nurture economic and social growth? How can optimism and competition be nurtured? How can the nay-sayers be convinced to pull together for our joint future?

- **Natalie Byrne**, Founder, Blank Space, USA
- **Sandy R. Climan**, Founder and Chairman, Entertainment Media Ventures, USA
- **Gregory Millen**, Principal and Managing Director, Tailhit, New Zealand
- **Archie Ravishankar**, Co-founder, Cogni, USA

Chaired by

- tbc

Horasis

The Global Visions Community

Carbon Removal at Scale: The Third Pillar of Global Climate Transformation

There are three pillars to solving the planet's climate crisis: mitigation (addressing the causes greenhouse gases), adaptation (addressing the impacts that climate change has), and restoration (removing the legacy carbon from the atmosphere). The first two are receiving massive attention at public and private levels, but restoration is behind the curve. What policies and practices need to be implemented to address carbon removal on a global scale to truly restore the earth's health and society's future?

- **Frédéric de Mevius**, Co-Founder and Managing Partner, Planet First Partners, United Kingdom

- **Rick Parnel**, Chief Executive Officer, Foundation for Climate Restoration, USA

Chaired by

- **Sanjeev Khagram**, Dean, Thunderbird School of Global Management, USA

21.30-22.15 Closing Parallel Sessions

Corporate Leadership post-COVID: Unite. Inspire. Create.

The traditional corporate decision making has been disrupted by COVID and there are no recent examples of such severity to use as model scenarios. How will leaders unite and inspire their staffs to be creative? Innovation is a firm's life-blood, how to nurture this though lockdowns?

- **Francis Govers**, Autonomy Lead, Bell Helicopter, USA

- **Dawn Ely**, Chief Executive Officer, Palladium Group International, USA

- **Joe Landon**, Vice President, Lockheed Martin, USA

- **Terence Mauri**, Author, *The Leader's Mindset: How To Win In The Age of Disruption*, UK

- **Sanjay Poonen**, Chief Operating Officer, VMware, USA

Chaired by

- **Akiko Fujita**, Anchor and Reporter, Yahoo Finance, USA

Behavioral Changes Post-COVID

Across the world consumers are becoming more cautious about joining crowds as the numbers of COVID cases rise. Consumers are not convinced that full airplanes, trains and theaters are safe: sport's teams worry, even as they play in empty stadia. What are the ramifications? Will public and work behaviors be changed forever?

- **Sunday Adejo**, Co-Founder, Biodry2Energy, United Kingdom

- **Krista J. Boyer**, Founder, Retail For The People, USA

- **Ciprian Dan Costea**, Member of the Board, Autonova, Romania

- **Sandra López**, Vice President, Intel, USA

Chaired by

- **Rick Noack**, Reporter, The Washington Post, Germany

Horasis

The Global Visions Community

Populism vs Multilateralism

Across the globe many people have voted for change to a so-called people's government, sometimes presided over by a cult figure who promise a more active government, especially against Covid-19. How can radical change be enacted so that all voters agree? Do populist governments incline at all towards multilateralism?

- **Pallavi Ahluwalia**, Managing Attorney, Ahluwalia Law Offices, USA
- **Scott Francis**, Chief Executive Officer, BP3, USA
- **Joseph P Garske**, Chairman, The Global Conversation, USA
- **Hans Köchler**, Professor, University of Innsbruck, Austria
- **Lukasz Paszkiewicz**, Co-founder, Finance World Expo, Poland

Chaired by

- **Brendan Davis**, Producer and Partner, International Troublemakers Inc., USA

Venture Capital Post-Covid

The Covid pandemic has disrupted traditional strategic decision making about capital acquisition and thus the VC players are also cautious. What will free-up financial decision making? How is Covid changing the VC landscape? Has business sentiment shifted permanently?

- **Jouko Ahvenainen**, Founder and Executive Chairman, Grow VC Group, USA
- **Raphael Fraga**, Founder and Chief Executive Officer, Ita Capital, Brazil
- **Chris Garabedian**, Chairman and Chief Executive Officer, Xontogeny, USA
- **Sari Miller**, Chief Executive Officer, Sarjay, Inc., USA
- **Thomas Thurston**, Partner and Chief Technology Officer, WR Hambrecht Ventures, USA

Chaired by

- **tbc**

Awakening to a Digital World

The UN suggested that economies would be better served by a fast Internet in cities and across the countryside. The Covid-19 lockdown has emphasized the usefulness of a digital connection for work and leisure. How will government ministries cope with poor incoming data from digitally less educated people?

- **Samuel Huber**, Founder, Admix.in, United Kingdom
- **Amy Peck**, Founder and Chief Executive Officer, EndeavorVR, USA
- **Florence Mauchant**, Founder and CEO, NeverTechLate, USA
- **Orlando Remédios**, Chief Executive Officer, Sensefinity, Portugal
- **Jon Soberg**, Managing Partner, MS&AD Ventures, USA

Chaired by

- **Sylvia Vaquer**, Co-Founder and Chief Creative Officer, SocioFabrica, USA

Cluster Hubs Post-Covid

Cluster hubs initially in the US innovation regions, spread round the globe wherever there were centres of intense tech development: they were closely knit lively ideas communities. Post-Covid close socializing is not allowed – what will innovators do? Will they thrive at a distance, or will they atrophy? What new work mode can be substituted?

- **Carl Guardino**, President and Chief Executive Officer, Silicon Valley Leadership Group, USA
- **Pina Hirano**, Founder and Chief Executive Officer, Asteria, Japan
- **Sven C. Oehme**, President, European-American Business Organization, USA
- **Evgeniya Shamis**, Founder and Chief Executive Officer, Sherpa S Pro, Russia
- **Christian Tidona**, Founder, BioMed X Institute, Germany

Chaired by

- **Manfred Zeuch**, Vice President, Concordia University of Edmonton, Canada

Horasis

The Global Visions Community

Advancing the Fifth Industrial Revolution

Earlier industrial revolutions broke existing boundaries with creative disruption. The 5th Industrial Revolution will disrupt as well - by means of heightened digitalization - but with humanity and humility as it shall make the world better rather than just more efficient. How can the Fifth Industrial Revolution help us beat COVID-19?

- **Sam Glassenberg**, Chief Executive Officer and Founder, Level Ex, USA
- **F. Mark Modzelewski**, General Manager, Treeline, USA
- **Michele Mosca**, Co-founder and President, evolutionQ Inc., Canada
- **Emidio Do Sacramento**, Founder and Chief Executive Officer, Zebiometrics, Switzerland
- **Yali Saar**, Founder and Chief Executive Officer, Tailor Brands, USA

Chaired by

- **Isabel Maxwell**, Founder, Magellan, USA

The Satisfying Zing of Cryptocurrencies

Cryptocurrencies are touted as the best tool for global trades, but banks seem to be wary: some accept their trades, others refuse. Will COVID-19 accelerate the arrival of cryptocurrencies?? What has to be done to ensure their safety – to deny their theft? Are they really going to revolutionize global trade or lead to a market crash?

- **Ara Brutian**, Director, Sustainalytics, Canada
- **Benjamin Dahl**, Co-Founder, Swedish Blockchain Association, Sweden
- **Ray Fares**, Founder and Chief Executive Officer, Chatello Technologies, Inc., USA
- **Stephen Meade**, Chief Executive Officer and Founder, MonetaPro, USA
- **Paul Sanar**, Chief Executive Officer, Rio Advancement Inc, USA

Chaired by

- **Ramesh Raskar**, Associate Professor, MIT, USA

Coaching in Times of COVID

Executives need coaching more than ever as the tackling of the challenges leaders face in a COVID-19 world is a delicate balancing act. The extent of this crisis means that existing business paradigms are out of place. Who might coach the top leaders? Are C-suite leaders above mundane lessons?

- **John Blakey**, Founder, The Trusted Executive Foundation, United Kingdom
- **Ahmet Bozer**, Advisory Board Member, Swire Coca-Cola, Hong Kong
- **Ned Cloonan**, President, Ned Cloonan Associates, USA
- **Firdaus Kharas**, Chairman, Chocolate Moose Media, Canada
- **Marc Verissimo**, Executive Chairman, Lighter Capital, USA

Chaired by

- **tbc**

Mutuality amid COVID-19

According to conventional wisdom, corporations have responsibility to shareholders only. In the new economics of mutuality, they shall also contribute to societal and environmental welfare. In a world blighted by the COVID-19 crisis, how to measure the mutuality of benefits delivered across the broad corporate value chain? How to position mutuality as business model?

- **Christina M. Alfonso-Ercan**, Chief Executive Officer, Madeira Global, USA
- **Ernesto Nuñez**, Chief Executive Officer, Love4all, Mexico
- **Vivian Portella**, Chief Executive Officer, B&T Global, Brazil
- **Efe Ukala**, Founder, ImpactHER, USA
- **Sebastian Wernicke**, Chief Data Scientist, One Logic, Germany

Chaired by

- **Arun Sharma**, President of Grovepike Associates, USA

Horasis

The Global Visions Community

Globally Green Policies post-COVID

During the COVID lockdown fossil fuel use fell dramatically and noticeably strongly reduced pollution. Coincidentally, the EU has introduced its Green Deal to combat climate change. What transformations in energy production and use are needed everywhere to maintain a low-carbon life? Is there enough alternative energy to support vigorous global growth?

- **David Darmawan**, Founder and Chief Executive Officer, Socontix, Indonesia
- **Ranulf Scarbrough**, Chief Executive Officer, ACL, Cook Islands
- **Natalie Samovich**, Co-founder, Enercoutim, Portugal

Chaired by

- tbc

Reaching for the Future with Technology

Sustainable investing suggests aiding the poor, nurturing water supplies, raising food availability and better educating everyone: businesses might have different priorities by leveraging technology. How might the full spectrum of technology benefit the larger public? What are the plausible futures? Who will drive beneficial tech?

- **Dao Jensen**, Chief Executive Officer and Founder, Kaizen Technology Partners, USA
- **Amir Rubin**, Co-founder and Chief Executive Officer, Sixsense Enterprises, USA
- **William Ruh**, Chief Executive Officer, LendLease Digital, USA
- **Francisco Santolo**, Chief Executive Officer and Founder, Scalabl, Argentina
- **Anna Tische**, Co-Founder and Managing Director, HEED Capital, USA

Chaired by

- **Alexis Taylor**, Director for Global Engagement, Global Entrepreneurship Network, USA

The Un-led Global Crisis

The current global economic crisis is much worse than the 2008 crash as we are in a quagmire with no decisive leaders in charge - unilateralism and fragmented regulatory bodies will make it harder to deal with it. How bad might it get? How can we guard against a new Great Depression? And from where will global leadership arrive?

- **Adel Afiouni**, Former Minister of State for Investment and Technology, Lebanon
- **William Bohnett**, Chairman, Smithsonian Environmental Research Center, USA
- **Lyric Hughes Hale**, Editor-in-Chief, EconVue, USA
- **Obiora Ike**, Executive Director, Globethics.net, Nigeria
- **Clyde Hutchinson**, Partner, Journey Partners, Ireland

Chaired by

- **Paolo von Schirach**, President, Global Policy Institute, USA

22.15-23.00 Virtual Receptions

Horasis Community Building and Networking

Each participant will be randomly matched with another to speak for 5 minutes by video, then become paired with another, and so on. By these mechanisms' delegates will become acquainted with others of a like mind - exchanging ideas, and potentially creating partnerships.

Horasis

The Global Visions Community

Horasis Young Visionaries

We want to empower the young as catalysts for change, for it is they who will guide us later: we want them to challenge current beliefs and solutions. But how do young leaders get heard and how do we make inter-generational collaboration work. To create a true New Normal, we need the voice of the young to be taken seriously. In this session, we will work on concrete ideas to reduce inequality in a post-COVID world.

Chaired by

- **Yonca Braeckman**, Co-Founder and Chief Executive Officer, Impact Shakers, USA

Announcing the 2021 Horasis Global Meeting

The 2021 Horasis Global Meeting will take place in Cascais, Portugal over 5-8 June. The City of Cascais and Portuguese Government officials will give an overview of the meeting.

High-level Delegates Horasis Extraordinary Meeting

1 October 2020, Virtual Events

Heads-of-Governments:

- **Nana Akufo-Addo**, President of Ghana, Ghana
- **Hage G. Geingob**, President of Namibia, Namibia
- **Iliana Iotova**, Vice President of Bulgaria, Bulgaria
- **Mariyana Nikolova**, Deputy Prime Minister for Economic and Demographic Policies, Bulgaria
- **Armen Sarkissian**, President of Armenia, Armenia
- **Kassym-Jomart Tokayev**, President of Kazakhstan, Kazakhstan

Representatives of the United Nations:

- **António Vitorino**, Director General, International Organization for Migration (IOM), Switzerland
- **Fabrizio Hochschild**, Under-Secretary General, United Nations, USA
- **Nikhil Seth**, Executive Director, United Nations Institute for Training and Research, Switzerland
- **Petteri Taalas**, Secretary-General, World Meteorological Organization, Switzerland
- **Tatiana Valovaya**, Director-General, United Nations Office at Geneva, Switzerland
- **Vitaly Vanshelboim**, Assistant Secretary-General, United Nations Office for Project Services, (UNOPS), Denmark

Ministers:

- **Carmelo Abela**, Minister Within the Office of the Prime Minister, Malta
- **Aurélien Agbénonci**, Minister of Foreign Affairs, Benin
- **Rania A. Al-Mashat**, Minister of International Cooperation, Egypt
- **Nina Angelovska**, Minister of Finance, North Macedonia
- **Robert Dussey**, Minister of Foreign Affairs & Cooperation, Togo
- **Nitin Gadkari**, Minister for Road Transport & Highways, India
- **Jean Claude Gakosso**, Minister of Foreign Affairs, Congo
- **Teka Gebreyesus**, State Minister of Trade and Industry, Ethiopia
- **Julie Anne Genter**, Minister for Women, New Zealand
- **Yemane Ghebremeskel**, Minister of Information, Eritrea
- **Ibrahima Guimba-Saldou**, Minister and Special Advisor to the President of Niger, Niger
- **Dalibor Jevtic**, Minister for Communities and Return, Kosovo
- **Diego Mesa**, Minister of Mines and Energy, Colombia
- **Paul Oquist Kelley**, Minister of Presidency and National Policies, Nicaragua
- **Jonathan Malagón**, Minister of Housing, Cities and Territories, Colombia
- **Shamma Al Mazrui**, Minister of State for Youth Affairs, UAE
- **Eduard Shalsi**, Minister of State for the Protection of Entrepreneurship, Albania
- **Audley Shaw**, Minister of Industry, Commerce, Agriculture and Fisheries, Jamaica
- **V.K. Singh**, Minister of State for Road Transport and Highways, India
- **Vera Daves de Sousa**, Minister of Finance, Angola
- **Adam Vojtěch**, Minister of Health, Czech Republic
- **Sadiq Hirsi Warfa**, Minister for Labor and Social Affairs, Somalia
- **Lindiwe Zulu**, Minister of Social Development, South Africa

Vice Ministers, State Secretaries, Representatives of Regional Governments:

- **Kate Brown**, Governor of Oregon, USA
- **Jenny Gilruth**, Minister for Europe and International Development Government of Scotland, United Kingdom
- **Dylan Jones**, Deputy Minister for Western Economic Diversification, Canada
- **Ro Khanna**, Congressman for California, USA
- **Simón Levy**, Undersecretary of Tourism, Mexico
- **Viljar Lubi**, Vice Minister of Economic Affairs and Communications, Estonia
- **Vladimir Radulovic**, State Secretary, Ministry of Foreign Affairs, Montenegro
- **Teresa Ribeiro**, Secretary of State of Foreign Affairs and Cooperation, Portugal
- **Rana Gurmit Singh Sodhi**, Minister of Sports & Youth Affairs, Government of Punjab, India

Former Heads-of-Governments:

- **Esko Aho**, Former Prime Minister of Finland, Finland
- **Shaukat Aziz**, Former Prime Minister of Pakistan, Pakistan
- **Rosalía Arteaga Serrano**, Former President of Ecuador, Ecuador
- **Pierre Buyoya**, Former President of Burundi, Burundi
- **Helen Clark**, Former UNDP Administrator, Former Prime Minister, New Zealand
- **Hamid Karzai**, Former President of Afghanistan, Afghanistan
- **Ernest Bai Koroma**, Former President of Sierra Leone, Sierra Leone
- **Yves Leterme**, Former Prime Minister of Belgium, Belgium
- **Ehud Olmert**, Former Prime Minister, Israel
- **Amos Sawyer**, Former President of Liberia, Liberia
- **Carlos Veiga**, Former Prime Minister, Cape Verde
- **Ranil Wickremesinghe**, Former Prime Minister, Sri Lanka

Representatives of International Organizations:

- **Yonov Fred Agah**, Deputy Director-General, World Trade Organization (WTO), Switzerland
- **Luca Jahier**, President, European Economic and Social Committee, European Union
- **Enzo Quattrocio**, Secretary General, EBRD, United Kingdom
- **Michael Spindelegger**, Director General, International Centre for Migration Policy Development, Austria
- **Nandini Sukumar**, Chief Executive Officer, The World Federation of Exchanges, United Kingdom
- **Luca Visentini**, General Secretary, European Trade Union Confederation (ETUC), Belgium

Business Leaders:

- **Ibukun Awosika**, Chairman, First Bank of Nigeria, Nigeria
- **Barbara Ann Bernard**, Chief Executive Officer, Wincrest Capital, Bahamas
- **Michael Carlos**, Member of the Supervisory Board, Givaudan, Switzerland
- **Binod K. Chaudhary**, President, Chaudhary Group, Nepal
- **Luisa Delgado**, Member of the Supervisory Board, Ikea, The Netherlands
- **Sherif El-Gabaly**, Chairman, Polyserve Fertilizer and Chemical Group, Egypt
- **Colin Hunt**, Chief Executive Officer, Allied Irish Banks, Ireland
- **Michael Johnston**, Member of the Board, The Capital Group Companies, USA
- **Jonathan T. M. Reckford**, Chief Executive Officer, Habitat for Humanity International, USA
- **David Relling**, Chairman and Chief Executive Officer, Sunrise Banks, USA
- **Marguerite Soeteman-Reijnen**, Chairman Executive Board, Aon Holding, The Netherlands
- **Eva-Lotta Sjöstedt**, Member of the Supervisory Board, Metro, Germany
- **Saran Song**, Chief Executive Officer, Amru Rice, Cambodia
- **John Studzinski**, Vice Chairman, PIMCO, USA
- **Alejandro Valenzuela**, Chief Executive Officer, Banco Azteca, Mexico
- **Anthony Venus**, Co-Founder and Chief Executive Officer, YayPay, USA
- **Deborah Wince-Smith**, President, United States Council on Competitiveness, USA

Other High-level Delegates

- **Ajmal Ahmady**, Governor of the Central Bank, Afghanistan
- **Lord John Bird**, Member of the House of Lords; Fonder, The Big Issue, United Kingdom
- **Michael D. Brown**, United States Senator, District of Columbia, USA
- **Konstantin Dobrynin**, Former Senator of the Russian Parliament, Russia
- **Mohamed ElBaradei**, Former Vice-President of Egypt, Nobel Peace Prize 2005, Egypt
- **J.D. Gordon**, Former National Security Advisor to US President Donald Trump, USA
- **Mats Hellström**, Former Minister for Foreign Trade, Sweden
- **Baroness Susan Kramer**, Member of the House of Lords, United Kingdom
- **Faisal Bin Muaammar**, Secretary General, KAICIID Dialogue Centre, Austria
- **HH Princess Märtha Louise of Norway**, Norway
- **Senida Mesi**, Deputy Chair European Integration Committee of Parliament, Former Deputy Prime Minister, Albania
- **Annette Nijs**, Former Cabinet Minister for Education, Science and Culture, The Netherlands
- **Joel Rubin**, Former Deputy Assistant Secretary of State, USA
- **Canon Sarah Snyder**, Archbishop of Canterbury's Adviser for Reconciliation, United Kingdom
- **Verica Trstenjak**, Former Judge and Advocate General at Court of Justice of the EU, Slovenia

Academia

- **Türker Bas**, Professor, Galatasaray University, Turkey
- **Erik Berglof**, Professor, London School of Economics and Political Science, United Kingdom
- **Soumitra Dutta**, Professor of Management, Cornell University, USA
- **Ernst Hafen**, Professor for Molecular Systems Biology, ETH Zürich, Switzerland
- **Lou Marinoff**, Professor of Philosophy, City College of New York, USA
- **Alf Rehn**, Professor of Innovation and Design, University of Southern Denmark, Denmark
- **Ozcan Saritas**, Professor, Higher School of Economics, Russia
- **Andrei Sharonov**, Dean, The Moscow School of Management SKOLKOVO, Russia

Media leaders

- **Gerard Baker**, Editor at Large, Wall Street Journal, USA
- **Asa Bennett**, Brexit Editor, Daily Telegraph, United Kingdom
- **Brian Caplen**, Editor, The Banker, United Kingdom
- **Stephen Castle**, Correspondent, New York Times, United Kingdom
- **Andrew Cave**, Business Columnist, Daily Telegraph, United Kingdom
- **Jane Dudman**, Public Leadership Editor, The Guardian, United Kingdom
- **Courtney Fingar**, Editor-in-chief FDI, NS Media Group, United Kingdom
- **Dan Hodges**, Columnist, The Mail on Sunday, United Kingdom
- **Rosalind Mathieson**, Executive Editor, International Government, Bloomberg News, United Kingdom
- **Chris Morris**, Correspondent, BBC News, United Kingdom
- **Swaha Pattanaik**, Global Economics Editor, Reuters Breakingviews, United Kingdom
- **Norman Pearlstine**, Executive Editor, Los Angeles Times, USA
- **Pranjal Sharma**, Contributing Editor, BusinessWorld, India
- **Spriha Srivastava**, Executive Editor for Europe, Business Insider, United Kingdom
- **Axel Threlfall**, Editor-at-Large, Reuters, United Kingdom

Re: SECRETARY OF HEALTH MR. ALEX AZAR. ISRAEL TREATMENT TO DEFEAT COVID-19.

Emile Mimran <[REDACTED]>

Mon 8/17/2020 5:13 PM

To: Alex.azar@hhs.gov <Alex.azar@hhs.gov>

Cc: Jo.bonner@governor.alabama.gov <Jo.bonner@governor.alabama.gov>; Dave.White@governor.alabama.gov <Dave.White@governor.alabama.gov>; ben.stevens@alaska.gov <ben.stevens@alaska.gov>; dscarpinato@az.gov <dscarpinato@az.gov>; alison.williams@governor.arkansas.gov <alison.williams@governor.arkansas.gov>; brittney.roy@governor.arkansas.gov <brittney.roy@governor.arkansas.gov>; katie.beck@governor.arkansas.gov <katie.beck@governor.arkansas.gov>; ann.oleary@gov.ca.gov <ann.oleary@gov.ca.gov>; angie.wei@gov.ca.gov <angie.wei@gov.ca.gov>; lisa.kauffman@state.co.us <lisa.kauffman@state.co.us>; Paul.Mounds@ct.gov <Paul.Mounds@ct.gov>; Josh.Geballe@ct.gov <Josh.Geballe@ct.gov>; Sheila.Grant@delaware.gov <Sheila.Grant@delaware.gov>; Albert.Shields@delaware.gov <Albert.Shields@delaware.gov>; Shane.Strum@eog.myflorida.com <Shane.Strum@eog.myflorida.com>; tim.fleming@georgia.gov <tim.fleming@georgia.gov>; linda.c.takayama@hawaii.gov <linda.c.takayama@hawaii.gov>; zach.hauge@gov.idaho.gov <zach.hauge@gov.idaho.gov>; anne.caprara@illinois.gov <anne.caprara@illinois.gov>; egoode@gov.in.gov <egoode@gov.in.gov>

Good Afternoon.

I would like to believe that you all want to save your states and will be open minded to even the smallest possibility.

It is important that you hear from people who have used the treatment. Eli Beer and Amram Adar.

Enclosed are two testimonials you should hear.

1. Eli Beer (CEO United Hatzalah of Israel). United Hatzalah of Israel is the largest volunteer ambucycle in the world with 6000+ volunteers and 1000+ ambucycles. They respond to thousands of emergency calls a day in 90 seconds or less and save hundreds of lives every day. He was Covid-19 positive on a respirator while in an induced coma. Became negative and was still having side effects from the virus for months before taking our treatment. **If he feels safe taking it, then all of us should.**

While sick in the hospital - <https://www.youtube.com/watch?v=4VCHcmaEeUQ>

While recovering - <https://www.youtube.com/watch?v=4VCHcmaEeUQ>

After using our treatment - <https://youtu.be/Yx3BDhdS53U>

About United Hatzalah of Israel - <https://israelrescue.org>

Who is the CEO - Eli Beer - <https://israelrescue.org/uhstaff>

2. Amram Adar (FL - Cantor and singer, father of four) who was positive and sick. https://youtu.be/hzRiypZc_Jc

You are in control of your own destiny. What happens next is up to you.

Emile

On Wed, Aug 12, 2020 at 2:05 PM Emile Mimran <[REDACTED]> wrote:

To the secretary of Health and Human Services Mr. Alex Azar and all Governors Chief of Staff.

My name is Emile Mimran. I have been asked by a number of governor chief of staff to share this email with each one of you. As a group, with all your determination and influence with hospitals, universities, news agencies, and politicians we can defeat Covid-19.

There is a treatment from Israel capable of helping a person's immune system do exactly what it was designed to do: Beat the Covid-19 virus.

We need your physical help.

If there ever was a cause for everyone to bond together, defeating Covid-19 is it. You individually, or through your state offices, or contacts have influence with hospitals, universities, news agencies, and politicians. Please use it. Make the world aware.

Money is not what is needed.

Your voices and influence are what's needed.

We will do the work.

Don't be put off by the length of this email. It is designed with exit points so you can stop reading it at any time.

Each of your states citizens and businesses has been affected by Covid-19. Although all of us belong to different political parties, we all agree on the importance of opening up our states safely at the earliest moment possible. For the wellbeing of our states, our families, our citizens, our companies, and our country. Even though some of us have witnessed the treatment overwhelmingly working, it is all of our responsibility to look into it and work together even if there would be a one percent chance of it working.

Although patients should come first, it has not always been the case. The challenge is to take care of the patient without threatening the medical professionals and establishment. Big Pharma.

First, to make it simple to understand by medical professionals and establishments so they do not panic, let's call this product what it is. A natural herbal one-a-day multivitamin treatment whose whole purpose is to help build up a person's immune system. **No other claims.**

If you are currently taking medications or just for peace of mind, consult your doctor and ask if there is any harm with you taking this one-a-day multivitamin with the following ingredients? You are not asking if there is any benefit. Most will never admit to a benefit. You are asking if there is any harm? Almost all doctors will tell you that there is no harm and that whatever your body will not use will get flushed out.

Read the elements page: *Listed in order of largest percentage ingredient in the multivitamins drops*: Enclosed is Toxicity report. Except for certain conditions, one can take a whole 10ml bottle a day of this multivitamin and nothing will happen to them. It will just get flushed out.

Alcohol, Water, Cat's Claw, Una De Gato extract (*Uncaria tomentosa*), Lacquered bracket fungus extract (*Ganoderma lucidum*), Elder extract (*Sambucus nigra*), Turmeric extract (*Curcuma longa*), Agaricus (*Agaricus hortensis*), Angelica extract (*Angelica sinensis*), Fennel extract (*Foeniculum vulgare*), Liquorice extract (*Glycyrrhiza glabra*), Seville Orange (*Citrus aurantium*), Greater Galangal (*Alpinia galanga*), Myrrh extract (*Commiphora myrrha*), Saffron (*Crocus sativus*), Flowering thick-stemmed sugar (*Saccharum*), Green Purslane (*Portulaca oleracea*), Turmeric (*Curcuma longa*), Peppermint oil (*Mentha x piperita*), Ginger extract (*Zingiber officinale*), Lavender oil (*Lavandula angustifolia*), Lemon (*Citrus limon*), Rosemary extract (*Rosmarinus officinalis*).

Our product is approved by the Israel Public Health. The manufacturing plant is FDA approved. All the ingredients are FDA approved. Due to the FDA offices being partially opened and only working on big drug companies Covid-19 issues, they are not handling anything else. Since we are not a drug company, we are not able to get anything done regarding getting our labeling approved. Your voices will also make it a priority.

...Now that we determined that this is not a medical threat to yourself, go on.

More than 350 people ill with the virus in Israel -- Covid-19 positive – took this vitamin in the last couple of months with a 100% success rate.

If each one of you hopes to defeat this virus, you and your peers, as a unit, will have to stand and take charge of our future and rely less solely on a miracle from Big Pharma and government bailouts. Each and every one of you is where you are today because you took charge. Specifically, you need to make sure that this treatment gets unfiltered attention away from special interests that have no intention of getting this resolved anytime soon. Either for personal political and/or financial gain.

If we have learned anything from this virus is that young or old, regardless of country, beliefs, religion, power, fame, race, competitiveness, or party lines, we are all affected. Whether we like it or not, whatever happens to one will happen to all of us. There are too many so-called 'Monday Morning Quarterback' who just report or are quick to comment on what should have happened yet never having the courage to take the lead. Having the guts to take control by asking questions and demanding answers. Answers that make sense. Putting yourself out there, takes true faith, strength, and conviction.

Nine months ago, would you have believed that a small little virus was going to bring the world to its knees? I didn't.

With that knowledge now, if someone was to tell you that a natural herbal product as small as one-a day multivitamin pill, could help the immune system defeat this virus would you even consider it?

Most of you would move on. Some would say yes, do nothing, and move on. I and a handful of you, would say no to ourselves, however believing in God and that anything is possible, would say show me.

Time is not on our side or our friend. Many, including Dr. Fauci, are telling us not to expect a vaccine that will cure all anytime soon. I do not need to remind you that till today there are illnesses that have no vaccine. One being, HIV. Thirty years plus later, millions of lives lost, and trillions of dollars spent, there still is no vaccine.

... If you believe that anything is possible, read on.

Think of this as a major boxing match between two opponents. The Immune system, weak or strong, going against the super powerful still unknown Covid-19 virus. To beat it, the immune system has to be totally fit so that it can weaken the virus round by round until it knocks it out. For that to happen, you will need to intensely train your immune system so it can be in top form.

How? By taking this multivitamin treatment.

Below is what happened to people taking this multivitamin in the sequence advised.

Beating Covid-19 is about strengthening your immune system to protect your body. Gilad Viralis Immunotherapy, a leader in homeopathic remedies, developed this product, devoid of any chemicals or so-called miracle ingredients that claim to directly kill the Covid-19 virus.

Gilad Viralis Immunotherapy is an all-natural, organic mixture of oils and plant extracts (in layman terms, vitamins) provided in the proper dose and sequence, to supply your body with the help to build up your immune system to protect your organs in the event of viral attacks.

In doing so, your body's strengthened immune system marshals the forces to fight the virus directly by building antibodies. There are NO CHEMICALS and therefore NO SIDE EFFECTS.

Gilad Viralis consists of many different plant extracts, each having special functions:

- A number of plant extracts build the immune system.
- A number of plant extracts, clean, build, protect, the respiratory system.
- A number of plant extracts clean the liver and pancreas from toxins.
- A number of plant extracts help blood circulation and other bodily fluids.
- A number of plant extracts help the body produce antibodies to fight the virus.
- Etc.

... If this still makes sense to you, read on:

In order not to be premature in backing it, do as I did to convince yourself: run your own personal test. This can be done in a couple of stages over the course of 10 days.

First, locate a couple of friends or relatives ill with Covid-19 showing degrees of the illness. Have them try the multivitamin and treatment. Within a couple of days, you will witness or perhaps hear that they will feel considerably better. Within a week, they will revert to normal. Then, perhaps try it with a wider circle of friends and see the results. The multivitamin and treatment will also work on those no longer positive but still have lingering effects by boosting their immune system to fight and return their bodies to normalcy.

Only then, make sure that the powerful word-of-mouth news gets out in full force. In turn this will leave no choice to those who wish to dismiss it. Even anecdotal evidence will lead healthcare professionals to endorse it as they act on it as they try it. This will not take months but just weeks.

... Still with me? Then read on:

Q: At this stage, as a patient, why not just mention to doctors that this treatment can help the immune system beat the virus and you want to take it?

A: In their eyes, now you are playing doctor and making it personal.

Whatever their motivations, they will ask: "Where is the data?" or state "There is no data."

As we all know, medicines come with small printed data sheets warning of side effects a mile long. Vitamins do not. Taken properly, they cause no harm nor have side effects. Whatever the body does not utilize gets flushed out of the system.

Doctors rely more on Big Pharma and their chemical meds than they do on their gut feelings. Currently, rightfully from desperation to keep their patients alive, they are willing to try meds meant for other illnesses, ones with serious side effects having no track record in winning against Covid-19, rather than first entertain a simple natural multivitamin treatment that has no side effects. **This should not be unless it is a matter of immediate life and death.**

Common sense dictates that you, as the patient or his/her proxy, should ask why doctors would employ certain Covid-19 drugs with side effects on patients instead of administering a simple harmless regimen of natural vitamins and extracts?

Possible answers:

1. The Big Pharma's are promoting the drugs heavily to doctors and hospitals with financial incentives to administer them with even bigger incentives if they work.
2. How will the medical and pharma establishment justify that a simple botanical vitamin treatment is able to build up a person's immune system to fight Covid-19?
3. They have no idea that this botanical treatment exists.
4. They just forgot about the ability of our immune system.

So where is OUR data?

We have over 350 healthy individuals that *were* sick and took the Gilad Viralis Immunotherapy Botanical treatment (herbal multivitamins and treatment sequence) and are now healed, tested negative, and feel 100% healthy and happy, back to their selves without side effects and without fatalities.

So, why are we not running lengthy clinical studies?

Although we are considered a vitamin and herbal food supplement that does not require FDA approval, we have tried finding universities and/or hospitals to run clinical tests. They are all too busy with Big Pharma and the money being thrown at them. They have no time for us. Unfortunately, money is dictating where their time is best spent and not potential for a natural cure.

Who is affected and why the different reactions?

Young infected people with no medical pre-existing history (low risk)

The younger and healthier the person, the better the chances that their immune system will build the antibodies needed to fight the virus. The inherent danger from these individuals is their ability to infect many unknowingly. Between their immune system being stronger and Gilad Viralis immunotherapy, the virus will be eradicate-ed from their system in a couple of days thus making them less able to infect people.

Older persons and all other persons (at risk)

The elderly and others at risk have immune systems simply not strong enough to kill the virus before organs are damaged or worse yet, die. Gilad Viralis immunotherapy can give their immune system immediate strength to build antibodies to fight the virus while at the same time strengthening the immune system that pertains to many organs that can be affected in the short and long term.

Others who suffer mentally, physically and financially because they are too afraid to go on living due to fear of catching Covid-19

Yes, people have to take precautions. Yes, people have to social distance themselves. Yes, people should wear masks and practice hand-hygiene. But people should not stop living. No, people should not stop laughing. All can be solved once people feel comfortable that this virus is treatable, manageable, and ultimately beatable.

Children can take this product. Treatments can be commenced on those 18 months and older. Adults on respirators unable to take it orally can also take it by injection.

If we are to defeat the virus (and whatever forces that do not seem to want a cure at the moment) we must all combine our efforts to make sure that no stone unturned nor possibility goes unexplored no matter how small. If we don't pursue all the opportunities we only have ourselves to blame.

At its worst, we can proudly say we tried; we gave sick people immune-boosting multivitamins, yet we are still in the same place. Best case, we give patients multivitamins that aid their immune system to beat the virus with no side effects, and we've bettered the world with a daring but more caring approach and acceptance of each other.

Right now, **Gilad Viralis treatment is available and is actually saving lives.**

It doesn't claim to vanquish Covid-19 but rather fortifies your immune system naturally that helps build the antibodies to kill the virus.

Once more, each and every one of you is being challenged to take charge and lead. The power to act is now in your hands. Let us work together.

The alternative of sitting back and doing nothing could very well be that all we will have in our hands is time. I assure you it will not be friendlier than.

Waiting to hear from you.

If there are others you feel could help and should be included in the group, please feel free to forward them the email and cc me.

Attached to the email are some documents you will find comforting.

Resume of head of R&D and partner, Vered Gilad.

Toxicity report enclosed.

Israel Public Health Services document

Sincerely,

Emile

--

Please confirm receipt

Emile Mimran

Cell: [REDACTED]

--

Please confirm receipt

Emile Mimran

Cell: [REDACTED]

FW: COVID-19 Response Executive Report

Miltenberger, Matt <matt.miltenberger@nebraska.gov>

Tue 8/18/2020 1:52 PM

To: 'Ricketts, Pete' <[REDACTED]>

📎 1 attachments (365 KB)

COVID19 Response Executive Summary 8-18-20.docx;

From: Zabokrtsky, Dustin <Dustin.Zabokrtsky@nebraska.gov>

Sent: Tuesday, August 18, 2020 8:51 AM

Subject: COVID-19 Response Executive Report

Please see attached. Some good info on the LTC facility.

Thanks,

Dustin S. Zabokrtsky MA MBA |

Executive Strategic Advisor

OFFICE OF THE CHIEF EXECUTIVE OFFICER

Nebraska Department of Health and Human Services

OFFICE/CELL: [REDACTED]

DHHS.ne.gov | [Facebook](#) | [Twitter](#) | [LinkedIn](#)

Lab & Community Testing
Bryan Buss

Text

Number of COVID-19 Test Results Reported by Performing Laboratory – Nebraska, 8/10-8/16/2020					
Laboratory Name	No. tests/day	Total tests ^a (Non-resident tests ^b)	Positive		TAT ^c (days)
	(mean)	(n)	(n)	(%)	mean, median (range)
TestNebraska	2575.3	18027 (179)	891	4.94%	3.72, 4 (0-17)
NPHL	179.7	1195 (36)	208	17.41%	1.73, 1 (1-21)
Nebraska Medicine	405.1	2836 (258)	215	7.58%	1.13, 1 (0-11)
CHI/Creighton	152.4	1067 (128)	146	13.68%	2.08, 2 (1-6)
LabCorp	259.7	1776 (4)	158	8.90%	2.83, 3 (1-32)
Quest	114.3	800 (1)	84	10.50%	4.19, 4 (1-17)
P-Lab	181.1	1268 (159)	115	9.07%	1.56, 1 (1-19)
All Laboratories^d	4367.4	30572 (815)	2443	8.01%	3.70, 3 (0-90)^e

^aTotal counts include tests for both Nebraska and out-of-state residents

^bNumbers in parentheses = No. of non-resident tests (No. is included in "Total Tests" column)

^cTAT = Turn Around Time (specimen collection date to test result date)

^dCount includes 5,603 results from other laboratories not represented in this table

^eTAT includes TestNE results but excludes those from other non-traditional ELR interfaces

This table includes ALL tests including those from persons with >1 test performed during the time period.

Key Issues and Risks

- Metrics and testing turn-around time
- Whole genome sequencing (WGS)

Action Steps and Mitigation

1. Monitor and report metrics and turn-around time (TAT) for major labs reporting to Nebraska.
 2. Coordinate with NPHL on (WGS).
- Stretch Goals**
1. Continue to report lab metrics.

Target Date

- Weekly
- Ongoing
- Ongoing

Date	City	Facility
Monday Aug 17	Alliance	Box Butte General Hospital
	Beatrice	Community Hospital
	Chadron	Chadron Community Hospital
	Columbus	Community Hospital
	Columbus	Good Neighbor Community Health Center
	David City	Butler County Health Center
	Fremont	Methodist Fremont
	Fremont	Three Rivers Public Health Department
	Grand Island	Central District Health Dept
	Hastings	Mary Lanning Healthcare
	Kearney	Good Samaritan & Kearney Regional
	Kearney	Good Samaritan & Two Rivers
	Lincoln	Gateway Mall
	Lincoln	University of Nebraska Lincoln
	Madison	Midtown Health Center
	Norfolk	Faith Regional
	Norfolk	Midtown Health Center
	North Platte	West Central District Health Department
	Omaha	Oakview Mall
	Omaha	Crossroads Mall
Scottsbluff	Regional West Medical Center	
Superior	Brodstone Memorial Hospital	
Wahoo	Saunders Medical Center	
Tuesday Aug 18	Alliance	Box Butte General Hospital
	Blair	Memorial Community Hospital
	Fairbury	Jefferson Community Health & Life
	Gordon	Gordon Memorial Hospital
	Gothenburg	Two Rivers Health Department
	Grand Island	Central District Health Dept
	Holdrege	Phelps County Fairground
	Lincoln	Gateway Mall
	Lincoln	University of Nebraska Lincoln
	Minden	Two Rivers Health Department
	Norfolk	Faith Regional
	Omaha	Oakview Mall
	Omaha	Visiting Nurse's Association
	Omaha	Crossroads Mall
	Schuyler	CHI Health Schuyler
	Scottsbluff	Regional West Medical Center
	Sidney	Sidney Regional Medical Center
	Wahoo	Saunders Medical Center
	West Point	Franciscan Healthcare
	West Point	Franciscan Care Services
Wednesday Aug 19	Alliance	Box Butte General Hospital
	Aurora	Central District Health Dept
	Blair	Memorial Community Hospital
	Columbus	Community Hospital
	Falls City	Community Medical Center
	Franklin	Franklin County Memorial Hospital
	Fremont	Methodist Fremont
	Fremont	Three Rivers Public Health Department
	Kearney	Good Samaritan & Kearney Regional
	Kearney	Good Samaritan & Two Rivers
	Lexington	Lexington Regional Health Center
	Lincoln	Gateway Mall
	Lincoln	University of Nebraska Lincoln
	McCook	Community Hospital
	Nebraska City	CHI Health St. Mary's
	Norfolk	Faith Regional
	Norfolk	Midtown Health Center
	North Platte	West Central District Health Department
	Omaha	Oakview Mall
	Omaha	Visiting Nurse's Association
Omaha	Crossroads Mall	
Ord	Valley County Health System	
Scottsbluff	Regional West Medical Center	
Superior	Brodstone Memorial Hospital	
Valentine	Cherry County Hospital	
Wayne	Faith Regional Health Services	
York	York General Hospital	

Date	City	Facility
Thursday Aug 20	Alliance	Box Butte General Hospital
	Arapahoe	Mark's Pharmacy
	Cambridge	Mark's Pharmacy
	Gordon	Gordon Memorial Hospital
	Hastings	Mary Lanning Healthcare
	Holdrege	Phelps County Fairground
	Lincoln	Gateway Mall
	Lincoln	University of Nebraska Lincoln
	Omaha	Oakview Mall
	Omaha	Crossroads Mall
	Schuyler	CHI Health Schuyler
	Scottsbluff	Regional West Medical Center
	Sidney	Sidney Regional Medical Center
	Tecumseh	Johnson County Hospital
West Point	Franciscan Care Services	
West Point	Franciscan Care Services	
Friday Aug 21	Alliance	Box Butte General Hospital
	Broken Bow	Melham Medical Center
	Chadron	Chadron Community Hospital
	Columbus	Community Hospital
	Columbus	Good Neighbor Community Health Center
	Fremont	Methodist Fremont
	Fremont	Three Rivers Public Health Department
	Grand Island	Central District Health Dept
	Kearney	Good Samaritan & Two Rivers
	Lincoln	Gateway Mall
	Lincoln	University of Nebraska Lincoln
	North Platte	West Central District Health Department
	Omaha	Oakview Mall
	Omaha	Crossroads Mall
Seward	Memorial Hospital	
Superior	Brodstone Memorial Hospital	
Saturday Aug 22	Lincoln	Gateway Mall
	Omaha	Oakview Mall
	Omaha	Crossroads Mall

LTC Testing
Becky Wisell
Dan Taylor

Holding individual sessions with facilities to review processes for registration, specimen collection, packaging and shipping to CHI St. Elizabeth Lab, and result reporting to increase facility understanding and success and to minimize errors and the additional work of correcting those errors.

LTC facility test kit orders through August 14, 2020.

	NH	ALF	Independent Living	Other	Total Facility Requests	Total Staff	Total Residents*
Week 1	64	72	5	2	143	8,621	1,050
Week 2	52	53	1	0	106	8,051	1,654
Week 3	6	10	0	0	16	1,236	92
Week 4	18	15	2	3	38	2,780	773
Week 5	22	20	2	4	48	3,113	800
Week 6	7	15	0	6	28	2,640	297
Week 7	4	6	0	3	13	477	155
Week 8	2	2	0	0	4	93	0
Week 9	4	2	0	0	6	419	150
Totals	179	195	10	18	402	27,430	4,971

*Residents tested only if facility has had a positive test of staff or resident

Surveyed LTC facilities on status of baseline testing. Results as of August 14, 2020:

- 222 responded to survey
- 183 have completed baseline testing of all staff
- 39 have not completed baseline testing of all staff
- 161 indicated using Test Nebraska as their testing service
- 11 plan to complete baseline testing of all staff in August
- 12 plans to complete baseline testing of all staff in September
- 96 have begun to allow outside visitors into the facility (Phase III)
- 10 plan to begin allowing outside visitors into the facility within the next week
- 15 plan to begin allowing outside visitors into the facility within the next 2 weeks
- 76 plan to begin allowing outside visitors into the facility within the next month

Key Issues and Risks

— Tracking results

Action Steps and Mitigation

1. Tracking test results
2. Scheduling LTC testing orders
3. Communication with LHDs and LTC Facilities
4. Frequently asked questions

Target Date

Ongoing
Ongoing
Ongoing
Ongoing

Stretch Goals

1. Increased Automation of Process and Reporting

Ongoing

Test Nebraska
Doug Carlson

899k assessments, 295k unique, 159k scheduled, 159K specimens tested.
Second lab getting set up this week.

Key Issues and Risks

— Lab

Action Steps and Mitigation

1. Stand-up second testing site in Douglas county
2. Finalize 2nd lab and operational
3. Continue finalizing in-progress contracts

Target Date

8/7/20
8/14/20

Stretch Goals

1. 7,000 tests a day
2. Proactive

DHHS COVID19 Response – Executive Report

August 18, 2020

Contact Tracing Jason Jackson Blake Hendrickson Jeff Fry	Training of 5 of 10 Team Leads is completed and they are starting to make case calls. 13 of 20 disease investigators have completed training and are ready to start calling contacts. Nelnet (calling capacity) and UNMC College of Public Health (training) contacts are signed. UNMC has provided a temporary HIPAA training for Nelnet admin/managers, Blake has provided additional training. Full UNMC training for DHHS Team Leads, Disease Investigators, and Nelnet callers is projected for the week of Aug 24th.	
Key Issues and Risks —Obtaining 1,000 person capacity. —Exploring longer term technical solution. —Providing high quality metrics and tracking progress. —Planning for large events such as Husker football games.	Action Steps and Mitigation 1. Nelnet contract is signed. They will have 25 active and 375 reserve reps Sept 1 st . 475 reserves by Oct 1 st . 2. Business Requirements with process improvement coordinator are completed. Team is looking at top 5 options and scoring them based on Business Requirements. 3. Hired 1 of 2 epidemiologists who will be concentrating on enhancing metrics provided on case investigations and contact tracing efforts statewide. 4. Visited Memorial Stadium to measure seats & determine which fans should be contacted in the event of an exposure. Football schedule has been postponed by Big Ten until spring. We have continued to move forward to develop future procedures. Exploring texting solution to check with fans if they are showing symptoms. Stretch Goals 1. Over 90% of cases and contacts identified called for the first time on the same day as identified.	Target Date November 1 August 30 Ongoing September 5 Ongoing

Week of 8/17	Local/Reserves		State Level				Total Contact Tracers		
	LHDs	DHHS Reserves	DHHS Active	PRC	IGT	Nelnet (Aug24)	Local/Reserves Total	State Level Total	Grand Total
Active	218	0	18	125	63	0	218	206	424
Trained	218	275	18	398	63	0	493	479	972

<p>Facilities Shelly Schwedhelm</p>	<p>Conduct <u>onsite technical assistance visits</u> to facilities experiencing outbreaks in the state to provide mitigation guidance on engineering and administrative controls, and PPE strategies, transmission modes, and IPC practice.</p> <p>TOTAL ONSITE VISITS to date:</p> <ul style="list-style-type: none"> o MPP Plant Visits: 14 onsite; 3 follow up calls; 6 virtual visits –follow up visit to JBS Meats-Omaha 8/18 o Dairy Facility: 1 o NETEC LTC & ALF Onsite Visits: 70 o Shelter Visits: 10; Technical Assistance 6 o Schools: 9/ approx.. 63 school district reps attended these 9 visits 	
<p>Key Issues and Risks</p> <ul style="list-style-type: none"> — Long Term Care and Assisted Living Facility outbreaks — Outbreaks in other facilities (meat packing plants, shelters, correctional facilities, etc.) — Lack of understanding about IPC and transmission modes 	<p>Action Steps and Mitigation</p> <ol style="list-style-type: none"> 1. Conduct LTC/AL Onsite Visits: <ul style="list-style-type: none"> o Good Shephard Home (8/18) o Papillion Manor (8/19) 2. Shelter Onsite Visits: <ul style="list-style-type: none"> o Ongoing phone calls for technical assistance 3. School Visits <ul style="list-style-type: none"> o Last week: <ul style="list-style-type: none"> -Several OPS visits-to include JP Lord School -Presentation & Q&A NE Supts and School Board members (8/14) <p>Stretch Goals:</p> <ol style="list-style-type: none"> 1. Identify strategy to get healthcare workers in LTC facilities fit tested prior to wave 2 of the pandemic. 	<p>Target Date</p> <p>Ongoing</p> <p>Ongoing</p> <p>Ongoing</p>


Facilities-LTC
M. Salman Ashraf
Connie Vogt

Working closely with long-term care facilities, local health departments and other partners to ensure continuation of operations, safe environments for residents and staff, and to mitigate the infection and spread.

Case Updates: Overall 206 facilities have seen a total of 301 outbreak investigations so far. **During the last two weeks** 34 facilities have identified new cases of COVID-19. Majority (16) of them are experiencing their first outbreak, 12 of them their second outbreak and 6 of them their third outbreak. (Note: New outbreak investigations usually starts when a new case is identified at a facility that has not seen a case in last 28 days).

Key Issues and Risks	Action Steps and Mitigation	Target Date
<ul style="list-style-type: none"> — PPE — Staffing — Testing — Containment 	<ol style="list-style-type: none"> 1. Collecting LTC epi data inc death by fac. And LHD 2. Continuing 1:1 mentoring and support for each LTCF with a COVID-19+ resident or staff 3. Developing capacity to perform additional Tele-ICAR to review preparedness of facilities that do not have COVID-19 cases 4. Referring LTC facilities to available guidance on how to look for additional staffing support, and requesting more PPE. 5. Prioritizing LTCF with COVID-19 positive residents for onsite visits and regularly meeting to revise strategies as needed. 6. Sharing lessons learned from onsite visits on weekly webinar 7. Assisting LTCF in getting prepared for baseline testing, reopening and implementing containment measures, when needed. 8. Noticed increased call volume for positive cases from different facilities in the last month which is now starting to trend down (see graph below). Continuing to pair the facility with an IP to provide continued support for containment. (see outbreak chart below). 9. Working with colleagues in the state to figure out ways to decrease turnaround time for getting results back quicker from Test Nebraska as in some cases the results have been delayed for a week. 10. Licensure Unit will continue to meet with LTC facilities at least monthly. 11. Complete Focused Infection Control (FIC) surveys based on LTC facility data submitted to NHSN within the mandated 3-5 day time frame. We currently average 6 per week. 12. Develop/revise template for Assisted Living Facilities (ALF) for FIC surveys. 13. Continue to work with facilities on Directed Plans of Correction (DPOC) per CMS to provide consistent training for COVID prevention and containment. 	<p>Daily</p> <p>Daily</p> <p>9/15/20</p> <p>Ongoing</p> <p>Every M. and Th</p> <p>Every Th</p> <p>Ongoing</p> <p>Ongoing</p> <p>8/24/20</p>
	<p>Stretch Goals</p> <ol style="list-style-type: none"> 1. Increase capacity of ICAP and NETEC teams to meet the educational, technical and onsite support demands as more facilities reporting COVID-19 positive cases. 2. Work with ICAP and NETEC to develop and implement training for the POC COVID testing machines to be distributed to LTC facilities per CMS. 3. Work with ICAP, NETEC, LeadingAge and NHCA to develop and implement a FIC template for ALF facilities. 	<p>9/15/20</p>

Number of New LTCF Outbreak Investigations/Responses Starting Each Week March-Aug 2020 (N = 301)



<p>Immunization Jeri Weberg-Bryce</p>	<p>Immunization program has received some of the cooling equipment ordered for flu outreach and COVID vaccinations, flu vaccine has started to arrive but is very limited at this time, NESIIS team will be working on implementing IZ Gateway, VAMS in on our radar, help for the program is on the way, and it is Immunization month.</p>	
<p>Key Issues and Risks</p> <ul style="list-style-type: none"> — Vaccine Planning — Tier Identification — Provider/Partnerships — Enhance Flu vaccination rates 	<p>Action Steps and Mitigation</p> <ol style="list-style-type: none"> 1. Flu vaccine has started to arrive-not released <ol style="list-style-type: none"> a. Ideal that more than one presentation is available b. Looking for at least 10% of what has been pre-booked 2. Equipment <ol style="list-style-type: none"> a. 24 cool cubes are in <ol style="list-style-type: none"> 1) we have 25 total to share but we are going to need more 2) working on delivery and shipping across the state 3) Refrigerator has been ordered for one location-will be shipped directly 3. NESIIS <ol style="list-style-type: none"> a. IZ Gateway is scheduled <ol style="list-style-type: none"> 1) August 26-Test 2) August 27-Bugs 3) August 28-Live b. VAMS pilot is complete <ol style="list-style-type: none"> 1) CDC planning compile findings 2) Fix bugs 3) Present VAMS beginning of September 4. Interviews should start this week and next for an SOS 5. Immunization month- Flu messaging posted along with COVID <p>Stretch Goals</p> <ol style="list-style-type: none"> 1. NESIIS ready 2. Providers in place, trained, ready 3. Enhance Flu Vaccination rates 4. Vaccinate Tier 1 5. Vaccinate Tier 2 	<p>Target Date</p> <p>Ongoing</p> <p>Ongoing</p> <p>Aug. 26-28th</p> <p>TBD</p> <p>Aug.1 – Aug 31st</p>

WH IGA COVID-19 Federal Guidance - August 18

JP Fish <Fish.JP@va.gov>

Tue 8/18/2020 10:42 PM

Dear Governors' Chief of Staff & Washington Directors,

For your reference

J.P. Fish

Director, State & Local Government Relations

U.S. Department of Veterans Affairs

810 Vermont Avenue, NW

Washington, DC 20420

(202)461-7424 – Office

 Mobile

WH Additional Guidance (as of 8/18 at, 6 p.m.):

- **WH** - Remarks by President Trump in Press Briefing | August 15, 2020 ([Click here](#))
- **WH** - Remarks by Vice President Pence and Governor Justice of West Virginia in a COVID-19 Briefing | White Sulphur Springs, WV ([Click here](#))
- **WH** - Remarks by President Trump in Press Briefing | August 13, 2020 ([Click here](#))
- **WH** - Reopening Schools Is Key to Unlocking the Full Potential of America's Children ([Click here](#))
- **WH** - Press Briefing by Press Secretary Kayleigh McEnany | 8/13/2020 ([Click here](#))
- **HHS** - Trump Administration Collaborates with McKesson for COVID-19 Vaccine Distribution ([Click here](#))
- **HHS** - Trump Administration to Begin Distributing \$1.4 Billion in Relief Funds to Certain Children's Hospitals ([Click here](#))
- **HHS** - HHS Invests in Diagnostic Labs to Expand COVID-19 Testing Capacity in the United States ([Click here](#))
- **HHS** - Secretary Azar Pays Respects to President Lee and Highlights Burgeoning U.S.-Taiwan Economic Relationship ([Click here](#))
- **CDC** - Cases & Deaths by County ([Click here](#))
- **CDC** - Contact Tracing Resources ([Click here](#))
- **CDC** - Cases, Data, and Surveillance ([Click here](#))
- **CDC** - Businesses and Workplaces ([Click here](#))
- **CMS** - CMS News Alert August 17, 2020 ([Click here](#))
- **CMS** - Guidance Memo: Key Components for Continued COVID-19 Management for Dialysis Facilities ([Click here](#))
- **CMS** - Trump Administration Has Issued More Than \$15 Million in Fines to Nursing Homes During COVID-19 Pandemic ([Click here](#))
- **FDA** - Coronavirus (COVID-19) Update: Daily Roundup August 18, 2020 ([Click here](#))
- **FDA** - FDA Insight: Health Fraud and COVID-19 ([Click here](#))
- **FDA** - Coronavirus (COVID-19) Update: Daily Roundup August 17, 2020 ([Click here](#))
- **FDA** - Coronavirus (COVID-19) Update: FDA Issues Emergency Use Authorization to Yale School of Public Health for SalivaDirect, Which Uses a New Method of Saliva Sample Processing ([Click here](#))
- **HUD** - Secretary Carson Approves New Uses For Communities' Coronavirus Relief Funds ([Click here](#))

- **DOC** - U.S. Department of Commerce Invests \$1.65 Million in CARES Act Funding to Boost Economic Development Programs Critical to Helping Alaska Respond to Coronavirus ([Click here](#))
- **DOL** - U.S. Department of Labor Acts To Help American Workers and Employers During the Coronavirus Pandemic ([Click here](#))

FW: COVID-19 Response Executive Report 08/25/20

Miltenberger, Matt <matt.miltenberger@nebraska.gov>

Mon 8/24/2020 6:42 PM

To: 'Ricketts, Pete' <[REDACTED]>

📎 1 attachments (501 KB)

COVID19 Response Executive Summary 8-25-20.docx;

From: Zabokrtsky, Dustin <Dustin.Zabokrtsky@nebraska.gov>

Sent: Monday, August 24, 2020 12:38 PM

Subject: COVID-19 Response Executive Report 08/25/20

Team,

Please see attached.

Thanks,

Dustin S. Zabokrtsky MA MBA |

Executive Strategic Advisor

OFFICE OF THE CHIEF EXECUTIVE OFFICER

Nebraska Department of Health and Human Services

OFFICE/CELL: [REDACTED]

DHHS.ne.gov | [Facebook](#) | [Twitter](#) | [LinkedIn](#)

Lab & Community
Testing
Bryan Buss

Number of COVID-19 Test Results Reported by Performing Laboratory – Nebraska, 8/17-8/23/2020					
Laboratory Name	No. tests/day	Total tests ^a (Non-resident tests ^b)	Positive		TAT ^c (days)
	(mean)	(n)	(n)	(%)	mean, median (range)
TestNebraska	1719.3	12035 (182)	588	4.89%	9.54, 3 (1-11)
NPHL	152.4	1067 (13)	164	15.37%	1.41, 1 (1-4)
Nebraska Medicine	430.6	3014 (319)	210	6.97%	1.23, 1 (0-11)
CHI/Creighton	162.9	1140 (142)	148	12.98%	2.02, 2 (1-4)
LabCorp	182.7	1279 (13)	112	8.76%	2.69, 2 (2-39)
Quest	121.1	848 (2)	90	10.61%	3.92, 3 (2-36)
P-Lab	215.7	1510 (221)	131	8.68%	1.77, 1 (1-5)
All Laboratories^d	3410.9	23876 (969)	1829	7.66%	3.6, 3 (0-97)^e

^aTotal counts include tests for both Nebraska and out-of-state residents

^bNumbers in parentheses = No. of non-resident tests (No. is included in "Total Tests" column)

^cTAT = Turn Around Time (specimen collection date to test result date)

^dCount includes 2,983 results from other laboratories not represented in this table

^eTAT includes TestNE results but excludes those from other non-traditional EHR interfaces

This table includes ALL tests including those from persons with >1 test performed during the time period.

Key Issues and Risks

— Metrics and testing turn-around time

Action Steps and Mitigation

1. Monitor and report metrics and turn-around time (TAT) for major labs reporting to Nebraska.

Stretch Goals

2. Continue to report lab metrics.

Target Date

Weekly

Ongoing.

DHHS COVID19 Response – Executive Report

August 25, 2020

Date	City	Facility
Monday Aug 24	Alliance	Box Butte General Hospital
	Bassett	North Central Health District
	Beatrice	Beatrice Medical Center
	Broken Bow	Melham Medical Center
	Chadron	Chadron Community Hospital
	Columbus	Community Hospital
	Columbus	Good Neighbor Community Health Center
	Curtis	Community Hospital (McCook)
	David City	Butler County Health Center
	Fremont	Fremont - Three Rivers Public Health Department
	Fremont	Methodist Fremont
	Grand Island	Central District Health Dept
	Hastings	Mary Lanning Healthcare
	Lincoln	Gateway Mall
	Lincoln	UNL Campus
	Madison	Midtown Health Center
	Norfolk	Midtown Health Center
	North Platte	North Platte - West Central District Health
	Omaha	Crossroads Mall
	Omaha	Metro Comm College
Omaha	Oakview Mall	
Superior	Brodstone Memorial Hospital	
Wahoo	Saunders Medical Center	
Tuesday Aug 25	Alliance	Box Butte General Hospital
	Beatrice	Beatrice Medical Center
	Blair	Memorial Community Hospital
	Columbus	Community Hospital
	Fairbury	Jefferson Community Health & Life
	Gethenburg	Two Rivers Health Department
	Gordon	Gordon Memorial Hospital
	Lincoln	Gateway Mall
	Lincoln	UNL Campus
	Minden	Two Rivers Health Department
	Norfolk	Faith Regional
	Omaha	Crossroads Mall
	Omaha	Metro Comm College
	Omaha	Oakview Mall
	Omaha	Visiting Nurse's Association
	O'Neill	North Central Health District
	Plainview	CHI Health Plainview
	Schuyler	CHI Health Schuyler
	Sidney	Sidney Regional Medical Center
	Trenton	Community Hospital (McCook)
Wahoo	Saunders Medical Center (fairgrounds)	
Wayne	Faith Regional	
West Point	Franciscan Care Services	

Date	City	Facility	
Wednesday Aug 26	Alliance	Box Butte General Hospital	
	Aurora	Central District Health Dept	
	Blair	Memorial Community Hospital	
	Columbus	Community Hospital	
	Columbus	Good Neighbor Community Health Center	
	Falls City	Community Medical Center	
	Fremont	Methodist Fremont	
	Hastings	Mary Lanning Healthcare	
	Kearney	Good Samaritan & Kearney Regional	
	Kearney	Two Rivers Health Department	
	Lexington	Lexington Regional Health Center	
	Lincoln	Gateway Mall	
	Madison	Midtown Health Center	
	Nebraska City	CHI Health St. Mary's	
	Norfolk	Faith Regional	
	Norfolk	Midtown Health Center	
	Ogallala	Banner Health	
	Omaha	Crossroads Mall	
	Omaha	Metro Comm College	
	Omaha	Oakview Mall	
Omaha	Visiting Nurse's Association		
Ord	Valley County Health System		
Superior	Brodstone Memorial Hospital		
Valentine	Cherry County Hospital		
Wahoo	Saunders Medical Center		
Wayne	Faith Regional		
York	York General Hospital		
Thursday Aug 27	Alliance	Box Butte General Hospital	
	Alma	Two Rivers Health Department	
	Beatrice	Beatrice Medical Center	
	Cambridge	Mark's Pharmacy	
	Gordon	Gordon Memorial Hospital	
	Holdrege	Two Rivers Health Department	
	Lincoln	Gateway Mall	
	Madison	Midtown Health Center	
	Omaha	Crossroads Mall	
	Omaha	Metro Comm College	
	Omaha	Oakview Mall	
	Oxford	Mark's Pharmacy	
	Plainview	CHI Health Plainview	
	Schuyler	CHI Health Schuyler	
	Sidney	Sidney Regional Medical Center	
	Friday Aug 28	Alliance	Box Butte General Hospital
		Beatrice	Beatrice Medical Center
		Chadron	Chadron Community Hospital
		Fremont	Methodist Fremont
		Grand Island	Central District Health Dept
Lincoln		Gateway Mall	
North Platte		West Central Health District	
Omaha		Crossroads Mall	
Omaha		Metro Comm College	
Omaha		Oakview Mall	
Seward		Memorial Hospital	
Superior		Brodstone Memorial Hospital	
Wahoo		Saunders Medical Center	
West Point		Franciscan Care Services	
Saturday Aug 29		Hastings	Mary Lanning Healthcare
	Lincoln	Gateway Mall	
	Omaha	Crossroads Mall	
Omaha	Oakview Mall		

LTC Testing
Becky Wisell
Dan Taylor

Holding individual sessions with facilities to review processes for registration, specimen collection, packaging and shipping to CHI St. Elizabeth Lab, and result reporting to increase facility understanding and success and to minimize errors and the additional work of correcting those errors.

LTC facility test kit orders through August 21, 2020.

	NH	ALF	Independent Living	Other	Total Facility Requests	Total Staff	Total Residents*
Week 1	64	72	5	2	143	8,621	1,050
Week 2	52	53	1	0	106	8,051	1,654
Week 3	6	10	0	0	16	1,236	92
Week 4	18	15	2	3	38	2,780	773
Week 5	22	20	2	4	48	3,113	800
Week 6	7	15	0	6	28	2,640	297
Week 7	4	6	0	3	13	477	155
Week 8	2	2	0	0	4	93	0
Week 9	4	2	0	0	6	419	150
Week 10	2	4	0	0	6	330	66
Totals	181	199	10	18	408	27,760	5,037

*Residents tested only if facility has had a positive test of staff or resident

Surveyed LTC facilities on status of baseline testing. Results as of August 14, 2020:

- 222 responded to survey
- 183 have completed baseline testing of all staff
- 39 have not completed baseline testing of all staff
- 161 indicated using Test Nebraska as their testing service
- 11 plan to complete baseline testing of all staff in August
- 12 plans to complete baseline testing of all staff in September
- 96 have begun to allow outside visitors into the facility (Phase III)
- 10 plan to begin allowing outside visitors into the facility within the next week
- 15 plan to begin allowing outside visitors into the facility within the next 2 weeks
- 76 plan to begin allowing outside visitors into the facility within the next month

Key Issues and Risks

— Tracking results

Action Steps and Mitigation

1. Tracking test results
2. Scheduling LTC testing orders
3. Communication with LHDs and LTC Facilities
4. Frequently asked questions

Stretch Goals

1. Increased Automation of Process and Reporting

Target Date

Ongoing
Ongoing
Ongoing
Ongoing

Ongoing

Test Nebraska
Doug Carlson

919k assessments, 304K unique, 169k scheduled, 168.5K specimens tested. Stand-up third testing site in Douglas county – South Omaha location. It is fully operational as of 8/24

Key Issues and Risks

— Lab

Action Steps and Mitigation

1. We continue to push the second lab to be fully operational. Equipment is in place and personnel are hired. Need to ensure equipment is all working properly.

Stretch Goals

1. 7,000 tests a day
2. Proactive


Target Date

08/25/20

Contact Tracing Jason Jackson Blake Hendrickson Jeff Fry	Training of 5 of 10 Team Leads is completed and they are starting to make case calls. 13 of 20 disease investigators have completed training and are calling contacts. Nelnet (calling capacity) and UNMC College of Public Health (training) contacts are signed. UNMC has provided a temporary HIPAA training for Nelnet admin/managers, Blake has provided additional training. Full UNMC training for DHHS Team Leads, Disease Investigators, and Nelnet callers is projected for the week of Aug 24th	
Key Issues and Risks — Obtaining 1,000 person capacity — Exploring longer term technical solution — Providing high quality metrics and tracking progress — Planning for large events such as Husker football games.	Action Steps and Mitigation 1. Nelnet contract is signed. They will have 25 active and 375 reserve reps Sept 1st. 475 reserves by Oct 1st. 2. Business Requirements with process improvement coordinator are completed. Team is looking at top 5 options and scoring them based on Business Requirements. 3. Hired 1 of 2 epidemiologists who will be concentrating on enhancing metrics provided on case investigations and contact tracing efforts statewide. 4. Visited Memorial Stadium to measure seats & determine which fans should be contacted in the event of an exposure. Football schedule has been postponed by Big Ten until spring. We have continued to move forward to develop future procedures. Exploring texting solution to check with fans if they are showing symptoms. Stretch Goals 1. Over 90% of cases and contacts identified called for the first time on the same day as identified.	Target Date 11/01/20 08/30/20 Ongoing 09/05/20 Ongoing

Week of 8/24	Local/Reserves		State Level				Total Contact Tracers		
	LHDs	DHHS Reserves	DHHS Active	PRC	IGT	Nelnet (Aug24)	Local/Reserves Total	State Level Total	Grand Total
Active	218	0	18	150	58	0	218	226	444
Trained	218	275	18	415	58	0	493	491	984

<p>Facilities Shelly Schwedhelm</p>	<p>Conduct <u>onsite technical assistance visits</u> to facilities experiencing outbreaks in the state to provide mitigation guidance on engineering and administrative controls, and PPE strategies, transmission modes, and IPC practice.</p> <p>TOTAL ONSITE VISITS to date:</p> <ul style="list-style-type: none"> o MPP Plant Visits: 14 onsite; 3 follow up calls; 6 virtual visits --follow up visit to plant in Omaha- 8/18 o Dairy Facility: 1 o NETEC LTC & ALF Onsite Visits: 72 o Shelter Visits: 10; Technical Assistance 6 o Schools: 10/ approx. 63 school district reps attended these visits 	
<p>Key Issues and Risks</p> <ul style="list-style-type: none"> — Long Term Care and Assisted Living Facility outbreaks — Outbreaks in other facilities (meat packing plants, shelters, correctional facilities, etc.) — Lack of understanding about IPC and transmission modes 	<p>Action Steps and Mitigation</p> <ol style="list-style-type: none"> 1. Conduct LTC/AL Onsite Visits <ul style="list-style-type: none"> o Hands on PPE training with facility staff 8/22 2. Shelter Onsite Visits 3. School Visits <ul style="list-style-type: none"> o Montessori school, Catholic school visits o Technical assistance calls with public health leaders <p>Stretch Goals:</p> <ol style="list-style-type: none"> 1. Identify strategy to get healthcare workers in LTC facilities fit tested prior to wave 2 of the pandemic. 	<p>Target Date</p> <p>Ongoing</p> <p>Ongoing</p> <p>Ongoing</p>



Facilities-LTC
 M. Salman Ashraf
 Connie Vogt

Working closely with long-term care facilities, local health departments and other partners to ensure continuation of operations, safe environments for residents and staff, and to mitigate the infection and spread.


Case Updates: Overall 218 facilities have seen a total of 319 outbreak investigations so far. **During the last two weeks** 43 facilities have identified new cases of COVID-19. Majority (20) of them are experiencing their first outbreak, 18 of them their second outbreak and 5 of them their third outbreak. (Note: New outbreak investigations usually starts when a new case is identified at a facility that has not seen a case in last 28 days).

Key Issues and Risks	Action Steps and Mitigation	Target Date
<ul style="list-style-type: none"> — PPE — Staffing — Testing — Containment 	<ol style="list-style-type: none"> 1. Collecting LTC epi data inc death by fac. And LHD 2. Continuing 1:1 mentoring and support for each LTCF with a COVID-19+ resident or staff 3. Developing capacity to perform additional Tele-ICAR to review preparedness of facilities that do not have COVID-19 cases 4. Referring LTC facilities to available guidance on how to look for additional staffing support, and requesting more PPE. 5. Prioritizing LTCF with COVID-19 positive residents for onsite visits and regularly meeting to revise strategies as needed. 6. Sharing lessons learned from onsite visits on weekly webinar 7. Assisting LTCF in getting prepared for baseline testing, reopening and implementing containment measures, when needed. 8. Continuing to pair the facility with an IP to provide continued support for containment in facilities reporting COVID-19 cases. (see outbreak chart below). 9. Working with colleagues in the state to figure out ways to decrease turnaround time for getting result back quicker from Test Nebraska as in some cases the results have been delayed for a week. 10. Working on guidance for long-term care facilities on how to utilize and report rapid antigen tests (SNF are starting to receive their rapid antigen test equipments) 11. Continue to perform FIC (Focused Infection Control- COVID 19) surveys per CMS and outbreaks 12. Continue training with LTC facilities, NHCA and Leading Age 13. Work with Epidemiology to develop a Redcap reporting system for SNF/ALF reporting to DHHS Licensure, Epidemiology and LHD's 	<ol style="list-style-type: none"> 1. Daily 2. Daily 3. 9/15/20 4. Ongoing 5. Every M. and Th 6. Every Th 7. Ongoing 8. Ongoing 9. 8/31/20 10. 9/7/2020 11. Weekly 12. At least Monthly
	Stretch Goals	
	<ol style="list-style-type: none"> 1. Increase capacity of ICAP and NETEC teams to meet the educational, technical and onsite support demands as more facilities reporting COVID-19 positive cases 	

DHHS COVID19 Response – Executive Report

August 25, 2020

Number of New LTCF Outbreak Investigations/Responses Starting Each Week March-Aug 2020 (N = 319)



<p>Immunization Jeri Weberg-Bryce</p>	<p>This information is last weeks and will be updated following meeting on 08/24/20 later in the day. Immunization program has received some of the cooling equipment ordered for flu outreach and COVID vaccinations, flu vaccine has started to arrive but is very limited at this time, NESIIS team will be working on implementing IZ Gateway, VAMS in on our radar, help for the program is on the way, and it is Immunization month.</p>	
<p>Key Issues and Risks — Vaccine Planning — Tier Identification — Provider/Partnerships Enhance Flu vaccination rates</p>	<p>Action Steps and Mitigation</p> <ol style="list-style-type: none"> 1. Flu vaccine has started to arrive-not released <ol style="list-style-type: none"> a. Ideal that more than one presentation is available b. Looking for at least 10% of what has been pre-booked 2. Equipment <ol style="list-style-type: none"> a. 24 cool cubes are in <ol style="list-style-type: none"> 1) we have 25 total to share but we are going to need more 2) working on delivery and shipping across the state 3) Refrigerator has been ordered for one location-will be shipped directly 3. NESIIS <ol style="list-style-type: none"> a. IZ Gateway is scheduled <ol style="list-style-type: none"> 1) August 26-Test 2) August 27-Bugs 3) August 28-Live b. VAMS pilot is complete <ol style="list-style-type: none"> 1) CDC planning compile findings 2) Fix bugs 3) Present VAMS beginning of September 4. Interviews should start this week and next for an SOS 5. Immunization month- Flu messaging posted along with COVID <p>Stretch Goals</p> <ol style="list-style-type: none"> 1. NESIIS ready 2. Providers in place, trained, ready 3. Enhance Flu Vaccination rates 4. Vaccinate Tier 1 Vaccinate Tier 2 	<p>Target Date Ongoing Ongoing Aug. 26-28th TBD Aug.1 – Aug 31st</p>

Urgent Action: Ensure Access to Vaccinations and Essential Care at Pharmacies

Kathleen Jaeger <KJaeger@NACDS.org>

Mon 8/24/2020 8:54 PM

To: Ricketts, Pete <pete.ricketts@nebraska.gov>

Cc: Steve Anderson <SAnderson@NACDS.org>; Miltenberger, Matt <matt.miltenberger@nebraska.gov>; Smith, Dannette <Dannette.Smith@nebraska.gov>; Anthonie, Gary <Gary.Anthonie@nebraska.gov>

Dear Governor Ricketts and State Executive Team Members,

Last Wednesday, August 19th, the U.S. Department of Health and Human Services (HHS) authorized pharmacists and pharmacy interns to order and administer vaccines to individuals ages 3 to 18 years, subject to certain requirements during the COVID-19 pandemic. This critical action ([link to third amendment to the declaration](#)) was taken by HHS Secretary Azar under the Public Readiness and Emergency Preparedness Act (PREP Act), designed to increase access to lifesaving childhood vaccines while decreasing risk of vaccine-preventable disease outbreaks. Yet, more synergistic action is needed by Nebraska to ensure pharmacies are empowered to meet the health and wellness needs of your residents. More specifically, the recommendations include:

1. Affirmation: HHS' Critical Action on Childhood Vaccinations

HHS' action is clear in paving the way for pharmacists and pharmacy interns to provide vaccines to children. Yet, in providing utmost clarity, NACDS strongly urges your state to affirm that by complying with the HHS declaration pharmacists are not in violation of your state's pharmacy laws or regulations. We applaud North Carolina (NC) Board of Pharmacy (BoP) for promptly issuing such guidance and encourage your state to follow suit.

Example of Affirming State Guidance (NC BoP): "North Carolina immunizing pharmacist who orders and administers pediatric vaccines in compliance with DHHS' declaration during the federally-declared COVID-19 public health emergency shall not be deemed by the Board of Pharmacy to be in violation of the North Carolina Pharmacy Practice Act."

2. Executive Order: Remove Barriers for ADULT Flu & Other CDC Recommended Vaccines

The HHS action paves the way for pharmacists/pharmacy interns to provide vaccines to children. We urge your state to proactively take action to expand this initiative so that people of **all ages, in all communities** across the state can benefit from frictionless pharmacy-based vaccinations. Simply put, issuing an Executive Order to allow pharmacists to initiate, order and administer adult vaccinations for all residents, including ethnic and racial minorities, socioeconomically disadvantaged, those with chronic diseases, and urban and rural populations is vital to advance the health of the communities and the health of the state's economy.

3. Executive Order: Prepare Now: Remove Barriers to COVID-19 Immunizations

Likewise, we also urge your state to prepare now by issuing an executive order that explicitly allows pharmacists to initiate, order and administer FDA-authorized vaccines to individuals age 3 and older without restrictions and to provide coverage for this professional service. Such action will align with CDC's pandemic plans to utilize pharmacists and for communities to be prepared for a vaccine when it becomes available. Proposed language is below:

Example EO Language: "Licensed pharmacists are hereby authorized to independently initiate, order and administer vaccines authorized by the Food and Drug Administration to patients of all ages. Licensed pharmacists may delegate technical, non-clinical immunization tasks to pharmacy staff such as pharmacy technicians and pharmacy interns."

4. Executive Order: Make Existing Pharmacy Operations and Care Flexibilities Permanent

Several states have taken impressive action to provide pharmacies flexibility during COVID-19 to meet the needs of patients. For instance, nearly all states have removed barriers to COVID-19 testing, 40 states allow

for remote processing of prescriptions, and 11 states allow for therapeutic interchange. While some states have taken impressive action before or during the pandemic to make sure flexibilities are permanent, we urge your state to take action to make pharmacy operations flexibilities permanent, including end-to-end testing services, which would benefit patients every day.

We greatly appreciate your immediate action to ensure patient care access for residents of your state.

Sincerely,

Steven C. Anderson, FASAE, CAE, IOM
STEVEN C. ANDERSON, FASAE, CAE, IOM
President & Chief Executive Officer
sanderson@nacds.org
P: [REDACTED]
F: (703) 549.7764

National Association of Chain Drug Stores (NACDS)
1776 Wilson Blvd. Suite 200 Arlington, VA 22209
www.nacds.org
www.facebook.com/NACDS.org
www.twitter.com/@NACDS

Reopening NEBRASKA Post COVID19 - Your Partner to Source Stockpile

Jagmohan Singh Sekhon <jssekhon@1worldenergy.com>

Sat 8/29/2020 12:52 PM

To: Miltenberger, Matt <matt.miltenberger@nebraska.gov>

Cc: Divyesh Kakadia <dkakadia@1worldenergy.com>

Hi,

Greetings. I hope you, your family and your team are all safe and doing well in this challenging time that 2020 has brought us.

CDC has issued [guidelines](#) on following 4 areas for reopening [Schools and Communities](#) and [Business and Workplaces](#)

- 1) Promoting Behaviors that reduce COVID-19's spread.
- 2) Maintaining Healthy Environments.
- 3) Maintaining Healthy Operations, and
- 4) Preparing for When Someone Gets Sick.

PPE is central to the above reopening game plan. [Tracking evolving PPE](#) needs and matching them with existing or emerging PPE stockpiles is the biggest challenge to the state and federal administrations. We at 1WEC as always have anticipated these needs and organized our support services to the new "**REOPENING REALITY**"

COVID19 Services - To support the COVID19 challenge, since March 2020 we have originated, imported and successfully placed with all 150 federal agencies and the 50 US state government all of the following (**FDA/CDC/EUA/NIOSH/CE compliant**) at very competitive prices and have inventory for ready disposal which are weekly replenished.

- **FFR** (3M 8210, 3M1860, N95, KN95, FFP2, P2, K1, DS).
- **Masks 3 Ply / 4 Ply / 5 Ply** (Medical/ Non Medical).
- **Nitrile / Vinyl / Latex Gloves** - Powder Free. Medical / Non Medical.
- **Face Shields / Safety Glasses / Goggles / PAPR.**
- **Shoe Covers, Hair Covers, Sleeve Covers, Beard Covers.**
- **Gowns / Coveralls** (AAMI Levels 1,2,3,4 / Tyvek Suits/Coveralls).
- **Testing Kits** (RT-PCR /IgM. / IgG / RT-LAMP) / Nasal Swabs.
- **COVID19 Testing Transport Tubes.**
- **ThermoMeters** (Non Contact Infrared / Regular / Human Temperature Scanners / Entry Temperature Scanners).
- **Disinfectants / Sanitizers / Sanitizing Wipes** (2 oz, 5 oz, 17 oz , 100 ml, 250 ml , 500 ml).
- **Cotton Pads.**
- **Hospital Linen** (Bed Sheets/ Curtains, Towels etc).
- **Medical Equipment** (Ventilators, O2 Concentrator, CT-MRI-X-ray machines, catheters etc).
- **Medical Refrigeration/Cold Chain Equipment/Blood Management Solution.**
- **Modular Hospitals and Furniture** (Beds, Cots, Stretcher etc).
- **Bio Hazard Bags / Body Bags.**
- **UV Sterilizers / Disinfectants.**
- **Vials/Bottles (Glass / Plastic).**
- **Rubber Stoppers / Aluminum Seals, Needles, Syringes & Cartridges (Glass / Plastic).**
- **Borosilicate Glass/Rubber/PE/Aluminum/Steel/Boron Trioxide.**

- **Logistics** - Drones/ e-Vehicles/ Chargers/ Batteries & Swap Stations.
- **Digital Vaccination Planning** (Hardware / Software).

Given the continued challenges of COVID19 as your state opens up, we would like to explore associations to procure all of your stockpile supplies from within our supply networks worldwide. Please check our website and let us know what you would like to buy from our vast global network. Together we are well-positioned to meet all collaborative requirements using an efficient and streamlined process.

About Us : -

- **Introduction - 1World Energy Corporation** is a Global Trading Conglomerate headquartered in NYC with its trading / portfolio spanning across Oil, Gas, Renewable Energy, NGL, Petroleum, Energy, Petrochemicals, Chemicals, Textiles, Agro, Metals, Hospitality, Healthcare, Engineering, Infrastructure commodities. We specialize in importation of these commodities with deep insights into supply chains from countries/domestic locations that have surpluses.
- **Registered Federal Vendor** - We are officially registered vendor to the US 150 Federal Agencies that have an annual spending of 4.45 Trillion USD (Currently 9 Tr USD). We cover all NAICS and hence all products of mostly all industries. Which means you can buy through us anything and everything to support all our federal tenders. Read more here <https://bit.ly/3layzCq>.
- **Incorporation Details** - LLC, formed in Delaware State, **Tax ID#:** 85-0753598, **DUNS#:** 117534187, **SAM.gov CAGE code:** 8LUZ6
- **Corporate Profile** - Available at this link <https://bit.ly/396hrbj>.
- **Hospitality Profile** - Available at this link <https://bit.ly/2DoNTKQ>.
- **HealthCare Profile** — Available at this link <https://bit.ly/3ftVjZT>.
- **Our Strengths** -
 - 1WEC maintains a short chain of command to facilitate efficient decision-making, which ensures we act decisively to secure advantages in the interest of our partners and clients. Our executive team works in close coordination and comprises a part of the company's private shareholder base.
 - Our global team has extensive experience in the broader commodity business, built on enduring customer relationships. 1WEC's reputation for delivering results reliably and over the long-term is a hard-earned asset, underpinning the confidence shown by those who rely on us.

Thank you so much and we look forward to working together.

Be well and safe!

J S Sekhon

Executive Director

1World Energy Corporation

M: [REDACTED]

80 Maiden Lane Room 1404

New York City,

NY 10038

www.1worldenergy.com

[LinkedIn](#)



WH IGA COVID-19 Federal Guidance - September 1

JP Fish <Fish.JP@va.gov>

Wed 9/2/2020 2:14 PM

Dear Governors' Chief of Staff & Washington Directors,

For your reference.

J.P. Fish

Director, State & Local Government Relations

U.S. Department of Veterans Affairs

810 Vermont Avenue, NW

Washington, DC 20420

(202)461-7424 – Office

██████████ Mobile

WH Guidance (as of 9/1 at, 7 p.m.):

- **WH** - Press Briefing by Press Secretary Kayleigh McEnany | 8/31/2020 ([Click here](#))
- **WH** - Readout from the Vice President's Governors Briefing on COVID-19 Response & Best Practices ([Click here](#))
- **WH** - Memorandum on the Extension of the Use of the National Guard to Respond to COVID-19 and to Facilitate Economic Recovery (Louisiana) ([Click here](#))
- **WH** - Statement from the Press Secretary Regarding the Administration's Purchase of 150 Million Rapid COVID-19 Tests ([Click here](#))
- **HHS** - Federal Communications Commission, U.S. Department of Health and Human Services, and U.S. Department of Agriculture Team Up for Rural Health Initiative ([Click here](#))
- **HHS** - Trump Administration Will Deploy 150 Million Rapid Tests in 2020 ([Click here](#))
- **CDC** - Limiting Workplace Violence Associated with COVID-19 Prevention Policies in Retail and Services Businesses ([Click here](#))
- **CDC** - United States COVID-19 Cases and Deaths by State ([Click here](#))
- **CDC** - Contact Tracing Resources for Health Departments ([Click here](#))
- **CDC** - Staffing Resources ([Click here](#))
- **CDC** - Children and Teens ([Click here](#))
- **CDC** - About COVID-19 ([Click here](#))
- **CDC** - Contact Tracing for COVID-19 ([Click here](#))
- **CDC** - Operational Considerations for Schools ([Click here](#))
- **CDC** - Responder Stories ([Click here](#))
- **CDC** - Interim Guidance for Rapid Antigen Testing for SARS-CoV-2 ([Click here](#))
- **FDA** - Coronavirus (COVID-19) Update: Daily Roundup September 1, 2020 ([Click here](#))
- **FDA** - Coronavirus (COVID-19) Update: FDA Announces Advisory Committee Meeting to Discuss COVID-19 Vaccines ([Click here](#))
- **NIH** - NIH-supported study to track prevalence and impact of SARS-CoV-2 among pregnant women in low- and middle-income countries ([Click here](#))
- **NIH** - Phase 3 Clinical Testing in the US of AstraZeneca COVID-19 Vaccine Candidate Begins ([Click here](#))
- **NIH** - People with intellectual and developmental disabilities disproportionately affected by COVID-19 ([Click here](#))
- **USDA** - Federal Communications Commission, U.S. Department of Health and Human Services, and U.S. Department of Agriculture Team Up for Rural Health Initiative ([Click here](#))
- **USDA** - USDA Extends Free Meals for Kids Through December 31, 2020 ([Click here](#))
- **USDA** - Farmers to Families Food Box Program Reaches 75 Million Boxes Delivered ([Click here](#))

- **HUD** - HUD Provides \$100 Million In Cares Act Funding To Native American Tribes To Support Coronavirus Recovery Efforts ([Click here](#))
- **DOT** - U.S. Transportation Secretary Elaine L. Chao Announces More Than \$1.2 Billion in Infrastructure Grants to America's Airports ([Click here](#))
- **DOT** - CARES Act Service Exemptions for Allegiant Air, United Airlines, and Hawaiian Airlines ([Click here](#))
- **DOL** - U.S. Department of Labor Awards \$13.5 Million In Dislocated Worker Grants In Response To Coronavirus Public Health Emergency ([Click here](#))
- **VA** - VA announces new clinical trial for Veterans with COVID-19 ([Click here](#))
- **FEMA** - FEMA Releases New Policy for COVID-19 Declarations ([Click here](#))
- **Treasury**: Statement of Secretary Steven T. Mnuchin Before the U.S. House Select Subcommittee on the Coronavirus Crisis ([Click here](#))

CONFIRMATION & READ-AHEAD DOCUMENTS -- 9/9 at 4:00 pm ET Governors-Only Briefing Call/VTC with Secretary Azar & the White House Coronavirus Task Force

Lopez, Diego Christopher EOP/WHO <DiegoChristopher.Lopez2@who.eop.gov>

Wed 9/9/2020 6:42 PM

To: Lopez, Diego Christopher EOP/WHO <DiegoChristopher.Lopez2@who.eop.gov>

Cc: Hoelscher, Douglas L. EOP/WHO <Douglas.L.Hoelscher@who.eop.gov>; Obenshain, Tucker T. EOP/OVP <Anne.T.Obenshain@ovp.eop.gov>; Pottebaum, Nic D. EOP/WHO <Nicholas.D.Pottebaum@who.eop.gov>; Friedman, Haley Z. EOP/WHO <Haley.Z.Friedman@who.eop.gov>; Swint, Zachariah D. EOP/WHO <Zachariah.D.Swint2@who.eop.gov>

📎 2 attachments (1 MB)

Read-Ahead Documents - 09-09-2020.pdf; Additional Documents - 09-09-2020.pdf;



THE WHITE HOUSE

Governor's Senior Staff (Chief of Staff, State-Federal Director, and Scheduler),

Your Governor is **CONFIRMED** for today's Governors-only Briefing Video Teleconference on COVID-19 response and recovery, and an update on efforts to develop, approve, manufacture, and distribute a safe and effective vaccine.

Briefing Call/VTC Details

- **Date:** Wednesday, September 9, 2020
- **Time:** 4:00 p.m. Eastern Time (expected to last 60-90 minutes)
- **Dial-In Information:** Audio and VTC dial-in information already provided.
- **Reminder:** This is a Governor-only briefing (i.e., one call-in per state). Participation in this call is for governors only, but we encourage governors to be joined by their state health official, state vaccine coordinator, state emergency manager, and other state leaders working on the state's COVID-19 response and recovery efforts.

Read-Ahead & Additional Documents for the Briefing

Today's briefing will focus on COVID-19 response and recovery, and an update on efforts to develop, approve, manufacture, and distribute a safe and effective vaccine. Below and attached are documents we wanted to provide to you and your team as a read-ahead and additional background information.

Attachment 1: Read-Ahead Documents

- Fact Sheet: Explaining Operation Warp Speed
- HHS Secretary Azar Op-Ed in the USA Today: How We're Developing a COVID-19 Vaccine at 'Warp Speed'
- Dr. Slaoui & Dr. Hepburn Op-Ed in The New England Journal of Medicine: Developing Safe & Effective Covid Vaccines - Operation Warp Speed's Strategy & Approach

- o FDA Commissioner Hahn Op-Ed in the Washington Post: No Matter What, Only a Safe, Effective Vaccine Will Get Our Approval

Attachment 2: Additional Documents

- o Governor Letter from Director Robert Redfield, *M.D., Centers for Disease Control & Prevention (CDC)* (August 27, 2020)
- o State & Local Public Health Leaders Letter from Nancy Messonnier, *M.D., Director, National Center for Immunization and Respiratory Diseases, Centers for Disease Control & Prevention (CDC)* (August 4, 2020)
- o CDC Document – COVID-19 Vaccination Program Planning Assumptions for Jurisdictions
- o CDC Document – Early COVID-19 Vaccination Program Action Items for Jurisdictions
- o CDC Document – COVID-19 Vaccination Scenarios for Jurisdictional Planning—Phase 1, Q4 2020

Federal Participants (Subject to Change)

Below is a list of expected participants for today’s briefing focused on COVID-19 response and recovery, and an update on efforts to develop, approve, manufacture, and distribute a safe and effective vaccine.

- Secretary Alex Azar, *U.S. Department of Health & Human Services (HHS)*
- Ambassador Deborah Birx, *M.D., White House Coronavirus Task Force Coordinator*
- Commissioner Stephen Hahn, *M.D., U.S. Food & Drugs Administration (FDA)*
- Director Robert Redfield, *Centers for Disease Control & Prevention (CDC)*
- Administrator Seema Verma, *Centers for Medicare & Medicaid Services (CMS)*
- Director Anthony Fauci, *M.D., National Institute for Allergies & Infections Disease (NIAID)*
- General Gustave Perna, *Chief Operation Officer, OWS, U.S. Army Materiel Command, U.S. Department of Defense (DOD)*
- Moncef Slaoui, *PhD., Chief Advisor, Operation Warp Speed (OWS)*
- Director Peter Marks, *M.D., PhD., Centers for Biologics Evaluation & Research, FDA*
- Rear Admiral John Polowczyk, *Joint Chiefs of Staff, DOD*
- The Office of the Vice President
- The White House Office Intergovernmental Affairs

If you have any additional questions, please reach out to the White House Intergovernmental Affairs Office or the Office of the Vice President.

Name	Cell Phone	Email
Nic Pottebaum	[REDACTED]	Nicholas.D.Pottebaum@who.eop.gov
Tucker Obenshain	[REDACTED]	Anne.T.Obenshain@ovp.eop.gov
Zach Swint	[REDACTED]	Zachariah.D.Swint2@who.eop.gov
Haley Friedman	[REDACTED]	Haley.Z.Friedman@who.eop.gov
Christopher Lopez	[REDACTED]	DiegoChristopher.Lopez2@who.eop.gov

Christopher Lopez

The White House | Office of Intergovernmental Affairs

Cell: [REDACTED] Office: 202-456-1680

Read-Ahead Documents

September 9, 2020

- **Fact Sheet:** Explaining Operation Warp Speed ([Here](#))
- **HHS Secretary Azar Op-Ed in the USA Today:** How We're Developing a COVID-19 Vaccine at 'Warp Speed'
- **Dr. Slaoui & Dr. Hepburn Op-Ed in The New England Journal of Medicine:** Developing Safe & Effective Covid Vaccines - Operation Warp Speed's Strategy & Approach
- **FDA Commissioner Hahn Op-Ed in the Washington Post:** No Matter What, Only a Safe, Effective Vaccine Will Get Our Approval



Explaining Operation Warp Speed

What's the goal?

Operation Warp Speed's goal is to produce and deliver 300 million doses of safe and effective vaccines with the initial doses available by January 2021, as part of a broader strategy to accelerate the development, manufacturing, and distribution of COVID-19 vaccines, therapeutics, and diagnostics (collectively known as countermeasures).

How will the goal be accomplished?

By investing in and coordinating countermeasure development, OWS will allow countermeasures such as a vaccine to be delivered to patients more rapidly while adhering to standards for safety and efficacy.

Who's working on Operation Warp Speed?

OWS is a partnership among components of the Department of Health and Human Services (HHS), including the Centers for Disease Control and Prevention (CDC), the Food and Drug Administration (FDA), the National Institutes of Health (NIH), and the Biomedical Advanced Research and Development Authority (BARDA), and the Department of Defense (DoD). OWS engages with private firms and other federal agencies, including the Department of Agriculture, the Department of Energy, and the Department of Veterans Affairs. It will coordinate existing HHS-wide efforts, including the NIH's Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) partnership, NIH's Rapid Acceleration of Diagnostics (RADx) initiative, and work by BARDA.

What's the plan and what's happened so far?

DEVELOPMENT: To accelerate development while maintaining standards for safety and efficacy, OWS has been selecting the most promising countermeasure candidates and providing coordinated government support.

Protocols for the demonstration of safety and efficacy are being aligned, which will allow these harmonized clinical trials to proceed more quickly, and the protocols for the trials will be overseen by the federal government (NIH), as opposed to traditional public-private partnerships, in which pharmaceutical companies decide on their own protocols. Rather than eliminating steps from traditional development timelines, steps will proceed simultaneously, such as starting manufacturing of vaccines and therapeutics at industrial scale well before the demonstration of efficacy and safety as happens normally. This increases the financial risk, but not the product risk.

Select actions to support OWS vaccine and therapeutic development so far include:

- **March 30:** HHS announced \$456 million in funds for Johnson & Johnson's (Janssen) candidate vaccine. Phase 1 clinical trials began in Belgium on July 24th and in the U.S on July 27th.
- **April 16:** HHS made up to \$483 million in support available for Moderna's candidate vaccine, which began Phase 1 trials on March 16 and received a fast-track designation from FDA. This agreement was expanded on July 26 to include an additional \$472 million to support late-stage clinical development, including the expanded Phase 3 study of the company's mRNA vaccine, which began on July 27th.
- **May 21:** HHS announced up to \$1.2 billion in support for AstraZeneca's candidate vaccine, developed in conjunction with the University of Oxford. The agreement is to make available at least 300 million doses of the vaccine for the United States, with the first doses delivered as early as October 2020, if the product successfully receives FDA EUA or licensure. AstraZeneca's large-scale Phase 3 clinical trial began on August 31, 2020.
- **July 7:** HHS announced \$450 million in funds to support the large-scale manufacturing of Regeneron's COVID-19 investigational anti-viral antibody treatment, REGN-COV2. This agreement is the first of a number of OWS awards to support potential therapeutics all the way through to manufacturing. As part of the manufacturing demonstration project, doses of the medicine will be packaged and ready to ship immediately if clinical trials are successful and FDA grants EUA or licensure.
- **July 7:** HHS announced \$1.6 billion in funds to support the large-scale manufacturing of Novavax's vaccine candidate. By funding Novavax's manufacturing effort, the federal government will own the 100 million doses expected to result from the demonstration project.
- **July 22:** HHS announced up to \$1.95 billion in funds to Pfizer for the large-scale manufacturing and nationwide distribution of 100 million doses of their vaccine candidate. The federal government will own the 100 million doses of vaccine initially produced as a result of this agreement, and Pfizer will deliver the doses in the United States if the product successfully receives FDA EUA or licensure, as outlined in FDA guidance, after completing demonstration of safety and efficacy in a large Phase 3 clinical trial, which began July 27th.
- **July 31:** HHS announced approximately \$2 billion in funds to support the advanced development, including clinical trials and large scale manufacturing, of Sanofi and GlaxoSmithKline's (GSK) investigational adjuvanted vaccine. By funding the manufacturing effort, the federal government will own the approximately 100 million doses expected to result from the demonstration project. The adjuvanted vaccine doses could be used in clinical trials or, if the FDA authorizes use, as outlined in agency guidance, the doses would be distributed as part of a COVID-19 vaccination campaign.
- **August 5:** HHS announced approximately \$1 billion in funds to support the large-scale manufacturing and delivery of Johnson & Johnson's (Janssen) investigational vaccine candidate. Under the terms of the agreement, the U.S. Government will own the resulting 100 million doses of vaccine, and will have the option to acquire more. The company's investigational vaccine relies on Janssen's recombinant adenovirus technology, AdVac, a technology used to develop and manufacture Janssen's Ebola vaccine with BARDA support; that vaccine received European Commission approval and was used in the Democratic Republic of the Congo (DRC) and Rwanda during the 2018-2020 Ebola outbreak that began in the DRC.

- **August 11:** HHS **announced** up to \$1.5 billion in funds to support the large-scale manufacturing and delivery of Moderna's investigational vaccine candidate. Under the terms of the agreement, the U.S. Government will own the resulting 100 million doses of vaccine, and will have the option to acquire more. The vaccine, called mRNA-1273, has been co-developed by Moderna and scientists from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. NIAID has continued to support the vaccine's development including nonclinical studies and clinical trials. Additionally, BARDA has supported phase 2/3 clinical trials, vaccine manufacturing scale up and other development activities for this vaccine. The Phase 3 clinical trial, which began July 27, is the first government-funded Phase 3 clinical trial for a COVID-19 vaccine in the United States.
- **August 23:** As part of the agency's efforts to combat COVID-19, the FDA **issued** an emergency use authorization (EUA) for investigational convalescent plasma. Based on available scientific evidence, the FDA determined convalescent plasma may be effective in lessening the severity or shortening the length of COVID-19 illness in hospitalized patients, and that the known and potential benefits of the product outweigh the known and potential risks. The EUA authorizes the distribution of convalescent plasma in the U.S. as well as its administration by health care providers, as appropriate, to treat suspected or confirmed cases of COVID-19. [Click here](#) to learn more about EUAs.

As announced on May 15, the vaccine development plan is as follows, subject to change as work proceeds:

- **Fourteen** promising candidates have been chosen from the 100+ vaccine candidates currently in development—some of them already in clinical trials with U.S. government support.
- **The 14** vaccine candidates are being narrowed down to about seven candidates, representing the most promising candidates from a range of technology options (nucleic acid, viral vector, protein subunit), which will go through further testing in early-stage clinical trials.
- **Large-scale** randomized trials for the demonstration of safety and efficacy will proceed for the most promising candidates.

MANUFACTURING: The federal government is making investments in the necessary manufacturing capacity at its own risk, giving firms the confidence to invest aggressively in development which will allow faster distribution of an eventual vaccine. Manufacturing capacity for selected candidates will be advanced while they are still in development, rather than scaled up after approval or authorization. Manufacturing capacity developed will be used for whatever vaccine is eventually successful, if possible given the nature of the successful product, regardless of which firms have developed the capacity.

Select actions to support OWS manufacturing efforts so far include:

- **The May 21, April 16, and March 30** HHS agreements with AstraZeneca, Moderna, and Johnson & Johnson respectively include investments in manufacturing capabilities.
- **June 1:** HHS announced a task order with Emergent BioSolutions to advance domestic manufacturing capabilities and capacity for a potential COVID-19 vaccine as well as therapeutics, worth approximately \$628 million, using Emergent's BARDA-supported Center for Innovation in Advanced Department and Manufacturing.

- **July 27:** HHS announced a task order with Texas A&M University and FUJIFILM to advance domestic manufacturing capabilities and capacity for a potential COVID-19 vaccine, worth approximately \$265 million, using another BARDA-supported CIADM.
- **August 4:** Grand River Aseptic Manufacturing Inc., (GRAM) Grand Rapids, Michigan, was awarded a \$160 million firm-fixed-price contract for domestic aseptic fill and finish manufacturing capacity for critical vaccines and therapeutics in response to the COVID-19 pandemic.

DISTRIBUTION: Before the countermeasures are approved or authorized, the program will build the necessary plans and infrastructure for distribution.

HHS plans for a tiered approach to vaccine and therapeutic distribution, which will build on allocation methodology developed as part of pandemic flu planning and be adjusted based on experience from the COVID-19 response so far, data on the virus and its impact on populations and the performance of a given countermeasure, and the needs of the essential workforce. OWS will expand domestic manufacturing and supplies of specialized materials and resources, such as glass vials, that can be necessary for distribution. DoD's involvement will enable faster distribution and administration than would have otherwise been possible.

Select actions to support OWS vaccine and therapeutic development so far include:

- **May 12:** DoD and HHS announced a \$138 million contract with ApJect for more than 100 million prefilled syringes for distribution across the United States by year-end 2020, as well as the development of manufacturing capacity for the ultimate production goal of over 500 million prefilled syringes in 2021.
- **June 9:** HHS and DoD announced a joint effort to increase domestic manufacturing capacity for vials that may be needed for vaccines and treatments.
- **June 11:** HHS announced \$204 million in funds to Corning to expand the domestic manufacturing capacity to produce approximately 164 million Valor Glass vials per year if needed. Valor Glass provides chemical durability to minimize particulate contamination. The specialized glass allows for rapid filling and capping methods that can increase manufacturing throughput by as much as 50 percent compared with conventional filling lines, which in turn can reduce the overall manufacturing time for vaccines and therapies.
- **June 11:** HHS announced \$143 million to SiO₂ Materials Science to ramp up capacity to produce the company's glass-coated plastic container, which can be used for drugs and vaccines. The new lines provide the capacity to produce an additional 120 million vials per year if needed.
- **August 14:** HHS and DoD announced that McKesson Corporation will be a central distributor of future COVID-19 vaccines and related supplies needed to administer the pandemic vaccinations. The CDC is executing an existing contract option with McKesson to support vaccine distribution. The company also distributed the H1N1 vaccine during the H1N1 pandemic in 2009-2010. The current contract with McKesson, awarded as part of a competitive bidding process in 2016, includes an option for the distribution of vaccines in the event of a pandemic. Detailed planning is underway to ensure rapid distribution as soon as the FDA authorizes one or more vaccines. Once these decisions are made, McKesson will work under CDC's guidance to ship COVID-19 vaccines to administration sites.

Who's leading Operation Warp Speed?

HHS Secretary Alex Azar and Defense Secretary Mark Esper oversee OWS, with Dr. Moncef Slaoui designated as chief advisor and General Gustave F. Perna confirmed as the chief operating officer. To allow these OWS leaders to focus on operational work, in the near future the program will be announcing separate points of contact, with deep expertise and involvement in the program, for communication with Congress and the public.

What are you doing to make these products affordable for Americans?

The Administration is committed to providing free or low-cost COVID-19 countermeasures to the American people as fast as possible. Any vaccine or therapeutic doses purchased with US taxpayer dollars will be given to the American people at no cost.

How is Operation Warp Speed being funded?

Congress has directed almost \$10 billion to this effort through supplemental funding, including the CARES Act. Congress has also appropriated other flexible funding. The almost \$10 billion specifically directed includes more than \$6.5 billion designated for countermeasure development through BARDA and \$3 billion for NIH research.

How we're developing a COVID-19 vaccine at 'Warp Speed': Alex Azar

Date: September 2, 2020

By: Alex M. Azar II, Secretary of the Department of Health and Human Services and Dr. Moncef Slaoui

Summary: We are encouraged by the progress so far, and hope to celebrate the successful delivery of a safe and effective vaccine soon.

This article first appeared in [USA Today](#) on September 2, 2020

President Trump launched Operation Warp Speed (OWS) to accomplish something the world has never done before: harnessing the full power of the Federal government, the private sector, the military and the scientific community to deliver substantial quantities of a safe and effective vaccine within a year after the discovery of a new virus. The strategy we devised for OWS will allow us to accomplish this goal while following all the same procedures for safety and efficacy, applied by the same apolitical FDA experts, that Americans expect with all vaccines.

So far, the OWS strategy is working. We originally established our objective — substantial quantities of a safe and effective vaccine no later than January 2021 — as an optimistic target. While one can never guarantee success in any scientific endeavor, it is now becoming increasingly likely we will deliver this historic victory for the American people and the world.

The strategy of OWS meant to accelerate the timeline

The strategy behind OWS was recently described in a [perspective published](#) in The New England Journal of Medicine. In brief, the strategy aims to accelerate the timeline and maximize the probability of delivering a safe and effective vaccine by carefully selecting scientifically sound and promising candidates, building a diverse portfolio of vaccine candidates to mitigate risk of technical failure, providing unprecedented levels of support for clinical trials, and engaging simultaneously in industrial-scale manufacturing "at risk"— i.e., manufacturing the vaccine candidates while still conducting the clinical trials.

Each of these elements of the strategy makes OWS a unique public-private partnership and an unprecedented alliance of scientific and industrial expertise. This partnership will substantially shorten the timeline needed to bring a vaccine to the American people and, through transparent sharing of all safety and efficacy data with the scientific community, ensure that FDA's assessment meets the same standards as those applied for any other vaccine, without undue pressure or influence.

To select the candidates, four criteria were developed in consultation with experts across the Federal Government — from the National Institutes of Health, the Biomedical Advanced Research and Development Authority, the Food and Drug Administration, the Department of Defense's scientific components, and elsewhere.

Candidate vaccines needed robust scientific data supporting them. They needed the potential to enter large-scale Phase 3 trials for efficacy by the summer or fall of 2020. They had to be based on vaccine technologies that permit rapid and effective manufacturing. Finally, they had to use one of four vaccine-platform technologies we believed most likely to yield a safe and effective vaccine against COVID-19. These four platforms — the messenger RNA platform, the replication-defective live-vector platform, the recombinant subunit adjuvanted protein platform, and the attenuated replicating live-vector platform — represent a continuum, from unproven but highly promising technologies to technologies used to deliver vaccines for decades. By aiming to select eight candidates for support, two from each platform, we have built a portfolio that will maximize our chances at success.

Each of the candidates selected has received support for some combination of research and development, clinical trials, and industrial manufacturing. These financial investments, thus far totaling more than \$10 billion, combined with significant technical and logistical support, allow each company to undertake several steps of the vaccine development process in parallel, mitigating its financial risk without compromising the safety and efficacy of its vaccine.

For instance, companies have used these investments to conduct clinical trial site preparation for Phase 3 trials as soon as they began Phase 1 studies. With the active support of Federal partners, companies are recruiting 30,000 to 50,000 volunteers in each of the Phase 3 trials, which is a larger scale than typical vaccine trials, to allow fast answers on efficacy and a broader set of data for determining safety. More patients are enrolling in trials at a faster pace than we have ever seen, and work continues with trusted partners to ensure we have diverse populations represented in these trials.

Things are underway with OWS

OWS is supporting the selected companies in building or adapting manufacturing facilities needed for the vaccines, while also supporting manufacturing of ancillary products such as needles, syringes, stoppers and vials. The messenger RNA vaccines are already being manufactured at scale, while manufacturing sites for other candidates are in the process of being refurbished and will soon begin manufacturing.

Results from all these efforts are promising: three OWS-supported candidates are in Phase 3 trials in the United States, and more are expected to enter United States Phase 3 trials by the end of September. While there are no guarantees in science, we can assure Americans that OWS is structured, resourced and led to maximize the probability of success.

Thanks to OWS, the entire process for delivering a safe and effective vaccine — to be assessed by FDA's apolitical scientific experts just as any other vaccine would be — is underway and on track. We are immensely encouraged by the progress so far, and hope to celebrate the successful delivery of a safe and effective vaccine in large quantities in the months to come.

Alex M. Azar II (@SecAzar) is U.S. Secretary of Health and Human Services. Moncef Slaoui is chief scientific advisor to Operation Warp Speed.



Perspective

Developing Safe and Effective Covid Vaccines — Operation Warp Speed's Strategy and Approach

Moncef Slaoui, Ph.D., and Matthew Hepburn, M.D.

Announced on May 15, Operation Warp Speed (OWS) — a partnership of the Department of Health and Human Services (HHS), the Department of Defense (DOD), and the private sector

— aims to accelerate control of the Covid-19 pandemic by advancing development, manufacturing, and distribution of vaccines, therapeutics, and diagnostics. OWS is providing support to promising candidates and enabling the expeditious, parallel execution of the necessary steps toward approval or authorization of safe products by the Food and Drug Administration (FDA).

The partnership grew out of an acknowledged need to fundamentally restructure the way the U.S. government typically supports product development and vaccine distribution. The initiative was premised on setting a “stretch goal” — one that initially seemed impossible but that is becoming increasingly achievable.

The concept of an integrated structure for Covid-19 countermeasure research and development across the U.S. government was based on experience with Zika and the Zika Leadership Group led by the National Institutes of Health (NIH) and the assistant secretary for preparedness and response (ASPR). One of us (M.S.) serves as OWS chief advisor. We are drawing on expertise from the NIH, ASPR, the Centers for Disease Control and Prevention (CDC), the Biomedical Advanced Research and Development Authority (BARDA), and the DOD, including the Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense and the Defense Advanced Research Projects Agency. OWS

has engaged experts in all critical aspects of medical countermeasure research, development, manufacturing, and distribution to work in close coordination.

The initiative set ambitious objectives: to deliver tens of millions of doses of a SARS-CoV-2 vaccine — with demonstrated safety and efficacy, and approved or authorized by the FDA for use in the U.S. population — beginning at the end of 2020 and to have as many as 300 million doses of such vaccines available and deployed by mid-2021. The pace and scope of such a vaccine effort are unprecedented. The 2014 West African Ebola virus epidemic spurred rapid vaccine development, but though preclinical data existed before the outbreak, a period of 12 months was required to progress from phase 1 first-in-human trials to phase 3 efficacy trials. OWS aims to compress this time frame even further. SARS-CoV-2 vaccine devel-

opment began in January, phase 1 clinical studies in March, and the first phase 3 trials in July. Our objectives are based on advances in vaccine platform technology, improved understanding of safe and efficacious vaccine design, and similarities between the SARS-CoV-1 and SARS-CoV-2 disease mechanisms.

OWS's role is to enable, accelerate, harmonize, and advise the companies developing the selected vaccines. The companies will execute the clinical or process development and manufacturing plans, while OWS leverages the full capacity of the U.S. government to ensure that no technical, logistic, or financial hurdles hinder vaccine development or deployment.

OWS selected vaccine candidates on the basis of four criteria. We required candidates to have robust preclinical data or early-stage clinical trial data supporting their potential for clinical safety and efficacy. Candidates had to have the potential, with our acceleration support, to enter large phase 3 field efficacy trials this summer or fall (July to November 2020) and, assuming continued active transmission of the virus, to deliver efficacy outcomes by the end of 2020 or the first half of 2021. Candidates had to be based on vaccine-platform technologies permitting fast and effective manufacturing, and their developers had to demonstrate the industrial process scalability, yields, and consistency necessary to reliably produce more than 100 million doses by mid-2021. Finally, candidates had to use one of four vaccine-platform technologies that we believe are the most likely to yield a safe and effective vaccine against Covid-19:

the mRNA platform, the replication-defective live-vector platform, the recombinant-subunit-adjuvanted protein platform, or the attenuated replicating live-vector platform.

OWS's strategy relies on a few key principles. First, we sought to build a diverse project portfolio that includes two vaccine candidates based on each of the four platform technologies. Such diversification mitigates the risk of failure due to safety, efficacy, industrial manufacturability, or scheduling factors and may permit selection of the best vaccine platform for each subpopulation at risk for contracting or transmitting Covid-19, including older adults, frontline and essential workers, young adults, and pediatric populations. In addition, advancing eight vaccines in parallel will increase the chances of delivering 300 million doses in the first half of 2021.

Second, we must accelerate vaccine program development without compromising safety, efficacy, or product quality. Clinical development, process development, and manufacturing scale-up can be substantially accelerated by running all streams, fully resourced, in parallel. Doing so requires taking on substantial financial risk, as compared with the conventional sequential development approach. OWS will maximize the size of phase 3 trials (30,000 to 50,000 participants each) and optimize trial-site location by consulting daily epidemiologic and disease-forecasting models to ensure the fastest path to an efficacy readout. Such large trials also increase the safety data set for each candidate vaccine.

With heavy up-front investment, companies can conduct clin-

ical operations and site preparation for these phase 3 efficacy trials even as they file their Investigational New Drug application (IND) for their phase 1 studies, thereby ensuring immediate initiation of phase 3 when they get a green light from the FDA. To permit appropriate comparisons among the vaccine candidates and to optimize vaccine utilization after approval by the FDA, the phase 3 trial end points and assay readouts have been harmonized through a collaborative effort involving the National Institute of Allergy and Infectious Diseases (NIAID), the Coronavirus Prevention Network, OWS, and the sponsor companies.

Finally, OWS is supporting the companies financially and technically to commence process development and scale up manufacturing while their vaccines are in preclinical or very early clinical stages. To ensure that industrial processes are set, running, and validated for FDA inspection when phase 3 trials end, OWS is also supporting facility building or refurbishing, equipment fitting, staff hiring and training, raw-material sourcing, technology transfer and validation, bulk product processing into vials, and acquisition of ample vials, syringes, and needles for each vaccine candidate. We aim to have stockpiled, at OWS's expense, a few tens of millions of vaccine doses that could be swiftly deployed once FDA approval is obtained.

This strategy aims to accelerate vaccine development without curtailing the critical steps required by sound science and regulatory standards. The FDA recently reissued guidance and standards that will be used to assess each vaccine for a Biologics License

Application (BLA). Alternatively, the agency could decide to issue an Emergency Use Authorization to permit vaccine administration before all BLA procedures are completed.

Of the eight vaccines in OWS's portfolio, six have been announced and partnerships executed with the companies: Moderna and Pfizer/BioNTech (both mRNA), AstraZeneca and Janssen (both replication-defective live-vector), and Novavax and Sanofi/GSK (both recombinant-subunit-adjuvanted protein). These candidates cover three of the four platform technologies and are currently in clinical trials. The remaining two candidates will enter trials soon.

Moderna developed its RNA vaccine in collaboration with the NIAID, began its phase 1 trial in March, recently published encouraging safety and immunogenicity data,¹ and entered phase 3 on July 27. Pfizer and BioNTech's RNA vaccine also produced encouraging phase 1 results² and started its phase 3 trial on July 27. The ChAdOx1 replication-defective live-vector vaccine developed by AstraZeneca and Oxford University is in phase 3 trials in the United Kingdom, Brazil, and South Africa, and it should enter U.S. phase 3 trials in August.³ The Janssen Ad26 Covid-19 replication-defective live-vector vaccine has demonstrated excellent protection in nonhuman primate models and began its U.S. phase 1 trial

on July 27; it should be in phase 3 trials in mid-September. Novavax completed a phase 1 trial of its recombinant-subunit-adjuvanted protein vaccine in Australia and should enter phase 3 trials in the United States by the end of September.⁴ Sanofi/GSK is completing preclinical development steps and plans to commence a phase 1 trial in early September and to be well into phase 3 by year's end.⁵

On the process-development front, the RNA vaccines are already being manufactured at scale. The other candidates are well advanced in their scale-up development, and manufacturing sites are being refurbished.

While development and manufacturing proceed, the HHS-DOD partnership is laying the groundwork for vaccine distribution, subpopulation prioritization, financing, and logistic support. We are working with bioethicists and experts from the NIH, the CDC, BARDA, and the Centers for Medicare and Medicaid Services to address these critical issues. We will receive recommendations from the CDC Advisory Committee on Immunization Practices, and we are working to ensure that the most vulnerable and at-risk persons will receive vaccine doses once they are ready. Prioritization will also depend on the relative performance of each vaccine and its suitability for particular populations. Because some technologies have limited previous data on safety in hu-

mans, the long-term safety of these vaccines will be carefully assessed using pharmacovigilance surveillance strategies.

No scientific enterprise could guarantee success by January 2021, but the strategic decisions and choices we've made, the support the government has provided, and the accomplishments to date make us optimistic that we will succeed in this unprecedented endeavor.

Disclosure forms provided by the authors are available at NEJM.org.

From Operation Warp Speed, Department of Health and Human Services, Washington, DC.

This article was published on August 26, 2020, at NEJM.org.

1. Jackson LA, Anderson EJ, Rouphael NG, et al. An mRNA vaccine against SARS-CoV-2 — preliminary report. *N Engl J Med*. DOI: 10.1056/NEJMoa2022483.
2. Mulligan MJ, Lyke KE, Kitchin N, et al. Phase 1/2 study to describe the safety and immunogenicity of a COVID-19 vaccine candidate (BNT162b1) in adults 18 to 55 years of age; interim report. July 1, 2020 (<https://www.medrxiv.org/content/10.1101/2020.06.30.20142570v1>). preprint.
3. Folegatti PM, Ewer KJ, Aley PK, et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. *Lancet* 2020; 396:467-78.
4. Keech C, Albert G, Reed P, et al. First-in-human trial of a SARS CoV 2 recombinant spike protein nanoparticle vaccine. August 6, 2020 (<https://www.medrxiv.org/content/10.1101/2020.08.05.20168435v1.full.pdf+html>); preprint.
5. Sanofi and GSK selected for Operation Warp Speed to supply United States government with 100 million doses of COVID-19 vaccine. Press release of Sanofi, July 31, 2020 (<https://www.sanofi.com/en/media-room/press-releases/2020/2020-07-31-13-00-00>).

DOI: 10.1056/NEJMp2027405

Copyright © 2020 Massachusetts Medical Society.

FDA Commissioner: No Matter What, Only a Safe, Effective Vaccine Will Get Our Approval

Date: August 5, 2020

By: Stephen M. Hahn, a physician, is commissioner of the Food and Drug Administration.

This article first appeared in the [Washington Post](#) on August 5, 2020

Since the outbreak of the covid-19 pandemic, developing a safe and effective vaccine has been an urgent worldwide priority: to save lives, and to bolster the public's confidence in returning to a semblance of normal life.

At the Food and Drug Administration and our parent agency, the Department of Health and Human Services, we recognize the vital importance of vaccine development. The framework in the United States to support a covid-19 vaccine is now in place. Testing is underway and manufacturing capacity is rapidly expanding. But let's be clear: The development effort must adhere to standards that will ensure any covid-19 vaccine's safety and effectiveness.

Large-scale clinical trials already have begun for several promising vaccine candidates. The data from these trials will enable the scientists at the FDA to determine which of these candidates has the greatest potential to provide protection from the virus, what the possible side effects are and how long immunity is likely to last. FDA scientists will need the information to decide whether approval of the vaccine for general use is justified. This fall, we expect to start identifying which vaccine candidates are truly viable.

At the same time, our colleagues at Operation Warp Speed, which operates independently of the FDA as a partnership between HHS and the Defense Department, have been arranging for the stockpiling of vials and other equipment needed for a national immunization program.

Success will hinge, of course, on the data that emerges from clinical trials. This testing by its very nature takes time: It takes time for the human body to develop immunity, and it often takes time for side effects to emerge. While speed is essential in this global emergency, we at the FDA are committed to maintaining strict scientific principles and protection of those who volunteer as vaccine test subjects.

To prepare for the completion of tests and data submission, our agency has announced that any authorized or approved covid-19 vaccine would need to show that it prevents the disease or decreases its severity in at least 50 percent of people who are vaccinated. This is a reasonable standard given the nature and impact of the pandemic.

One key element in the FDA's testing requirements is assuring diversity among the test subjects. All phases of vaccine clinical development should include the people most affected thus far by covid-19, specifically racial and ethnic minorities, elderly individuals, and people with other medical conditions. Only by gathering data on these populations can we gain a full understanding of a vaccine candidate's safety and effectiveness.

I have been asked repeatedly whether there has been any inappropriate pressure on the FDA to make decisions that are not based on good data and good science. I have repeatedly said that all FDA decisions have been, and will continue to be, based solely on good science and data. The public can count on that commitment.

Once FDA scientists determine that a covid-19 vaccine candidate meets the appropriate regulatory standards for safety and efficacy, a pathway will be created by the government to make the vaccine available without delay. And, of course, after authorization or approval by the FDA, the safety of any vaccine will be closely monitored.

Since we at the FDA are the final arbiters of whether a particular vaccine is safe and effective, I cannot make any predictions about timing of an emergency use or final approval of a covid-19 vaccine. But I can attest that every FDA resource has been, and will continue to be, at the ready to facilitate clinical testing programs, and to review clinical data and manufacturing facilities. I can further provide assurances that any vaccine authorized for widespread use will meet the appropriate standards for quality, safety and efficacy.

Additional Documents

September 9, 2020

- **Governor Letter from Director Robert Redfield, M.D., Centers for Disease Control & Prevention (CDC)** (August 27, 2020)
- **State & Local Public Health Leaders Letter from Nancy Messonnier, M.D., Director, National Center for Immunization and Respiratory Diseases, Centers for Disease Control & Prevention (CDC)** (August 4, 2020)
- **CDC Document – COVID-19 Vaccination Program Planning Assumptions for Jurisdictions**
- **CDC Document – Early COVID-19 Vaccination Program Action Items for Jurisdictions**
- **CDC Document – COVID-19 Vaccination Scenarios for Jurisdictional Planning—Phase 1, Q4 2020**



Centers for Disease Control
and Prevention (CDC)
Atlanta GA 30329-4027

August 27, 2020

Dear Governors:

The U.S. Department of Health and Human Services and the Centers for Disease Control and Prevention (CDC) are rapidly making preparations to implement large-scale distribution of COVID-19 vaccines in the fall of 2020. This vaccine distribution program is expected to be a public health effort of significant scale, potentially involving hundreds of millions of vaccine doses to be distributed across the U.S. CDC has contracted with McKesson Corporation ("McKesson") to distribute these vaccines to state and local health departments, medical facilities, doctor offices and other vaccine providers. In order to accomplish this massive task, McKesson must quickly open new distribution centers and obtain new permits and licenses. These applications may be submitted in McKesson's name or in the name of one of its subsidiaries. The normal time required to obtain these permits presents a significant barrier to the success of this urgent public health program.

In the near future, the appropriate state licensing agency will receive permit applications for the new McKesson distribution facilities. These permits are needed to allow McKesson to distribute the vaccine into or from your state. McKesson may also be applying for related business and building permits from local and state governmental entities. CDC urgently requests your assistance in expediting applications for these distribution facilities and, if necessary, asks that you consider waiving requirements that would prevent these facilities from becoming fully operational by November 1, 2020. The requirements you may be asked to waive in order to expedite vaccine distribution will not compromise the safety or integrity of the products being distributed.

Your assistance in helping expedite the issuance of necessary licenses and permits required for distribution centers to become operational will be critical to the success of this public health effort to mitigate the threat presented by COVID-19. Thank you for your time and consideration.

Sincerely,

Robert R. Redfield, M.D.
Director, CDC

cc: Governor's Chief of Staff
Director of State Health Department
Director of State Licensing Agency



August 4, 2020

COVID-19 Pandemic Vaccination Planning: Update for State and Local Public Health Programs

Dear Colleague:

CDC is working with other federal members of Operation Warp Speed (OWS) to plan and implement a COVID-19 vaccination program as soon as vaccine(s) is available. Thoughtful allocation of COVID-19 vaccine will be critical to prevent morbidity and mortality and reduce the impact of COVID-19 on society. Prioritization of populations to be reached early in the vaccination response when vaccine supply is limited is being considered by the Advisory Committee on Immunization Practices and the National Academy of Medicine.

To better assist in updating and implementing of existing pandemic vaccination plans and assess needs, five selected jurisdictions are serving as pilot sites for joint planning missions. These jurisdictions are:

- North Dakota
- Florida
- California
- Minnesota
- Philadelphia

The pilot jurisdictions will work with a multiagency federal team, including staff from CDC and Department of Defense, to plan and prepare for the COVID-19 vaccination response in their specific jurisdictions. In addition to supporting state, local, and tribal efforts in the selected jurisdictions, these will serve as a pilot for supporting other jurisdictions and will provide valuable insight into state/local planning efforts. A planning tool with model approaches will be developed from this work that will facilitate CDC and OWS support for all jurisdictions' COVID-19 vaccination planning efforts.

Although operational guidance for state programs has not been finalized, in this communication we are providing interim assumptions and recommended action steps.

Planning Assumptions

Many vaccine candidates are in development, and clinical trials are being conducted simultaneously with large-scale manufacturing. It is not known which vaccines will be approved. Planning needs to be flexible, but for the purpose of planning, certain vaccination assumptions will be made.

- Limited COVID-19 vaccine doses will be available in fall 2020.
- Initial populations recommended for COVID-19 vaccination will likely be those in the critical workforce who provide health care and maintain essential functions of society and

staff and residents in long term care facilities.

- Initial doses of COVID-19 vaccine may be authorized for use under an Emergency Use Authorization (EUA) issued by the Food and Drug Administration (FDA), based on available safety and efficacy data.
- Two doses of COVID-19 vaccine, separated by ≥ 21 or ≥ 28 days, will be needed for immunity for some vaccine candidates; both doses will need to be with the same product. This will require tracking vaccine administered and patient reminders.
- Some vaccine candidates require ultra low cold (ULC) chain.
- Recommendations for groups to target will likely change after vaccine is available, depending on characteristics of each vaccine, vaccine supply, and disease epidemiology.
- Because of uncertainty, planning needs to include high demand and low demand scenarios.
- Routine immunization programs will continue.

Although plans may change, CDC currently assumes COVID-19 vaccine distribution and tracking based on the following principles:

- COVID-19 vaccine distribution will be managed centrally, although vaccines may be handled through more than one distributor. Distribution may be expanded to include additional healthcare organizations and vaccination providers who can provide pandemic vaccinations to targeted groups. Vaccine will be sent directly to vaccination providers (e.g. physician's office) or designated depots for secondary distribution to administration sites (e.g. chain drug stores central distribution).
- COVID-19 vaccine will be allocated to each jurisdiction and selected commercial and federal partners. The amount of COVID-19 vaccine allocated to each jurisdiction will be based on several factors, including population size.
 - Pre-planning by jurisdictions should assume vaccine will be distributed directly to vaccine providers, whether directly by USG or by another entity.
 - COVID-19 vaccine providers must enroll with their jurisdiction's immunization program to receive vaccine. Multijurisdictional providers may have a Memorandum of Agreement (MOA) with the federal government and will need agreed-upon channels for communicating with each jurisdiction.
 - Enrolled vaccination providers receiving vaccine through their jurisdiction allocations will order COVID-19 vaccine from their jurisdiction's immunization program's allocation.
 - Jurisdictions should anticipate that allocations may shift during the course of the program based on supply, demand and disease epidemiology.
- COVID-19 vaccine and ancillary supplies (including needles and syringes for vaccine reconstitution and administration and limited masks and face shields) will be procured and distributed to providers proportionately by the federal government at no cost to enrolled pandemic vaccination providers.
- Insurance reimbursement for vaccine and administration costs are under consideration.
- Dose level accountability and reporting for ordering, distribution, and administration of two-dose vaccine series.

State and local public health programs should be completing these prioritized COVID-19 vaccination planning efforts:

- Convene a COVID vaccine program planning team that includes the relevant collaborators from your jurisdiction, HHS Regional Directors, professional organizations, etc.
- Develop/modify COVID-19 vaccination plan, in coordination with immunization and emergency preparedness counterparts. Jurisdictions should anticipate review of their plans by CDC and OWS. Plan should be drafted before October 1st, to coincide with earliest possible release of COVID-19 vaccine.
 - Plans should include timelines, deliverables and metrics. CDC will be providing additional detail on these deliverables and metrics and monitoring progress weekly prior to and during the vaccination campaign.
- Identify critical occupational groups (frontline HCP, safety, emergency, education, and other essential services) in each jurisdiction, and ensure relationships and plans are in place for targeted vaccination efforts.
- Finalize plans for temporary mass vaccination clinics.
- Prepare for dose level accountability and reporting for ordering, distribution, and administration of two-dose vaccine series.
 - Immunization information systems (IISs) that meet CDC's standards for COVID-19 response, including data sharing via the Immunization Gateway, timeliness, and completeness, may be used to document vaccination.
 - CDC is developing additional systems and tools for jurisdictions that are unable to meet these standards. A Vaccine Administration Monitoring System (VAMS) is in development to facilitate vaccination clinic scheduling, record-keeping for the vaccine recipient, and reporting.
- Augment routine community vaccination services to rapidly vaccinate the public when COVID-19 vaccine supply is sufficient.
 - Conduct additional outreach and onboard pharmacies, health systems, and long-term care partners that may be needed to rapidly execute a COVID-19 immunization program.
 - Sign agreements with providers specifying requirements to receive and administer COVID-19 vaccines. A federal provider agreement will be forthcoming.
 - Finalize legal agreements needed to connect to the Immunization Gateway to share data with federal response partners and other jurisdictions.
 - Onboard health care providers treating persons at highest risk for severe outcomes of COVID-19 (e.g., those with advanced age, hypertension, diabetes, cardiovascular disease, chronic obstructive pulmonary disease, immunosuppression, liver disease) to ensure efficient education and vaccination of these groups when COVID-19 vaccine supply increases.
- Identify communities at highest risk where additional vaccination outreach, including strong partnerships with trusted agents and community health centers, mobile outreach, and other efforts may be required to achieve high vaccine uptake.


USG actions to support jurisdictional planning efforts

- CDC will provide model plans, including concept of operations for targeting select populations (essential workers, long term care facilities, underserved communities).
- CDC will review jurisdiction-specific plans, and provide technical assistance as needed to ensure success.
- The Federal government will establish Memoranda of Agreement (MOA) with multijurisdictional providers (select large drug store chains, federal providers). Additional details on MOA and resources that may be provided are in development.

Assuming SARS-CoV-2 continues to circulate, vaccination plans must continue to ensure those seeking vaccine are protected from exposure. Health care settings must continue to include considerations for personal protective equipment (PPE), social distancing or spacing of patients and staff, and scheduling individual vaccination appointments, among other approaches. Vaccination clinics held at satellite, temporary, or off-site locations, including mass vaccination clinics, will require additional considerations. Additionally, curbside and drive-through clinics may provide the best option for staff and patient safety during the COVID-19 pandemic.

We appreciate all you and your staff have done over the past few months to respond to the COVID-19 pandemic. We look forward to working with you as we continue to plan and execute the COVID-19 vaccination response.

Sincerely,




Nancy Messonnier, MD
Director
National Center for Immunization and Respiratory Diseases
Centers for Disease Control and Prevention

Cc: Immunization Awardee Program Managers
Preparedness Directors
ASTHO

COVID-19 VACCINATION PROGRAM PLANNING ASSUMPTIONS FOR JURISDICTIONS

Many COVID-19 vaccine candidates are in development, and clinical trials are being conducted simultaneously with large-scale manufacturing. It is not known which vaccines will be approved. COVID-19 vaccination program plans must be flexible and accommodate multiple scenarios. For the purpose of initial planning, consider the following assumptions.



COVID-19 VACCINE

- Limited COVID-19 vaccine doses may be available by early November 2020, but COVID-19 vaccine supply will increase substantially in 2021.
- Initially available COVID-19 vaccines will either be approved as licensed vaccines or authorized for use under an Emergency Use Authorization (EUA) issued by the U.S. Food and Drug Administration (FDA).
- Cold chain storage and handling requirements for each COVID-19 vaccine product will vary from refrigerated (2° to 8°C) to frozen (-20°C) to ultra-cold (-60° to -80°C) temperatures, and ongoing stability testing may impact these requirements. *Note: These temperatures are based on information available as of August 26, 2020. Updated information will be provided as it becomes available.*
- Jurisdictions should develop strategies to ensure the correct match of COVID-19 vaccine products and dosing intervals. For most vaccines, two doses of COVID-19 vaccine, separated by either ≥ 21 or ≥ 28 days, will be needed for immunity, and second-dose reminders for patients will be necessary. Both doses will need to match each other (i.e., be the same vaccine product).
- Some COVID-19 vaccine products will likely require reconstitution with diluent or adjuvant at the point of administration.

COVID-19 VACCINE ALLOCATION

- The federal government will issue guidance on groups to prioritize for initial COVID-19 vaccination; populations of focus for initial COVID-19 vaccination will likely be:
 - Critical workforce that provides health care and maintains essential functions of society (see <https://www.cisa.gov/identifying-critical-infrastructure-during-covid-19>)
 - Staff and residents in long-term care and assisted living facilities
- Allocation of COVID-19 vaccine to jurisdictions will be based on multiple factors, including:
 - Populations recommended by the Advisory Committee on Immunization Practices (with input from the National Academy of Medicine)
 - Current local spread/prevalence of COVID-19
 - COVID-19 vaccine production and availability
- Jurisdictions should anticipate that allocations may shift during the response based on supply, demand, and risk.
- Each jurisdiction should plan for high-demand and low-demand scenarios.

COVID-19 VACCINATION PROVIDER OUTREACH AND ENROLLMENT

- To receive and administer COVID-19 vaccine and ancillary supplies, vaccination providers must enroll in the United States Government (USG) COVID-19 vaccination program, coordinated through their jurisdiction's immunization program, by signing and agreeing to conditions outlined in the *COVID-19 Vaccination Program Provider Agreement*.
- CDC will make this agreement available to each jurisdiction's immunization program for use in conducting outreach and enrolling vaccination providers. Jurisdictions will be required to maintain these agreements on file for a minimum of three years.
- Jurisdictions will be required to collect and submit to CDC information on each enrolled vaccination provider/site, including provider type and setting, patient population (i.e., number and type of patients served), refrigerated/frozen/ultra-cold temperature storage capacity, and logistical information for receiving COVID-19 vaccine shipments.

- Some multijurisdictional vaccination providers (e.g., select large drugstore chains, Indian Health Service [IHS], and other federal providers) will enroll directly with CDC to order and receive COVID-19 vaccine. These direct partners will be required to report vaccine supply and uptake information back to each respective jurisdiction. CDC will share additional information when available on these procedures to ensure jurisdictions have full visibility for planning and documentation purposes.
- Jurisdictions may choose to partner with commercial entities to reach the initial populations of focus.
- Routine immunization programs will continue.

To be determined:

- *Method of communicating provider enrollment and profile data between jurisdictions and CDC*
- *Specific multijurisdictional providers to be served directly by CDC*
- *Jurisdiction responsibility/involvement concerning multijurisdictional provider training*

COVID-19 VACCINE ORDERING AND DISTRIBUTION

- COVID-19 vaccine and ancillary supplies will be procured and distributed by the federal government at no cost to enrolled COVID-19 vaccination providers. CDC will share more information about reimbursement claims for administration fees as it becomes available.
- CDC will use its current centralized distribution contract to fulfill orders for most COVID-19 vaccine products as approved by jurisdiction immunization programs. Some vaccine products, such as those with ultra-cold temperature requirements, will be shipped directly from the manufacturer.
- Jurisdiction-enrolled vaccination providers will follow the jurisdiction's vaccine ordering procedures.
- COVID-19 vaccination providers will be required to report ongoing COVID-19 vaccine inventory.
- Vaccine orders will be approved and transmitted in CDC's Vaccine Tracking System (VTrackS) by jurisdiction immunization programs for vaccination providers they enroll.
- Vaccine (and adjuvant, if required) will be shipped to provider sites within 24 hours of order approval by the immunization program, if supply is available. Ancillary supply kits and diluent (if required) will ship separately from the vaccine due to different cold chain requirements, but shipment will be timed to arrive with or before the vaccine.
- Ancillary supply kits will include needles, syringes, alcohol prep pads, COVID-19 vaccination record cards for each vaccine recipient, and a minimal supply of personal protective equipment (PPE), including surgical masks and face shields, for vaccinators.
 - Each kit will include supplies needed to administer 100 doses of vaccine.
 - Jurisdictions may need to plan for additional PPE, depending on vaccination site needs.
 - For COVID-19 vaccines that require reconstitution with diluent or mixing adjuvant at the point of administration, these ancillary supply kits will include additional necessary syringes, needles, and other supplies for this purpose.
 - Sharps containers, gloves, bandages, and other supplies will not be included.
- Minimum order size for CDC centrally distributed vaccines will be 100 doses per order for most vaccines. Minimum order size for direct-ship vaccines may be much larger. CDC will provide more detail as it becomes available.
- Vaccine will be sent directly to vaccination provider locations for administration or designated depots for secondary distribution to administration sites (e.g., chain drugstores' central distribution).
- Once vaccine products have been shipped to a provider site, the federal government will not redistribute product.
- Jurisdictions will be allowed to redistribute vaccines while maintaining the cold chain. However, with the challenge of meeting cold chain requirements for frozen or ultra-cold vaccines, jurisdictions should be judicious in their use of redistribution and limit any redistribution to refrigerated vaccines only.
- Jurisdictions are not advised to purchase ultra-cold storage equipment at this time; ultra-cold vaccine may be shipped from the manufacturer in coolers that are packed with dry ice, can store vaccine for an extended period of time, and can be repacked for longer use. CDC will provide additional detail as it becomes available.

To be determined:

- *Frequency requirement for provider-level COVID-19 vaccine inventory reporting*
- *Vaccine disposal/recovery procedures*

COVID-19 VACCINE ADMINISTRATION DATA REPORTING

- Jurisdictions will be required to report CDC-defined data elements related to vaccine administration daily (i.e., every 24 hours). CDC will provide information on these data elements to jurisdictions.
- All vaccination providers may be required to report and maintain their COVID-19 vaccination information on CDC's [Vaccine Finder](#).
- CDC's Vaccine Administration Management System (VAMS) will be available to jurisdictions/provider sites that need assistance in patient registration and scheduling, clinic flow, supply management, patient record management, and reporting.
- CDC has prioritized jurisdiction onboarding to the Immunization (IZ) Gateway* to allow Immunization Information Systems (IISs) to receive data directly from national providers, nontraditional vaccination providers, and VAMS, as well as to report vaccine administration data to CDC.
- Data Use Agreements (DUAs) will be required for data sharing via the IZ Gateway and other methods of vaccine administration data sharing with CDC, and will be coordinated by each jurisdiction's immunization program.

To be determined:

- *Jurisdiction responsibility/involvement concerning reporting of data from multijurisdictional providers*
- *Method and frequency for vaccination providers to report information to Vaccine Finder*

COMMUNICATION

- CDC will develop communication resources for jurisdictions to use with key audiences. These resources will be available on a public-facing website currently under development, but jurisdictions will likely need to tailor messaging and resources specific to special populations in their communities.
- CDC will work with national organizations to disseminate key messages.
- Communication and educational materials about COVID-19 vaccination provider enrollment, COVID-19 vaccine ordering, COVID-19 vaccine storage, handling, administration (i.e., reconstitution, adjuvant use, administration techniques), etc. will be available in a variety of formats.
- When vaccine supply is available for expanded groups among the general population, a national COVID-19 vaccine finder will be available on the public-facing [Vaccine Finder](#).
- A screening tool on the CDC website will help individuals determine their own eligibility for COVID-19 vaccine and direct them to the Vaccine Finder.


COVID-19 VACCINE SAFETY

- Clinically important adverse events following any vaccination should be reported to the Vaccine Adverse Event Reporting System ([VAERS](#)).
- Adverse events will also be monitored through electronic health record (EHR)- and claims-based systems (e.g., [Vaccine Safety Datalink](#)).
- Additional vaccine safety monitoring may be required under the EUA.

* The IZ Gateway is a portfolio of project components which share a common IT infrastructure. The IZ Gateway aims to rapidly onboard IISs to support readiness for COVID-19 vaccine response through data exchange, both among IIS and between IIS and federal providers, mass vaccination reporting and consumer access tools. The IZ Gateway aims to increase the availability and volume of complete and accurate immunization data stored within IIS and available to providers and consumers regardless of their jurisdictional boundaries.

EARLY COVID-19 VACCINATION PROGRAM ACTION ITEMS FOR JURISDICTIONS

Use this checklist to assist in **early** planning for the COVID-19 vaccination program. Jurisdictions must be prepared to **immediately** vaccinate identified critical populations when the earliest COVID-19 vaccine doses are available and approved by the U.S. Food and Drug Administration (FDA). Jurisdictions should also begin planning for vaccination of the rest of the general population when COVID-19 vaccine supply allows.



DETERMINE ORGANIZATIONAL STRUCTURE AND PARTNER INVOLVEMENT

- Convene internal planning and coordination team(s) whose members represent a wide array of expertise.
 - Include representatives from immunization program, preparedness program, emergency management agency, health care coalition, media/public affairs, and crisis and emergency risk communications to develop plans and coordinate activities.
 - Assign roles and responsibilities based on areas of expertise.
- Establish COVID-19 vaccine implementation committee(s) of community members with expertise in care and access issues for critical populations to enhance development of plans, reach of activities, and risk/crisis response communication messaging and delivery.
 - Include representatives from key vaccination providers for groups identified by CDC as being at increased risk of severe COVID-19 and others likely to be prioritized for initial vaccination.
 - Include representatives from other sectors within the community, such as health systems, pharmacies, long-term care/assisted living facilities, business, education, corrections, religious, tribal, and racial and ethnic minority-serving organizations, etc.

IDENTIFY GAPS IN PREPAREDNESS

- Review and use current CDC-provided planning assumptions.
- Review experience and lessons learned from 2009 H1N1 pandemic vaccination campaign.
- Consider tabletop, functional, or full-scale exercises to test operational plans and capabilities for access to vaccine, communications, data reporting, and possible cold chain challenges.
- Determine baseline readiness and address any barriers to launching the COVID-19 vaccination program.

REVIEW REQUIREMENTS AND ASSESS CAPACITY OF IMMUNIZATION INFORMATION SYSTEM (IIS) OR OTHER REPORTING SYSTEM

- Determine baseline IIS capacity for a substantial increase in users, documenting vaccine administration, dose-level accountability, ordering, inventory management, and reporting CDC-defined core data elements.
- Facilitate onboarding to the Immunization Gateway (IZ Gateway) for both Connect and Share to use a national immunization data exchange solution for mass vaccine administration.
- Identify vaccination providers not currently reporting to the IIS for outreach and onboarding opportunities.
- Determine internal processes (e.g., Institutional Review Board [IRB] review, internal department reviews, etc.) needed to execute the signing of Data Use Agreements with CDC and/or other entities deemed critical by CDC.
- If the IIS does not meet all of CDC's technology and data requirements, develop a plan to use the

Vaccine Administration Management System (VAMS), including necessary training of immunization program staff and providers.

- Identify opportunities to adopt 2D barcode scanning technology during vaccine inventory management and administration to improve data quality and minimize transcription errors during mass vaccination events.

IDENTIFY CRITICAL POPULATIONS

- Identify and estimate sizes of critical populations, particularly those to receive first available doses of vaccine, and other populations that may require special consideration in each jurisdiction for distribution and expanded access:
 - Critical infrastructure/essential workers (e.g., health care, homeland and national security, public safety, education, food, and agriculture workers)
 - People at increased risk for severe illness (e.g., persons ≥ 65 years of age, people with underlying medical conditions that are risk factors for severe COVID-19, long-term care/assisted living facility residents, people from tribal communities, and people from racial and ethnic minority populations)
 - People living in group settings (e.g., people who are incarcerated/detained, experiencing homelessness or living in shelters, attending colleges/universities)
 - People with limited access to vaccination services (e.g., rural communities, individuals with disabilities, under- or uninsured people)
- Describe and identify where these critical populations live, including places of employment for critical workforce.

PREPARE FOR EARLY COVID-19 VACCINE ADMINISTRATION

- Identify vaccination providers and settings for rapid vaccination of early populations of focus: likely healthcare and other essential workforce. Focus on arrangements that will allow for maximum throughput of persons to be vaccinated while maintaining social distancing and other infection control procedures. Consider collaborating with:
 - Large hospitals and health systems
 - Commercial partners (e.g., pharmacies)
 - Mobile vaccination providers
 - Occupational health for large employers
- Target these vaccination providers for immediate enrollment.
- Determine points of contact for each population group to be vaccinated and establish methods of communication and coordination.
- Secure locations for temporary clinics and develop logistical plans for each.

PLAN FOR EXPANSION OF COVID-19 VACCINATION PROVIDER OUTREACH AND ENROLLMENT

- After finalizing initial vaccination plans for healthcare and other critical workforce populations, determine vaccination provider types and settings to target for enrollment when vaccine supply increases to expand access to COVID-19 vaccination services.
- Identify all existing community vaccination providers and services to serve other critical populations as well as the general population. Consider:
 - Healthcare provider offices and other outpatient settings
 - Inpatient settings (e.g., hospitals, long-term care facilities)
 - Pharmacies
 - School-based health centers
 - Workplaces and other occupational health settings
 - Satellite, temporary, or off-site clinics
- Identify and document the locations of these vaccination providers and services.

- Develop and implement a vaccination provider outreach and training plan, focusing first on vaccination providers and services likely to serve remaining critical populations.
- Determine each vaccination provider's vaccination capacity by reviewing patient panel size and vaccine administration data from the peak week of 2019–20 influenza vaccination.
- Determine each vaccination provider's storage capacity *by volume* at routine refrigerated (2° to 8°C), frozen (-20°C), and ultra-cold (-60° to -80°C) temperatures. *Note: These temperatures are based on information available as of August 26, 2020. Updated information will be provided as it becomes available.*
- Determine need for additional vaccination services, such as satellite, temporary, or off-site clinics, to serve critical populations, particularly those with limited access to vaccination services. Work with partners to implement vaccination in these settings.
- Ensure all providers participating in the COVID-19 vaccination program:
 - Understand and have signed a *CDC COVID-19 Vaccination Program Provider Agreement*.
 - Collect and submit all CDC-required COVID-19 vaccination provider profile data elements to CDC.
 - Have capacity to store and handle COVID-19 vaccine according to manufacturer specifications.
- Onboard enrolled COVID-19 vaccination providers to the jurisdiction's chosen system for (1) vaccine ordering and (2) vaccine administration documentation and reporting.
- Provide training and related CDC resources to ensure providers understand:
 - COVID-19 vaccine recommendations, when available
 - Ordering and receiving COVID-19 vaccine
 - Vaccine storage and handling, including transport requirements, specific to COVID-19 vaccine
 - Vaccine administration, including reconstitution, use of adjuvants, diluents, etc.
 - Documenting and reporting vaccine administration via the jurisdiction's IIS or other mass vaccination module
 - Managing and reporting vaccine inventory (e.g., IIS, VAMS)
 - Documenting and reporting vaccine wastage/spoilage
 - Procedures for reporting to the Vaccine Adverse Event Reporting System (VAERS)
 - Providing Emergency Use Authorization (EUA) fact sheets and/or vaccine information statements (VISs) to vaccine recipients
- Enter ship-to site information for each enrolled provider into the Vaccine Tracking System (VTrcks).

DETERMINE COVID-19 VACCINE ALLOCATIONS

- Determine allocation method to COVID-19 vaccination providers for identified critical populations in early and limited supply scenarios.
- Base allocation plans on:
 - Advisory Committee on Immunization Practices (ACIP) recommendations (when available)
 - Estimated number of doses allocated to jurisdiction and timing of availability
 - Vaccination provider site vaccine storage and handling capacity

DEVELOP COMMUNICATIONS PLAN

- Determine process for frequent communication with participating COVID-19 vaccination providers about vaccine recommendations, supply, ordering, reporting, etc.
- Engage with community leaders and vaccination providers of critical populations on supplementary dose allocations when vaccine supply is limited.
- Determine culturally and linguistically responsive communication approaches for critical populations as well as the general public, based on CDC messaging.
- Explore use of multiple methods and systems to provide second-dose reminders for vaccine recipients as warranted.

COVID-19 VACCINATION SCENARIOS FOR JURISDICTIONAL PLANNING—PHASE 1, Q4 2020



The planning scenarios described below should be used by state and local jurisdictions to develop operation plans for early COVID-19 vaccination when vaccine supply may be constrained. The scenarios describe potential COVID-19 vaccine requirements, early supply estimates after vaccine product approvals, and populations that may be recommended for vaccination during this early period. These scenarios are designed to support jurisdictional, federal, and partner planning, but they are still considered hypothetical. The COVID-19 vaccine landscape is evolving and uncertain, and these scenarios may evolve as more information is available.

Planners should assume that by January 2021 significantly more COVID-19 vaccine will be available for distribution and plans will need to evolve to address additional vaccine availability. Please refer to COVID-19 vaccine planning assumptions and additional guidance from CDC.

Scenario 1: Vaccine A demonstrates sufficient efficacy/safety for EUA in 2020

Availability Assumptions

Candidate	Vaccine availability by			Notes
	End of Oct 2020	End of Nov 2020	End of Dec 2020	
Vaccine A	~2M doses	10–20M doses	20–30M doses	Ultra-cold (-70 °C), for large sites only

Distribution, Storage, Handling, and Administration Assumptions

Vaccine A

<p>SHIPMENT</p> <p><i>3 separately acquired components (mixed on site)</i></p> <ol style="list-style-type: none"> Vaccine <ul style="list-style-type: none"> Direct to site from manufacturer (on dry ice) Multidose vials (5 doses/vial) Diluent <ul style="list-style-type: none"> Direct to site from USG (at room temperature) Ancillary supply kits <ul style="list-style-type: none"> Direct to site from USG (at room temperature) 	<p>ON-SITE VACCINE STORAGE</p> <p><i>Frozen (-70 °C ± 10 °C)</i></p> <ul style="list-style-type: none"> Must be used/recharged within 10 days Storage in shipping container OK (replenish dry ice as needed) <p><i>Thawed but NOT reconstituted (2–8 °C)</i></p> <ul style="list-style-type: none"> Must use within 24–48 hours <p><i>Reconstituted (room temperature)</i></p> <ul style="list-style-type: none"> Must use within 6 hours
<p>ORDERS</p> <p><i>Large quantities, to large administration sites only</i></p> <ul style="list-style-type: none"> Minimum order: ~1000 doses Maximum order: ~5,000 doses 	<p>ADMINISTRATION</p> <p><i>2-dose series (21 days between doses)</i></p> <ul style="list-style-type: none"> On-site mixing required; reconstitute with diluent just prior to administration Administer by intramuscular (IM) injection
<p>PRIORITIZED POPULATIONS AND ANTICIPATED VACCINE ADMINISTRATION SITES</p> <p><i>Health care professionals (incl. LTCF staff)</i> – public health closed temporary mass vaccination clinics + potential for mobile clinics</p> <p><i>Essential workers (specifics TBA)</i> – public health closed temporary mass vaccination clinics + potential for mobile clinics</p> <p><i>National Security populations</i> – public health closed temporary mass vaccination clinics + DoD sites</p> <p><i>LTCF residents & staff</i> – potential for mobile clinics to facilities</p>	


Additional Considerations for Early Vaccination Planning

COVID-19 VACCINATION SCENARIOS FOR JURISDICTIONAL PLANNING—PHASE 1, Q4 2020



- Jurisdictions should plan for real-time shipment of doses.
- Administration sites (during Phase 1) will not be required to store vaccine products beyond the period of time Vaccine A can be stored in the ultra-cold shipment box.
- Vaccine will be free of cost, but administration fees may not be reimbursable while a vaccine product is administered under an EUA.
- Given the challenging storage, handling, and administration requirements, early vaccination should focus on administration sites that can reach prioritized populations with as much throughput as possible.
- Stability testing is ongoing for Vaccine A; the storage and handling requirements presented here may shift. The requirements in these scenarios are likely the strictest set of requirements for which planning is needed.
- Jurisdictions should consider partnering with the private sector and with local hospital systems to provide vaccine in closest proximity to the prioritized populations as possible, given the limitations with the product. For example: Vaccine A may be administered through mobile clinics if multiple mobile clinics are planned over a short period of time to ensure high enough throughput.

COVID-19 VACCINATION SCENARIOS FOR JURISDICTIONAL PLANNING—PHASE 1, Q4 2020



Scenario 2: Vaccine B demonstrates sufficient efficacy/safety for EUA in 2020

Availability Assumptions

Candidate	Vaccine availability by			Notes
	End of Oct 2020	End of Nov 2020	End of Dec 2020	
Vaccine B	~1M doses	~10M doses	~15M doses	Central distro capacity required (-20 °C)


Distribution, Storage, Handling, and Administration Assumptions

Vaccine B	
SHIPMENT <i>2 separately shipped components</i> <ol style="list-style-type: none"> Vaccine <ul style="list-style-type: none"> To central distributor (at -20 °C) Multidose vials (10 doses/vial) Ancillary supply kits <ul style="list-style-type: none"> Direct to site from USG (at room temperature) 	ON-SITE VACCINE STORAGE <i>Frozen (-20 °C)</i> <ul style="list-style-type: none"> Storage in shipping container OK <i>Refrigerated (2–8 °C)</i> <ul style="list-style-type: none"> Must use within 7-14 days <i>Room temperature</i> <ul style="list-style-type: none"> Must use within 6 hours
ORDERS <i>Central distribution capacity required</i> <ul style="list-style-type: none"> Required by Dec 2020 Maintained at -20 °C 	ADMINISTRATION <i>2-dose series (28 days between doses)</i> <ul style="list-style-type: none"> No on-site mixing required Administer by intramuscular (IM) injection
PRIORITIZED POPULATIONS AND ANTICIPATED VACCINE ADMINISTRATION SITES <i>Health care professionals (incl. LTCF staff)</i> – health care clinics + health care occupational health clinics + public health closed temporary mass vaccination clinics + mobile clinics <i>Essential workers (specifics TBA)</i> – hospital occupational health + hospital clinics + public health closed temporary mass vaccination clinics <i>National Security populations</i> – DoD + closed temporary mass vaccination clinics + mobile clinics <i>LTCF residents & staff</i> – commercial pharmacy partners + mobile clinics	

Additional Considerations for Early Vaccination Planning

- Jurisdictions should plan for real-time shipment of doses.
- Administration sites (during Phase 1) will not be required to store vaccine products beyond the period of Vaccine B can be stored at 2–8 °C.
- Vaccine will be free of cost, but administration fees may not be reimbursable while a vaccine product is administered under an EUA.
- Given the challenging storage, handling, and administration requirements, early vaccination should focus on administration sites that can reach prioritized populations with as much throughput as possible.
- Stability testing is ongoing for Vaccine B; the storage and handling requirements presented here may shift. The requirements in these scenarios are likely the strictest set of requirements for which planning is needed.
- Jurisdictions should consider partnering with the private sector and with local hospital systems to provide vaccine in closest proximity to the prioritized populations as possible, given the limitations with the product.

COVID-19 VACCINATION SCENARIOS FOR JURISDICTIONAL PLANNING—PHASE 1, Q4 2020



Scenario 3: Vaccines A and B demonstrate sufficient efficacy/safety for EUA in 2020


Availability Assumptions

Candidate	Vaccine availability by			Notes
	End of Oct 2020	End of Nov 2020	End of Dec 2020	
Vaccine A	~2M doses	10–20M doses	20–30M doses	Ultra-cold (-70 °C), for large sites only
Vaccine B	~1M doses	~10M doses	~15M doses	Central distro capacity required (-20 °C)
Total	~3M doses	20–30M doses	35–45M doses	

Distribution, Storage, Handling, and Administration Assumptions

Vaccine A	
SHIPMENT 3 separately acquired components (mixed on site) <ol style="list-style-type: none"> Vaccine <ul style="list-style-type: none"> Direct to site from manufacturer (on dry ice) Multidose vials (5 doses/vial) Diluent <ul style="list-style-type: none"> Direct to site from USG (at room temperature) Ancillary supply kits <ul style="list-style-type: none"> Direct to site from USG (at room temperature) 	ON-SITE VACCINE STORAGE Frozen (-70 °C ± 10 °C) <ul style="list-style-type: none"> Must be used/recharged within 10 days Storage in shipping container OK (replenish dry ice as needed) Thawed but NOT reconstituted (2–8 °C) <ul style="list-style-type: none"> Must use within 24-48 hours Reconstituted (room temperature) <ul style="list-style-type: none"> Must use within 6 hours
ORDERS Large quantities, to large administration sites only <ul style="list-style-type: none"> Minimum order: ~1,000 doses Maximum order: ~5,000 doses 	ADMINISTRATION 2-dose series (21 days between doses) <ul style="list-style-type: none"> On-site mixing required; reconstitute with diluent just prior to administration Administer by intramuscular (IM) injection
PRIORITIZED POPULATIONS AND ANTICIPATED VACCINE ADMINISTRATION SITES Health care professionals (incl. LTCF staff) – public health closed temporary mass vaccination clinics + potential for mobile clinics Essential workers (specifics TBA) – public health closed temporary mass vaccination clinics + potential for mobile clinics National Security populations – public health closed temporary mass vaccination clinics + DoD sites LTCF residents & staff – potential for mobile clinics to facilities	
Vaccine B	
SHIPMENT 2 separately shipped components <ol style="list-style-type: none"> Vaccine <ul style="list-style-type: none"> To central distributor (at -20 °C) Multidose vials (10 doses/vial) Ancillary supply kits <ul style="list-style-type: none"> Direct to site from USG (at room temperature) 	ON-SITE VACCINE STORAGE Frozen (-20 °C) <ul style="list-style-type: none"> Storage in shipping container OK Refrigerated (2–8 °C) <ul style="list-style-type: none"> Must use within 7-14 days Room temperature <ul style="list-style-type: none"> Must use within 6 hours
ORDERS Central distribution capacity required <ul style="list-style-type: none"> Required by Dec 2020 Maintained at -20 °C 	ADMINISTRATION 2-dose series (28 days between doses) <ul style="list-style-type: none"> No on-site mixing required Administer by intramuscular (IM) injection
PRIORITIZED POPULATIONS AND ANTICIPATED VACCINE ADMINISTRATION SITES Health care professionals (incl. LTCF staff) – health care clinics + health care occupational health clinics + public health closed temporary mass vaccination clinics + mobile clinics Essential workers (specifics TBA) – hospital occupational health + hospital clinics + public health closed temporary mass vaccination clinics National Security populations – DoD + closed temporary mass vaccination clinics + mobile clinics	

COVID-19 VACCINATION SCENARIOS FOR JURISDICTIONAL PLANNING—PHASE 1, Q4 2020



LTCF residents & staff – commercial pharmacy partners + mobile clinics.

Additional Considerations for Early Vaccination Planning

- Jurisdictions should plan for real-time shipment of doses.
- Administration sites (during Phase 1) will not be required to store vaccine products beyond the period of time Vaccine A can be stored in the ultra-cold shipment box or Vaccine B can be stored at 2–8 °C.
- Vaccine will be free of cost, but administration fees may not be reimbursable while a vaccine product is administered under an EUA.
- Given the challenging storage, handling, and administration requirements, early vaccination should focus on administration sites that can reach prioritized populations with as much throughput as possible.
- Stability testing is ongoing for Vaccine A and Vaccine B; the storage and handling requirements presented here may shift. The requirements in these scenarios are likely the strictest set of requirements for which planning is needed.
- Jurisdictions should consider partnering with the private sector and with local hospital systems to provide vaccine in closest proximity to the prioritized populations as possible, given the limitations with the product. For example: Vaccine A may be administered through mobile clinics if multiple mobile clinics are planned over a short period of time to ensure high enough throughput.

Re: Vaccine Distribution Planning

Bohac, Daryl Lee Maj Gen USAF NG NEANG (USA) <daryl.l.bohac.mil@mail.mil>

Fri 9/11/2020 12:37 PM

To: Miltenberger, Matt <matt.miltenberger@nebraska.gov>; Newmyer, Ashley <Ashley.Newmyer@nebraska.gov>

Good plan - we will add it to the agenda.

D

From: "Miltenberger, Matt" <matt.miltenberger@nebraska.gov>

Date: Friday, September 11, 2020 at 7:14:17 AM

To: "Bohac, Daryl Lee Maj Gen USAF NG NEANG (USA)" <daryl.l.bohac.mil@mail.mil>, "Newmyer, Ashley" <Ashley.Newmyer@nebraska.gov>

Subject: [Non-DoD Source] RE: Vaccine Distribution Planning

Gen Bohac-

Adding Ashley to the email. There is already a group working on this, as well as a process in place for implementation. Maybe we could the topic to the agenda at the next Monday meeting/call so Ashley's team can brief and then we can determine if anyone else needs brought in.

Matt

-----Original Message-----

From: Bohac, Daryl Lee Maj Gen USAF NG NEANG (USA) <daryl.l.bohac.mil@mail.mil>

Sent: Thursday, September 10, 2020 8:05 AM

To: Miltenberger, Matt <matt.miltenberger@nebraska.gov>

Subject: Vaccine Distribution Planning

Matt - I've been tracking the information flow on the potential for a fall vaccine distribution. Any appetite for a working group on this issue? Deloitte has also reached out to see if we want their input/participation. Not sure I see that need - but perhaps an interagency working group led by DHHS?

Maj Gen Daryl L. Bohac
Nebraska's Adjutant General

State COVID-19 Working Group Agenda

Bohac, Daryl Lee Maj Gen USAF NG NEANG (USA) <daryl.l.bohac.mil@mail.mil>

Sat 9/12/2020 6:34 PM

To: Springer, Nancy <nancy.m.springer.nfg@mail.mil>

Cc: Newmyer, Ashley <Ashley.Newmyer@nebraska.gov>; Richard H Dahlman <richard.h.dahlman.mil@mail.mil>; Mild, Mary W Col USAF 155 ARW (USA) <mary.w.mild.mil@mail.mil>; Behn, Jan K COL USARMY (USA) <jan.k.behn.mil@mail.mil>; Miltenberger, Matt <matt.miltenberger@nebraska.gov>

Nancy - please add the following item to the Agenda:

Vaccine Distribution Planning

Ashley Newmyer from DHHS has the lead on this.

MG Dahlman is planning on participating from Offutt AFB and conducting the meeting as I normally would. In the event he cannot, then either Col Mild or COL Behn will take on that role.

Thanks

Maj Gen Daryl L. Bohac
Nebraska's Adjutant General

White House IGA Weekly Recap + National COVID-19 Call Invite 📞

JP Fish <Fish.JP@va.gov>

Mon 9/14/2020 2:00 AM

Registration Notice – WH Briefing Call September 16, 2020 – 1:00pm

Dear Governors' Chief of Staff & Washington Directors, For your review.

J.P. Fish

Director, State & Local Government Relations


U.S. Department of Veterans Affairs

810 Vermont Avenue, NW

Washington, DC 20420

(202)461-7424 – Office

██████████ – Mobile

 The White House
Office of Intergovernmental Affairs

White House IGA Weekly Recap (9/11/2020)

for State, local, Tribal officials

On behalf of the White House Office of Intergovernmental Affairs (IGA), we are providing you this top-line update of this week's resources, news, and guidance from your Federal partners to help you serve your fellow citizens. Also below is registration information for the White House National COVID-19 State, local, Tribal briefing call. Though subject to change, we will be joined by representatives from the White House Coronavirus Task Force, Centers for Disease Control and Prevention, U.S. Department of Education, and Federal Emergency Management Agency.

 **National COVID-19 Briefing Call Registration**

Date: Wednesday, September 16, 2020

Time: 1:00 PM Eastern (please note start time and time zone)

Call-In Registration: [CLICK HERE](#)

Note: Call-in lines are limited. RSVP's will be allocated in the order they are received. You must register to join the call.

Below, find pertinent updates of recent Administration actions including:

- President Trump, the First Lady, and Administration Officials Commemorate 9/11 Anniversary
- Readout from White House Coronavirus Task Force Briefing with our Nation's Governors
- Trump Administration Takes Action to Expand Access to COVID-19 Vaccines
- Trump Administration Awards Nearly \$2 Billion in CDBG Relief Funds, Focusing on Communities with Higher Risk of Eviction

- President Trump Announces Additions to United States Supreme Court Justice Nominee List
- Trump Administration Extends and Expands Offshore Drilling Moratorium
- Responding to Wildfires in the West; National Preparedness Month
- All 50 States Are Now REAL ID Compliant
- Making Communities Safer; Operation Legend Update
- Protecting the Integrity of America's Elections
- President Trump Forges a Historic Peace Agreement between Israel & Bahrain

We appreciate your partnership and will continue to share pertinent updates as they become available. As a reminder, IGA is the primary liaison between the White House and America's State and local elected officials and Tribal governments. Please do not hesitate to reach out if we can ever be of assistance.

Sincerely,

The White House Office of Intergovernmental Affairs

William F. Crozer

Special Assistant to the President & Deputy Director

O: 202-456-8491 | C: [REDACTED] | E: William.F.Crozer@who.eop.gov
@WilliamCrozer45

Nick Barbknecht

Associate Director

Cell [REDACTED]

Nicolas.Barbknecht2@who.eop.gov

Gabby Uli

Deputy Associate Director

Cell [REDACTED]

Gabriella.M.Uli2@who.eop.gov

President Trump and First Lady Melania Trump Commemorate 9/11 Anniversary




On Friday, September 11, President Donald J. Trump, joined by First Lady Melania Trump, visited Shanksville, Pennsylvania and the Flight 93 National Memorial to mark the 19th Anniversary of the September 11, 2001, terrorist attacks on our country and to honor and remember the lives tragically lost.


Read More: [Trump Says US 'Will Always Fight Back' During 9/11 Ceremony in Shanksville, PA](#)

Watch: [President Trump and the First Lady Visit the Flight 93 National Memorial](#)



Presidential Proclamation: *In 2001, our Nation, united under God, made an unbreakable promise never to forget the nearly 3,000 innocent Americans who were senselessly killed on September 11. On this sacred day — Patriot Day — we solemnly honor that commitment. As the bells toll, we call by name those who perished in the terrorist attacks in New York, New York; Arlington, Virginia; and Shanksville, Pennsylvania. In cities and towns across our great country, we stand in solidarity to remember the victims and mourn their stolen hopes and dreams. Patriot Day, 2020*


 @Mike_Pence: Today, our Nation pauses to remember those who fell on 9/11/01 and we honor the unimaginable sacrifice they made for our Country. Their memory lives on in the heart of every American and we will never forget the courage and heroism shown on that fateful morning.
#NeverForget


 @FLOTUS: Today we paused at @Flight93NPS to honor the passengers & crew of #Flight93 & those senselessly taken from us in New York & the Pentagon. On #September11 & every day, let's remember the innocent lost, pray for their families & NeverForget.

 @DeptofDefense: 9/11 remembrance flag unfurling at the Pentagon. #NeverForget #September11



 Pittsburgh Post-Gazette - Interior Secretary David Bernhardt: Remembering Flight 93 and Heroes of 9/11

 Washington Examiner - Acting Homeland Security Secretary Chad Wolf: Threats Have Evolved Since Sept. 11, but DHS Stands Ready to Protect the Nation

 Washington Times - Attorney General William Barr: AG William Barr Praises Law Enforcement on 9/11 Anniversary.


Readout from White House Coronavirus Task Force Briefing with our Nation's Governors



On Wednesday, September 9, U.S. Health and Human Services Secretary Alex Azar led a discussion with the chief executives of approximately 50 States, territories, and the city of Washington, DC, and the White House Coronavirus Task Force to discuss local, State, and Federal COVID-19 response and recovery, and an update on Operation Warp Speed efforts to develop, manufacture, and distribute a safe and effective vaccine.

Ambassador Deborah Birx provided an update on data and trends from across the nation, and discussed her recent visits to states in the upper Midwest including Illinois, Michigan, Minnesota, North Dakota, Pennsylvania, Wisconsin, and her upcoming travels through the southeast.


HHS Secretary Alex Azar led discussion on Federal efforts in coordination with State and local governments to develop, manufacture, and distribute a safe and effective vaccine. Dr. Slaoui reported on the status of the vaccine candidates, outlining the integrity of the robust development and approval process. Dr. Marks discussed the FDA's role in the vaccine approval process and outlined the safeguards that ensure confidence in safety and efficacy. Administrator Verma delivered an update on efforts to protect the vulnerable in nursing homes.

 @WhiteHouse: On today's bipartisan call with America's Governors, the @WhiteHouse Coronavirus Task Force discussed the ongoing response and recovery and delivered an update on Operation #WarpSpeed progress to develop, manufacture, and distribute a safe and effective COVID-19 vaccine.

General Gustave Perna discussed how Operation Warp Speed is planning for the manufacturing and distribution of a vaccine, including the creation of multiple contingencies based on various potential scenarios and characteristics of the eventual vaccine(s). General Perna highlighted efforts to prepare the entire vaccine supply chain for the distribution of a vaccine including the production of additional supplies such as syringes.

CDC Director Robert Redfield discussed how the Federal government will coordinate with state and local governments through the public health infrastructure to distribute a vaccine and discussed several actions governors can be taking now to prepare. Director Redfield also highlighted the five pilot states and communities with which CDC has already worked on microplans (California, Florida, Minnesota, North Dakota, and the city of Philadelphia, Pennsylvania) and preparation best practices.

Trump Administration Takes Action to Expand Access to COVID-19 Vaccines



On Wednesday, September 9, under the leadership of President Trump, the U.S. Department of Health and Human Services (HHS), through the Assistant Secretary for Health, issued guidance under the Public Readiness and Emergency Preparedness Act (PREP Act) to expand access to safe and effective COVID-19 vaccines when they are made available. This guidance authorizes state-licensed pharmacists to order and administer, and state-licensed or registered pharmacy interns acting under the supervision of the qualified pharmacist to administer, COVID-19 vaccinations to persons ages 3 or older, subject to certain requirements.

"This action builds upon our Administration's progress toward delivering a safe, effective, and widely available vaccine by 2021," said Assistant Secretary for Health ADM Brett P. Giroir, M.D. "Allowing pharmacists to order and administer COVID-19 vaccines will greatly expand convenient access for the American people."

HHS Secretary Alex Azar: [How We're Developing a COVID-19 Vaccine at 'Warp Speed'](#)

Trump Administration Awards Nearly \$2 Billion in CDBG Relief Funds, Focusing on Communities with Higher Risk of Eviction

On Friday, September 11, U.S. Department of Housing and Urban Development Secretary Bern Carson announced the allocation of the remaining \$1.988 billion CARES Act funding for the Community Development Block Grant (CDBG) program. The allocation focuses funds towards places with households facing higher risk of eviction. To date, HUD has provided nearly \$5 billion in CDBG funding nationwide to help communities combat the Coronavirus and alleviate economic hardship.

These funds can be used to provide temporary financial assistance to meet rental obligations for up to 6 months. The funds are focused toward places with households facing higher risk of eviction.


Specifically:

- Communities with high rates of individuals in industries with high job loss in states with high unemployment;
- Communities with high rates of businesses in industries with high job loss in states with high unemployment; and
- Concentrations of those most at risk for transmission and risk of eviction, with higher amounts for states with high rates of Coronavirus.

Read More: [HUD Awards Nearly \\$2 Billion in Cares Act Relief Funds](#)

President Trump Announces Additions to United States Supreme Court Justice Nominee List

On Wednesday, September 9, President Trump announced 20 additions to his original list of candidates for the United States Supreme Court. Should there be another vacancy on the Supreme Court during President Trump's presidency, the nominee will come from the names that President Trump has shared with the American public, including the original list and these 20 additions.

 [@WhiteHouse: By the end of President Trump's first term, we will have confirmed a record number of Federal judges.](#)


 [Watch: President Trump Delivers Remarks on Judicial Appointments](#)

To date, the President has successfully nominated and had confirmed over 200 qualified Federal judges who will serve for decades to come. This includes both Supreme Court Justices Neil Gorsuch and Brett Kavanaugh as well as over 50 Federal appeals court judges.

Trump Administration Extends and Expands Offshore Drilling Moratorium

On Tuesday, September 8, President Donald J. Trump traveled to Jupiter, Florida and delivered remarks on his Administration's continued conservation and environmental protection efforts benefiting our nation's coastal communities. Joined by Federal, State, and local officials, the President signed a [Presidential Memorandum](#) extending the moratorium on offshore drilling on Florida's Gulf Coast and expanding it to Florida's Atlantic Coast and the coasts of Georgia and South Carolina.

READ MORE: [President Trump Expands Ban on New Offshore Drilling Sites in Atlantic](#)



 [President Trump Delivers Remarks on Environmental Accomplishments for the American People](#)

This important action continues President Trump and his Administration's commitment to promoting environmental conservation. On August 18, the Trump Administration [announced](#) a historic expansion of hunting and fishing opportunities on public lands in Georgia and across the country. And on August 4, President Trump [signed](#) the Great American Outdoors Act - a historic, bipartisan law that marks the largest-ever investment into America's national parks and public lands.

The Trump Administration Has Mobilized the Full Resources of the Federal Government to Respond to Wildfires in the West

The President took early action and leveraged the full resources of the federal government to support areas impacted by wildfires. The Administration is closely monitoring the wildfire situation on the ground, and the President has mobilized the Federal Government to support response efforts. The White House, Federal Emergency Management Agency, Department of the Interior, and the Forest Service continue to remain in constant contact with state and local officials.



Ongoing Trump Administration support provided to State, local, and Tribal officials in California, Colorado, Montana, Oregon, Utah, Washington and Wyoming includes:

- President Trump approved a Presidential Major Disaster Declaration for California effective August 14 for individual and public assistance and deployed extensive Federal resources to assist state and local efforts on the ground.
- President Trump approved Oregon's Emergency Declaration on September 10
- The Trump Administration has approved 34 Fire Management Assistance Grants since August that provide 75% Federal cost share for the mitigation, management, and control of fires, in coordination with state and local officials. This support directly helps state and local officials in California, Colorado, Montana, Oregon, Utah, Washington and Wyoming. Find list of approvals here.
- The Federal Government has deployed more than 26,000 personnel from 500+ crews and 1,900 engines to respond to fires as well as 230 helicopters, a RC-26 Aircraft, and 2 C-130 air tankers to support wildland fire operations.
- FEMA's National and Regional Response Coordination Centers have been activated to coordinate with local governments, non-governmental organizations, and the private sector.
- FEMA has adapted plans in partnership with affected states to address the realities of responding to the wildfires during the COVID-19 pandemic.

And the Trump Administration has led efforts to bolster fire prevention and preparedness. In 2018, President Trump signed an executive order to reduce wildfire risk and urged state and local officials to take action to improve forest management and increase preparedness efforts.


Additional Natural Disaster Response and Recovery Guidance:

- FEMA Operational Guidance for the 2020 Emergency Season: In preparing for the 2020 natural disaster season, the Federal Emergency Management Agency (FEMA) released guidance – COVID-19 Pandemic Operational Guidance for the 2020 Hurricane Season – to State, local, Tribal, and Territorial officials to help them prepare for response and recovery operations. While the document focuses on hurricane season preparedness, most planning considerations can also be applied to any disaster operation in the COVID-19 environment, including no-notice incidents, spring flooding and wildfire seasons, and typhoon response.

- Federal Disaster Recovery and Response Guide: The White House Office of Intergovernmental Affairs has prepared a federal disaster guide – [Recovery Through Federal-State-Local Partnership](#) – outlining the federal disaster response and recovery process (including the initiation and approval of Federal disaster and/or emergency declarations). This guide provides States, Local, and Tribal officials with a broad overview of this process and outlines federal agency specific disaster response and coordination actions. You can also find supplemental guidance from FEMA here – [A Guide to the Disaster Declaration Process and Federal Disaster Assistance](#).
-

All U.S. States Now Compliant Ahead of REAL ID Deadline

Yesterday, September 10, 2020, the Department of Homeland Security (DHS) announced that after more than 15 years since Congress passed the REAL ID Act, all 50 states are now in full compliance issuing these cards, with most states becoming compliant in the last four years. To date, the 50 states have issued more than 105 million REAL ID-compliant driver's licenses and identification cards, representing 38 percent of all driver's licenses and identification card holders.



Passed by Congress in 2005 following a 9/11 Commission recommendation, the REAL ID Act establishes minimum security standards for state-issued driver's licenses and identification cards and prohibits federal agencies, like the Transportation Security Administration, from accepting licenses and identification cards for official purposes from states that do not meet these standards after specific deadlines.

Because of the potential for confusion about the REAL ID Act enforcement milestones, residents can use the following guidelines to be fully informed and prepared.

- Check your state-issued driver's license or identification card for the star. REAL ID-compliant cards generally have a star marking in the upper left- or right-hand corner. Most acceptable alternatives, such as state-issued Enhanced Driver's Licenses, do not have the star, but are acceptable for official REAL ID Act compliance purposes. [Read more here for more information on EDLs.](#)

- Bring identity documents to the airport that are acceptable for flying domestically. Check to see if you have the proper identification to fly here. If you need to obtain a new form of ID, please allow sufficient processing time before you travel. For example, the current processing times for U.S. passports are 6-8 weeks for routine service and 2-3 weeks for expedited service.
- Check with the federal agency you plan to visit, in advance, to find out whether identification is required, and if so, what types of identity documents are acceptable. While most Federal agencies will continue to accept non-compliant driver's licenses and identification cards until the enforcement deadline of October 1, 2021, some – like Department of Defense facilities and posts – no longer accept them.

READ MORE: [Answers to REAL ID frequently asked questions.](#)

Making Communities Safer - Operation Legend Update

This week, Attorney General William P. Barr traveled to Chicago, Illinois, and Phoenix, Arizona, to announce updates on Operation Legend and the results of Operation Crystal Shield, respectively. In Chicago yesterday, Attorney General Barr held a press conference at the U.S. Attorney's Office for the Northern District of Illinois and provided updates on Operation Legend.

Since Operation Legend was launched on July 8, there have been more than 2,000 arrests, with nearly 600 defendants charged in federal courts. And since launching in Chicago on July 22, the homicide rate has declined significantly. In fact, when comparing the seven weeks prior to the operation's launch with the five weeks immediately following the launch, homicides in Chicago declined 50%.

Attorney General Barr also announced that as a designated Operation Legend city, the Bureau of Justice Assistance will make available \$3.5 million in funding to reimburse the Chicago Police Department and City of Chicago for the work of local law enforcement on the federal task forces supporting Operation Legend's violent crime reduction efforts. The COPS Office has also made \$9.375 million available to the Chicago Police Department to fund the hiring of 75 officers.

Read More: [Readout of Attorney General William P. Barr's Visits to Chicago and Phoenix](#)

From the Media: [AG Talks Chicago Crime, 'Progressive Prosecutors' and Mistakes Made in Kenosha](#)



And on Wednesday, September 2, President Trump signed a memorandum to hold local politicians accountable for refusing to protect their communities from rioting, looting, and mass property destruction. Through this action, the Trump Administration will explore avenues to ensure Federal funds are spent to uphold the President's promise to protect life, liberty, and property. Find the memorandum [here](#) and a Fact Sheet [here](#).

Additional Operation Legend and DOJ Community Safety Updates

- Wisconsin Man Charged with Trafficking Heroin, Fentanyl, and Methamphetamine; Illegally Possessing Numerous Firearms
- Chicago Street Gang Member Sentenced to 27 Years in Federal Prison on Murder and Racketeering Conspiracy Charges ([here](#))
- A Portland Resident Has Been Charged with Civil Disorder, a Felony, for Punching a Portland Police Officer in the Face During a Declared Riot on July 3, 2020 ([here](#))
- Three Portlanders Have Been Charged with Civil Disorder for Assaulting Local Police Officers ([here](#))
- Six Individuals Charged for Crimes Committed During Demonstrations Throughout South Carolina, including Arson, inciting a Riot, and Civil Disorders ([here](#))
- Alaska Man Charged Federally with Setting Fire at Seattle Police East Precinct ([here](#))
- Three Kansas City Men Charged in Armed Carjacking that Resulted in Police Pursuit, Fatal Collision ([here](#))

The Trump Administration Is Protecting the Integrity of America's Elections

President Trump has firmly denounced any kind of foreign meddling in our elections and has taken strong action to safeguard the integrity of America's election system. The President has made clear

time and again that his Administration will never tolerate any form of election interference from any country and has repeatedly stood up to Russia's malign activities that threaten our institutions and interests.

To combat election interference, the administration has provided on-site cybersecurity support to states during elections, and President Trump has declared foreign election interference a national emergency and signed legislation to provide hundreds of millions of dollars to states to harden their election security technology and infrastructure.

@WHNSC: Russia seeks to sow divisions and create chaos across America and other democratic societies. Today, the Administration utilized EO13848 to designate four Russia-linked individuals for attempting to influence the U.S. electoral process.

The Trump Administration has held exercises with state and local officials to improve their ability to respond to cyber incidents and has taken action to enhance information sharing with election officials across all 50 states and has participated in more than 25 election security-specific hearings or briefings with Congress since May 2019 alone.

Utilize the Election Security Risk Profile Assessment - developed by the Election Assistance Commission's (EAC) and Cybersecurity and Infrastructure Security Agency (CISA) - to determine your local jurisdiction's security risks and vulnerabilities.

- Visit the Election Risk Profile tool here to help mitigate your election security risks locally.
- Download the Elections Cybersecurity Tabletop Exercise Manual here to increase your local election security capabilities for staff.

President Trump Forges Historic Peace Agreement between Israel & Bahrain

On Friday, September 11, President Trump announced in the Oval Office that a historic peace agreement was reached between Israel and Bahrain.



@realDonaldTrump: Another HISTORIC breakthrough today! Our two GREAT friends Israel and the Kingdom of Bahrain agree to a Peace Deal - the second Arab country to make peace with Israel in 30 days!


This is a historic breakthrough to further peace in the Middle East. Opening direct dialogue between these two dynamic societies and advanced economies will continue the positive transformation of the Middle East and increase stability, security, and prosperity in the region.

Read More: Bahrain-Israel Deal Is 'Spectacular' Development for 'More Peaceful World,' says White house Spokesperson

The Kingdom of Bahrain has also accepted President Trump's invitation to join Israel and the United Arab Emirates at the historic signing ceremony on September 15, 2020 at the White House where Prime Minister Benjamin Netanyahu of Israel and Foreign Minister Abdullatif Al Zayani of Bahrain will be signing a historic Declaration of Peace.

Read More: [Joint Statement of the United States, the Kingdom of Bahrain, and the State of Israel](#)

This is the second such agreement between Israel and an Arab nation in less than one month. Israel and Bahrain have committed to begin the exchange of embassies and ambassadors, start direct flights between their countries, and launch cooperation initiatives across a broad range of sectors. This peace deal is a significant step forward for both Israel and Bahrain -- it further enhances their security while creating opportunities for them to deepen their economic ties.



This deal comes on the heels of the [historic normalization agreement](#) between Israel and the United Arab Emirates -- the United Arab Emirates and Bahrain are the first Arab nations to normalize relations with Israel in more than 25 years.

The United States will continue to support the people of Bahrain as they work to counter terrorism and extremism, develop economically, and build new peaceful partnerships across the region

Office of Intergovernmental Affairs · 1600 Pennsylvania Ave NW · Washington, DC 20500-0003 ·
USA · 202-456-1111

RE: EXTERNAL EMAIL: RE: Nebraska COVID Vaccine Letter - Companies

Rob Geddes <rob.geddes@albertsons.com>

Tue 9/15/2020 9:15 PM

To: Miltenberger, Matt <matt.miltenberger@nebraska.gov>

Thank you very much. I appreciate you getting it to right individuals.

Rob Geddes, PharmD

Director, Pharmacy Legislative and Regulatory Affairs

Albertsons Companies, Inc.

208-395-3987 Office

[REDACTED] Cell

From: Miltenberger, Matt <matt.miltenberger@nebraska.gov>

Sent: Tuesday, September 15, 2020 12:25 PM

To: Rob Geddes <rob.geddes@albertsons.com>

Cc: Cushman, Jesse <Jesse.Cushman@nebraska.gov>; LeGrand, Khalilah <Khalilah.LeGrand@nebraska.gov>;

Anthony Provenzano <Anthony.Provenzano@albertsons.com>; Brian Hille <Brian.Hille@albertsons.com>

Subject: EXTERNAL EMAIL: RE: Nebraska COVID Vaccine Letter - Companies

Rob-

Thank you for your email and willingness to help in our COVID response efforts. I'll make sure the correct folks on our DHHS team get a copy of your email.

Thank you again.

Matt

From: Rob Geddes <rob.geddes@albertsons.com>

Sent: Friday, September 11, 2020 1:22 PM

To: Miltenberger, Matt <matt.miltenberger@nebraska.gov>

Cc: Cushman, Jesse <Jesse.Cushman@nebraska.gov>; LeGrand, Khalilah <Khalilah.LeGrand@nebraska.gov>;

Anthony Provenzano <Anthony.Provenzano@albertsons.com>; Brian Hille <Brian.Hille@albertsons.com>

Subject: Nebraska COVID Vaccine Letter - Companies

Mr. Miltenberger,

Thank you for all of your hard work and dedication during these unprecedented times. I hope this email finds you well. Albertsons Companies is committed to being a part of the solution to COVID in the communities where we are located. Attached is a letter to request our inclusion in the State COVID vaccine plans as well as highlighting our capabilities to provide the vaccine through our pharmacies. I have copied the Board of Pharmacy and the Department of Health. If there are other key individuals or workgroups who need to see this letter please forward on our behalf. Thank you very much for your consideration and we look forward to working closely with the state to immunize your residents against COVID as soon as the vaccines are available.

Kind Regards,

Rob Geddes, PharmD

Director, Pharmacy Legislative and Regulatory Affairs

Albertsons Companies, Inc.

(M) [REDACTED]

(O) 208.395.3987

(F) 623.336.6641

Rob.geddes@albertsons.com

Warning: All e-mail sent to this address will be received by the corporate e-mail system, and is subject to archival and review by someone other than the recipient. This e-mail may contain proprietary information and is intended only for the use of the intended recipient(s). If the reader of this message is not the intended recipient(s), you are notified that you have received this message in error and that any review, dissemination, distribution or copying of this message is strictly prohibited. If you have received this message in error, please notify the sender immediately.

Warning: All e-mail sent to this address will be received by the corporate e-mail system, and is subject to archival and review by someone other than the recipient. This e-mail may contain proprietary information and is intended only for the use of the intended recipient(s). If the reader of this message is not the intended recipient(s), you are notified that you have received this message in error and that any review, dissemination, distribution or copying of this message is strictly prohibited. If you have received this message in error, please notify the sender immediately.



September 11, 2020

Governor Pete Ricketts
C/O Matt Miltenberger, Chief of Staff
P.O. Box 94848
Lincoln, NE 68509-4848

Re: Albertsons Companies Role in the upcoming COVID-19 Vaccine strategy.

Dear Mr. Miltenberger,

Albertsons Companies expresses gratitude for your hard work and diligence during these challenging times. We operate 5 community pharmacies across the state under one well-known banner: Safeway. Our pharmacies and staff provide patients with critical access to life saving medications, immunizations, and clinical advice. Now more than ever, pharmacies play an increasing role in patient care and allow for ready access to health care services when many provider offices have been shuttered or offer limited services due to the COVID-19 pandemic.

Albertsons Companies is focused on providing vaccinations and other clinical services to support the health and well-being of our customers and patients in the communities that we practice. We have pharmacies located in 34 states under multiple banner names giving us a unique presence on a national scale. Throughout the Public Health Emergency, we have offered to our patients uninterrupted access to their important medications, trained healthcare professionals, and clinical services such as vaccinations and medication administration. We are currently rolling out a nationwide COVID-19 testing solution to further increase public testing options and support our communities. We understand the importance of working together with an all-hands-on deck approach to respond appropriately and adequately to the pandemic and have been following closely COVID-19 immunization developments. I would like to take this opportunity to highlight how we can be of assistance to your state in your COVID-19 vaccine distribution plan.

As noted in a recent study, using pharmacies to administer vaccines during a pandemic can reduce the overall time to achieve 80% single dose coverage by up to seven weeks.¹ This is accomplished in part by the fact that almost 90% of Americans live within 5 miles of a pharmacy.² Leaning on our extensive experience in providing vaccinations under normal circumstances, our pharmacists are well-positioned to contribute to the effort of quickly vaccinating the residents of your state when a COVID-19 vaccine(s) becomes available. In accordance with CDC guidelines, we have developed multiple pathways for

¹ Schwerzmann J, Graitcer SB, Jester B, Krahl D, Jernigan D, Bridges CB, Miller J. Evaluating the Impact of Pharmacies on Pandemic Influenza Vaccine Administration. Disaster Med Public Health Prep. 2017 Oct;11(5):587-593. <https://www.ncbi.nlm.nih.gov/pubmed/28219461>

² <https://www.nacds.org/pdfs/government/2020/Pharmacies-Reopening-America-COVID-19-NACDS-May2020.pdf>



patients to obtain access to a COVID-19 vaccine. As part of this effort we are exploring providing these vaccines in the following ways:

- Appointment based and walk-in availability
- Large and small format vaccination events
 - Parking lot drive thru events
 - Business focused events

Patients will have easy access to electronic online tools for scheduling and eligibility determinations prior to receiving the vaccine. For vaccinations that may require multiple doses, many of the vaccines we routinely offer require multiple doses, and we employ methods such as email, text messaging, or phone calls to remind and coordinate return follow-up visits. Attached in Appendix A is a more detailed representation of our anticipated flows for distributing and administering the COVID 19 vaccine.


As an added benefit, we are already integrated with McKesson for our drug and vaccine wholesale needs. This will allow us to seamlessly facilitate the distribution of the COVID-19 vaccine through our existing channels. As you are aware, McKesson was recently chosen by Operation Warp Speed to be the lead distributor for this effort.

Recently the United States Department of Health and Human Services took action under the PREP Act to authorize pharmacists to provide important childhood immunizations to the children aged 3 to 18 where not already allowed.³ This exemplifies the trust the federal government has in the profession of pharmacy to stand up and fill an important healthcare access gap.

We have 14 trained immunizing individuals in your state who are ready to support your COVID-19 pandemic response. We urge you to include our company in the planning and the ultimate solution for administering this important vaccine to the residents of your state.

If you have any additional questions please direct them to myself at brian.hille@albertsons.com or [REDACTED]

Sincerely,



Brian Hille, PharmD
Vice President, Pharmacy Specialty Clinical and Wellness Services
Albertsons Companies

Cc: State Board of Pharmacy; State Department of Health

³ <https://www.hhs.gov/sites/default/files/third-amendment-declaration.pdf>

Appendix A

Albertsons Companies Inc.
COVID-19 Vaccine Capabilities

Overview

Albertsons Companies is focused on providing vaccinations and other clinical services within its pharmacies to support the health and well-being of our customers, patients, and members of our communities. Our pharmacists are highly trained, innovative, and patient-focused and with pharmacy locations in 34 states under multiple banner names, we have a unique presence on a national scale.

Our company has a shared interest and vision with the government and public health agencies with respect to COVID-19. Our pharmacists already have experience quickly activating influenza immunization clinics; this experience can be drawn upon and our flu clinics can be replicated to – once available – deliver a COVID-19 vaccine to protect the community and prevent morbidity and mortality due to SARS-CoV-2 infection. Thanks to long-standing relationships among our government relations and public affairs teams, local and state governments and departments of public health, and local media, our company is ideally positioned to facilitate the administration of a COVID vaccine. Through these relationships we can identify community facilities for COVID-19 vaccination events and activate the media to direct the public to qualify, register and schedule their COVID-19 vaccinations.

Our pharmacy teams will comply with COVID-19 vaccine prioritization and eligibility tiering established by federal or local health officials. We already adhere to CDC guidelines for planning and implementation of satellite, temporary, or off-site vaccination clinics. As such, we are well equipped to deal with the complexities associated with COVID vaccine storage, handling, and administration.

According to literature one of the highly probable COVID-19 vaccines will have storage requirements at or below –20C and another will have cryogenic storage requirements.

We have a long history of –20C storage due to being one of the top immunizers of Zostavax when that vaccine required –20C storage. We led the pharmacy industry in protecting patients against shingles due to our unique ability to store and administer the vaccine in all our pharmacy locations. This history translates well into effective immunization with COVID-19 vaccines that have –20C storage requirements.

The other highly probable early COVID-19 vaccine will have cryogenic storage requirements but will allow for non-cryogenic storage for 10 or more days before use. Knowing non-cryogenic storage is possible, even for a limited time, allows for our pharmacies to utilize a familiar distribution model, the annual distribution of influenza vaccine.

Albertsons Companies currently utilizes McKesson as its distributor.⁴ By coordinating directly with manufacturers and/or wholesalers able to accommodate cryogenic storage, our pharmacies can direct large shipments of COVID-19 vaccine directly from the manufacturer or wholesaler to pre-determined immunization events.

⁴ McKesson is the lead distributor selected for Operation Warp Speed, the public-private partnership designed to accelerate the development of the COVID-19 vaccine.

In advance of an immunization clinic, we direct patients to electronic patient engagement tools which will pre-screen patients for eligibility (according to the vaccine eligibility tiering), allow patients to complete their immunization consent and release forms, and allow patients to choose an appointment time and immunization clinic event site.

What follows is our model COVID-19 vaccination clinic implementation plan.

Contents

- 1. Identification of Locations**
- 2. Leadership and Staffing**
- 3. Maintaining Storage and Stability**
- 4. Patient Registration and Series Dose Completion**
- 5. Large-Scale Clinics**
- 6. Parking Lot Clinics**
- 7. Alternate Site**

1. Identification of Locations

Albertsons Companies will work with public health officials to identify facilities and sites suited for large-scale COVID-19 immunization clinics:

Sites may include: –

- Albertsons owned sites, including stores, distribution centers, manufacturing plants, and vacant locations.
- Community event facilities, including gyms, churches, auditoriums, theaters, or other public spaces.
- Large parking lots that can be used for unidirectional vehicle-guided clinics (either Albertsons- or community-owned)

2. Leadership and Staffing

Staffing plans are scalable to the expected number of doses that will be supplied for the clinic.

Our designated clinic leaders will coordinate the following :

- Staffing and logistics;
- Training of employees involved;
- Vaccine supply, including storage and handling;
- On-site infection control measures, including PPE management and proper disposal according to OSHA regulations and guidance issued during the Public Health Emergency;
- Security planning and implementation, including evacuation plans, as necessary;
- Emergency medical services (EMS) or other options for handling emergency situations at a clinic;
- Post-clinic reports and recording of vaccinations administered.

3. Maintaining Storage and Stability

Vaccine supply will be shipped directly to the clinic site whenever possible. If vaccine must be transported from another facility to the site, validated shipping containers will be used and leadership at the site will check the shipment immediately upon arrival to confirm temperature stability.

Storage requirements will be maintained and monitored throughout the clinic workday. Vaccine will be stored in a stable storage unit and monitored with an approved temperature monitoring device. If available on-site storage does satisfy the storage requirements, portable vaccine storage units or validated storage containers will be used.

All temperature excursions outside of the acceptable ranges will be handled according to manufacturer guidelines.


4. Patient Registration and Series Dose Completion

Vaccinations may be offered by appointment or available on a walk-in basis. Patients will have access to an online consent form to reduce touchpoints when receiving a vaccine. Traditional paper consent forms will be available for walk-in requests and at the patient's request. Screening for COVID-19 vaccination will be performed when the patient fills out the online consent form, as well as when the patient presents to receive their immunization.

If the vaccine administered is part of a series, the patient will be contacted via their preferred contact method (text, email, or phone call) to return to the pharmacy or an event location for the follow-up dose administration.

5. Large-Scale Clinic

Albertsons will adhere to the indoor or outdoor walk-through guidance provided by the CDC:



Clinic staff – In addition to the staff listed above each large-scale clinic will be staffed with the following personnel:

- **Greeter(s)** - responsible for crowd control, providing direction, and helping to ensure social distancing is adhered to.
- **Registration personnel** – responsible for ensuring the consent and release forms are complete and all required information is obtained including insurance information.
- **Vaccine provider** – based on state regulations, vaccine providers will be licensed pharmacists, supervised, trained pharmacy technicians; and/or pharmacy interns.
- **Security** – dependent upon location and size of clinic, security may be needed. This will be coordinated with our loss prevention team in advance of the event.
- **Emergency medical personnel** – prior to the event the clinic leader will coordinate with the local hospital to arrange for emergency medical personnel availability.

Clinic Set Up -

- Unidirectional flow – arrows will identify the path to each of the designated stations. Between lines the use of ropes or stanchion signs can help prevent issues with crowd management. Arrows will be placed 6 feet apart to visually identify social distancing.

- E.g. directional arrow:



- Outside the facility, signage will be used to identify entrance and exit. Greeters will be stationed to help with directional flow, maintain social distancing and to answer questions.

- E.g. stay 6 feet apart sign:




- Screening area / Registration – screeners will confirm submitted electronic demographics and data
- Vaccination area – vaccinators will verify identification, ask verbal screening questions, and provide the vaccination according to package insert and CDC guidance.
- Post vaccination waiting area – to ensure the patient does not have an allergic reaction, after receiving the vaccination the patient will be asked to wait 15 minutes in a designated area that accommodates social distancing.

6. Parking Lot

Albertsons has extensive experience with providing immunizations in a parking lot drive thru format, with or without an appointment. Leadership planning these clinics will ensure compliance with all state and local laws and regulations.

Albertsons will adhere to the curbside or drive-through clinics guidance provided by the CDC:

Curbside or drive-through clinics



General Information


- This format can be adapted for both appointment and non-appointment-based clinics
- If there is inclement weather, clinics may need to be moved to inside if space allows or rescheduled

Additional Supplies:

- Tents, where needed
- Brightly colored vest for traffic director
- Signs to direct traffic (e.g. entrance, exit, station numbers)

Parking Lot Flow:

- Parking lot should have directional flow with cones set up for clear traffic patterns utilizing a lane format
- Designated waiting area for during/after vaccination for patients to wait 15 minutes




Alternate Site

We can also hold immunization events inside our stores or in other community settings depending on layout. Leadership planning these clinics will ensure compliance with all state and local laws and regulations.

General Information:

- We will use a space to accommodate one-way traffic. Options include:
 - Repurposing conference rooms
 - Repurposing store owned locations such as pubs, cafes and eating areas
 - Utilizing vestibule area on one side of the store
 - Utilizing one entrance solely for flu clinic
 - Consider outdoor or sidewalk overflow for those waiting to enter the vestibule in inclement weather and temperature extremes



WH Invitation - State, Local, Tribal COVID-19 National Briefing Call (TODAY, September 16, 1:00 PM Eastern)

JP Fish <Fish.JP@va.gov>

Wed 9/16/2020 1:36 PM

Reminder Notice – WH Briefing Call September 16, 2020 – 1:00pm

Dear Governors' Chief of Staff & Washington Directors,

For your review.

J.P. Fish

Director, State & Local Government Relations

U.S. Department of Veterans Affairs

810 Vermont Avenue, NW

Washington, DC 20420

(202)461-7424 – Office

[REDACTED] – Mobile

State, Local, and Tribal Leaders –

As a reminder, the White House Office of Intergovernmental Affairs will host a **COVID-19 National Briefing Call for State, Local, and Tribal Officials** on Wednesday, September 16, at 1:00 PM Eastern Time. Though subject to change, we will be joined by **Ambassador Deborah Birx** (*Coordinator, White House Coronavirus Task Force*), **Dr. Jay Butler** (*Deputy Director for Infectious Diseases, Centers for Disease Control and Prevention*), **Administrator Pete Gaynor** (*Federal Emergency Management Agency*), **Admiral Brett Giroir** (*Assistant Secretary of Health, U.S. Department of Health and Human Services*), and **Principal Deputy Undersecretary Diane Jones** (*U.S. Department of Education*). Registration instructions are below. Please disregard this email if you are already registered.

Please also note that we have begun sharing call registration and other pertinent information through an email platform. If you are not receiving our communications, please check your spam folder and make sure to add IGA.state@who.eop.gov to your approved email list.

Briefing Call Registration

Date: Wednesday, September 16

Time: 1:00 PM Eastern Time (please note start time and time zone)

Call-In Registration: [CLICK HERE](#) (if you have already registered, please disregard)

Note: Call-in lines are limited. RSVP's will be allocated in the order they are received. Please register only if you are able to join the call.

Thank you for your continued partnership. As a reminder, the Office of Intergovernmental Affairs is the primary liaison between the White House and America's State and local elected officials and Tribal governments. Please do not hesitate to reach out if we can be helpful.

The White House Office of Intergovernmental Affairs

William F. Crozer

Special Assistant to the President/Deputy Director

White House Office of Intergovernmental Affairs

O: 202-456-8491 | C: [REDACTED] | E: William.F.Crozer@who.eop.gov


[@WilliamCrozer45](#)

From: White House Office of Intergovernmental Affairs <IGA.state@who.eop.gov>

Sent: Friday, September 11, 2020 6:46 PM

To: Crozer, William F. EOP/WHO <William.F.Crozer@who.eop.gov>

Subject: White House IGA Weekly Recap + National COVID-19 Call Invite 📞

 The White House
Office of Intergovernmental Affairs

White House IGA Weekly Recap (9/11/2020)

for State, local, Tribal officials

On behalf of the White House Office of Intergovernmental Affairs (IGA), we are providing you this top-line update of this week's resources, news, and guidance from your Federal partners to help you serve your fellow citizens. Also below is registration information for the White House National COVID-19 State, local, Tribal briefing call. Though subject to change, we will be joined by representatives from the White House Coronavirus Task Force, Centers for Disease Control and Prevention, U.S. Department of Education, and Federal Emergency Management Agency.

National COVID-19 Briefing Call Registration

Date: Wednesday, September 16, 2020

Time: 1:00 PM Eastern (please note start time and time zone)

Call-In Registration: [CLICK HERE](#)

Note: Call-in lines are limited. RSVP's will be allocated in the order they are received. You must register to join the call.

Below, find pertinent updates of recent Administration actions including:

- President Trump, the First Lady, and Administration Officials Commemorate 9/11 Anniversary
- Readout from White House Coronavirus Task Force Briefing with our Nation's Governors
- Trump Administration Takes Action to Expand Access to COVID-19 Vaccines
- Trump Administration Awards Nearly \$2 Billion in CDBG Relief Funds, Focusing on Communities with Higher Risk of Eviction

- President Trump Announces Additions to United States Supreme Court Justice Nominee List
- Trump Administration Extends and Expands Offshore Drilling Moratorium
- Responding to Wildfires in the West; National Preparedness Month
- All 50 States Are Now REAL ID Compliant
- Making Communities Safer; Operation Legend Update
- Protecting the Integrity of America's Elections
- President Trump Forges a Historic Peace Agreement between Israel & Bahrain

We appreciate your partnership and will continue to share pertinent updates as they become available. As a reminder, IGA is the primary liaison between the White House and America's State and local elected officials and Tribal governments. Please do not hesitate to reach out if we can ever be of assistance.

Sincerely,

The White House Office of Intergovernmental Affairs

William F. Crozer

Special Assistant to the President & Deputy Director

O: 202-456-8491 | C: [REDACTED] | E: William.F.Crozer@who.eop.gov
[@WilliamCrozer45](https://twitter.com/WilliamCrozer45)

Nick Barbknecht

Associate Director

Cell [REDACTED]

Nicolas.Barbknecht2@who.eop.gov

Gabby Uli

Deputy Associate Director

Cell [REDACTED]

Gabriella.M.Uli2@who.eop.gov

President Trump and First Lady Melania Trump Commemorate 9/11 Anniversary




On Friday, September 11, President Donald J. Trump, joined by First Lady Melania Trump, visited Shanksville, Pennsylvania and the Flight 93 National Memorial to mark the 19th Anniversary of the September 11, 2001, terrorist attacks on our country and to honor and remember the lives tragically lost.


Read More: [Trump Says US 'Will Always Fight Back' During 9/11 Ceremony in Shanksville, PA](#)

 **Watch: President Trump and the First Lady Visit the Flight 93 National Memorial**




Presidential Proclamation: *In 2001, our Nation, united under God, made an unbreakable promise never to forget the nearly 3,000 innocent Americans who were senselessly killed on September 11. On this sacred day—Patriot Day—we solemnly honor that commitment. As the bells toll, we call by name those who perished in the terrorist attacks in New York, New York; Arlington, Virginia; and Shanksville, Pennsylvania. In cities and towns across our great country, we stand in solidarity to remember the victims and mourn their stolen hopes and dreams. Patriot Day, 2020*


 **@Mike_Pence: Today, our Nation pauses to remember those who fell on 9/11/01 and we honor the unimaginable sacrifice they made for our Country. Their memory lives on in the heart of every American and we will never forget the courage and heroism shown on that fateful morning. #NeverForget**


 **@FLOTUS: Today we paused at @Flight93NPS to honor the passengers & crew of #Flight93 & those senselessly taken from us in New York & the Pentagon. On #September11 & every day, let's remember the innocent lost, pray for their families & NeverForget.**

 **@DeptofDefense: 9/11 remembrance flag unfurling at the Pentagon. #NeverForget #September11**



 **Pittsburgh Post-Gazette - Interior Secretary David Bernhardt: Remembering Flight 93 and Heroes of 9/11**

 **Washington Examiner - Acting Homeland Security Secretary Chad Wolf: Threats Have Evolved Since Sept. 11, but DHS Stands Ready to Protect the Nation**

 **Washington Times - Attorney General William Barr: AG William Barr Praises Law Enforcement on 9/11 Anniversary**

**Readout from White House Coronavirus Task Force Briefing with our Nation's
Governors**



On Wednesday, September 9, U.S. Health and Human Services Secretary Alex Azar led a discussion with the chief executives of approximately 50 States, territories, and the city of Washington, DC, and the White House Coronavirus Task Force to discuss local, State, and Federal COVID-19 response and recovery, and an update on Operation Warp Speed efforts to develop, manufacture, and distribute a safe and effective vaccine.

Ambassador Deborah Birx provided an update on data and trends from across the nation, and discussed her recent visits to states in the upper Midwest including Illinois, Michigan, Minnesota, North Dakota, Pennsylvania, Wisconsin, and her upcoming travels through the southeast.

HHS Secretary Alex Azar led discussion on Federal efforts in coordination with State and local governments to develop, manufacture, and distribute a safe and effective vaccine. Dr. Slaoui reported on the status of the vaccine candidates, outlining the integrity of the robust development and approval process. Dr. Marks discussed the FDA's role in the vaccine approval process and outlined the safeguards that ensure confidence in safety and efficacy. Administrator Verma delivered an update on efforts to protect the vulnerable in nursing homes.

@WhiteHouse: On today's bipartisan call with America's Governors, the @WhiteHouse Coronavirus Task Force discussed the ongoing response and recovery and delivered an update on Operation #WarpSpeed progress to develop, manufacture, and distribute a safe and effective COVID-19 vaccine.

General Gustave Perna discussed how Operation Warp Speed is planning for the manufacturing and distribution of a vaccine, including the creation of multiple contingencies based on various potential scenarios and characteristics of the eventual vaccine(s). General Perna highlighted efforts to prepare the entire vaccine supply chain for the distribution of a vaccine including the production of additional supplies such as syringes.

CDC Director Robert Redfield discussed how the Federal government will coordinate with state and local governments through the public health infrastructure to distribute a vaccine and discussed several actions governors can be taking now to prepare. Director Redfield also highlighted the five pilot states and communities with which CDC has already worked on microplans (California, Florida, Minnesota, North Dakota, and the city of Philadelphia, Pennsylvania) and preparation best practices.

Trump Administration Takes Action to Expand Access to COVID-19 Vaccines



On Wednesday, September 9, under the leadership of President Trump, the U.S. Department of Health and Human Services (HHS), through the Assistant Secretary for Health, **issued guidance** under the Public Readiness and Emergency Preparedness Act (PREP Act) to expand access to safe and effective COVID-19 vaccines when they are made available. **This guidance authorizes state-licensed pharmacists to order and administer, and state-licensed or registered pharmacy interns acting under the supervision of the qualified pharmacist to administer, COVID-19 vaccinations to persons ages 3 or older, subject to certain requirements.**

"This action builds upon our Administration's progress toward delivering a safe, effective, and widely available vaccine by 2021," said Assistant Secretary for Health ADM Brett P. Giroir, M.D. "Allowing pharmacists to order and administer COVID-19 vaccines will greatly expand convenient access for the American people."

HHS Secretary Alex Azar: How We're Developing a COVID-19 Vaccine at 'Warp Speed'

Trump Administration Awards Nearly \$2 Billion in CDBG Relief Funds, Focusing on Communities with Higher Risk of Eviction

On Friday, September 11, U.S. Department of Housing and Urban Development Secretary Barn Carson announced the allocation of the remaining \$1.988 billion CARES Act funding for the Community Development Block Grant (CDBG) program. The allocation focuses funds towards places with households facing higher risk of eviction. To date, HUD has provided nearly \$5 billion in CDBG funding nationwide to help communities combat the Coronavirus and alleviate economic hardship.

These funds can be used to provide temporary financial assistance to meet rental obligations for up to 6 months. The funds are focused toward places with households facing higher risk of eviction. Specifically:

- Communities with high rates of individuals in industries with high job loss in states with high unemployment;
- Communities with high rates of businesses in industries with high job loss in states with high unemployment; and
- Concentrations of those most at risk for transmission and risk of eviction, with higher amounts for states with high rates of Coronavirus.

Read More: [HUD Awards Nearly \\$2 Billion in Cares Act Relief Funds](#)

President Trump Announces Additions to United States Supreme Court Justice Nominee List

On Wednesday, September 9, President Trump announced 20 additions to his original list of candidates for the United States Supreme Court. Should there be another vacancy on the Supreme Court during President Trump's presidency, the nominee will come from the names that President Trump has shared with the American public, including the **original list** and these **20 additions**.

 **@WhiteHouse: By the end of President Trump's first term, we will have confirmed a record number of Federal judges.**

 **Watch: President Trump Delivers Remarks on Judicial Appointments**

To date, the President has successfully nominated and had confirmed over 200 qualified Federal judges who will serve for decades to come. This includes both Supreme Court Justices Neil Gorsuch and Brett Kavanaugh as well as over 50 Federal appeals court judges.

Trump Administration Extends and Expands Offshore Drilling Moratorium

On Tuesday, September 8, President Donald J. Trump traveled to Jupiter, Florida and delivered remarks on his Administration's continued conservation and environmental protection efforts benefiting our nation's coastal communities. Joined by Federal, State, and local officials, the President signed a **Presidential Memorandum** extending the moratorium on offshore drilling on Florida's Gulf Coast and expanding it to Florida's Atlantic Coast and the coasts of Georgia and South Carolina.

READ MORE: [President Trump Expands Ban on New Offshore Drilling Sites in Atlantic](#)



President Trump Delivers Remarks on Environmental Accomplishments for the American People

This important action continues President Trump and his Administration's commitment to promoting environmental conservation. On August 18, the Trump Administration **announced** a historic expansion of hunting and fishing opportunities on public lands in Georgia and across the country. And on August 4, President Trump **signed** the Great American Outdoors Act - a historic, bipartisan law that marks the largest-ever investment into America's national parks and public lands.

The Trump Administration Has Mobilized the Full Resources of the Federal Government to Respond to Wildfires in the West

The President took early action and leveraged the full resources of the federal government to support areas impacted by wildfires. The Administration is closely monitoring the wildfire situation on the ground, and the President has mobilized the Federal Government to support response efforts. The White House, Federal Emergency Management Agency, Department of the Interior, and the Forest Service continue to remain in constant contact with state and local officials.

Image

Ongoing Trump Administration support provided to State, local, and Tribal officials in California, Colorado, Montana, Oregon, Utah, Washington and Wyoming includes:

- President Trump **approved** a Presidential Major Disaster Declaration for California effective August 14 for individual and public assistance and deployed extensive Federal resources to assist state and local efforts on the ground.
- President Trump **approved** Oregon's Emergency Declaration on September 10
- The Trump Administration has approved 34 **Fire Management Assistance Grants** since August that provide 75% Federal cost share for the mitigation, management, and control of fires, in coordination with state and local officials. This support directly

helps state and local officials in California, Colorado, Montana, Oregon, Utah, Washington and Wyoming. Find list of approvals [here](#).

- The Federal Government has deployed more than 26,000 personnel from 500+ crews and 1,900 engines to respond to fires as well as 230 helicopters, a RC-26 Aircraft, and 2 C-130 air tankers to support wildland fire operations.
- FEMA's National and Regional Response Coordination Centers have been activated to coordinate with local governments, non-governmental organizations, and the private sector.
- FEMA has adapted plans in partnership with affected states to address the realities of responding to the wildfires during the COVID-19 pandemic.

And the Trump Administration has led efforts to bolster fire prevention and preparedness. In 2018, President Trump signed an [executive order](#) to reduce wildfire risk and urged state and local officials to take action to improve forest management and increase preparedness efforts.

Additional Natural Disaster Response and Recovery Guidance:

- **FEMA Operational Guidance for the 2020 Emergency Season:** In preparing for the 2020 natural disaster season, the Federal Emergency Management Agency (FEMA) released guidance – [COVID-19 Pandemic Operational Guidance for the 2020 Hurricane Season](#) – to State, local, Tribal, and Territorial officials to help them prepare for response and recovery operations. While the document focuses on hurricane season preparedness, most planning considerations can also be applied to any disaster operation in the COVID-19 environment, including no-notice incidents, spring flooding and wildfire seasons, and typhoon response.
- **Federal Disaster Recovery and Response Guide:** The White House Office of Intergovernmental Affairs has prepared a federal disaster guide – [Recovery Through Federal-State-Local Partnership](#) – outlining the federal disaster response and recovery process (including the initiation and approval of Federal disaster and/or emergency declarations). This guide provides States, Local, and Tribal officials with a broad overview of this process and outlines federal agency specific disaster response and coordination actions. You can also find supplemental guidance from FEMA here - [A Guide to the Disaster Declaration Process and Federal Disaster Assistance](#).

All U.S. States Now Compliant Ahead of REAL ID Deadline

Yesterday, September 10, 2020, the Department of Homeland Security (DHS) announced that **after more than 15 years since Congress passed the REAL ID Act, all 50 states are now in full compliance issuing these cards, with most states becoming compliant in the last four years.** To date, the 50 states have issued more than 105 million REAL ID-compliant driver's licenses and identification cards, representing 38 percent of all driver's licenses and identification card holders.



Passed by Congress in 2005 following a 9/11 Commission recommendation, the REAL ID Act establishes minimum security standards for state-issued driver's licenses and identification cards and prohibits federal agencies, like the Transportation Security Administration, from accepting licenses and identification cards for official purposes from states that do not meet these standards after specific deadlines.

Because of the potential for confusion about the REAL ID Act enforcement milestones, residents can use the following guidelines to be fully informed and prepared.

- **Check your state-issued driver's license or identification card for the star.** REAL ID-compliant cards generally have a star marking in the upper left- or right-hand corner. Most acceptable alternatives, such as state-issued Enhanced Driver's Licenses, do not have the star, but are acceptable for official REAL ID Act compliance purposes. **[Read more here for more information on EDLs.](#)**
- **Bring identity documents to the airport that are acceptable for flying domestically.** **[Check to see if you have the proper identification to fly here.](#)** If you need to obtain a new form of ID, please allow sufficient processing time before you travel. For example, the current processing times for U.S. passports are 6-8 weeks for routine service and 2-3 weeks for expedited service.
- **Check with the federal agency you plan to visit, in advance, to find out whether identification is required, and if so, what types of identity documents are acceptable.** While most Federal agencies will continue to accept non-compliant driver's licenses and identification cards until the enforcement deadline of October 1, 2021, some – like Department of Defense facilities and posts – no longer accept them.

READ MORE: [Answers to REAL ID frequently asked questions.](#)

Making Communities Safer - Operation Legend Update

This week, Attorney General William P. Barr traveled to Chicago, Illinois, and Phoenix, Arizona, to announce updates on Operation Legend and the results of Operation Crystal Shield, respectively. In Chicago yesterday, Attorney General Barr held a press conference at


the U.S. Attorney's Office for the Northern District of Illinois and provided updates on Operation Legend.

Since Operation Legend was launched on **July 8**, there have been more than 2,000 arrests, with nearly 600 defendants charged in federal courts. And since launching in Chicago on **July 22**, the homicide rate has declined significantly. In fact, when comparing the seven weeks prior to the operation's launch with the five weeks immediately following the launch, homicides in Chicago declined 50%.

Attorney General Barr also announced that as a designated Operation Legend city, the Bureau of Justice Assistance will make available \$3.5 million in funding to reimburse the Chicago Police Department and City of Chicago for the work of local law enforcement on the federal task forces supporting Operation Legend's violent crime reduction efforts. The COPS Office has also made \$9.375 million available to the Chicago Police Department to fund the hiring of 75 officers.

Read More: [Readout of Attorney General William P. Barr's Visits to Chicago and Phoenix](#)

From the Media: [AG Talks Chicago Crime, 'Progressive Prosecutors' and Mistakes Made in Kenosha](#)



And on Wednesday, September 2, President Trump signed a memorandum to hold local politicians accountable for refusing to protect their communities from rioting, looting, and mass property destruction. Through this action, the Trump Administration will explore avenues to ensure Federal funds are spent to uphold the President's promise to protect life, liberty, and property. Find the memorandum [here](#) and a Fact Sheet [here](#).

Additional Operation Legend and DOJ Community Safety Updates

- **Wisconsin Man Charged with Trafficking Heroin, Fentanyl, and Methamphetamine; Illegally Possessing Numerous Firearms**
- **Chicago Street Gang Member Sentenced to 27 Years in Federal Prison on Murder and Racketeering Conspiracy Charges ([here](#))**
- **A Portland Resident Has Been Charged with Civil Disorder, a Felony, for Punching a Portland Police Officer in the Face During a Declared Riot on July 3, 2020 ([here](#))**
- **Three Portlanders Have Been Charged with Civil Disorder for Assaulting Local Police Officers ([here](#))**
- **Six Individuals Charged for Crimes Committed During Demonstrations Throughout South Carolina, including Arson, inciting a Riot, and Civil Disorders ([here](#))**
- **Alaska Man Charged Federally with Setting Fire at Seattle Police East Precinct ([here](#))**
- **Three Kansas City Men Charged in Armed Carjacking that Resulted in Police Pursuit, Fatal Collision ([here](#))**

The Trump Administration Is Protecting the Integrity of America's Elections

President Trump has firmly denounced any kind of foreign meddling in our elections and has taken strong action to safeguard the integrity of America's election system. The President has made clear time and again that his Administration will never tolerate any form of election interference from any country and has repeatedly stood up to Russia's malign activities that threaten our institutions and interests.

To combat election interference, the administration has provided on-site cybersecurity support to states during elections, and **President Trump has declared foreign election interference a national emergency** and signed legislation to provide hundreds of millions of dollars to states to harden their election security technology and infrastructure.

@WHNSC: Russia seeks to sow divisions and create chaos across America and other democratic societies. Today, the Administration utilized EO13848 to designate four Russia-linked individuals for attempting to influence the U.S. electoral process.

The Trump Administration has **held exercises with state and local officials** to improve their ability to respond to cyber incidents and has taken action to enhance information sharing with election officials across all 50 states and has participated in more than 25 election security-specific hearings or briefings with Congress since May 2019 alone.

Utilize the Election Security Risk Profile Assessment - developed by the Election Assistance Commission's (EAC) and Cybersecurity and Infrastructure Security Agency (CISA) - to determine your local jurisdiction's security risks and vulnerabilities.

- **Visit the Election Risk Profile tool here** to help mitigate your election security risks locally.
- **Download the Elections Cybersecurity Tabletop Exercise Manual here** to increase your local election security capabilities for staff.

President Trump Forges Historic Peace Agreement between Israel & Bahrain

On Friday, September 11, President Trump announced in the Oval Office that a historic peace agreement was reached between Israel and Bahrain.



@realDonaldTrump: Another HISTORIC breakthrough today! Our two GREAT friends Israel and the Kingdom of Bahrain agree to a Peace Deal - the second Arab country to make peace with Israel in 30 days!

This is a historic breakthrough to further peace in the Middle East. Opening direct dialogue between these two dynamic societies and advanced economies will continue the positive transformation of the Middle East and increase stability, security, and prosperity in the region.

Read More: Bahrain-Israel Deal Is 'Spectacular' Development for 'More Peaceful World,' says White house Spokesperson

The Kingdom of Bahrain has also accepted President Trump's invitation to join Israel and the United Arab Emirates at the historic signing ceremony on September 15, 2020 at the White House where Prime Minister Benjamin Netanyahu of Israel and Foreign Minister Abdullatif Al Zayani of Bahrain will be signing a historic Declaration of Peace.

Read More: Joint Statement of the United States, the Kingdom of Bahrain, and the State of Israel

This is the second such agreement between Israel and an Arab nation in less than one month. Israel and Bahrain have committed to begin the exchange of embassies and ambassadors, start direct flights between their countries, and launch cooperation initiatives across a broad range of sectors. This peace deal is a significant step forward for both Israel and Bahrain -- it further enhances their security while creating opportunities for them to deepen their economic ties.



This deal comes on the heels of the **historic normalization agreement** between Israel and the United Arab Emirates -- the United Arab Emirates and Bahrain are the first Arab nations to normalize relations with Israel in more than 25 years.

The United States will continue to support the people of Bahrain as they work to counter terrorism and extremism, develop economically, and build new peaceful partnerships across the region

Office of Intergovernmental Affairs · 1600 Pennsylvania Ave NW · Washington, DC 20500-0003 · USA · 202-456-1111

Nebraska Response to Covid 19/Zorpro

mdavis daviscei.com <mdavis@daviscei.com>

Wed 9/16/2020 4:00 PM

To: Miltenberger, Matt <matt.miltenberger@nebraska.gov>

Dear Mr. Miltenberger:

I am writing in regards to the Nebraska state response to the Covid-19 pandemic.

Great strides are being made in Covid-19 testing. Abbott Labs was just granted emergency FDA approval to manufacture it's Covid-19 Antigen Test which generates results in 15 minutes. Antigen tests are less accurate than the other method of Covid-19 testing, reverse transcription polymerase (PCR), which has a sensitivity rate of 84.3% according to the CDC. No sensitivity figures are currently available for antigen testing. Clearly both methods have large Covid-19 detection gaps.

Elevated temperatures are a clear symptom of all avian retroviruses at their most contagious periods, including Covid-19, along with seasonal flu and other health conditions. The Zorpro (www.zorpro.com) stand-alone temperature scanners are contact-free (subject extends forehead or wrist 2 inches from sensor), and can accommodate adults, children, and those in wheelchairs.

Zorpro is currently the only US manufacturer of commercial temperature sensors - the rest of the industry is primarily China based. Zorpro scanners would greatly aid the mission of the Nebraska state government today, as well as in the future, especially regarding contagious diseases such as Covid-19.

The Zorpro devices produce audio/visual scan results in 1 second. The most sophisticated model, the Zortemp 1000, can be modified to provide facial recognition, database, even sanitation misting . If the tested subject exceeds the set temp threshold, they can be sequestered for 5 minutes and tested again to eliminate elevated temperature caused by physical exertion.

Many Covid-19 vaccines are currently under development. When, and if, one or more are approved and administered nationwide, given the number of Americans with co-morbidities, vaccine efficacy will be greatly diminished. Also, the true effectiveness of the vaccine (s) will have to be determined over time. Vaccinated individuals should be monitored in the interim.

Malign actors worldwide have seen the devastation Covid-19 has done to the US and it is very likely ongoing, multiple attempts will be made to deploy one or more of the hundreds of known avian retroviruses both domestically, and against strategic US assets abroad.

The US population is seized with fear about Covid-19. Frequent temperature testing, combined with Covid-19 testing, as well as a Covid-19 vaccine (s), will help life get back to normal, but given the problems previously stated, temperature testing should be a permanent feature for our nation to help keep us safe.

Schools in particular need to demonstrate to parents all reasonable steps are being taken to protect the health of children regarding Covid 19, as well as all other contagious medical conditions.

Zorpro can provide one of those steps by providing convenient, fast, inexpensive, accurate temperature testing. We welcome the opportunity to discuss with you how Zorpro can help the citizens of Nebraska.

Very Best Regards,

Martin Davis
Principal
Davis Company Enterprises Inc.


mdavis@daviscei.com

RE: High School Sports contact tracing and quarantining (Two Rivers) ****

Hardin, Brittany <brittany.hardin@nebraska.gov>

Wed 9/16/2020 8:47 PM

To: Miltenberger, Matt <matt.miltenberger@nebraska.gov>

Great - -thanks.

Brittany Hardin

Business Development Division

Central and Western Nebraska Director, Office of Governor Pete Ricketts

Nebraska Department of Economic Development

CELL [REDACTED]

brittany.hardin@nebraska.gov

opportunity.nebraska.org | [Facebook](#) | [Twitter](#)

From: Miltenberger, Matt <matt.miltenberger@nebraska.gov>

Sent: Wednesday, September 16, 2020 3:46 PM

To: Hardin, Brittany <brittany.hardin@nebraska.gov>

Subject: RE: High School Sports contact tracing and quarantining (Two Rivers) ****

We're working on this very issue with DHHS and a group of local health directors. The goal is better uniformity and fewer kids being quarantined. We should have more info by the end of the week.

From: Hardin, Brittany <brittany.hardin@nebraska.gov>

Sent: Wednesday, September 16, 2020 3:41 PM

To: Miltenberger, Matt <matt.miltenberger@nebraska.gov>

Subject: FW: High School Sports contact tracing and quarantining (Two Rivers) ****

Importance: High

Matt –

Please see correspondence below regarding Two Rivers Health District and their protocols on quarantining for sports.

I also received a phone call today from a coach with similar concerns as those stated in the email below. In addition to what is listed in these emails, the high school volleyball coach (Amherst) who called today reported that Two Rivers contradicted their statement below regarding contact tracing. She was told that if a player on her team, or an opposing team, tested positive for COVID-19, then only those who had close contact with the player would be quarantined – whether or not they were wearing masks. The message from Two Rivers (stated in the third of the string of emails below) states the following:

If you attend an away game and your team is properly masked but the other team is not, a COVID positive player on your team would result in quarantines for the unmasked members of the opposing team. If the COVID positive player was on their team, it would result in quarantines for both teams, but a definite advantage for your team, since your players will be much less likely to contract COVID since they were wearing masks.

Concerns have escalated since several entire teams in central NE were quarantined this week.

Concerns and questions I have received are:

- 1) Two Rivers did not publicly state that they wanted all athletes wearing masks, but have said this in direct discussions with coaches. Communication and consistency are needed for all coaches/schools to follow.

Doing so may help level the playing field for all schools in the district. Right now, some are wearing masks to play, and others aren't. The coach I spoke with today said that Two Rivers indicated that a mask mandate for sports, in any district, must be implemented by the NSAA.

2) How much jurisdiction does a health district have regarding contact tracing in Phase 4?

Brittany Hardin

Business Development Division

Central and Western Nebraska Director, Office of Governor Pete Ricketts.

Nebraska Department of Economic Development

CELL [REDACTED]

brittany.hardin@nebraska.gov

opportunity.nebraska.org | [Facebook](#) | [Twitter](#)

From: Natalie Hagan <hagannt@unk.edu>

Sent: Wednesday, September 16, 2020 2:40 PM

To: Hardin, Brittany <brittany.hardin@nebraska.gov>

Subject: High School Sports contact tracing and quarantining (Two Rivers)

Brittany:

This is a message I sent to Senator Lowe in our district, but I also wanted to share with you as well. Hope together we can ALL make a change in the right direction!

From: Natalie Hagan

Sent: Tuesday, September 15, 2020 9:03 AM

To: jlowe@leg.ne.gov

Subject: High School Sports contact tracing and quarantining (Two Rivers)

Senator Lowe:

I want to reach out regarding the major over-stepping of boundaries by our local TWO Rivers Health Department. Our high school was notified of the below email regarding the use of "masking" to protect our student-athletes in our high school.

The issue is I feel there needs to be (1) CLEAR guideline that is used for all indoor sports to be followed. If a TEAM MASKS they are at a CLEAR DISADVANTAGE due to ability to get fresh air, ability to signal plays to their team and communicate in Comparison to a TEAM that Chooses to NOT MASK that has clear access to air, and can clearly communicate to teammates. The problem lies upon a member of ANY one of these two competing teams receiving a POSTIVE COVID-10 test. According to the email below, TWO RIVERS STATES that a positive Test in this situation would require BOTH TEAMS to quarantine even with one team being MASKED!

Two Rivers has now become the manager of determining the FATE of success or ENDING/COMPLETION of a SEASON by their guidelines which is NOT their job or duty.

Imagine this scenario...School A that is ranked highly in the Class and is anticipated to easily make it to the state Tourney in Volleyball. School B will be playing School A right before Sub-Districts. A "fan/parent" dislikes School A and happens to have an illness or something that RESEMBLES COVID-19 (headache, body ache, loss of taste/smell, allergies, darn near anything) and reports to TWO RIVERS. AND REPORTS they were around SCHOOL A that was either masked/unmasked. Now SCHOOL A has to quarantine and misses on the opportunity to compete in

subdistricts and state due to School B reporting. How can this be fair? I am afraid there is going to be a lot of back-stabbing to teams.

And even if the School A is masked they would still have to quarantine on a POSTIVE Testing! So what is the point of masking in the scenario above other than just a DISADVANTAGE in competition? Lots of questions and the direction TWO RIVERS is acting on is a SEVERE Disadvantage to our area athletes in the district.

Somebody needs to step in and we are asking you help!

Natalie Hagan
Manager of Marketing and Promotions
UNK Athletics
2501 15th Avenue, HSC 118
Kearney, NE 68849
hagannr@unk.edu

Sent: Tuesday, September 15, 2020 8:16 AM
Subject: Fwd: contact tracing and quarantining

See two rivers response below. Unbelievable !

Begin forwarded message:

Date: September 15, 2020 at 8:08:25 AM CDT
Subject: Re: contact tracing and quarantining

No kidding.

Imagine team A being masked up at districts and team B is not and covid positive on team B them Team A is quarantined out of the state tourney!
Watch the purposed sabotaging begin. Or team A's sate bound road is shut down due to an over reactive parent on team b

On Sep 15, 2020, at 8:04 AM, wrote:

OMG!

I am callin them and the governors Offices. They are overstepping their boundaries.

Sent from my iPhone

On Sep 15, 2020, at 7:53 AM, wrote:

Get a load of two rivers response

Begin forwarded message:

Date: September 15, 2020 at 6:17:34 AM CDT
Subject: Fwd: contact tracing and quarantining

Here is Two Rivers response.

----- Forwarded message -----

From: Susan Puckett <spuckett@trphd.org>
Date: Mon, Sep 14, 2020 at 2:50 PM
Subject: RE: contact tracing and quarantining
To: Cc: Jodi Sowl <jsowl@trphd.org>, Jeremy Eschliman <Jeschliman@trphd.org>

Hi,

Thanks for reaching out to Two Rivers Public Health this morning. It was great talking with you and I could tell that you have really acquired an above-average understanding of the CDC guidelines for isolation and quarantine related to masking (or a lack thereof).

In an indoor or enclosed environment, the risk of unmasked persons being a direct contact (and therefore, quarantined) is high if a COVID positive person is in their midst. I would encourage you to assess the risk less in terms of the exact distance from the infected person and use a smoker in the room for determining likelihood of exposure. If these two or ten people were in a confined space together and one of them lit a cigarette and smoked it, how many of them would smell the smoke?

In your example of opposing teams, I would like to put a little bit of a positive spin on the same story. According to the NSAA, if you notify a visiting team coming to your school of your policy for masking at all times, including spectators, you can fully expect the visiting team will comply. In this instance, a COVID positive player would result in no quarantines. You can always control what is happening on your courts. If you attend an away game and your team is properly masked but the other team is not, a COVID positive player on your team would result in quarantines for the unmasked members of the opposing team. If the COVID positive player was on their team, it would result in quarantines for both teams, but a definite advantage for your team, since your players will be much less likely to contract COVID since they were wearing masks.

I hope these explanations have been helpful. I have attached two articles that may be of interest to you, one at the top and one below:

https://kearneyhub.com/lifestyles/health-med-fit/what-a-smoky-bar-can-teach-us-about-the-6-foot-rule-during-the-covid/article_53006b91-4ace-50d6-8690-c71014372041.html?utm_campaign=snd-autopilot&utm_medium=social&utm_source=facebook Ke

[arney_Hub&fbclid=IwAR3B7yLkPSc-sqU6Xgvm24xIMnon49McEJ_SuFP5izdlaMBnOniajNQCvyM](#)

Susan

Susan Puckett, RN | Community Health Nurse

516 West 11th Street, Suite 108B, Kearney, NE 68845
OFFICE: 888-669-7154 | FAX: 308-455-4182

[TRPHD.org](#) | [Facebook](#) | [Twitter](#) | [Instagram](#)

<image002.png>

This message is intended for the use of the individual or entity to which it is addressed and may contain information that is privileged, confidential and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient or the employee or agent responsible for delivering this message to the intended recipient, you are hereby notified that any dissemination, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please notify us immediately by email reply or telephone @ 888-669-7154 and immediately delete this message and any attachments. Thank you.

From:

Sent: Monday, September 14, 2020 9:54 AM

To: Susan Puckett <spuckett@trphd.org>

Subject: contact tracing and quarantining

Susan,

I have two questions concerning wearing masks and playing Volleyball.

1, What are Two Rivers guidelines for quarantining if some players on the same team are wearing masks and others are not during a game, in practice, on a bus, or riding around together in a car?

2. On one team everyone is wearing masks all the time, On the other team some players are wearing masks others are not. What happens to the team wearing masks if someone on the other team tests positive for the virus?

Thank You

CAUTION: This email originated from outside of the organization. Do not click links or open attachments unless you recognize the sender and know the content is safe.

<NEJM Face Masking and Variolation as We Await a Vaccine for COVIDnejmp2026913.pdf>

Governor-Only Briefing Call/VTC with the Vice President on Monday, September 21 at 3:00 p.m. ET

Lopez, Diego Christopher EOP/WHO <DiegoChristopher.Lopez2@who.eop.gov>

Thu 9/17/2020 3:45 PM

To: Lopez, Diego Christopher EOP/WHO <DiegoChristopher.Lopez2@who.eop.gov>

Cc: Pottebaum, Nic D. EOP/WHO <Nicholas.D.Pottebaum@who.eop.gov>; Obenshain, Tucker T. EOP/OVP <Anne.T.Obenshain@ovp.eop.gov>; Friedman, Haley Z. EOP/WHO <Haley.Z.Friedman@who.eop.gov>; Swint, Zachariah D. EOP/WHO <Zachariah.D.Swint2@who.eop.gov>



THE WHITE HOUSE

Governor's Senior Staff (Chief of Staff, State-Federal Director, and Scheduler),

Our Nation's Governors are invited to a **Governors-only Briefing Video Teleconference (with an audio option) with Vice President Mike Pence on COVID-19 response and recovery**. The briefing will be on **Monday, September 21, 2020 at 3:00 p.m. Eastern Time**.

Briefing Call/VTC Details

- **Date:** Monday, September 21, 2020
- **Time:** 3:00 p.m. Eastern Time
- **Expected Length:** 60-90 minutes (*Please communicate if your governor is expected to be late or depart early from the briefing*)
- **Federal Participants:** Vice President Mike Pence and Additional Senior Administration Officials.
- **Video Teleconference Option:** Most states have video teleconference (VTC) capabilities and we can provide you details upon request. If you are interested in joining through VTC please indicate so in the RSVP.
- **Reminder:** This is a Governor-only briefing (i.e., one call-in per state): Participation in this call is for governors only, but we encourage governors to be joined by their representative state health officer and other state health officials, key state leaders in state's effort to distribute and administer a safe vaccine, homeland security advisor, state emergency manager, state economic development director, state workforce director, etc.

RSVP & Call-In/VTC Information – Deadline to RSVP is Friday, September 18, at 5:00 p.m. ET

To RSVP your governor, please email me (DiegoChristopher.Lopez2@who.eop.gov) by **no later than Friday, September 18 at 5:00 p.m. Eastern Time**. Once you RSVP your governor, you will receive a call-in information link and guidance. VTC guidance will be provided upon request.

If you have any additional questions, please reach out to the White House Intergovernmental Affairs Office or the Office of the Vice President.

Name	Cell Phone	Email
Nic Pottebaum	[REDACTED]	Nicholas.D.Pottebaum@who.eop.gov
Tucker Obenshain	[REDACTED]	Anne.T.Obenshain@ovp.eop.gov
Zach Swint	[REDACTED]	Zachariah.D.Swint2@who.eop.gov

Haley Friedman	[REDACTED]	Haley.Z.Friedman@who.eop.gov
Christopher Lopez	[REDACTED]	DiegoChristopher.Lopez2@who.eop.gov

Sincerely,

Christopher Lopez
The White House | Office of Intergovernmental Affairs
Cell: [REDACTED] Office: 202-456-1680

Governor's Task Force Weekly Update

Schroeder, Chris <chris.schroeder@nebraska.gov>

Mon 9/21/2020 6:08 PM

To: CJ Poltack <cjpolmack@west-central-nebraska.com>; Garry Clark <garry.clark@fremontecodev.org>; Kelly Gentrup <Kelly.Gentrup@fremontecodev.org>; Albin, John <John.Albin@nebraska.gov>; Regan Anson <regan@neimpact.org>; Robin Ambroz <robin.ambroz@nifa.org>; arnettsa@bankonheritage.com <arnettsa@bankonheritage.com>; Lisa Ashby <crisisdogs@gmail.com>; dbaratta@habitatomaha.org <dbaratta@habitatomaha.org>; Bargmann, Molly <molly.bargmann@nebraska.gov>; Lorilee Beeson <lorilee.beeson@gmail.com>; Maj. Gen. Daryl L. Bohac <daryl.l.bohac.mil@mail.mil>; cyndi@thekingsgarden.org <cyndi@thekingsgarden.org>; Bradley, Jesse <Jesse.Bradley@nebraska.gov>; Brennan, Jake <jake.brennan@nebraska.gov>; Jon Cannon <jon.cannon@nacone.org>; Chaffin, Lash <lashc@lonm.org>; Christensen, Donny <donny.christensen@nebraska.gov>; Soni Cochran <scochran@unl.edu>; Mark Coffin <mcoffin@habitatomaha.org>

4 attachments (9 MB)

L.T.R. URO Dashboard.2020.09.18.docx; September GTF Meeting Presentation.pptx; DR-4420 LTRRP Strategy Tracker 2020.09.18.xlsx; The Red Cross Needs You!.pdf;

Good Afternoon All,

A big thank you to all those who were able to attend last Thursday's monthly coordination meeting. These recur on the third Thursday of every month at 1PM, with the next occurring on October 15th. I will provide a reminder message with video conference details as the meeting date draws closer.

For your use, review, and situational awareness, the following documents are attached to this message:

- The Long-Term Recovery and Mass Care component of last week's Unified Recovery Outcomes (URO) dashboard.
- The slides discussed during Thursday's Task Force coordination meeting.
- A Tracker** listing all of the Strategies in the State's Long-Term Recovery and Resilience Plan, with a color-coded indication of each in terms of our recovery from the 2019 flooding.

**I will be sending this out regularly with updates and notes, but this is very much a working document and I am open to any and all feedback.

- An urgent call for volunteers from the American Red Cross.

Additionally, Legal Aid of Nebraska is hosting a virtual luncheon and conversation on October 8th with Matthew Desmond, bestselling author of "Evicted: Poverty and Profit in the American City", on housing, evictions, and prevention:

<https://www.legalaidofnebraska.org/foia2020/>

Finally, below is a message with webinars and learning opportunities from the First Responders Foundation.

Please do not hesitate to contact me if there are any questions or there is anything I can do to be of service. Thank you for all you do.

All the Best,
Chris

Chris Schroeder

Long-Term Recovery Specialist

Nebraska Emergency Management Agency

Mobile

Office

402-471-7007

chris.schroeder@nebraska.gov


[View this email in your browser](#)



Monday, September 21st, starting at 6pm

Come and visit with the First Responders Foundation sponsored Race Team, at The Good Life Sports Bar and Grill, at 1203 S. 180th Street. Register to win a family pack (4 tickets) to the Guns & Hoses I-80 Speedway Event and Salute

to First Responders Night 2021. Meet the Team, See the Race Car, and Enter for a Chance To WIN!



First Responders Support Team

The First Responders Support Team has many upcoming free classes and programs for first responders and their families.


Introducing Yoga! Three nights of free yoga sessions for first responders and families. As we start to develop our class schedules we are offering three session with different types of yoga.

We are also offering Spouse Support Sessions and Groups, a First Responders and Significant Others Workshop, a Nutrition Class, an End of Career Class, and a Family Retreat at HETRA. Many of the classes are offered in person, via Zoom and/or Telehealth. See below for more details!

If you are not a first responder please consider a donation to help the Foundation continue serving first responders and their families.

[If you would like to make a donation to support the programming of the First Responders Foundation click here](#)

Yin Yoga Sept. 28th




From 6-7pm. Yin yoga is a very passive approach to yoga where you perform the majority of the poses seated on the floor or laying down and poses are held for longer periods of time, sometimes 3 - 5 minutes or more. Yin yoga offers deeper access to the body targeting our connective tissues, fascia and ligaments with the aim of lubricating and protecting our joints.

“FRY” First Responders Yoga Sept. 29th



From 6-7pm. FRY offers 4 benefits for first responders. Practice breathing for calming before and after a call. Developing mindful awareness to help function better at home and on the job. Helps improve sleep and helps remove stress from the mind and body. Less physical and mental injuries occur on the job when yoga is practiced regularly.

Nidra Yoga Sept. 30th



From 6-7pm. In this Nidra yoga class you will unwind and relax deeper than you ever have before. Instructor Hope Goldsmith will guide you on an unexpected, inside journey, step by step relaxing you deeper into self-soothing. You will relax into your own safe, comfortable place of healing, where you will start releasing any stress or anxiety you are carrying. The class starts and concludes with light stretching. You will end the class

Instructor is former
OPD Officer Mechelle
Keller.

Instructor is FRST
Therapist Stephanie
Levy

feeling renewed and
restored.

Spouse Session



**Monday, September
28th from 6-8pm.**


These sessions held
quarterly are tailored
for spouses and the
family of first
responders. Sessions
help first responders
families develop
understanding and
how to provide support
in the home.

Spouse Support Group



**October 2nd from
3:30pm-4:30pm.** The
Spouse Support
Group is a clinician-led
group open to spouses
and adult family
members of first
responders.
Individuals can attend
a group whenever
support is needed.
The support group
meets on the first
Friday of every month
from 3:30pm -
4:30pm. At this time,
the group is held via
Zoom. Contact the
FRST Team for login
information.


Family Retreat at HETRA



**October 10th, from 1-
4pm.** Family Retreat
at HETRA (Heartland
Equine Therapeutic
Riding Academy)


HETRA invites all First
Responders, spouses
and children (ages 5+)
to visit the campus for
a special care retreat.
Activities include a
brief classroom
portion, witnessing
herd dynamics,
grooming horses, and
leading horses through
obstacles.

Nutrition Class



October 17th in the morning, exact time TBD. Some of the leading causes of death can be prevented with a healthy diet. This class will teach proper eating habits, what happens to your body when you eat different foods, and food safety. Learn how to eat for your body to function at its best.

Stronger Together Workshop



Stronger Together Workshop, Oct. 24th 8:30am-12:30pm. A proactive workshop for First Responders and their significant other, to prepare for traumatic/critical events together. Participants will learn how these experiences can have a short term or permanent lasting effect upon individuals. This free one time 4 hour class will extend careers, marriages, relationships, and life!

With Honor Worship



When a career has come to an end for a first responder the residual effects of the work do not fade away easily. This two-hour workshop helps provide knowledge and skills to first responders to prepare, adjust, and grow when the end of their career comes and to do so **With Honor. Coming in early November.**

The FRST Team Welcomes a New Therapist, Leslie Hartmann. Leslie is a Licensed Mental Health Practitioner (LMHP), some of her experience is working with children, and adolescents with behavioral

and social challenges, and families. Leslie's experience also includes working in the correctional setting dealing with inmates and correctional staff. Leslie will specialize in working with spouses and adolescents and she will facilitate a substance support group. If you would like to speak to Leslie or make an appointment, contact her at leslie@firstrespondersfoundation.org.

To register or for more information, and/or for Zoom login information, click here. Or call Diann at 402-218-1234. Option 1 #3

If you would like to make a donation to support the programming of the First Responders Foundation click here



Copyright © 2020. All rights reserved.

Our mailing address is:
10605 Burt Circle. Omaha, NE 68114

NEWS & BOTTOM LINES UP FRONT

--DED has begun receiving feedback from HUD on CDBG-DR (\$108.9M) Action Plan, still awaiting further notes and complete details -- receipt of which is expected at any time.

--A lot of concern and calls for action in local communities around reopening applications for the Pandemic-EBT (P-EBT) program and extending SNAP emergency maximum allotments.

CRITICAL NEEDS: LONG-TERM FLOOD & PANDEMIC RECOVERY

Permanent, Affordable, Local Housing Solutions.

--CDC eviction moratorium is a beneficial but temporary solution, and one which could lead to an immense amount of evictions in January 2021.

--Currently no statutory limit in Nebraska on late fee or penalty amounts that a landlord can assess.

--Reports continuing to come in of more homeless and chronically homeless families needing a solution of some kind before the winter season -- with local partners working to identify most at-risk and unsafe cases.

--Hundreds of families still in need of home repairs, complete home replacements, new well systems, and/or new septic tanks. Many are still, even now, coming forward for assistance for the first time after exhausting personal finances and resources -- and some have been living in uninhabitable circumstances since last March.

Funding for Additional, Local Recovery Staff.

--Many local partners, volunteers, and teammates redeployed to Iowa derecho and other disasters, further thinning Nebraska recovery staff numbers and capacity.

--Thousands of flood survivors still needing assigned to a Disaster Case Manager so needs can be identified, all DCMs already overloaded with active cases.

Increased Food Security.

--Demand on Food Bank of Lincoln, Food Bank for the Heartland, and local pantries continuing to rise -- all purchasing, distributing food in record amounts.

--Searches underway for vacant or unused, drive-thru-capable buildings and facilities to adapt mobile pantry operations for snowfall and winter months.

Increased Mental Health Support.

--Nebraska Strong Recovery Project and other behavioral health providers are working statewide to connect with people -- issue of capacity similar to Disaster Case Managers.

Increased Financial Security & Individual Household Needs.

--Many large requests from families still coming in for rent and utility assistance due to build-up of costs from the months when eviction and shut-off moratoriums were in place. Some families now making extreme decisions (ex.: selling the household's only vehicle) to make ends meet.

--Even more rent/utility requests expected to come in January following current CDC eviction moratorium.

--New unemployment claims up more than 400% compared to this time last year. Continued claims up more than 600% compared to this time last year.

NEBRASKA EMERGENCY MANAGEMENT AGENCY

Governor's Long-Term Recovery Task Force Coordination Meeting

September 17, 2020

NEBRASKA

Good Life. Great Strength.

AGENDA

Review of Task Force Recovery Principles.

Update on DR-4521: COVID-19 Pandemic.

Update on DR-4420: 2019 Flooding.

Update on Current Fire Weather Outlook & Drought Monitor.

Detail of Biggest Needs at Local Level.

Detail of Takeaways & Next Steps.

RECOVERY PRINCIPLES

- Maintain focus and momentum on challenges that existed pre-disasters and were likely exacerbated post-disasters.
- Concentrate on preserving Nebraska's agricultural identity, emphasizing support and thoughtfulness of rural communities.
- Reflect the "new normal" for individuals and families in Nebraska.
- Prioritize mitigation in high-risk areas, ensuring that communities are able to build back better and enhance preparedness for all hazards.
- Comply with all local, state, and Federal regulations, policies, and laws.
- Leverage local resources and support local economies to the fullest extent possible.
- Public communications will be accessible through varied means.
- Make ongoing adjustments to this Plan to effectively meet the needs of Nebraskans as new disasters occur.

Dashboard Information Current as of 0700, 17-Sept-2020

DR-4521: LIFELINES & DASHBOARD





Coronavirus COVID-19 Nebraska Cases by the Nebraska Department of Health and Human Services (DHHS)

Total Positive Cases
39,419

Total Tested
413,473

Confirmed
373,432

Died
439





Dashboard Information Current as of 0700, 17-Sept-2020

DR-4521: LIFELINES & DASHBOARD

Number of positive tests by county in the last 14 days

1,173	Lancaster
1,076	Douglas
358	Saras
179	Buffalo
142	Madison
119	Saurate
99	Platte
98	Dodge
88	Dakota
69	Hall
56	Adams
45	Dawson
40	Gage
37	Washington
35	Knox
33	Case
31	Pierce
31	Saline
28	Seward
27	Wayne
26	Dawes
26	York
25	Scotts Bluff



DR-4521: COVID-19 PANDEMIC

- Recent increase in positive cases largely attributed to schools reopening and large gatherings of college-aged students.
- Hospital capacity very good, low ventilator use in Omaha & Lincoln.
- Contact tracing to follow up on positive tests robust and efficient.
- \$37M expended on PPE to date; \$35M dedicated to local governments.
- Federal government working with states on vaccination plans, including receipt of supplies, tracking systems, prioritization of groups for testing.
 - Potential Phase 1 rollout as soon as November.

DR-4420: LONG-TERM FLOOD RECOVERY



LONG-TERM RECOVERY & RESILIENCE PLAN



DR-4420: Current update on Strategies across all Recovery Support Functions.

RED: NOT YET STARTED

YELLOW: GETTING UNDERWAY

GREEN: ACTIVELY IN PROGRESS

**Informal, subjective estimates meant to show cumulative progress.



LTRRP: STATUS OF ALL STRATEGIES

-**Cross-Cutting Issues:** 12 in progress; 5 underway.

-**Infrastructure:** 10 in progress; 3 underway.

-**Housing:** 8 in progress; 3 underway; 1 not yet started.

-**Economics:** 7 in progress; 3 underway.

-**Agriculture:** 2 in progress; 1 underway.

-**Health & Social Services:** 7 in progress; 1 underway.

-**Natural & Cultural Resources:** 4 in progress; 2 underway; 1 not yet started.

TOTALS

Long-Term Recovery & Resilience Plan composed of 70 Strategies across all fronts and Recovery Support Functions.

2 are not yet started. (3%)

18 are getting underway. (26%)

50 are actively in progress. (71%)

** Informal, subjective estimates meant to show cumulative progress.


Information Current as of 0700, 17-Sept-2020

WILDFIRE ACTIVITY MAP



Information Current as of 0700, 17-Sept-2020


FIRE WEATHER OUTLOOK



Information Current as of 0700, 17-Sept-2020

NEBRASKA FIRE DANGER

Nebraska Rangeland Fire Danger - Tomorrow - Does not account for snow cover
Valid: September 18, 2020




National Weather Service
Omaha/Valley Nebraska
09/17/2020 08:02 AM CDT




Follow Us:
weather.gov/Omaha

DROUGHT MONITOR: September 17, 2020



	None	D0-D4 (Dry)	D1-D4 (Moderate)	D2-D4 (Severe)	D3-D4 (Extreme)	D4 (Catastrophic)
DROUGHT INTENSITY						
Current	22.11%	77.89%	53.44%	23.52%	0.59%	0.00%
Last Week	19.32%	80.67%	55.91%	25.92%	2.48%	0.00%
One Year Ago (9-17-2019)	100.0%	0.00%	0.00%	0.00%	0.00%	0.00%



- New Drought Monitor Maps are updated every Tuesday & released every Thursday.

The drought monitor focuses on broad-scale conditions. Local conditions may vary. For additional information:
<http://droughtmonitor.unl.edu>



ISSUES & NEEDS AT LOCAL LEVEL

- Increased mental health resources.
 - Nebraska Strong Recovery Project facilitating Crisis Counseling Program statewide.
 - Social distancing, virtual contact creating issues of capacity.
- Increased financial security, individual household needs.
 - Households drained savings on flood recovery, have no personal resources to handle the current pandemic. Many making extreme decisions (ex.: selling the family's only vehicle) to make ends meet.
 - Exacerbated by increasing unemployment numbers.
 - Thousands of large requests for assistance with rent, utilities.
 - Continued rise in number of evictions.
- Lack of volunteers to continue or begin home repairs.
 - Cautiously targeting the fall season for certain service areas.
 - Man-power and resources redeployed to other disasters.
 - Local, licensed contractors already overbooked.

ISSUES & NEEDS AT LOCAL LEVEL

- CDC moratorium on evictions.
 - Went into effect September 4, in place through December 31.
 - Putting the financial squeeze on landlords, property owners.
 - Currently no statutory limit in Nebraska on late/penalty fees that can be charged.
- Unemployment numbers still very high.
 - New unemployment claims up 432% year-on-year from 2019.
 - Week of 5-Sept-2020: 2,451 – Week of 5-Sept-2019: 461
 - Ongoing claims up 621% year-on-year from 2019.
 - Week of 5-Sept-2020: 22,881 – Week of 5-Sept-2019: 3,174

ISSUES & NEEDS AT LOCAL LEVEL

- Additional recovery staff.
 - Disaster Case Managers currently on the ground overloaded with active cases, with hundreds of additional cases prioritized on waiting lists.
 - Multiple counties and communities have had no LTRG, meaning no dedicated Case Managers to address unmet household needs.
- Rampant, continued food insecurity.
 - Demand of Food Banks, pantries, providers continuing to increase.
 - Calls to reopen applications for P-EBT program and to extend SNAP emergency maximum allotments.
- Disaster fatigue.
 - 555 days since flooding began, 183 days since first COVID DHMs in NE.
 - Anxiety around the uncertainty of winter, potential flooding in spring.

WINTER & GENERAL PREPAREDNESS

Risk Factors and Foreseeable Threats

- Additional housing and shelter solutions needed for chronically homeless, at-risk, and vulnerable populations.
- Impacts to mobile pantries and food distribution efforts.
- Additional financial burdens of sustainable heat sources.
- Educational documents, pamphlets needed in multiple, various languages and in more accessible mediums.
- Quarantine, self-isolation, and Directed Health Measures exacerbated by inclement weather, impassable roads, power outages.

PROGRESS SINCE LAST MEETING

Public Assistance.

- \$28.8M back in the hands of NE communities, another \$4.5M in progress. **
- 999 payments made, another 86 in progress. **

Hazard Mitigation.

- H.M.G.P. projects getting approved by State, submitted to FEMA.
- Discussions underway about initial roll-out of BRIC program.

CDBG-DR.


- HUD has approved two of the Action Plan's four sections.


Landlord Assistance Program.

Extension of Summer Food Service Program.

"Operation Gratitude" Thanksgiving meal distribution initiative.

**Current as of 11-Sept-2020





TAKEAWAYS & NEXT STEPS

September: National Disaster Preparedness Month.

Continued RSF, Agency, and Organization meetings, check-ins.

--Communication and collaboration.

October: National Farm to School Month.

Governor's Task Force Annual Report.

--5 November: One year anniversary of activation.


--Written report to be distributed in November, more details forthcoming.

Next Coordination Meeting:

Thursday, 15 October 2020, 1PM

Via video conference

QUESTIONS?



IN PROGRESS: 24 (10%)

GETTING UNDERWAY: 18 (26%)

NOT STARTED: 5 (5%)

State of Nebraska Long-Term Recovery & Resilience Plan: 2019 Flooding (DR-4430)

Agriculture

Objective 1: Build capacity of agricultural information networks to support all phases of disaster.

- Strategy 1.1: Develop tools to collect and organize information resources. Notes: x
- Strategy 1.2: Develop master list of state-wide resources to support information collection, impact, and needs. Notes: x
- Strategy 1.3: Create state-wide outreach and education for crop, livestock, and equine industries. Notes: x

Cross-Cutting Issues

Objective 1: Minimize impediments without compromising public safety.

- Strategy 1.1: Amend regulatory, legislative policies that hinder recovery efforts. Notes: x
- Strategy 1.2: Minimize regulatory impediments to recovery activities. Notes: x

Objective 2: Create efficiencies to leverage Federal funds as rapidly as possible.

- Strategy 2.1: Build web capacity to apply for and manage Federal funds. Notes: x
- Strategy 2.2: Identify sources and solutions for funding available state or through state. Notes: x

Objective 3: Address access and functional needs in response, recovery, and preparedness.

- Strategy 3.1: Coordinate across all levels to identify and address challenges. Notes: x
- Strategy 3.2: Ensure available and understandable communications for all. Notes: x
- Strategy 3.3: Increase resilience of access and functional needs populations. Notes: x

Objective 4: Promote statewide awareness of needs, resource, and programs.

- Strategy 4.1: Develop communication plan and information campaigns. Notes: x
- Strategy 4.2: Develop strategies to identify needs, data needs, and groups. Notes: x

Objective 5: Maintain statewide support for mold identification and remediation.

- Strategy 5.1: Monitor public health trends and appropriate treatment plans. Notes: x
- Strategy 5.2: Develop and disseminate state-wide identification and remediation guidance. Notes: x

Objective 6: Update State and local Long-Term Recovery plans, documents, and decision-making tools.

- Strategy 6.1: Develop statewide model long-term recovery framework for local. Notes: x
- Strategy 6.2: Develop local recovery plans with the State available data/needs and data. Notes: x
- Strategy 6.3: Work with local emergency managers to meet all plans updated and revised. Notes: x

Objective 7: Maintain, distribute accurate and timely mapping of disaster impacted areas.

- Strategy 7.1: Monitor physical changes over time, as determined field assessments. Notes: x
- Strategy 7.2: Compile statewide inventory of damage that can be activated in a disaster. Notes: x

Objective 8: Implement mechanisms for monitor emerging and delayed impacts over time.

- Strategy 8.1: Use Periodic Needs Assessments to identify gaps, needs, and problem areas. Notes: x

Economics

Objective 1: Improve private-sector preparedness and resilience.

- Strategy 1.1: Conduct training for business owners to increase risk awareness. Notes: x
- Strategy 1.2: Develop disaster insurance outreach and education programs for business. Notes: x
- Strategy 1.3: Establish central location for risk reduction resources for businesses. Notes: x
- Strategy 1.4: Perform audit and outreach to business statewide about all phases of disaster. Notes: x
- Strategy 1.5: Develop program to increase the resilience of small businesses. Notes: x
- Strategy 1.6: Develop state resilience indicators to assess economic recovery needs, growth opportunities. Notes: x

Objective 2: Address revenue losses and economic recovery in rural areas.

- Strategy 2.1: Reduce long-term risk while promoting economic growth. Notes: x
- Strategy 2.2: Leverage available resources to help local governments bridge revenue gaps. Notes: x

Objective 3: Promote workforce development as a way to support economic recovery.

- Strategy 3.1: Provide career training for displaced workers and impacted communities. Notes: x
- Strategy 3.2: Create incentive programs to encourage retention of educated persons in rural areas. Notes: x

Health & Social Services

Objective 1: Increase utilization of treatment programs and services.

- Strategy 1.1: Promote service awareness and providing information on where to go. Notes: x
- Strategy 1.2: Minimize behavioral health barriers as they relate to care. Notes: x

Objective 2: Provide needed social service support to people and communities statewide.

- Strategy 2.1: Promote available information on resources, local risks, programs, and funding sources. Notes: x
- Strategy 2.2: Strengthen the support of disaster case management efforts. Notes: x
- Strategy 2.3: Develop a survivor-centric, outward-facing resource database. Notes: x
- Strategy 2.4: Incorporate recovery and resilience efforts into existing local needs and organizations. Notes: x

Objective 3: Increase capacity of behavioral health treatment programs to meet demand and increase resilience.

- Strategy 3.1: Increase treatment availability statewide, including personal care and telehealth. Notes: x
- Strategy 3.2: Increase treatment capacity for providing by phone-based, remote, telehealth care. Notes: x

Housing

Objective 1: Restore damaged housing to livable -- safe, secure, sanitary -- standards.

- Strategy 1.1: Develop and implement a plan for emergency repairs, temporary housing, and repairs. Notes: x
- Strategy 1.2: Develop a state-wide repair, rebuild and green and disaster recovery for residential. Notes: x
- Strategy 1.3: Develop program to support new developments in pre-damaged homes. Notes: x

Objective 2: Support local housing mitigation, development, and resilience statewide.

- Strategy 2.1: Demolish, replace damaged homes with affordable and accessible solutions. Notes: x
- Strategy 2.2: Create educational campaigns on National Flood Insurance Program. Notes: x
- Strategy 2.3: Minimize opportunities to speculate through local needs assessment surveys. Notes: x
- Strategy 2.4: Create a strategic planning framework for local communities and housing authorities. Notes: x
- Strategy 2.5: Evaluate current and future local, community-level mitigation, preparedness, and disaster. Notes: x
- Strategy 2.6: Create an affordable housing continuum of housing resources. Notes: x

Objective 3: Assist impacted communities in obtaining livable housing solutions for families until permanent solutions can be found.							
Strategy 3.1:	Provide continued housing and utility assistance to those leaving until full rent community	Notes: x					
Strategy 3.2:	Identify affordable housing solutions for those experiencing homelessness	Notes: x					
Objective 4: Develop secure, sharable inter-agency data and document collection system.							
Strategy 4.1:	Convene group of partners and data collectors to assess feasibility	Notes: x					
Infrastructure							
Objective 1: Rebuild and repair infrastructure to reduce future vulnerability.							
Strategy 1.1:	Efficiently implement inter-agency damage assessment teams	Notes: x					
Strategy 1.2:	Maximize focus on mitigation and support relocation from impacted areas	Notes: x					
Strategy 1.3:	Identify grant opportunities and channels for infrastructure projects	Notes: x					
Strategy 1.4:	Provide technical assistance to local governments on mitigation	Notes: x					
Strategy 1.5:	Develop cost estimates for individual and community critical upgrades statewide	Notes: x					
Strategy 1.6:	Identify local needs, funding sources and address challenges	Notes: x					
Strategy 1.7:	Address water and wastewater needs statewide at state and local levels	Notes: x					
Strategy 1.8:	Continue addressing restoration of flood control works	Notes: x					
Objective 2: Prepare for future flooding, hazards, and other disaster events.							
Strategy 2.1:	Assess critical infrastructure vulnerability with relocation and mitigation contingencies	Notes: x					
Strategy 2.2:	Create cost estimates and priority matrices for relocation, increased capacity	Notes: x					
Strategy 2.3:	Identify vulnerabilities and develop mitigation procedures for resources	Notes: x					
Strategy 2.4:	Evaluate State capacity to provide and maintain for both public and private	Notes: x					
Strategy 2.5:	Evaluate State capacity to manage other resources	Notes: x					
Natural & Cultural Resources							
Objective 1: Facilitate restoration and preservation of statewide natural assets.							
Strategy 1.1:	Conserve, rehabilitate, and restore natural and environmental assets	Notes: x					
Strategy 1.2:	Improve and expand parks and open spaces statewide to reduce vulnerability	Notes: x					
Objective 2: Support rehabilitation and mitigation of damaged historic buildings and resources.							
Strategy 2.1:	Help historic rehabilitator and historical workers arrange individual resources	Notes: x					
Strategy 2.2:	Develop programs to preserve and rehab privately-owned historic resources	Notes: x					
Objective 3: Integrate arts and culture throughout whole community recovery.							
		Notes: x					
Objective 4: Increase availability and use of open space in floodplains, wetlands to reduce long-term risk.							
Strategy 4.1:	Identify areas where potential floodplains, wetlands, and stream corridors is possible	Notes: x					
Strategy 4.2:	Increase land use planning to the benefit of floodplain wetland infrastructure	Notes: x					



WE NEED YOU...

To Inspire Hope, Comfort and Help Communities in Need

The American Red Cross continues to deliver critical services while following Covid-19 guidelines. We urgently need people like you to join as a volunteer in the following areas:

Disaster Shelter Service Associates (Disaster Deployment Opportunity)

Duties: Will work in person in a Red Cross shelter this hurricane/wildfire season. Volunteers in this role complete tasks necessary for shelter operations and associates support the day-to-day activities which may include working in reception, registration, feeding, dormitory, information, or other areas within a shelter.

Training: 3 hours of virtual self-paced training required

Disaster Shelter Service Supervisor (Disaster Deployment Opportunity)

Duties: Supervises a team of assigned workers to successfully complete tasks necessary for shelter operations and aid disaster clients. Supervisors guide and support the day-to-day activities which includes working in reception, registration, feeding, dormitory, information, or other areas within a shelter. A minimum of 2 years' experience supervising a team of 5 or more.



Training: 9 hours of virtual self-paced training required

Disaster Health Services Service Associate (Disaster Deployment/Virtual Opportunity)

Duties: Assist shelter residents with healthcare needs during this hurricane/wildfire season.

Required Qualifications: A current, unencumbered license in at least one of the following professions: * Registered Nurse (RN) * Licensed Practical Nurse (LPN) * Licensed Vocational Nurse (LVN) * Emergency Medical Technician (EMT)* Paramedic * Medical Doctor (MD) * Doctor of Osteopathy (DO) * Physician Assistant (PA) * Nurse Practitioner (NP) * Advanced Practice Registered Nurse (APRN).

Training: 4 hours of virtual self-paced training required

Please share with in your network of friends, family and partners
If you are interested in learning more, please contact:
Michael Fleming, 402-699-5652 or Michael.Fleming2@redcross.org
To apply: www.redcross.org/volunteer



American Red Cross
Nebraska and Iowa Region

Follow-Up - 9/21 Governors Briefing on COVID-19

Pottebaum, Nic D. EOP/WHO <Nicholas.D.Pottebaum@who.eop.gov>


Tue 9/22/2020 2:40 AM

To: Pottebaum, Nic D. EOP/WHO <Nicholas.D.Pottebaum@who.eop.gov>

Cc: Hoelscher, Douglas L. EOP/WHO <Douglas.L.Hoelscher@who.eop.gov>; Obenshain, Tucker T. EOP/OVP <Anne.T.Obenshain@ovp.eop.gov>; Swint, Zachariah D. EOP/WHO <Zachariah.D.Swint2@who.eop.gov>; Friedman, Haley Z. EOP/WHO <Haley.Z.Friedman@who.eop.gov>; Lopez, Diego Christopher EOP/WHO <DiegoChristopher.Lopez2@who.eop.gov>

📎 1 attachments (441 KB)

COVID-19 Test & Cases from 09-01-2020 - 09-14-2020.pdf;



THE WHITE HOUSE

Governors and Senior Staff,

Thank you for your efforts in the whole-of-America approach to responding to COVID-19. Below you will find additional updates for your COVID-19 response efforts.

Today, you received the following state-specific documents (please let us know if you need them resent or if you have any questions):

- State-Level COVID-19 Profile
- Supply Chain Control Tower Updates
 - Weekly State & County-Level PPE Shipment Data
 - Strategic National Stockpile & Supply Chain Control Tower Update Slide Deck
 - Hospital & Long-Term Care Facility Supplies Data
- Summary of Nursing Home COVID-19 State Analysis
- Updated Hospital-Level Data Collection by State

Additional Action Items

The Vice President asked governors and state leaders to take the following additional actions.

- **Vaccine Distribution Planning:** The Vice President asked governors to work with their state health officials and teams in developing their vaccination distribution plan. Plans are due to the CDC by October 16, 2020. You can find the CDC's COVID-19 Vaccination Program Interim Playbook for Jurisdiction Operations [Here](#).
- **Public Messaging:** The Vice President encouraged governors to highlight the science-driven vaccine development and approval process that will ensure a safe and effective vaccine before distribution as discussed on today's call by NIAID Director Dr. Tony Fauci and on the 9/8 Governors Briefing by FDA Dr. Peter Marks.
- **Building a 60-Day State Stockpile & Improving Data Quality/Reporting to the Federal Government:** The Vice President and Rear Admiral Polowczyk asked governors to (1) work with the state emergency managers and state health teams to ensure they are working towards a 60-day state

stockpile of PPE and supplies; (2) ensure their healthcare providers are providing quality and timeline reporting of supplies (e.g., hospital, long-term care facility) to ensure data-drive decisions. Governors of Arkansas, New Jersey, and Oklahoma highlighted best practices in building up their state stockpiles and working with their healthcare industry to ensure timely and quality reporting. The Federal government as discussed on the call is working towards 90-day stockpile for PPE and other healthcare supplies, and establishing ongoing mechanism to replenish the stockpile.

- **COVID-19 Tests & Cases Chart:** HHS Admiral Giroir wanted to provide the attached scatter plot chart demonstrating testing volume and COVID-19 positive cases. *See attachment.*
-

Readout from the Vice President's Governors Briefing on COVID-19 Response & Best Practices

Today, Vice President Mike Pence led a discussion with the chief executives of approximately 50 States, territories, and the city of Washington, DC, and the White House Coronavirus Task Force to discuss local, State, and Federal Coronavirus response and recovery best practices.

Vice President Pence provided an update on the modernization and enhancements to the Strategic National Stockpile and State efforts to build their own stockpiles of critical resources. Rear Admiral Polowczyk provided an update on the Strategic National Stockpile (SNS) modernization efforts, supply chain stability, including replenishing State and federal stockpiles, and best practices from State, hospitals, and industry. Admiral Polowczyk highlighted California's efforts to improve their stockpile and supply chain coordination and the following governors highlighted their supply chain stabilization efforts and provide best practices: Governor Asa Hutchinson of Arkansas, Governor Phil Murphy of New Jersey, and Governor Kevin Stitt of Oklahoma.

The Vice President also provided an update on COVID-19 response and discussed best practices with our Nation's governors on limiting Coronavirus spread, including protecting our most vulnerable citizens in nursing homes, leveraging our testing ecosystem, safely reopening America's schools, Operation Warp Speed's efforts to safely develop and distribute a vaccine, and encouraging Americans to adhere to State and local guidelines and to wear face coverings when social distancing cannot be maintained. Vice President Pence encouraged governors to build public confidence in the eventual vaccine and to be ready to assist in distribution when a vaccine becomes available.

Ambassador Birx provided an update on data and trends from across the nation, and discussed her recent visits to college campuses in South Carolina, Alabama, Mississippi, Kentucky, Tennessee, Virginia and Texas along with upcoming travel to additional college campuses this week.

Secretary Azar provided an update on Operation Warp Speed including Federal coordination efforts with State, local, and Tribal to plan for the distribution of a safe and effective vaccine. Secretary Azar reminded State executives to submit their vaccine plans to the Department of Health and Human Services is October 16, 2020. Director Redfield provided an update on the COVID-19 Vaccination Program Interim Playbook and State vaccination distribution plans. Dr. Fauci provided a tutorial on the stringent process to determine efficacy, and touched on the various independent boards and committees involved in that process.

Admiral Giroir provided an update on the purchase and planning for 150 million BinaxNOW rapid tests to be distributed across the country.

Participants from the White House Coronavirus Task Force:

- The Vice President
- Secretary Alex Azar, *U.S. Department of Health & Human Services (HHS)*
- Ambassador Deborah Birx, *M.D., White House Coronavirus Task Force Coordinator*
- Director Robert Redfield, *M.D., Centers for Disease Control & Prevention (CDC), HHS*
- Rear Admiral John Polowczyk, *Joint Chiefs of Staff, U.S. Department of Defense (DOD)*
- Admiral Brett Giroir, *M.D., Assistant Secretary for Health, HHS*
- Administrator Seema Verma, *Centers for Medicare & Medicaid Services (CMS), HHS*
- Director Anthony Fauci, *M.D., National Institute for Allergies & Infections Disease (NIAID), HHS*

Since January 2020, the Trump Administration has organized and hosted 37 governors'-only briefings to drive effective communication and collaboration at every level of government.



Operation Warp Speed Vaccine Distribution Process & Updates

Last week, the Centers for Disease Control & Prevention (CDC) released the **COVID-19 Vaccination Program Interim Playbook for Jurisdiction Operations**. You can find the full **Interim Playbook Here**.

- HHS Press Release on Releasing COVID-19 Vaccine Distribution Strategy (**Here**)
- Overview from the Factory to the Frontlines – The Operation Warp Speed Strategy for Distributing a COVID-19 Vaccine (*11 pages*; **Here**)
- COVID-19 Vaccination Program Interim Playbook for Jurisdiction Operations (*57 pages*, **Here**)
- Graphic Operation Warp Speed Vaccine Distribution Process (**Here**)
- *Additional updates on Operation Warp Speed can be found below.*

ICYMI: Defense Experience, Capabilities Further 'Herculean' Operation Warp Speed Efforts (Full Article [Here](#))

Below you will find additional information including:

- Contacting Your FEMA Regional Administrator
- Protecting the Most Vulnerable Resources
- Additional Operation Warp Speed Updates
- COVID-19 Testing Resources
- CDC Guidance for Schools & Higher Education Institutions Reopening

If you have any additional questions, please reach out to the Office of the Vice President or White House Intergovernmental Affairs Office.

Intergovernmental Affairs Office

Name	Cell Phone	Email
Doug Hoelscher	[REDACTED]	Douglas.L.Hoelscher@who.eop.gov
Nic Pottebaum	[REDACTED]	Nicholas.D.Pottebaum@who.eop.gov
Zach Swint	[REDACTED]	Zachariah.D.Swint2@who.eop.gov
Haley Friedman	[REDACTED]	Haley.Z.Friedman@who.eop.gov
Chris Lopez	[REDACTED]	DiegoChristopher.Lopez2@who.eop.gov

Office of the Vice President

Name	Cell Phone	Email
Tucker Obenshain	[REDACTED]	Anne.T.Obenshain@ovp.eop.gov

Thanks,

Nic

Nicholas D. Pottebaum

Special Assistant to the President and Deputy Director

White House Office of Intergovernmental Affairs

O: 202-456-2132 | C: [REDACTED] | E: Nicholas.D.Pottebaum@who.eop.gov

ADDITIONAL INFORMATION

Contacting Your FEMA Regional Administrator

The Federal Emergency Management Agency (FEMA) has activated the National Response Coordination Center (NRCC). All requests to the Federal government must be formally communicated by your State emergency manager to your FEMA Regional Administrator. This is the same process as natural disasters (e.g., hurricane recovery, flood recovery, tornado recovery, etc.). **If you have specific needs, please reach out to your FEMA Regional Administrator.**

Protecting the Most Vulnerable Resources

- **Independent Nursing Home COVID-19 Commission Findings Validate Unprecedented Federal Response:** Last week, CMS received the final report from the independent Coronavirus Commission for Safety & Quality in Nursing Homes, which was facilitated by MITRE. The Commission's findings align with the actions the Trump Administration and CMS have taken to contain the spread of the virus and to safeguard nursing home residents from the ongoing threat of the COVID-19 pandemic. Last week's announcement delivers on the Trump Administration's commitments to keeping nursing home residents safe and to transparency for the American people in the face of this unprecedented pandemic.
 - Full Independent Coronavirus Commission for Safety & Quality in Nursing Homes Report ([Here](#))
 - Trump Administration Response to Commission Findings ([Here](#))
 - CMS COVID-19 Guidance & Updates for Nursing Homes ([Here](#))
- **CMS New Guidance for Safe Visitation in Nursing Homes:** CMS has issued revised guidance providing detailed recommendations on ways nursing homes can safely facilitate visitation during COVID-19 pandemic. After several months of visitor restrictions designed to slow the spread of COVID-19, CMS recognizes that physical separation from family and other loved ones has taken a significant toll on nursing home residents. In light of this, and in combination with increasingly available data to guide policy development, CMS is issuing revised guidance to help nursing homes facilitate visitation in both indoor and outdoor settings and in compassionate care situations. The guidance also outlines certain core principles and best practices to reduce the risk of COVID-19 transmission to adhere to during visitations. Full guidance and more information can be found [here](#).
 - **Op-Ed from CMS Administrator Seem Verma** on CMS' decision to ease visitation restrictions for nursing homes and safely reunite residents with their families [here](#).
- CDC MMWR on Association Between CMS Quality Ratings & COVID-19 Outbreaks in Nursing Homes ([Here](#))
- Recent CMS Action on Strengthening COVID-19 Surveillance with New Reporting & Testing Requirements: CMS announced sweeping regulatory changes that require nursing homes to test staff and offer testing to residents for COVID-19 regularly.
 - Guidance on Frequency of Resident & Staff Testing can be found [here](#).
 - You can find additional details [here](#).
- Toolkit on State Action to Mitigate COVID-19 Prevalence in Nursing Homes ([Here](#))

Additional Operation Warp Speed Updates

Operation Warp Speed (OWS) aims to deliver 300 million doses of a safe, effective vaccine for COVID-19 by January 2021, as part of a broader strategy to accelerate the development, manufacturing, and distribution of COVID-19 vaccines, therapeutics, and diagnostics (collectively known as countermeasures).

- **Fact Sheet:** Explaining Operation Warp Speed ([Here](#))
- **Recent Op-Eds from Administration Officials**
 - Dr. Slaoui, Dr. Greene, & Dr. Woodcock Op-Ed in the New England Journal of Medicine: Bridging the Gap at Warp Speed – Delivering Options for Preventing and Treating Covid-19 ([Here](#))
 - Dr. Hahn & Dr. Marks Op-Ed: The FDA’s Scientific and Regulatory Oversight of Vaccines is Vital to Public Health ([Here](#))
- **Encourage Participation in Clinical Trials:** The Vice President has also asked governors to encourage your citizens to participate in clinical trials, including **encouraging a diverse population** to enroll in the vaccine trials. For more information, visit [CoronavirusPreventionNetwork.org](https://www.coronaviruspreventionnetwork.org).

COVID-19 Testing Resources

- **Abbott BinaxNOW Tests Purchase:** The Trump Administration has **announced** the purchase and production of 150 million rapid tests to be distributed across the country. Through Operation Warp Speed and in partnership with Abbott Laboratories, final production will be scaled to an unprecedented 50 million tests monthly. Distribution of the tests began last week, with vulnerable populations being prioritized first (nursing homes in red and yellow counties, assisted living facilities, home health agency workers, HBCUs, and Tribes). **Additional information on additional distribution is forthcoming.** You can find more information from HHS [here](#).
- **Maximizing Testing Ecosystem:** Governors and states are encouraged to maximize their entire testing ecosystem – state health lab through **pooled testing**, academic institutions including using non-CLIA certified labs for **surveillance testing**, **community-based testing sites**, and utilizing 13,000+ **FQHCs**.
- **FDA Approved Tests:** To date, the FDA has currently authorized 249 tests under EUAs; these include 199 molecular tests, 46 antibody tests, and 4 antigen tests. You can find the full list [here](#).
- **July – December 2020 COVID-19 State Testing Plans ([Here](#))**
- **Opening Up America Again Testing Blueprint ([Here](#); 11-pages) and Addendum to the Testing Blueprint: Using Tests for Diagnosis and Proactive Surveillance ([Here](#); 6-pages)**
- **Pooled Testing:** Sample pooled testing can be especially helpful for surveillance testing on college campuses. Universities can use excess lab capacity to conduct surveillance testing and utilize pooled testing methods at their non-CLIA certified labs (especially in veterinary labs). If your universities have questions about CLIA certification, please have them reach out to CMS. You do not need an emergency use authorization (EUA) from FDA to conduct surveillance testing. The FDA has guidance on facilitating diagnostic test availability for asymptomatic testing and sample pooling (more details [here](#)).
- **Coronavirus Treatment Acceleration Program (CTAP):** The FDA has created a special emergency program for possible coronavirus therapies. The program uses every available method to move new treatments to patients as quickly as possible, while at the same time finding out whether they are helpful or harmful. The FDA continues to support clinical trials that are testing new treatments for COVID so that we gain valuable knowledge about their safety and effectiveness. CTAP Dashboard [here](#).

Additional Guidance & Resources


- **Opening Up America Again Guidelines:** As a reminder, the Guidelines for Opening America Again based on up-to-date data and readiness, mitigating risk of resurgence, and protecting the most vulnerable can be found [here](#) (20-pages).
- **Updated CDC Contact Tracing Guidance, Resources, & Training Plan:** Can be found [here](#).
- **Additional Testing Resources:** FDA [Frequently Asked Questions \(FAQ\)](#) and 24/7 technical assistance for labs (1-888-463-6332).
- **Best Practices in Preserving PPE:** FEMA has released guidance summarizing best practices for the implementation to sustain personal protective equipment (PPE) while ensuring the protection of workers during COVID-19 response. Best practices in preserving PPE can be found [here](#).

CDC Guidance for Schools & Higher Education Institutions Reopening

The CDC has released science-based resources and tools for school administrators, teachers, parents, guardians, and caregivers when schools open this fall. The CDC discusses the importance of reopening America's schools this fall [here](#) noting that "as families and policymakers make decisions about their children returning to school, it is important to consider the full spectrum of benefits and risks of both in-person and virtual learning options."

- **School Mask Program Distribution of Cloth Face Masks:** The Trump Administration continues to work to support safe school reopening for students, teachers, and staff. HHS is providing 125 million cloth masks to states for distribution to schools. Shipments began last week to state departments of health for distribution to schools throughout their states. The Administration intends for these masks to support students, teachers, and staff in public and private schools reopening, with an emphasis on students who are low-income or otherwise with high needs and schools providing in-person instruction. Additional information and state-specific distribution amount can be found [here](#).
- K-12 Schools Guidance & Considerations [here](#).
- Higher Education Institutions Guidance & Considerations [here](#).

Recent Strategic National Stockpile 2.0 Efforts & Contracting Announcements



COVID-19 Response

UNDER A NEW CONTRACT WITH THE DEPARTMENT OF DEFENSE

9 U.S. COMPANIES

WILL PRODUCE MILLIONS OF COVID-19
DISPOSABLE ISOLATION GOWNS FOR
THE STRATEGIC NATIONAL STOCKPILE



COVID-19 Response

A TOTAL OF MORE THAN

1 BILLION SYRINGES & NEEDLES PROCURED

TO SUPPORT A POTENTIAL U.S.
COVID-19 VACCINATION CAMPAIGN



COVID-19 Response

THE STRATEGIC NATIONAL STOCKPILE IS ON TRACK TO HAVE


10 TIMES MORE MASKS

BY FALL 2020 THAN WERE AVAILABLE
PRIOR TO THE COVID-19 PANDEMIC



COVID-19 TESTS AND CASES: September 1-14, 2020

(per 100,000 population)



Cases per 100,000

● >10% pc

Walmart COVID-19 Vaccine Offer of Assistance

Ryan Irsik <Ryan.Irsik@walmart.com>

Tue 9/22/2020 4:35 PM

To: Miltenberger, Matt <matt.miltenberger@nebraska.gov>; Gage, Taylor <taylor.gage@nebraska.gov>

📎 1 attachments (22 KB)

NE COVID-Governor Letter - FINAL.docx;

Matt and Taylor,

I've attached a letter from Walmart's Health and Wellness Division offering our assistance to the State of Nebraska as you plan and implement the distribution and administration of the COVID-19 vaccine.

If your team has any questions, please don't hesitate to reach out.

Best Regards,

Ryan Irsik

Ryan Irsik Public Affairs & Government Relations
CO, KS, NE, SD

Cell [REDACTED]
ryan.irsik@walmart.com

Walmart
702 Southwest 8th Street
Bentonville, AR 72716-0350
Saving people money so they can live better.

September 21, 2020

The Honorable Pete Ricketts
Governor
State of Nebraska
1445 K St.
Lincoln, NE 68508

Dear Governor Ricketts:

We are writing to offer our assistance to the State of Nebraska as you plan and implement the distribution and administration of the COVID-19 vaccine.

As a community-based provider, Walmart can play a unique role in ensuring the public has access to the vaccine in every phase of distribution. With 135 pharmacists throughout Nebraska, Walmart has long been a critical access point for flu vaccines, and during the pandemic, our associates have administered 59 COVID-19 tests across the state.

- **Convenience:** The vaccines in development today all require two vaccines for effectiveness, making convenience for consumers even more important than flu vaccines. With 48 Walmart and Sam's Club locations many Nebraskans live within 10 miles of a store, citizens can easily receive their first and second vaccines during visits to the store for other reasons.
- **Volume of Visitors:** The CDC has recommended that providers and settings that maximize the number of people who can be vaccinated should be prioritized for enrollment in the network of permitted providers. Our pharmacists see thousands of people in our stores every day, and we are well-situated to maximize access safely and securely.
- **Pharmacist Experience:** Our pharmacists have a long history of providing flu and expanded vaccines to the public. They have the experience, knowledge and training to handle administration of the COVID-19 vaccine.
- **Logistics Experience:** Walmart is deeply experienced in the transport, storage and handling of vaccine products. Walmart has a joint-venture with McKesson, making coordination with the central distributor chosen by the federal government seamless.
- **Infrastructure:** Our pharmacies have the necessary infrastructure to receive and store vaccines that are required to remain in the cold chain.
- **Reporting Experience:** Our pharmacies are equipped with advanced health IT infrastructure that enables reporting to state public health registries, and can support connection to the new CDC VAMS system and to the IZ Gateway.
- **Safety:** Our commitment to ensuring the health and safety of our customers and associates has led to reduced store hours to allow more time to clean and sanitize, the creation of a Health Ambassador role, and the implementation of special procedures to protect associates and customers. We also have special shopping hours for anyone over the age of 60, first responders, customers with disabilities, and anyone designated high-risk by the CDC.

Most importantly, our pharmacists are trusted in their communities. Given the uncertainty and anxiety many people are feeling about the vaccine, our pharmacists can be your partners in disseminating information and answering questions.

Please let us know how we can assist in this effort. We would be proud to serve the state in any capacity. Please let us know how we can assist in this effort. We can be reached at Covid19Vaccine@walmart.com.

Sincerely,

Lisa Smith, PharmD, MBA
Senior Director II Clinical Excellence
Walmart Health and Wellness

[INVITE] Call with CDC on Vaccine Distribution Planning Update

Baker, Michael (OS/IEA) <Michael.Baker@hhs.gov>

Tue 9/22/2020 10:45 PM

To: Baker, Michael (OS/IEA) <Michael.Baker@hhs.gov>

Dear State Partner –

The Office of Intergovernmental and External Affairs would like to invite you to join a call with Centers for Disease Control and Prevention officials TOMORROW at 10:00 AM EDT. The call will discuss an announcement related to vaccine distribution planning. The call-in details are below.

Conference Details

Date: Wednesday, September 23, 2020

Time: 10:00 AM EDT

Dial in: [REDACTED]

Participant: [REDACTED]

We look forward to you joining us!

Sincerely,

Darcie Johnston
Director, Intergovernmental Affairs
Office of the Secretary
U.S. Department of Health and Human Services

FW: CDC State Plans for COVID-19 Vaccine Administration

Miltenberger, Matt <Matt.Miltenberger@nebraska.gov>

Fri 9/25/2020 1:47 PM

To: Newmyer, Ashley <Ashley.Newmyer@nebraska.gov>

📎 1 attachments (70 KB)

NE - UCA - Letter to Governor.docx;

From: Chappellear, Trinity <Trinity.Chappellear@nebraska.gov>

Sent: Friday, September 25, 2020 8:46 AM

To: Kintner, Lauren <Lauren.Kintner@nebraska.gov>; Miltenberger, Matt <Matt.Miltenberger@nebraska.gov>

Subject: FW: CDC State Plans for COVID-19 Vaccine Administration

Sorry. Here is the attachment.

From: Kim Youngblood <kyoungblood@ucaoa.org>

Sent: Thursday, September 24, 2020 6:25 PM

To: Berry, Stevens <Stevens.Berry@nebraska.gov>; Chappellear, Trinity <Trinity.Chappellear@nebraska.gov>; Ficke, Melissa <melissa.ficke@nebraska.gov>; Vaggalis, Denny <denny.vaggalis@nebraska.gov>; Wolff, Cheryl <cheryl.wolff@nebraska.gov>

Subject: CDC State Plans for COVID-19 Vaccine Administration

Good afternoon,

Please see the attached letter regarding the Centers for Disease Control COVID-19 Vaccination Program. The Urgent Care Association would like to ensure that we are included in state plans to distribute a new COVID-19 vaccine. With over 10,000 urgent care centers around the county we are available to assist with the administration of the vaccine. We would also request that at least one representative from the urgent care community be included in state planning and implementation activities.


Urgent care centers are leading the efforts for COVID-19 testing around the state and the country. We have the infrastructure and experience to administer the COVID-19 vaccine and we're located in every area of the state.

If you have any questions or would like to discuss this request in detail, please let me know. Thank you for your attention to this request. – Kim

Kim Youngblood | Chief Development Officer



Phone: [REDACTED] | Email: kyoungblood@ucaoa.org



September 23, 2020

The Honorable Pete Ricketts
Governor
State of Nebraska
1445 K St.
Lincoln, NE 68508

Dear Governor Ricketts:

Urgent care centers stand ready to support your efforts to ensure widespread, safe and equitable administration of the COVID-19 vaccine in your state. We request that at least one representative from the urgent care community be included in your planning and implementation.

As you know, the Department of Health and Human Services (HHS) and the Centers for Disease Control and Prevention (CDC) this week released an interim playbook for the COVID-19 Vaccination Program, instructing each state to develop their own micro-plan for vaccine distribution by October 16.

The CDC has recommended that providers and settings that can maximize the number of people who can be vaccinated should be prioritized for enrollment in the network of permitted providers. Urgent care centers ramped up quickly on COVID-19 testing and have administered approximately 10 percent of the COVID tests conducted in the U.S. Urgent care centers now have systems in place to maximize testing volume that can be replicated for vaccines.

Additionally, it is likely that the COVID-19 vaccine will require two doses at different times – an initial dose followed by a booster. In such an environment, convenience and capacity will be crucial, thereby making urgent care centers an important partner. Not only are urgent care facilities located all over your state, they offer services during hours when other health care settings are often closed, including weekends, evenings and holidays.

Finally, urgent care centers have the infrastructure and experience to administer the COVID-19 vaccine. We receive, store and administer the flu vaccine on an annual basis. In addition, 76.6% of the U.S. population resides within a 10-minute drive of one of the approximately 10,000 urgent care centers in the country. Urgent care centers are in every community and are ready to administer the COVID-19 vaccine when it is available.

We thank you for your continued leadership during this public health emergency. We look forward to working with you on this important effort. Please contact Kim Youngblood at kyoungblood@ucaoa.org with any questions.

Sincerely,

A handwritten signature in black ink, appearing to read 'Lou Ellen Horwitz', is written over a light blue horizontal line.

Lou Ellen Horwitz
CEO
Urgent Care Association

HHS COVID-19 Update, 9-24-2020

Stevens, Lee (OS/IEA) <Lee.Stevens@hhs.gov>

Fri 9/25/2020 1:18 PM

To: Johnston, Darcie (HHS/IEA) <Darcie.Johnston@hhs.gov>; Stevens, Lee (OS/IEA) <Lee.Stevens@hhs.gov>

Dear Colleague:

While not COVID-related, I know a number of you will be interested in President Trump's announcement yesterday outlining our "America First Healthcare Plan." Both Secretary Azar and Administrator Verma were on hand in North Carolina for the announcement. At the bottom of this email are the:

1. [HHS Press Release](#) with information on the HHS pieces of today's announcement, and the
2. [White House Fact Sheet, Executive Order](#), and White House email outlining today's announcements.

Personally, if you are looking for the proof that a complete approach to healthcare delivers our best bet for patient-centered and affordable coverage, I say look at that 34% DECREASE in PREMIUMS in Medicare Advantage from 2017 to 2021, highlighted today. Medicare Part D drug plans are down 12% since 2017.

Now, back to COVID-19!

Vaccine Update

Update on Vaccine Research From the Experts: NIH Director Dr. Francis Collins and NIAID Director Dr. Anthony Fauci teamed up to give an update on NIH COVID-19 research. You can watch their update on the [NIH Facebook page](#) or by clicking the [tweet](#) below.

Testing and Treatment

FDA Authorizes First Point-of-Care Antibody Test for COVID-19: FDA issued an emergency use authorization (EUA) for the first serology (antibody) point-of-care (POC) test for COVID-19. The Assure COVID-19 IgG/IgM Rapid Test Device was first authorized for emergency use by certain labs in July 2020 to help identify individuals with antibodies to SARS-CoV-2, indicating recent or prior COVID-19 infection. Today, that EUA is being reissued to authorize the test for POC use using fingerstick blood samples. This authorization means that fingerstick blood samples can now be tested in POC settings like doctor's offices, hospitals, urgent care centers and emergency rooms rather than having to be sent to a central lab for testing.

BARDA and Luminex Corporation to Develop an Advanced Serology Test for Use During the COVID-19 Pandemic: BARDA and Luminex Corporation entered into a public-private partnership to develop a cost effective, high throughput advanced serology test that assesses the level of neutralizing antibodies in plasma. This advanced serology effort builds on the Emergency Use Authorized (EUA) xMAP® SARS-CoV-2 Multi-Antigen IgG assay, which is a multiplex, microsphere-based, highly sensitive and specific assay that detects the presence of antibodies against three different SARS-CoV-2 antigens. This current test determines if a patient has previously had a COVID-19 infection.

Evidence to Support Emergency Use of Convalescent Plasma: FDA posted a document summarizing updated evidence to support the emergency use of COVID-19 Convalescent Plasma. The agency will continue to review the circumstances and appropriateness of the authorization for emergency use. To make this information accessible to the public, the document posted on the web presents FDA's review in relatively plain language.

Testing Updates: As of today, 252 tests are authorized by FDA under EUAs; these include 202 molecular tests, 46 antibody tests; and 4 antigen tests.

Research Updates

Scientists Discover Genetic and Immunologic Underpinnings of Some Cases of Severe COVID-19: New findings by scientists at the NIH and their collaborators help explain why some people with COVID-19 develop severe disease. The findings also may provide the first molecular explanation for why more men than women die from COVID-19. The researchers found that more than 10% of people who develop severe COVID-19 have misguided antibodies—autoantibodies—that attack the immune system rather than the virus that causes the disease. Another 3.5% or more of people who develop severe COVID-19 carry a specific kind of genetic mutation that impacts immunity.

Disparities in COVID-19 Incidence, Hospitalizations, and Testing, by Area-Level Deprivation: CDC released an MMWR on Disparities in COVID-19 Incidence, Hospitalizations, and Testing, by Area-Level Deprivation in Utah between March 3 and July 9, 2020. During March 3–June 9, 2020, odds of SARS-CoV-2 infection in very high-deprivation areas of Utah were three times higher than those in very low-deprivation areas; rates of hospitalization and testing were also higher in higher-deprivation areas. These areas were characterized by larger proportions of Hispanic and non-White residents, persons working in manual, essential, and public-facing sectors, more crowded housing, and food and health care insecurity. Enhanced mitigation strategies might include increasing availability and accessibility of SARS-CoV-2 testing, contact tracing, isolation options, preventive care, disease management, and prevention guidance in more-deprived areas.

Update – Characteristics of Health Care Personnel with COVID-19: CDC released an MMWR on Characteristics of Health Care Personnel with COVID-19 in the U.S. from February 12 through July 16, 2020. HCP with COVID-19 who died tended to be older, male, Asian, Black, and have an underlying medical condition when compared with HCP who did not die. Nursing and residential care facilities were the most commonly reported job setting and nursing the most common single occupation type of HCP with COVID-19 in six jurisdictions. Continued surveillance is vital to understand the impact of COVID-19 on essential workers. Ensuring access to personal protective equipment and training, and practices such as universal use of face masks at work, wearing masks in the community, and observing social distancing remain critical strategies to protect HCP and those they serve.

Another Reminder to Get Your Flu Shot!

Stay safe – and get your flu vaccine!

Laura

Laura C. Trueman
Director, Office of Intergovernmental and External Affairs
U.S. Department of Health and Human Services

News Release

FOR IMMEDIATE RELEASE
Thursday, September 24, 2020

HHS Takes Action as Part of President Trump's Healthcare Plan

On Thursday, President Trump unveiled his America First healthcare plan, signing an executive order to deliver Americans better care, lower costs, and more choice, continuing the work that HHS has been doing under his leadership.

"The President's plan delivers better care, more choice, and lower costs for all Americans," said HHS Secretary Alex Azar. "Because of the President's leadership, Americans will enjoy lower drug costs, lower insurance premiums, real access to prices of healthcare services and to their medical records, new protections from surprise bills, and the ability to work with their doctor to determine what treatments make sense for them."

As part of the President's plan, on Thursday, HHS:

- Issued a final rule and guidance from the Food and Drug Administration to open the first-ever pathway for states to use to safely import prescription drugs to lower patients drug costs.
- Solicited private-sector proposals, as called for in the President's July executive order, on allowing Americans to get lower-cost FDA-approved drugs and insulins from American pharmacies via importation and reimportation.
- Released the 2021 Medicare Advantage and Medicare Part D Premium landscape, showing that average 2021 premiums for Medicare Advantage plans are expected to decline 34.2 percent from 2017 while plan choice, benefits, and enrollment continue to increase, and that Part D premiums will be down 12 percent from 2017, with over 1,600 drug plans offering insulin at no more than \$35 per month.
- Issued a notice of proposed rulemaking from the Health Resources and Services Administration to pass on steep discounts at community health centers on insulin and epinephrine to Americans who are uninsured or have high cost-sharing, including the nearly 3 million health center patients with diabetes.

For more information about the Requests for Proposal Regarding Waivers for Individual Prescription Drug Importation Programs, visit [here](#).

For more information about the Request for Proposals Regarding Insulin Reimportation Programs, visit [here](#).

#

From: The White House <info@mail.whitehouse.gov>
Sent: Thursday, September 24, 2020 7:33 PM
To: Trueman, Laura (HHS/EA) <Laura.Trueman@hhs.gov>
Subject: BREAKING: President Trump just unveiled his America First Healthcare Plan

The White House •
September 24, 2020

BREAKING:
President Trump just unveiled his America First Healthcare Plan

Photo of the Day

President Trump traveled to Charlotte, North Carolina, this afternoon where he just unveiled his America First Healthcare Plan.

President Trump signs an executive order on the America First

"We will ensure the highest standard of care anywhere in the world: cutting-edge treatments, state-of-the-art medicine, groundbreaking cures, and true health security for you and your loved ones," the President said.

President Trump:
Better care at a
lower cost, with
more choice!

The America First plan has three goals: more choice, lower costs, and better care. It includes protections for pre-existing conditions, measures to stop surprise medical bills, and rules to guarantee price transparency so patients aren't left completely in the dark.

The result is that Americans will have more control over their own healthcare dollars rather than ceding power to Washington politicians or powerful corporations.

Unlike socialized medicine, President Trump's plan puts working families first with:

- **MORE CHOICE:** Patients will be in charge of their care, not bureaucrats at some faraway Federal agency. When President Trump took office, more than *half* of U.S. counties offered plans

[Privacy Policy](#) |
[Contact the White House](#)
|
[Unsubscribe](#)

from only a single insurance provider on the individual market. As of next month, more than 90 percent of American counties will have multiple options to choose from.

- **LOWER COSTS:** For years, patients have been shocked to receive unexpected bills for thousands of dollars in medical services they never even agreed to. President Trump's plan bans this deeply unfair practice and ends surprise medical billing. "The days of ripping off American patients are over," he said.

- **BETTER CARE:** With new ways for Medicare to pay providers, Americans will have access to doctors they trust—whenever they are needed. President Trump is also making sure that politicians don't get in the way of much-needed research and innovation, ensuring Americans access to the best health care in the world.

President Trump's plan puts American patients first. Unfortunately, under pressure from the far left, Democrats have endorsed healthcare legislation that would result in rationing care, keeping patients on waitlists, and driving the best

doctors away from practicing medicine.

"The Democrat Party is pushing a socialist nightmare," President Trump said.

Americans want real choice, affordability, and quality in their medical care. They don't want radical politicians playing games with their health and safety to get votes.

Under this President, America's families and seniors will always be protected.

[Read about President Trump's America First Healthcare Plan](#)

[WATCH: "The Democrat Party is pushing a socialist nightmare,"](#)

<< RTF: Rich object >>

The White House ·
1600 Pennsylvania Ave NW ·
Washington, DC 20500 ·
USA · 202 ·
456-1111

RE: Vaccine distribution follow up

Matthew T. Schaefer <schaefer@muellerrobak.com>

Fri 9/25/2020 8:12 PM

To: Miltenberger, Matt <matt.miltenberger@nebraska.gov>

Matt, I've tried Ashley by phone once and two emails an haven't heard from her.

Matthew T. Schaefer, J.D. | MUELLER | ROBAK LLC

530 South 13th Street | Suite 110 | Lincoln, NE 68508

T 402.434.3399 | F 402.434.3390 | C: [REDACTED]

Schaefer@MuellerRobak.com | www.MuellerRobak.com

From: Miltenberger, Matt <matt.miltenberger@nebraska.gov>

Sent: Friday, September 11, 2020 7:42 AM

To: Matthew T. Schaefer <schaefer@muellerrobak.com>; Newmyer, Ashley <Ashley.Newmyer@nebraska.gov>

Cc: Timothy G. Hruza <hruza@muellerrobak.com>; William J. Mueller <mueller@muellerrobak.com>

Subject: RE: Vaccine distribution follow up

Matt-

Always great chatting with you. We need to catch a Cubs game before this short season ends.

Adding Ashley Newmyer to the email. She can connect you with the right folks on her team regarding vaccine distribution. As to the RFI, I confirmed with her that they are not planning to move forward with an RFP.

Let me know if there is anything else I can help with.

Have a great weekend.

Matt

From: Matthew T. Schaefer <schaefer@muellerrobak.com>

Sent: Wednesday, September 9, 2020 11:58 AM

To: Miltenberger, Matt <matt.miltenberger@nebraska.gov>

Cc: Timothy G. Hruza <hruza@muellerrobak.com>; William J. Mueller <mueller@muellerrobak.com>

Subject: Vaccine distribution follow up

Matt – thanks for chatting last week about our client's mobile application/platform "Healthy Together". It has partnered with the states of Utah and Florida (and more on the way) on contract tracing software/management. **It can also help with vaccine distribution:**

1. Vaccine Program Communication
2. Vaccination Registration and Queuing
3. Prioritization and Alerting
4. Vaccination Booster Follow-up (if required)
5. Portable Vaccination Validation
6. Success Measurement of the Program

More info is attached.

If you had a chance to talk with Ashley about the HHS RFI please do let me know what you found out or let me know who we should chat with further.

Thanks!
Matt.

Matthew T. Schaefer, J.D. | MUELLER | ROBAK LLC
530 South 13th Street | Suite 110 | Lincoln, NE 68508
T 402.434.3399 | F 402.434.3390 | C [REDACTED]
Schaefer@MuellerRobak.com | www.MuellerRobak.com

RE: Hy-Vee COVID-19 Vaccine

Roth, Anne <ARoth@hy-vee.com>

Fri-9/25/2020 9:20 PM

To: Miltenberger, Matt <matt.miltenberger@nebraska.gov>

Matt,

Sounds great – thank you so much. Do not hesitate to ever reach out if Hy-Vee can be of assistance on this issue or any other that should arise.

I'm looking forward to meeting you in person sometime soon.

Have a great weekend,

Anne

Anne E. Roth

Director, Government Relations

Hy-Vee, Inc.

5820 Westown Parkway | West Des Moines, IA 50266

Mobile: [REDACTED]

Office: 515-695-3088

aroth@hy-vee.com

From: Miltenberger, Matt <matt.miltenberger@nebraska.gov>

Sent: Friday, September 25, 2020 7:43 AM

To: Roth, Anne <ARoth@hy-vee.com>

Subject: RE: Hy-Vee COVID-19 Vaccine

This message originated outside of the Hy-Vee email system. Use caution when opening attachments, clicking links, or responding to requests for information.

Anne-

Great talking with you the other day. I've shared your email with DHHS. I will make sure they follow up with you at the appropriate time.

Have a great weekend and thank you for your offer to help.

Matt

From: Roth, Anne <ARoth@hy-vee.com>

Sent: Thursday, September 24, 2020 10:39 AM

To: Miltenberger, Matt <matt.miltenberger@nebraska.gov>

Subject: Hy-Vee COVID-19 Vaccine

Matt,

Thank you so much for your time yesterday. As promised, here is the additional background for your consideration. As mentioned, Hy-Vee is ready and willing to be a partner in distributing the COVID-19 vaccines. We are also uniquely positioned to deliver to more rural parts of Nebraska and have the reporting infrastructure in place to handle the vaccine administration.

With a strong presence in rural America and parts of urban areas across the Midwest, Hy-Vee is willing and prepared to deploy community vaccination initiatives to establish innovative, drive-thru mobile and special, high-risk clinics as a means to assist OWS & CDC in this important public health and economic initiative. For your background:

- Over 275 pharmacy locations with more than 1,000 pharmacists certified to administer vaccines. See attached map for list of locations.
- Ability to offer contactless drive-thru vaccinations: digital consent forms and an online appointment scheduler for vaccines.
- Nine Hy-Vee Healthy You Mobiles: mobile buses equipped with two exam rooms that we are prepared to deploy across our region.
- All ACIP recommended vaccines available without a prescription.
- Patients can make an appointment or walk-up.
- Private administration areas adjacent to the pharmacy.
- Second-dose strategies.
- Immunization reporting to the individual states.

I look forward to our continued discussion on Hy-Vee's requested participation in Nebraska's COVID vaccination distribution strategy. Additionally, please let me know if it would be beneficial to set up a meeting with your team and our experts to discuss further.

Thank you,

Anne

Anne E. Roth

Director, Government Relations


Hy-Vee, Inc.

5820 Westown Parkway | West Des Moines, IA 50266

Mobile [REDACTED]

Office: 515-695-3088

aroth@hy-vee.com



RE: CDC Vaccine Plan

Miltenberger, Matt <matt.miltenberger@nebraska.gov>

Fri 9/25/2020 9:58 PM

To: Kintner, Lauren <Lauren.Kintner@nebraska.gov>

Yes she is

From: Kintner, Lauren <Lauren.Kintner@nebraska.gov>

Sent: Friday, September 25, 2020 3:25 PM

To: Miltenberger, Matt <matt.miltenberger@nebraska.gov>

Subject: FW: CDC Vaccine Plan

I received a follow-up. Will this contact person that the US govt is requesting be Angela Ling?

From: Urban, Lori (HHS/IEA) <Lori.Urban@hhs.gov>

Sent: Friday, September 18, 2020 7:35 PM


To: Buss, Bryan F. (CDC/DDPHSIS/CPR/DSLRL) <feu7@cdc.gov>; Smith, Dannette <Dannette.Smith@nebraska.gov>; Anthone, Gary <Gary.Anthone@nebraska.gov>; Kahrs, Jeff (HHS/IEA) <Jeff.Kahrs@hhs.gov>; Miltenberger, Matt <matt.miltenberger@nebraska.gov>; Kintner, Lauren <Lauren.Kintner@nebraska.gov>; Tuma, Bryan <bryan.tuma@nebraska.gov>; Johnston, Darcie (HHS/IEA) <Darcie.Johnston@hhs.gov>

Subject: CDC Vaccine Plan

Matt, Lauren and Team –

As you know, this week more information was provided and states have been asked to prepare their vaccine distribution strategy by October 16. A key resource is the CDC's "[COVID-19 Vaccination Program Interim Playbook for Jurisdiction Operations](#)," which provides your planning team with some guideposts and requirements for the plan.

We would like to do two things as next steps.

- 1. Your CDC Liaison: We want you to have an identified CDC Liaison for your planning team.** We know that some of you already have a CDC person integrated into your planning process. The identified liaison is not meant to supplant any CDC personnel you are already working with – they are simply a resource for those states and planning teams that need a stronger CDC presence for technical assistance in their planning efforts. We are still expecting your CDC Liaison – identified below - to check in weekly with your planning team, just to make sure that needs and questions are being met, and also to relay any new updates that may be added to the Playbook. **Your CDC Liaison is: Bryan Buss - CEFO FEU7@cdc.gov Bryan.Buss@nebraska.gov 402.471.8820**

- 2. Your Existing CDC POC for Distribution Planning, in Applicable:** If you already have a CDC person you have been working with and/or would prefer that they continue in that role, please let us know who that CDC point of contact is.
- 3. Your Designated State Lead(s) for Distribution Planning** We also need to know WHO the Governor has designated as your state's lead(s) for developing your distribution plan. **Please provide their name(s), email(s) and phone number(s) no later than COB Monday.**

As soon as we have your state leads and any existing CDC personnel involved with the planning process, we will make sure that an initial first technical assistance call is scheduled. CDC will reach out and set that call up.

In addition to myself and the CDC contact, I'm including your **HHS IEA Regional Director** on this email. We expect the Regional Director to be part of the technical assistance calls with your CDC Liaison and your planning lead to further triage any issues that may be outside the CDC purview.

So, next steps are:

- You **"reply all"** to this email identifying:
 - Your state POC(s) for state distribution planning
 - Any existing CDC staff your planning team is working with.
- The CDC Liaison follows that email with outreach to the state POC and the HHS IEA Regional Director to schedule the first Technical Assistance call.

Our goal here is proactive, establishing ongoing communication in the distribution planning process, ensuring that we are dealing with any questions or clarifications in real time.

We are committed to maintaining a close state/federal partnership as we work to insure all Americans have access to an eventual vaccine to protect them from the COVID-19 virus.

Best,

Darcie

Darcie Johnston, Director
Office of Intergovernmental Affairs
U.S. Department of Health and Human Services
